

## METHOD AND REAGENT FOR THE INHIBITION OF TELOMERASE ENZYME

**[0001]** This application is a continuation of U.S. Application No. 09/653,225 filed August 31, 2000 which claims the benefit of U.S. Provisional Application No. 60/151,713 filed on August 31, 1999 and U.S. Provisional Application No. 60/197,769 filed on April 14, 2000. All of the applications are incorporated by reference herein in their entireties, including the drawings.

**[0002]** The Sequence Listing file named "MBHB00,882-C SequenceListing.txt" (1,187,852 bytes in size) submitted in duplicate on Compact Disc-Recordable (CD-R) medium ("010913\_1300") in compliance with 37 C.F.R. §1.52(e) is incorporated herein by reference.

### Background Of The Invention

**[0003]** The present invention concerns compounds, compositions, and methods for the study, diagnosis, and treatment of conditions and diseases related to the level of telomerase enzyme.

**[0004]** The following is a brief description of the current understanding in the biology of telomerase and its components. The discussion is not meant to be complete and is provided only for understanding of the invention that follows. The summary is not an admission that any of the work described below is prior art to the claimed invention.

**[0005]** The ribonucleoprotein enzyme telomerase consists of an RNA template subunit and one or more protein subunits including telomerase reverse transcriptase (TERT), which function together to direct the synthesis of telomeres. Telomeres exist as non-nucleosome DNA/protein complexes at the physical ends of eukaryotic chromosomes. These capping structures maintain chromosome stability and replicative potential (Zakian, V. A., 1995, Science, 270, 1601-1607). Telomere structure is characterized by tandem repeats of

conserved DNA sequences rich in G-C base pairs. Additional conserved telomere elements include a terminal 3'-overhang in the G-rich strand and non-histone structural proteins that are complexed with telomeric DNA in the nucleus. (Blackburn, "E., 1990, JBC., 265, 5919-5921.). Observed shortening of telomeres coincides with the onset of cellular senescence in most somatic cell lines lacking significant levels of telomerase. This finding has had a profound impact on our views concerning the mechanisms of aging, age related disease, and cancer.

**[0006]** Conventional DNA polymerases are unable to fully replicate the ends of linear chromosomes (Watson, J. D., 1972, Nature, 239, 197-201). This inability stems from the 3' G-rich overhang that is a product of ribonuclease cleavage of the RNA primer used in DNA replication. The overhang prevents DNA polymerase replication since the recessed C-rich parent strand cannot be used as a template. Telomerase overcomes this limitation by extending the 3' end of the chromosome using deoxyribonucleotides as substrates and a sequence within the telomerase RNA subunit as a template. (Lingner, J., 1995, Science, 269, 1533-1534). As such, telomerase is considered a reverse transcriptase that is responsible for telomere maintenance.

**[0007]** Telomerase was first discovered by in *Tetrahymena thermophila* in 1985 (Greider, C. W., 1995, Cell, 43, 405-413). The RNA subunits and their respective genes were later discovered and characterized in protozoa, budding yeast, and mammals. Genetic studies of these genes confirmed the role of telomerase RNA (TR) in determining telomere sequence by mutating genes which encode the telomeric RNA (Yu, G. L., 1990, Nature, 344, 126-132), (Singer, M. S., 1994, Science, 266, 404-409), (Blasco, M. A., 1995, Science, 269, 1267-1270). These studies showed that telomerase activity parallels TR expression in protozoa, yeast and mice. However, the expression of human telomerase RNA (hTR) does not correlate well with telomerase activity in mammalian cells. Many human tissues express hTR but are devoid of telomerase activity (Feng, J., 1995, Science, 269, 1236-1241). Knockout mice, in which the mTR gene has been deleted from germline cells, have been shown to be

viable for at least six generations. Cells from later generations of these mice showed chromosomal abnormalities consistent with telomere degradation, indicating that mTR is necessary for telomere length maintenance, but is not required for embryonic development, oncogenic transformation, or tumor formation in mice (Blasco, M. A., 1997, *Cell*, 91, 25-34).

**[0008]** The first catalytically active subunit of telomerase (p123) was isolated from *Euplotes aediculatus* along with another subunit (p43) and a 66-kD RNA subunit (Linger, J., 1996, *Proc. Natl. Acad. Sci.*, 93, 10712-10717). Subsequent studies revealed telomerase catalytic subunit homologs from fission yeast (Est2p) and human genes (TRT1). The human homolog, TRT1 encoding hTERT, expressed mRNA with a strong correlation to telomerase activity in human cells (Nakamura, T. M., 1997, *Science*, 277, 955-959). Reconstitution of telomerase activity with *in vitro* transcribed and translated hTERT and hTR, either co-synthesized or simply mixed, demonstrated that hTERT and hTR represent the minimal components of telomerase. Furthermore, transient expression of hTERT in normal diploid human cells restored telomerase activity, demonstrating that hTERT is the only component necessary to restore telomerase activity in normal human cells (Weinrich, S. L., 1997, *Nature Genetics*, 17, 498-502). The introduction of telomerase into normal human cells using hTERT expression via transfection has resulted in the extension of life span in these cells. Such findings indicate that telomere loss in the absence of telomerase is the "mitotic clock" that controls the replicative potential of a cell prior to senescence (Bodnar, A. G., 1998, *Science*, 279, 349-352).

**[0009]** Expression of telomerase is observed in germ cell and most cancer cell lines. These "immortal" cell lines continue to divide without shortening of their telomeres (Kim, N. W., 1994, *Science*, 266, 2011-2015). A model of tumor progression has evolved from these findings, suggesting a role for telomerase expression in malignant transformation. Successful malignant transformation in human cells was accomplished for the first time by ectopic expression of hTERT in combination with two oncogenes, SV40 large-T and H-ras. Injection of nude mice with cells expressing these oncogenes and hTERT resulted in rapid

growth of tumors. These observations indicate that hTERT mediated telomere maintenance is essential for the formation of human tumor cells (Hahn, W. C., 1999, *Nature*, 400, 464-468).

**[0010]** Various methods have been developed to assay telomerase activity *in vitro*. The most widely used method to characterize telomerase activity is the telomeric repeat amplification protocol (TRAP). TRAP utilizes RT-PCR of cellular extracts to measure telomerase activity by making the amount of PCR target dependant upon the biochemical activity of the enzyme (Kim, N. W., 1997, *Nucleic Acids Research*, 25, 2595-2597).

**[0011]** A variety of animal models have been designed to assay telomerase activity *in vivo*. Inhibition of telomerase activity has been analyzed in rats via cell proliferation studies with MNU (N-methyl-N-nitrosurea) induced mammary carcinomas in response to treatment with 4-(hydroxyphenyl)retinamide (4-HPR), a known inhibitor of mammary carcinogenesis in animal models and premenopausal women (Bednarek, A., 1999, *Carcinogenesis*, 20, 879-883). Additional studies have focused on the up-regulation of telomerase in transformed cell lines from animal and human model systems (Zhang, P. B., 1998, *Leuk. Res.*, 22, 509-516), (Chadeneau, C., 1995, *Oncogene*, 11, 893-898), (Greenberg, R., 1999, *Oncogene*, 18, 1219-1226).

**[0012]** Human cell culture studies have been established to assay inhibition of telomerase activity in human carcinomas responding to various therapeutics. A human breast cancer model for studying telomerase inhibitors is described (Raymond, E., 1999, *Br. J. Cancer*, 80, 1332-1341). Human studies of telomerase expression as related to various other cancers are described including cervical cancer (Nakano, K., 1998, *Am. J. Pathol*, 153, 857-864), endometrial cancer (Kyo, S., 1999, *Int. J. Cancer*, 80, 60-63), meningeal carcinoma (Kleinschmidt-DeMasters, B. K., 1998, *J. Neurol. Sci.*, 161, 124-134), lung carcinoma (Yashima, K., 1997, *Cancer Research*, 57, 2372-2377), testicular cancer in



response to cisplatin (Burger, A. M., 1997, Eur. J. Cancer, 33, 638-644), and ovarian carcinoma (Counter, C. M., 1994, Proc. Natl. Acad. Sci., 91, 2900-2904).

**[0013]** Particular degenerative and disease states that can be associated with telomerase expression modulation include but are not limited to:

- Cancer: Almost all human tumors have detectable telomerase activity (Shay, J. W., 1997, Eur. J. Cancer, 33, 787-791). Treatment with telomerase inhibitors may provide effective cancer therapy with minimal side effects in normal somatic cells that lack telomerase activity. The therapeutic potential exists for the treatment of a wide variety of cancer types.
- Restinosis: Telomerase inhibition in vascular smooth muscle cells may inhibit restinosis by limiting proliferation of these cells.
- Infectious disease: Telomerase inhibition in infectious cell types that express telomerase activity may provide selective anti-infectious agent activity. Such treatment may prove especially effective in protozoan-based infection such as Giardia and Lesh Meniesis.
- Transplant rejection: Telomerase inhibition in endothelial cell types may demonstrate selective immunosuppressant activity. Activation of telomerase in transplant cells could benefit grafting success through increased proliferative potential.
- Autoimmune disease: Telomerase modulation in various immune cells may prove beneficial in treating diseases such as multiple sclerosis, lupus, and AIDS.
- Age related disease: Activation of telomerase expression in cells at or nearing senescence as a result of advanced age or premature aging could benefit conditions such as macular degeneration, skin ulceration, and rheumatoid arthritis.

**[0014]** The present body of knowledge in telomerase research indicates the need for methods to assay telomerase activity and for compounds that can regulate telomerase expression for research, diagnostic, trait alteration, animal health and therapeutic use.

**[0015]** Gaeta *et al.*, US patents No. 5,760,062; 5,767,278; 5,770,613 have described small molecule inhibitors of human telomerase RNA (hTR) subunit.

**[0016]** Blasco *et al.*, 1995, Science, 269, 1267-1270 describe the synthesis and testing of antisense oligonucleotides targeted against a specific region of the mouse telomerase RNA (mTR) subunit and reported reduction in telomerase activity in mice.

**[0017]** Bisoffi *et al.*, 1998, Eur. J. Cancer, 34, 1242-1249 have studied the down regulation of human telomerase activity by a retrovirus vector expressing antisense RNA targeted against the hTR RNA.

**[0018]** Norton *et al.*, 1996, Nature Biotechnology, 14, 615-619 have reported the use of a peptide nucleic acid (PNA) molecule targeting hTR RNA to down regulate telomerase activity in human immortal breast epithelial cells.

**[0019]** Yokoyama *et al.*, 1998, Cancer Research, 58, 5406-5410 have reported the synthesis and testing of hammerhead ribozyme constructs targeting hTR RNA resulting in a decrease in the telomerase activity in Ishikawa cells.

**[0020]** Henderson, European Patent Application No. 666,313-A2 describes methods of identifying and cloning hTR gene for use in gene therapy approaches for creating aberrant telomeric sequences in transfected human tumor cells. A ribozyme based gene therapy approach to inhibit the expression of hTR gene is described as well. The intended result of such therapies involves incurred genetic instability based on non-native telomeric sequences resulting in rapid cell death of the treated cells.

**[0021]** West *et al.*, US patent No. 5,489,508 describe methods for determining telomere length and telomerase activity in cells. Inhibitors of hTR RNA, including oligonucleotides and/or small molecules are described.

**[0022]** These foregoing approaches of targeting the telomerase RNA subunit (TR) may not be very beneficial, because as demonstrated by Feng *et al.*, (Feng, J., 1995, Science, 269, 1236-1241), telomerase activity in humans does not correlate well to hTR concentration.

**[0023]** Collins *et al.*, International PCT publication No. WO 98/01542 describes assays for the detection of telomerase activity. Four human telomerase subunit proteins are described called p140, p105, p48 and p43. In addition, hybridization probes and primers are described as inhibitors of telomerase gene function. Antibody based inhibitors of telomerase protein subunits are described.

**[0024]** A more attractive approach to telomerase regulation would involve the regulation of human telomerase by modulating the expression of the protein subunits of the enzyme, preferably the reverse transcriptase (hTERT) subunit. Based on reconstitution experiments, hTERT and hTR represent the minimal components of telomerase. Since hTR expression does not correlate well with telomerase activity in human cells and since many human cells express hTR without telomerase activity, targeting hTERT may prove more beneficial than targeting hTR. hTERT is the only component necessary to restore telomerase activity in normal human cells. A study in which the three major subunits of telomerase (hTR, TP1, and hTERT) were assayed in normal and malignant endometrial tissues determined that hTERT is a rate limiting determinant of enzymatic activity of human telomerase (Kyo, S., 1999, Int. J. Cancer, 80, 60-63). Additional protein subunits that have been isolated most likely serve only a structural role in telomerase activity, but may be important in enhancing the activity of the telomerase enzyme. As such, hTERT is one of the better targets for the ectopic regulation of telomerase activity.

**[0025]** Cech *et al.*, International PCT publication No. WO 98/14593 describe compositions and methods related to hTERT for diagnosis, prognosis and treatment of human diseases, for altering proliferative capacity in cells and organisms, and for screening compounds and treatments with potential use as human therapeutics.

**[0026]** Cech *et al.*, International PCT publication No. WO 98/14592 describe nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs of *Euplotes aediculatus*, and related sequences from *Schizosaccharomyces*, *Saccharomyces* sequences, and human telomerase. The polypeptides comprising telomeric subunits and functional polypeptides and ribonucleoproteins that contain these subunits are described as well. Cech *et al.*, International PCT Publication No. WO 98/14592, mentions in general terms the possibility of using antisense and ribozymes to down regulate the expression of human telomerase reverse transcriptase enzyme.

#### Summary Of The Invention

**[0027]** The invention features novel nucleic acid-based techniques [e.g., enzymatic nucleic acid molecules (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, antisense nucleic acids containing RNA cleaving chemical groups (Cook *et al.*, U.S. Patent 5,359,051)] and methods for their use to down regulate or inhibit the expression of telomerase enzyme.

**[0028]** In a preferred embodiment, the invention features use of one or more of the nucleic acid-based techniques to inhibit the expression of the genes encoding the protein subunits of the telomerase enzyme, preferably the catalytic subunit of the telomerase enzyme. Specifically, the invention features the use of nucleic acid-based techniques to specifically inhibit the expression of telomerase reverse transcriptase (TERT) gene.

**[0029]** In another preferred embodiment, the invention features the use of an enzymatic nucleic acid molecule, preferably in the hammerhead, NCH, G-cleaver and/or DNAzyme motif, to inhibit the expression TERT gene.

**[0030]** In another preferred embodiment, the invention features the inhibition or down regulation of telomerase activity by inhibiting or down regulating the expression of one or more activators of telomerase enzyme, such as protein encoded by *ras* gene. Such activator gene expression may be regulated by the use of nucleic acid-based techniques, such as enzymatic nucleic acid molecules and antisense oligonucleotides.

**[0031]** By “inhibit” it is meant that the activity of telomerase enzyme or level of RNAs or equivalent RNAs encoding one or more protein subunits of the telomerase enzyme is reduced below that observed in the absence of the nucleic acid. In one embodiment, inhibition with enzymatic nucleic acid molecule preferably is below that level observed in the presence of an enzymatically inactive or attenuated molecule that is able to bind to the same site on the target RNA, but is unable to cleave that RNA. In another embodiment, inhibition with antisense oligonucleotides is preferably below that level observed in the presence of for example, an oligonucleotide with scrambled sequence or with mismatches. In another embodiment, inhibition of TERT genes with the nucleic acid molecule of the instant invention is greater than in the presence of the nucleic acid molecule than in its absence. According to the invention, the activity of telomerase enzyme or the level of RNA encoding one or more protein subunits of the telomerase enzyme is inhibited if it is at least 10% less, 20% less, 50% less, 75% less or even not active or present at all, in the presence of a nucleic acid of the invention relative to the level in the absence of such a nucleic acid.

**[0032]** As used herein, the term “telomerase activity” refers to enzyme activity that replicates, for example, the TTAGGG repeats at the ends of linear chromosomes. Telomerase activity is comprised by a ribonucleoprotein enzyme comprising one or more protein subunits and an RNA subunit. The enzymatic activity extends the 5'-recessed end of

a linear chromosome using deoxyribonucleotides and an RNA sequence within the RNA subunit as a primer. Telomerase activity may be assayed as follows. Samples to be assayed for telomerase activity are prepared by extraction into CHAPS lysis buffer (10mM Tris pH 7.5, 1mM MgCl<sub>2</sub>, 1mM EGTA, 0.1 mM PMSF, 5mM  $\beta$ -mercaptoethanol, 1mM DTT, 0.5% 3-[(3-cholamidopropyl)-dimethyl-amino]-1- propanesulfonate (CHAPS), 10% glycerol and 40 U/ml RNase inhibitor (Promega, Madison, WI, U.S.A.). Cells are suspended in CHAPS lysis buffer and incubated on ice for 30 minutes, which allows lysis of 90-100% of cells. Lysate is then transferred to polyallomer centrifuge tubes and spun at 100,000 x g for 1 hour at 4 degrees C. The supernatant is the protein extract, and concentration ranges of 4-10  $\mu$ g/ $\mu$ l are suitable for telomerase assay. Extracts may be concentrated if necessary using a Microcon Microfilter 30 (Amicon, Beverly, MA U.S.A.) according to the manufacturer's instructions. Extracts may be stored frozen at -80 degrees C until assayed.

**[0033]** Telomerase may be assayed according to Kim and Wu, *Nucl. Acids Res.* 25: 2595-2597, incorporated herein by reference. Briefly, for the telomerase assay, 2 $\mu$ g of protein extract is used. The extract is assayed in 50 $\mu$ l of reaction mixture containing 0.1  $\mu$ g TS substrate primer (5'-AATCCGTCGAGCAGAGTT-3' (SEQ. ID. NO. 5569) end-labeled using alpha-<sup>32</sup>P-ATP and T4 polynucleotide kinase (SEQ. ID. NO. 5570) 0.1 $\mu$ g ACX return primer (5'-GCGCGG[CTTACC]<sub>3</sub> CTAACC-3'), 0.1  $\mu$ g NT internal control primer (5'-ATCGCTTCTCGGCCTTTT-3') (SEQ. ID. NO. 5571) 0.01 micromol TSNT internal control template (5'-AATCCGTCGAGCAGAGTTAAAAGGCCGAGAACGAT-3') (SEQ. ID. No. 5572) 50  $\mu$ M each deoxynucleoside triphosphate, 2 U of Taq DNA polymerase, and 2  $\mu$ l CHAPS protein extract, all in 1X TRAP buffer (20 mM Tris (pH 8.3), 68 mM KCl, 1.5 mM MgCl<sub>2</sub>, 1 mM EGTA, 0.05% Tween 20). Each reaction is placed in a thermocycler block preheated to 30 C and incubated at 30 C for 10 minutes, then cycled for 27 cycles of 94 degrees C for 30 seconds, 60 degrees C for 30 seconds. Reaction products are separated on a denaturing 8% polyacrylamide gel, followed by drying of the gel and autoradiography. The internal control (to control for possible Taq polymerase inhibition) generates a band of 36 nt.

Comparison of radioactive signal integrated (e.g., by phosphorimager analysis) for telomerase-extended bands with the radioactive signal from a reaction performed with a known amount of quantification standard template (termed R8; 5'-AATCCGTCGAGCAGAGTTAG [GGTTAG]<sub>7</sub>-3') (SEQ. ID. NO. 5573) allows expression of telomerase activity as an absolute value. The absolute value = TPG (total product generated) =  $[(TP - TP_i) / TI] / [(R8 - B) / RI] \times 100$ , where TP = telomerase products from test extract, TP<sub>i</sub> = telomerase products from a heat-inactivated (75°C, 10 minutes) extract reaction, TI = the signal from the internal control, R8 = the signal from the R8 qualification standard template reaction, B = signal from a lysis buffer-only blank reaction, and RI = the internal control value for the reaction containing R8 template and NT and TSNT control primers. TPG values of 0-10,000 are possible, with the linear range being from approximately 1 to 1000 TPG. The range of 1 to 1000 TPG encompasses the minimum and maximum levels of telomerase activity in most tumor samples tested, while non-tumor cells most often have no telomerase activity (TPG approximately zero).

**[0034]** An alternative telomerase assay, which does not employ PCR amplification, is described by Raymond et al. 1999, *Br. J. Cancer* 80: 1332-1341.

**[0035]** By "enzymatic nucleic acid molecule" it is meant an RNA molecule which has complementarity in a substrate binding region to a specified gene target, and also has an enzymatic activity which is active to specifically cleave target RNA. That is, the enzymatic RNA molecule is able to intermolecularly cleave RNA and thereby inactivate a target RNA molecule. This complementary regions allow sufficient hybridization of the enzymatic RNA molecule to the target RNA and thus permit cleavage. One hundred percent complementarity between RNA and the target gene or target RNA is preferred, but complementarity as low as 50-75% may also be useful in this invention. The nucleic acids may be modified at the base, sugar, and/or phosphate groups. The term enzymatic nucleic acid is used interchangeably with phrases such as ribozymes, catalytic RNA, enzymatic RNA, catalytic DNA, aptazyme or aptamer-binding ribozyme, regulatable ribozyme, catalytic

oligonucleotides, nucleozyme, DNzyme, RNA enzyme, endoribonuclease, endonuclease, minizyme, leadzyme, oligozyme or DNA enzyme. All of these terminologies describe nucleic acid molecules with enzymatic activity. The specific enzymatic nucleic acid molecules described in the instant application are not meant to be limiting and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is that it have a specific substrate binding site which is complementary to one or more of the target nucleic acid regions, and that it have nucleotide sequences within or surrounding that substrate binding site which impart a nucleic acid cleaving activity to the molecule (Cech *et al.*, U.S. Patent No. 4,987,071; Cech *et al.*, 1988, JAMA).

**[0036]** By "enzymatic portion" or "catalytic domain" is meant that portion/region of the enzymatic nucleic acid molecule essential for cleavage of a nucleic acid substrate (for example see Figure 1).

**[0037]** By "substrate binding arm" or "substrate binding domain" is meant that portion/region of a ribozyme which is complementary to (*i.e.*, able to base-pair with) a portion of its substrate. Generally, such complementarity is 100%, but can be less if desired. For example, as few as 10 bases out of 14 may be base-paired. Such arms are shown generally in Figure 1. That is, these arms contain sequences within a ribozyme which are intended to bring ribozyme and target RNA together through complementary base-pairing interactions. The ribozyme of the invention may have binding arms that are contiguous or non-contiguous and may be of varying lengths. The length of the binding arm(s) are preferably greater than or equal to four nucleotides and of sufficient length to stably interact with the target RNA; specifically 12-100 nucleotides; more specifically 14-24 nucleotides long. If two binding arms are chosen, the design is such that the length of the binding arms are symmetrical (*i.e.*, each of the binding arms is of the same length; *e.g.*, five and five nucleotides, six and six nucleotides or seven and seven nucleotides long) or asymmetrical (*i.e.*, the binding arms are of different length; *e.g.*, six and three nucleotides; three and six



nucleotides long; four and five nucleotides long; four and six nucleotides long; four and seven nucleotides long; and the like).

**[0038]** By DNAzyme is meant, an enzymatic nucleic acid molecule lacking a 2'-OH group. In particular embodiments the enzymatic nucleic acid molecule may have an attached linker(s) or other attached or associated groups, moieties, or chains containing one or more nucleotides with 2'-OH groups.

**[0039]** By "sufficient length" is meant an oligonucleotide of greater than or equal to 3 nucleotides, 5 nucleotides, 7 nucleotides, 9 nucleotides or even 12 nucleotides.

**[0040]** By "stably interact" is meant, interaction of the oligonucleotides with target nucleic acid (e.g., by forming hydrogen bonds with complementary nucleotides in the target under physiological conditions).

**[0041]** By "equivalent" RNA to telomerase enzyme is meant to include those naturally occurring RNA molecules having homology (partial or complete) to nucleic acid sequences encoding telomerase proteins or encoding for proteins with similar function as telomerase in various organisms, including human, rodent, primate, rabbit, pig, protozoans, fungi, plants, and other microorganisms and parasites. The equivalent RNA sequence also includes in addition to the coding region, regions such as 5'-untranslated region, 3'-untranslated region, introns, intron-exon junction and the like.

**[0042]** By "homology" is meant the nucleotide sequence of two or more nucleic acid molecules is partially or completely identical.

**[0043]** By "antisense nucleic acid" it is meant a non-enzymatic nucleic acid molecule that binds to target RNA by means of RNA-RNA or RNA-DNA or RNA-PNA (protein nucleic acid; Egholm et al., 1993 *Nature* 365, 566) interactions and alters the activity of the target RNA (for a review see Stein and Cheng, 1993 *Science* 261, 1004). Typically, antisense molecules will be complementary to a target sequence along a single contiguous sequence

of the antisense molecule. However, in certain embodiments, an antisense molecule may bind to substrate such that the substrate molecule forms a loop, and/or an antisense molecule may bind such that the antisense molecule forms a loop. Thus, the antisense molecule may be complementary to two (or even more) non-contiguous substrate sequences or two (or even more) non-contiguous sequence portions of an antisense molecule may be complementary to a target sequence or both.

**[0044]** By "2-5A antisense chimera" it is meant, an antisense oligonucleotide containing a 5' phosphorylated 2'-5'-linked adenylyate residues. These chimeras bind to target RNA in a sequence-specific manner and activate a cellular 2-5A-dependent ribonuclease which, in turn, cleaves the target RNA (Torrence *et al.*, 1993 *Proc. Natl. Acad. Sci. USA* 90, 1300).

**[0045]** By "triplex DNA" it is meant an oligonucleotide that can bind to a double-stranded DNA in a sequence-specific manner to form a triple-strand helix. Formation of such triple helix structure has been shown to inhibit transcription of the targeted gene (Duval-Valentin *et al.*, 1992 *Proc. Natl. Acad. Sci. USA* 89, 504).

**[0046]** By "gene" it is meant a nucleic acid that encodes an RNA.

**[0047]** By "complementarity" is meant that a nucleic acid can form hydrogen bond(s) with another RNA sequence by either traditional Watson-Crick or other non-traditional types. In reference to the nucleic molecules of the present invention, the binding free energy for a nucleic acid molecule with its target or complementary sequence is sufficient to allow the relevant function of the nucleic acid to proceed, e.g., ribozyme cleavage, antisense or triple helix inhibition. Determination of binding free energies for nucleic acid molecules is well known in the art (see, e.g., Turner *et al.*, 1987, CSH Symp. Quant. Biol. LII pp.123-133; Frier *et al.*, 1986, *Proc. Nat. Acad. Sci. USA* 83:9373-9377; Turner *et al.*, 1987, *J. Am. Chem. Soc.* 109:3783-3785. A percent complementarity indicates the percentage of contiguous residues in a nucleic acid molecule which can form hydrogen bonds (e.g., Watson-Crick base pairing) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out

of 10 being 50%, 60%, 70%, 80%, 90%, and 100% complementary). “Perfectly complementary” means that all the contiguous residues of a nucleic acid sequence will hydrogen bond with the same number of contiguous residues in a second nucleic acid sequence.

**[0048]** At least seven basic varieties of naturally-occurring enzymatic RNAs are known presently. Each can catalyze the hydrolysis of RNA phosphodiester bonds in *trans* (and thus can cleave other RNA molecules) under physiological conditions. Table I summarizes some of the characteristics of these ribozymes. In general, enzymatic nucleic acids act by first binding to a target RNA. Such binding occurs through the target binding portion of a enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA. Thus, the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base-pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor of gene expression, with the specificity of inhibition depending not only on the base-pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can completely eliminate catalytic activity of a ribozyme.

**[0049]** The enzymatic nucleic acid molecule that cleave the specified sites in telomerase-specific RNAs represent a novel therapeutic approach to treat a variety of pathologic indications, including, cancer, tumorigenesis, restenosis and others.

**[0050]** In one of the preferred embodiments of the inventions described herein, the enzymatic nucleic acid molecule is formed in a hammerhead or hairpin motif, but may also

be formed in the motif of a hepatitis delta virus, group I intron, group II intron or RNase P RNA (in association with an RNA guide sequence), *Neurospora* VS RNA, DNAzymes, NCH cleaving motifs, or G-cleavers. Examples of such hammerhead motifs are described by Dreyfus, *supra*, Rossi et al., 1992, *AIDS Research and Human Retroviruses* 8, 183; of hairpin motifs by Hampel et al., EP0360257, Hampel and Tritz, 1989 *Biochemistry* 28, 4929, Feldstein et al., 1989, *Gene* 82, 53, Haseloff and Gerlach, 1989, *Gene*, 82, 43, and Hampel et al., 1990 *Nucleic Acids Res.* 18, 299; Chowrira & McSwiggen, US. Patent No. 5,631,359; of the hepatitis delta virus motif is described by Perrotta and Been, 1992 *Biochemistry* 31, 16; of the RNase P motif by Guerrier-Takada et al., 1983 *Cell* 35, 849; Forster and Altman, 1990, *Science* 249, 783; Li and Altman, 1996, *Nucleic Acids Res.* 24, 835; *Neurospora* VS RNA ribozyme motif is described by Collins (Saville and Collins, 1990 *Cell* 61, 685-696; Saville and Collins, 1991 *Proc. Natl. Acad. Sci. USA* 88, 8826-8830; Collins and Olive, 1993 *Biochemistry* 32, 2795-2799; Guo and Collins, 1995, *EMBO. J.* 14, 363); Group II introns are described by Griffin et al., 1995, *Chem. Biol.* 2, 761; Michels and Pyle, 1995, *Biochemistry* 34, 2965; Pyle et al., International PCT Publication No. WO 96/22689; of the Group I intron by Cech et al., U.S. Patent 4,987,071 and of DNAzymes by Usman et al., International PCT Publication No. WO 95/11304; Chartrand et al., 1995, *NAR* 23, 4092; Breaker et al., 1995, *Chem. Bio.* 2, 655; Santoro et al., 1997, *PNAS* 94, 4262. NCH cleaving motifs are described in Ludwig & Sproat, International PCT Publication No. WO 98/58058; and G-cleavers are described in Kore et al., 1998, *Nucleic Acids Research* 26, 4116-4120 and Eckstein et al., International PCT Publication No. WO 99/16871. Additional motifs such as the Aptazyme (Breaker et al., WO 98/43993), Amberzyme (Class I motif; Figure 3; Beigelman et al., U.S. Serial No. 09/301,511) and Zinzyme (Beigelman et al., U.S. Serial No. 09/301,511) can also be used in the present invention. These specific motifs are not limiting in the invention and those skilled in the art will recognize that all that is important in an enzymatic nucleic acid molecule of this invention is that it has a specific substrate binding site which is complementary to one or more of the target gene RNA regions, and

that it have nucleotide sequences within or surrounding that substrate binding site which impart an RNA cleaving activity to the molecule (Cech *et al.*, U.S. Patent No. 4,987,071).

**[0051]** In preferred embodiments of the present invention, a nucleic acid molecule, e.g., an antisense molecule, a triplex DNA, or a ribozyme, is 13 to 100 nucleotides in length, e.g., in specific embodiments 35, 36, 37, or 38 nucleotides in length (e.g., for particular ribozymes or antisense). In particular embodiments, the nucleic acid molecule is 15-100, 17-100, 20-100, 21-100, 23-100, 25-100, 27-100, 30-100, 32-100, 35-100, 40-100, 50-100, 60-100, 70-100, or 80-100 nucleotides in length. Instead of 100 nucleotides being the upper limit on the length ranges specified above, the upper limit of the length range can be, for example, 30, 40, 50, 60, 70, or 80 nucleotides. Thus, for any of the length ranges, the length range for particular embodiments has lower limit as specified, with an upper limit as specified which is greater than the lower limit. For example, in a particular embodiment, the length range can be 35-50 nucleotides in length. All such ranges are expressly included. Also in particular embodiments, a nucleic acid molecule can have a length which is any of the lengths specified above, for example, 21 nucleotides in length.

**[0052]** In a preferred embodiment the invention provides a method for producing a class of nucleic acid –based gene inhibiting agents which exhibit a high degree of specificity for the RNA of a desired target. For example, the enzymatic nucleic acid molecule is preferably targeted to a highly conserved sequence region of target RNAs encoding telomerase proteins (specifically TERT gene) such that specific treatment of a disease or condition can be provided with either one or several nucleic acid molecules of the invention. Such nucleic acid molecules can be delivered exogenously to specific tissue or cellular targets as required. Alternatively, the nucleic acid molecules (e.g., ribozymes and antisense) can be expressed from DNA and/or RNA vectors that are delivered to specific cells.

**[0053]** By “highly conserved sequence region” is meant a nucleotide sequence of one or more regions in a target gene does not vary significantly from one generation to the other or from one biological system to the other.

**[0054]** The nucleic acid-based inhibitors of telomerase expression are useful for the prevention of the diseases and conditions including cancer, macular degeneration, restenosis, certain infectious diseases, transplant rejection and autoimmune disease such as multiple sclerosis, lupus, and AIDS; Age related disease such as macular degeneration, skin ulceration, and rheumatoid arthritis and any other diseases or conditions that are related to the levels of telomerase in a cell or tissue.

**[0055]** By “related” is meant that the reduction of telomerase expression (specifically TERT gene) RNA levels and thus reduction in the level of the respective protein will relieve, to some extent, the symptoms of the disease or condition.

**[0056]** The nucleic acid-based inhibitors of the invention are added directly, or can be complexed with cationic lipids, packaged within liposomes, or otherwise delivered to target cells or tissues. The nucleic acid or nucleic acid complexes can be locally administered to relevant tissues ex vivo, or in vivo through injection, infusion pump or stent, with or without their incorporation in biopolymers. In preferred embodiments, the enzymatic nucleic acid inhibitors comprise sequences which are complementary to the substrate sequences in **Tables III-VII**. Examples of such enzymatic nucleic acid molecules also are shown in **Tables III to VII**. Examples of such enzymatic nucleic acid molecules consist essentially of sequences defined in these Tables.

**[0057]** In yet another embodiment, the invention features antisense nucleic acid molecules and 2-5A chimera including sequences complementary to the substrate sequences shown in **tables III to VII**. Such nucleic acid molecules can include sequences as shown for the binding arms of the enzymatic nucleic acid molecules in **Tables III to VII**. Similarly, triplex molecules can be provided targeted to the corresponding DNA target

regions, and containing the DNA equivalent of a target sequence or a sequence complementary to the specified target (substrate) sequence. Typically, antisense molecules will be complementary to a target sequence along a single contiguous sequence of the antisense molecule. However, in certain embodiments, an antisense molecule may bind to substrate such that the substrate molecule forms a loop, and/or an antisense molecule may bind such that the antisense molecule forms a loop. Thus, the antisense molecule may be complementary to two (or even more) non-contiguous substrate sequences or two (or even more) non-contiguous sequence portions of an antisense molecule may be complementary to a target sequence or both.

**[0058]** By “consists essentially of” is meant that the active ribozyme contains an enzymatic center or core equivalent to those in the examples, and binding arms able to bind mRNA such that cleavage at the target site occurs. Other sequences may be present which do not interfere with such cleavage. Thus, a core region may, for example, include one or more loop, stem-loop structure, which does not prevent enzymatic activity. The underlined regions in the sequences in **Tables III** and **IV** can be such a loop, and can be represented generally as sequence “X”. For example, a core sequence for a hammerhead ribozyme can be a 5'-CUGAUGAG-3' and 5'-CGAA-3' connected by “X”, where X is 5'-GCCGUUAGGC-3' (SEQ ID NO 5574), or any other Stem II region known in the art.”

**[0059]** In another aspect of the invention, ribozymes or antisense molecules that cleave target RNA molecules and inhibit telomerase enzyme (specifically TERT) activity are expressed from transcription units inserted into DNA or RNA vectors. The recombinant vectors are preferably DNA plasmids or viral vectors. Ribozyme or antisense expressing viral vectors could be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. Preferably, the recombinant vectors capable of expressing the ribozymes or antisense are delivered as described above, and persist in target cells. Alternatively, viral vectors may be used that provide for transient expression of ribozymes or antisense. Such vectors might be repeatedly administered as necessary.

Once expressed, the ribozymes or antisense bind to the target RNA and inhibit its function or expression. Delivery of ribozyme or antisense expressing vectors could be systemic, such as by intravenous or intramuscular administration, by administration to target cells explanted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction into the desired target cell.

**[0060]** By "vectors" is meant any nucleic acid- and/or viral-based technique used to deliver a desired nucleic acid.

**[0061]** By "patient" is meant an organism which is a donor or recipient of explanted cells or the cells themselves. "Patient" also refers to an organism to which the nucleic acid molecules of the invention can be administered. Preferably, a patient is a mammal or mammalian cells. More preferably, a patient is a human or human cells.

**[0062]** The nucleic acid molecules of the instant invention, individually, or in combination or in conjunction with other drugs, can be used to treat diseases or conditions discussed above. For example, to treat a disease or condition associated with the levels of telomerase enzyme, the patient may be treated, or other appropriate cells may be treated, as is evident to those skilled in the art, individually or in combination with one or more drugs under conditions suitable for the treatment.

**[0063]** In a further embodiment, the described molecules, such as antisense or ribozymes can be used in combination with other known treatments to treat conditions or diseases discussed above. For example, the described molecules could be used in combination with one or more known therapeutic agents to treat cancer.

**[0064]** In another preferred embodiment, the invention features nucleic acid-based inhibitors (e.g., enzymatic nucleic acid molecules (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, antisense nucleic acids containing RNA cleaving chemical



groups) and methods for their use to down regulate or inhibit the expression of genes (e.g., TERT) capable of progression and/or maintenance of cancer.

**[0065]** In another preferred embodiment, the invention features nucleic acid-based techniques (e.g., enzymatic nucleic acid molecules (ribozymes), antisense nucleic acids, 2-5A antisense chimeras, triplex DNA, antisense nucleic acids containing RNA cleaving chemical groups) and methods for their use to down regulate or inhibit the expression of TERT gene expression.

**[0066]** By "comprising" is meant including, but not limited to, whatever follows the word "comprising". Thus, use of the term "comprising" indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present. By "consisting of" is meant including, and limited to, whatever follows the phrase "consisting of". Thus, the phrase "consisting of" indicates that the listed elements are required or mandatory, and that no other elements may be present. By "consisting essentially of" is meant including any elements listed after the phrase, and limited to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase "consisting essentially of" indicates that the listed elements are required or mandatory, but that other elements are optional and may or may not be present depending upon whether or not they affect the activity or action of the listed elements.

**[0067]** Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

#### Brief Description of the Drawings

**[0068]** Figure 1 shows the secondary structure model for seven different classes of enzymatic nucleic acid molecules. Arrow indicates the site of cleavage. — indicate the target sequence. Lines interspersed with dots are meant to indicate tertiary interactions. - is

meant to indicate base-paired interaction. **Group I Intron:** P1-P9.0 represent various stem-loop structures (Cech *et al.*, 1994, *Nature Struct. Bio.*, 1, 273). **RNase P (M1RNA):** EGS represents external guide sequence (Forster *et al.*, 1990, *Science*, 249, 783; Pace *et al.*, 1990, *J. Biol. Chem.*, 265, 3587). **Group II Intron:** 5'SS means 5' splice site; 3'SS means 3'-splice site; IBS means intron binding site; EBS means exon binding site (Pyle *et al.*, 1994, *Biochemistry*, 33, 2716). **VS RNA:** I-VI are meant to indicate six stem-loop structures; shaded regions are meant to indicate tertiary interaction (Collins, International PCT Publication No. WO 96/19577). **HDV Ribozyme:** : I-V are meant to indicate four stem-loop structures (Been *et al.*, US Patent No. 5,625,047). **Hammerhead Ribozyme:** : I-III are meant to indicate three stem-loop structures; stems I-III can be of any length and may be symmetrical or asymmetrical (Usman *et al.*, 1996, *Curr. Op. Struct. Bio.*, 1, 527). **Hairpin Ribozyme:** Helix 1, 4 and 5 can be of any length; Helix 2 is between 3 and 8 base-pairs long; Y is a pyrimidine; Helix 2 (H2) is provided with a least 4 base pairs (*i.e.*, n is 1, 2, 3 or 4) and helix 5 can be optionally provided of length 2 or more bases (preferably 3 - 20 bases, *i.e.*, m is from 1 - 20 or more). Helix 2 and helix 5 may be covalently linked by one or more bases (*i.e.*, r is  $\geq 1$  base). Helix 1, 4 or 5 may also be extended by 2 or more base pairs (*e.g.*, 4 - 20 base pairs) to stabilize the ribozyme structure, and preferably is a protein binding site. In each instance, each N and N' independently is any normal or modified base and each dash represents a potential base-pairing interaction. These nucleotides may be modified at the sugar, base or phosphate. Complete base-pairing is not required in the helices, but is preferred. Helix 1 and 4 can be of any size (*i.e.*, o and p is each independently from 0 to any number, *e.g.*, 20) as long as some base-pairing is maintained. Essential bases are shown as specific bases in the structure, but those in the art will recognize that one or more may be modified chemically (abasic, base, sugar and/or phosphate modifications) or replaced with another base without significant effect. Helix 4 can be formed from two separate molecules, *i.e.*, without a connecting loop. The connecting loop when present may be a ribonucleotide with or without modifications to its base, sugar or phosphate. "q"  $\geq$  is 2 bases. The connecting loop can also be replaced

with a non-nucleotide linker molecule. H refers to bases A, U, or C. Y refers to pyrimidine bases. "\_\_\_\_\_" refers to a covalent bond. (Burke *et al.*, 1996, *Nucleic Acids & Mol. Biol.*, 10, 129; Chowrira *et al.*, US Patent No. 5,631,359).

**[0069]** Figure 2 shows examples of chemically stabilized ribozyme motifs. **HH Rz**, represents hammerhead ribozyme motif (Usman *et al.*, 1996, *Curr. Op. Struct. Bio.*, 1, 527); **NCH Rz** represents the NCH ribozyme motif (Ludwig & Sproat, International PCT Publication No. WO 98/58058); **G-Cleaver**, represents G-cleaver ribozyme motif (Kore *et al.*, 1998, *Nucleic Acids Research* 26, 4116-4120). **N** or **n**, represent independently a nucleotide which may be same or different and have complementarity to each other; **rl**, represents ribo-Inosine nucleotide; arrow indicates the site of cleavage within the target. Position 4 of the HH Rz and the NCH Rz is shown as having 2'-C-allyl modification, but those skilled in the art will recognize that this position can be modified with other modifications well known in the art, so long as such modifications do not significantly inhibit the activity of the ribozyme.

**[0070]** Figure 3 shows an example of the Amberzyme ribozyme motif that is chemically stabilized (see for example Beigelman *et al.*, WO 99/55857; also referred to as Class I Motif).

**[0071]** Figure 4 shows an example of the Zinzyme A ribozyme motif that is chemically stabilized (see for example Beigelman *et al.*, WO 99/55857; also referred to as Class A Motif).

### Detailed Description of the Invention

#### Mechanism of action of Nucleic Acid Molecules of the Invention

**[0072]** Antisense: Antisense molecules may be modified or unmodified RNA, DNA, or mixed polymer oligonucleotides and primarily function by specifically binding to matching

sequences resulting in inhibition of peptide synthesis (Wu-Pong, Nov 1994, *BioPharm*, 20-33). The antisense oligonucleotide binds to target RNA by Watson Crick base-pairing and blocks gene expression by preventing ribosomal translation of the bound sequences either by steric blocking or by activating RNase H enzyme. Antisense molecules may also alter protein synthesis by interfering with RNA processing or transport from the nucleus into the cytoplasm (Mukhopadhyay & Roth, 1996, *Crit. Rev. in Oncogenesis* 7, 151-190).

**[0073]** In addition, binding of single stranded DNA to RNA may result in nuclease degradation of the heteroduplex (Wu-Pong, *supra*; Crooke, *supra*). To date, the only backbone modified DNA chemistry which will act as substrates for RNase H are phosphorothioates and phosphorodithioates. Recently it has been reported that 2'-arabino and 2'-fluoro arabino- containing oligos can also activate RNase H activity.

**[0074]** A number of antisense molecules have been described that utilize novel configurations of chemically modified nucleotides, secondary structure, and/or RNase H substrate domains (Woolf et al., International PCT Publication No. WO 98/13526; Thompson et al., USSN 60/082,404 which was filed on April 20, 1998; Hartmann et al., USSN 60/101,174 which was filed on September 21, 1998) all of these are incorporated by reference herein in their entirety.

**[0075]** Triplex Forming Oligonucleotides (TFO): Single stranded DNA may be designed to bind to genomic DNA in a sequence specific manner. TFOs are comprised of pyrimidine-rich oligonucleotides which bind DNA helices through Hoogsteen Base-pairing (Wu-Pong, *supra*). The resulting triple helix composed of the DNA sense, DNA antisense, and TFO disrupts RNA synthesis by RNA polymerase. The TFO mechanism may result in gene expression or cell death since binding may be irreversible (Mukhopadhyay & Roth, *supra*)

**[0076]** 2-5A Antisense Chimera: The 2-5A system is an interferon mediated mechanism for RNA degradation found in higher vertebrates (Mitra et al., 1996, *Proc Nat Acad Sci USA* 93, 6780-6785). Two types of enzymes, 2-5A synthetase and RNase L, are required for

RNA cleavage. The 2-5A synthetases require double stranded RNA to form 2'-5' oligoadenylates (2-5A). 2-5A then acts as an allosteric effector for utilizing RNase L which has the ability to cleave single stranded RNA. The ability to form 2-5A structures with double stranded RNA makes this system particularly useful for inhibition of viral replication.

**[0077]** (2'-5') oligoadenylate structures may be covalently linked to antisense molecules to form chimeric oligonucleotides capable of RNA cleavage (Torrence, *supra*). These molecules putatively bind and activate a 2-5A dependent RNase, the oligonucleotide/enzyme complex then binds to a target RNA molecule which can then be cleaved by the RNase enzyme.

**[0078]** Enzymatic Nucleic Acid: Seven basic varieties of naturally-occurring enzymatic RNAs are presently known. In addition, several *in vitro* selection (evolution) strategies (Orgel, 1979, *Proc. R. Soc. London, B* 205, 435) have been used to evolve new nucleic acid catalysts capable of catalyzing cleavage and ligation of phosphodiester linkages (Joyce, 1989, *Gene*, 82, 83-87; Beaudry *et al.*, 1992, *Science* 257, 635-641; Joyce, 1992, *Scientific American* 267, 90-97; Breaker *et al.*, 1994, *TIBTECH* 12, 268; Bartel *et al.*, 1993, *Science* 261:1411-1418; Szostak, 1993, *TIBS* 17, 89-93; Kumar *et al.*, 1995, *FASEB J.*, 9, 1183; Breaker, 1996, *Curr. Op. Biotech.*, 7, 442; Santoro *et al.*, 1997, *Proc. Natl. Acad. Sci.*, 94, 4262; Tang *et al.*, 1997, *RNA* 3, 914; Nakamaye & Eckstein, 1994, *supra*; Long & Uhlenbeck, 1994, *supra*; Ishizaka *et al.*, 1995, *supra*; Vaish *et al.*, 1997, *Biochemistry* 36, 6495; all of these are incorporated by reference herein). Each can catalyze a series of reactions including the hydrolysis of phosphodiester bonds in *trans* (and thus can cleave other RNA molecules) under physiological conditions.

**[0079]** Nucleic acid molecules of this invention will block to some extent telomerase protein expression (specifically TERT) and can be used to treat disease or diagnose disease associated with the levels of telomerase enzyme.

**[0080]** The enzymatic nature of a ribozyme has significant advantages, such as the concentration of ribozyme necessary to affect a therapeutic treatment is lower. This advantage reflects the ability of the ribozyme to act enzymatically. Thus, a single ribozyme molecule is able to cleave many molecules of target RNA. In addition, the ribozyme is a highly specific inhibitor, with the specificity of inhibition depending not only on the base-pairing mechanism of binding to the target RNA, but also on the mechanism of target RNA cleavage. Single mismatches, or base-substitutions, near the site of cleavage can be chosen to completely eliminate catalytic activity of a ribozyme.

**[0081]** Nucleic acid molecules having an endonuclease enzymatic activity are able to repeatedly cleave other separate RNA molecules in a nucleotide base sequence-specific manner. Such enzymatic nucleic acid molecules can be targeted to virtually any RNA transcript, and achieved efficient cleavage *in vitro* (Zaug *et al.*, 324, *Nature* 429 1986 ; Uhlenbeck, 1987 *Nature* 328, 596; Kim *et al.*, 84 *Proc. Natl. Acad. Sci. USA* 8788, 1987; Dreyfus, 1988, *Einstein Quart. J. Bio. Med.*, 6, 92; Haseloff and Gerlach, 334 *Nature* 585, 1988; Cech, 260 *JAMA* 3030, 1988; and Jefferies *et al.*, 17 *Nucleic Acids Research* 1371, 1989; Santoro *et al.*, 1997 *supra*).

**[0082]** Because of their sequence specificity, *trans*-cleaving ribozymes show promise as therapeutic agents for human disease (Usman & McSwiggen, 1995 *Ann. Rep. Med. Chem.* **30**, 285-294; Christoffersen and Marr, 1995 *J. Med. Chem.* **38**, 2023-2037). Ribozymes can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the RNA non-functional and abrogates protein expression from that RNA. In this manner, synthesis of a protein associated with a disease state can be selectively inhibited.

#### Target sites

**[0083]** Targets for useful ribozymes and antisense nucleic acids can be determined as disclosed in Draper *et al.*, WO 93/23569; Sullivan *et al.*, WO 93/23057; Thompson *et al.*,

WO 94/02595; Draper *et al.*, WO 95/04818; McSwiggen *et al.*, US Patent No. 5,525,468, and hereby incorporated by reference herein in totality. Other examples include the following PCT applications which concern inactivation of expression of disease-related genes: WO 95/23225, WO 95/13380, WO 94/02595, incorporated by reference herein. Rather than repeat the guidance provided in those documents here, below are provided specific examples of such methods, not limiting to those in the art. Ribozymes and antisense to such targets are designed as described in those applications and synthesized to be tested *in vitro* and *in vivo*, as also described. The sequence of human TERT RNAs were screened for optimal enzymatic nucleic acid and antisense target sites using a computer folding algorithm. Antisense, hammerhead, DNAzyme, NCH, or G-Cleaver ribozyme binding/cleavage sites were identified. These sites are shown in **Tables III to VII** (all sequences are 5' to 3' in the tables; the underlined region can be any base-paired sequence, the actual sequence is not relevant here). The nucleotide base position is noted in the Tables as that site to be cleaved by the designated type of enzymatic nucleic acid molecule. While human sequences can be screened and enzymatic nucleic acid molecule and/or antisense thereafter designed, as discussed in Stinchcomb *et al.*, WO 95/23225, mouse targeted ribozymes may be useful to test efficacy of action of the enzymatic nucleic acid molecule and/or antisense prior to testing in humans.

**[0084]** Antisense, hammerhead, DNAzyme, NCH, or G-Cleaver ribozyme binding/cleavage sites were identified. The nucleic acid molecules were individually analyzed by computer folding (Jaeger *et al.*, 1989 *Proc. Natl. Acad. Sci. USA*, 86, 7706) to assess whether the sequences fold into the appropriate secondary structure. Those nucleic acid molecules with unfavorable intramolecular interactions such as between the binding arms and the catalytic core were eliminated from consideration. Varying binding arm lengths can be chosen to optimize activity.

**[0085]** Antisense, hammerhead, DNAzyme, NCH, or G-Cleaver ribozyme binding/cleavage sites were identified and were designed to anneal to various sites in the RNA target. The

binding arms are complementary to the target site sequences described above. The nucleic acid molecules were chemically synthesized. The method of synthesis used follows the procedure for normal DNA/RNA synthesis as described below and in Usman *et al.*, 1987 *J. Am. Chem. Soc.*, 109, 7845; Scaringe *et al.*, 1990 *Nucleic Acids Res.*, 18, 5433; and Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677-2684; Caruthers *et al.*, 1992, *Methods in Enzymology* 211,3-19.

### Synthesis of Nucleic acid Molecules

**[0086]** Synthesis of nucleic acids greater than 100 nucleotides in length is difficult using automated methods, and the therapeutic cost of such molecules is prohibitive. In this invention, small nucleic acid motifs ("small" refers to nucleic acid motifs no more than 100 nucleotides in length, preferably no more than 80 nucleotides in length, and most preferably no more than 50 nucleotides in length; e.g., antisense oligonucleotides, hammerhead or the hairpin ribozymes) are preferably used for exogenous delivery. The simple structure of these molecules increases the ability of the nucleic acid to invade targeted regions of RNA structure. Exemplary molecules of the instant invention were chemically synthesized, and others can similarly be synthesized. Oligodeoxyribonucleotides were synthesized using standard protocols as described in Caruthers *et al.*, 1992, *Methods in Enzymology* 211,3-19, and is incorporated herein by reference.

**[0087]** The method of synthesis used for normal RNA including certain enzymatic nucleic acid molecules follows the procedure as described in Usman *et al.*, 1987 *J. Am. Chem. Soc.*, 109, 7845; Scaringe *et al.*, 1990 *Nucleic Acids Res.*, 18, 5433; and Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677-2684 Wincott *et al.*, 1997, *Methods Mol. Bio.*, 74, 59, and makes use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. In a non-limiting example, small scale syntheses were conducted on a 394 Applied Biosystems, Inc. synthesizer using a 0.2  $\mu$ mol scale protocol with a 7.75 min coupling step for alkylsilyl protected nucleotides



and a 2.5 min coupling step for 2'-O-methylated nucleotides. Table II outlines the amounts and the contact times of the reagents used in the synthesis cycle. Alternatively, syntheses at the 0.2  $\mu\text{mol}$  scale can be done on a 96-well plate synthesizer, such as the instrument produced by Protogene (Palo Alto, CA) with minimal modification to the cycle. A 15-fold excess (31  $\mu\text{L}$  of 0.1 M = 3.1  $\mu\text{mol}$ ) of phosphoramidite and a 38.7-fold excess of S-ethyl tetrazole (31  $\mu\text{L}$  of 0.25 M = 7.75  $\mu\text{mol}$ ) relative to polymer-bound 5'-hydroxyl was used in each coupling cycle. Average coupling yields on the 394 Applied Biosystems, Inc. synthesizer, determined by colorimetric quantitation of the trityl fractions, were 97.5-99%. Other oligonucleotide synthesis reagents for the 394 Applied Biosystems, Inc. synthesizer; detritylation solution was 3% TCA in methylene chloride (ABI); capping was performed with 16% *N*-methyl imidazole in THF (ABI) and 10% acetic anhydride/10% 2,6-lutidine in THF (ABI); oxidation solution was 16.9 mM  $\text{I}_2$ , 49 mM pyridine, 9% water in THF (PERSEPTIVE™). Burdick & Jackson Synthesis Grade acetonitrile was used directly from the reagent bottle. S-Ethyltetrazole solution (0.25 M in acetonitrile) was made up from the solid obtained from American International Chemical, Inc.

**[0088]** Deprotection of the RNA was performed using either a two-pot or one-pot protocol. For the two-pot protocol, the polymer-bound trityl-on oligoribonucleotide was transferred to a 4 mL glass screw top vial and suspended in a solution of 40% aq. methylamine (1 mL) at 65 °C for 10 min. After cooling to -20 °C, the supernatant was removed from the polymer support. The support was washed three times with 1.0 mL of EtOH:MeCN:H<sub>2</sub>O/3:1:1, vortexed and the supernatant was then added to the first supernatant. The combined supernatants, containing the oligoribonucleotide, were dried to a white powder. The base deprotected oligoribonucleotide was resuspended in anhydrous TEA/HF/NMP solution (300  $\mu\text{L}$  of a solution of 1.5 mL *N*-methylpyrrolidinone, 750  $\mu\text{L}$  TEA and 1 mL TEA•3HF to provide a 1.4 M HF concentration) and heated to 65 °C. After 1.5 h, the oligomer was quenched with 1.5 M  $\text{NH}_4\text{HCO}_3$ .

**[0089]** Alternatively, for the one-pot protocol, the polymer-bound trityl-on oligoribonucleotide was transferred to a 4 mL glass screw top vial and suspended in a solution of 33% ethanolic methylamine/DMSO:1/1 (0.8 mL) at 65 °C for 15 min. The vial was brought to r.t. TEA•3HF (0.1 mL) was added and the vial was heated at 65 °C for 15 min. The sample was cooled at -20 °C and then quenched with 1.5 M NH<sub>4</sub>HCO<sub>3</sub>.

**[0090]** For purification of the trityl-on oligomers, the quenched NH<sub>4</sub>HCO<sub>3</sub> solution was loaded onto a C-18 containing cartridge that had been prewashed with acetonitrile followed by 50 mM TEAA. After washing the loaded cartridge with water, the RNA was detritylated with 0.5% TFA for 13 min. The cartridge was then washed again with water, salt exchanged with 1 M NaCl and washed with water again. The oligonucleotide was then eluted with 30% acetonitrile.

**[0091]** Inactive hammerhead ribozymes or binding attenuated control (BAC) oligonucleotides) were synthesized by substituting a U for G<sub>5</sub> and a U for A<sub>14</sub> (numbering from Hertel, K. J., et al., 1992, Nucleic Acids Res., 20, 3252). Similarly, one or more nucleotide substitutions can be introduced in other enzymatic nucleic acid molecules to inactivate the molecule and such molecules can serve as a negative control.

**[0092]** The average stepwise coupling yields were >98% (Wincott et al., 1995 *Nucleic Acids Res.* 23, 2677-2684). Those of ordinary skill in the art will recognize that the scale of synthesis can be adapted to be larger or smaller than the example described above including but not limited to 96 well format, all that is important is the ratio of chemicals used in the reaction.

**[0093]** Alternatively, the nucleic acid molecules of the present invention can be synthesized separately and joined together post-synthetically, for example by ligation (Moore et al., 1992, *Science* 256, 9923; Draper et al., International PCT publication No. WO

93/23569; Shabarova *et al.*, 1991, *Nucleic Acids Research* 19, 4247; Bellon *et al.*, 1997, *Nucleosides & Nucleotides*, 16, 951; Bellon *et al.*, 1997 *Bioconjugate Chem.* 8, 204).

**[0094]** The nucleic acid molecules of the present invention are modified extensively to enhance stability by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-H (for a review see Usman and Cedergren, 1992 *TIBS* 17, 34; Usman *et al.*, 1994 *Nucleic Acids Symp. Ser.* 31, 163). Ribozymes are purified by gel electrophoresis using general methods or are purified by high pressure liquid chromatography (HPLC; See Wincott *et al.*, *Supra*, the totality of which is hereby incorporated herein by reference) and are re-suspended in water.

**[0095]** The sequences of the ribozymes that are chemically synthesized, useful in this study, are shown in **Tables III to VII**. Those in the art will recognize that these sequences are representative only of many more such sequences where the enzymatic portion of the ribozyme (all but the binding arms) is altered to affect activity. The ribozyme sequences listed in **Tables III to V and VII** may be formed of ribonucleotides or other nucleotides or non-nucleotides. Such ribozymes with enzymatic activity are equivalent to the ribozymes described specifically in the Tables.

#### Optimizing Activity of the nucleic acid molecule of the invention.

**[0096]** Chemically synthesizing synthesizing nucleic acid molecules with modifications (base, sugar and/or phosphate) that prevent their degradation by serum ribonucleases may increase their potency (see e.g., Eckstein *et al.*, International Publication No. WO 92/07065; Perrault *et al.*, 1990 *Nature* 344, 565; Pieken *et al.*, 1991 *Science* 253, 314; Usman and Cedergren, 1992 *Trends in Biochem. Sci.* 17, 334; Usman *et al.*, International Publication No. WO 93/15187; and Rossi *et al.*, International Publication No. WO 91/03162; Sproat, US Patent No. 5,334,711; and Burgin *et al.*, *supra*; all of these describe various chemical modifications that can be made to the base, phosphate and/or sugar moieties of the nucleic acid molecules herein). Modifications which enhance their efficacy in cells, and removal of

bases from nucleic acid molecules to shorten oligonucleotide synthesis times and reduce chemical requirements are desired. (All these publications are hereby incorporated by reference herein).

**[0097]** There are several examples in the art describing sugar, base and phosphate modifications that can be introduced into nucleic acid molecules with significant enhancement in their nuclease stability and efficacy. For example, oligonucleotides are modified to enhance stability and/or enhance biological activity by modification with nuclease resistant groups, for example, 2'-amino, 2'-C-allyl, 2'-fluoro, 2'-O-methyl, 2'-H, nucleotide base modifications (for a review see Usman and Cedergren, 1992 *TIBS* 17, 34; Usman *et al.*, 1994 *Nucleic Acids Symp. Ser.* 31, 163; Burgin *et al.*, 1996 *Biochemistry* 35, 14090). Sugar modification of nucleic acid molecules have been extensively described in the art (see Eckstein *et al.*, *International Publication* PCT No. WO 92/07065; Perrault *et al.* *Nature* 1990, 344, 565-568; Pieken *et al.* *Science* 1991, 253, 314-317; Usman and Cedergren, *Trends in Biochem. Sci.* 1992, 17, 334-339; Usman *et al.* *International Publication* PCT No. WO 93/15187; Sproat, *US Patent* No. 5,334,711 and Beigelman *et al.*, 1995 *J. Biol. Chem.* 270, 25702; Beigelman *et al.*, *International PCT publication* No. WO 97/26270; Beigelman *et al.*, *US Patent* No. 5,716,824; Usman *et al.*, *US patent* No. 5,627,053; Woolf *et al.*, *International PCT Publication* No. WO 98/13526; Thompson *et al.*, *USSN* 60/082,404 which was filed on April 20, 1998; Karpeisky *et al.*, 1998 *Tetrahedron Lett.* 39, 1131; all of the references are hereby incorporated in their totality by reference herein). Such publications describe general methods and strategies to determine the location of incorporation of sugar, base and/or phosphate modifications and the like into ribozymes without inhibiting catalysis, and are incorporated by reference herein. In view of such teachings, similar modifications can be used as described herein to modify the nucleic acid molecules of the instant invention.

**[0098]** While chemical modification of oligonucleotide internucleotide linkages with phosphorothioate, phosphorothioate, and/or 5'-methylphosphonate linkages improves

stability, too many of these modifications may cause some toxicity. Therefore when designing nucleic acid molecules the amount of these internucleotide linkages should be minimized. The reduction in the concentration of these linkages should lower toxicity resulting in increased efficacy and higher specificity of these molecules.

**[0099]** Nucleic acid molecules having chemical modifications which maintain or enhance activity are provided. Such nucleic acid is also generally more resistant to nucleases than unmodified nucleic acid. Thus, in a cell and/or *in vivo* the activity may not be significantly lowered. Therapeutic nucleic acid molecules delivered exogenously must optimally be stable within cells until translation of the target RNA has been inhibited long enough to reduce the levels of the undesirable protein. This period of time varies between hours to days depending upon the disease state. Clearly, nucleic acid molecules must be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of RNA and DNA (Wincott *et al.*, 1995 *Nucleic Acids Res.* 23, 2677; Caruthers *et al.*, 1992, *Methods in Enzymology* 211,3-19) incorporated by reference herein) have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above.

**[00100]** Use of these the nucleic acid-based molecules of the invention will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple antisense or enzymatic nucleic acid molecules targeted to different genes, nucleic acid molecules coupled with known small molecule inhibitors, or intermittent treatment with combinations of molecules (including different motifs) and/or other chemical or biological molecules)). The treatment of patients with nucleic acid molecules may also include combinations of different types of nucleic acid molecules.

**[00101]** Therapeutic nucleic acid molecules (e.g., enzymatic nucleic acid molecules and antisense nucleic acid molecules) delivered exogenously must optimally be stable within cells until translation of the target RNA has been inhibited long enough to reduce the levels of the

undesirable protein. This period of time varies between hours to days depending upon the disease state. Clearly, these nucleic acid molecules must be resistant to nucleases in order to function as effective intracellular therapeutic agents. Improvements in the chemical synthesis of nucleic acid molecules described in the instant invention and in the art have expanded the ability to modify nucleic acid molecules by introducing nucleotide modifications to enhance their nuclease stability as described above.

**[00102]** By "enhanced enzymatic activity" is meant to include activity measured in cells and/or *in vivo* where the activity is a reflection of both catalytic activity and ribozyme stability. In this invention, the product of these properties is increased or not significantly (less than 10 fold) decreased *in vivo* compared to an all RNA ribozyme.

**[00103]** In yet another preferred embodiment, nucleic acid catalysts having chemical modifications which maintain or enhance enzymatic activity is provided. Such nucleic acid is also generally more resistant to nucleases than unmodified nucleic acid. Thus, in a cell and/or *in vivo* the activity may not be significantly lowered. As exemplified herein such ribozymes are useful in a cell and/or *in vivo* even if activity over all is reduced 10 fold (Burgin *et al.*, 1996, *Biochemistry*, 35, 14090). Such ribozymes herein are said to "maintain" the enzymatic activity on all RNA ribozyme.

**[00104]** In another aspect the nucleic acid molecules comprise a 5' and/or a 3'- cap structure.

**[00105]** By "cap structure" is meant chemical modifications, which have been incorporated at the terminus of the oligonucleotide (see for example Wincott *et al.*, WO 97/26270, incorporated by reference herein). These terminal modifications protect the nucleic acid molecule from exonuclease degradation, and may help in delivery and/or localization within a cell. The cap may be present at the 5'-terminus (5'-cap) or at the 3'-terminus (3'-cap) or may be present on both terminus. In non-limiting examples: the 5'-cap is selected from the group comprising inverted abasic residue (moiety), 4',5'-methylene nucleotide; 1-(beta-D-

erythrofuransyl) nucleotide, 4'-thio nucleotide, carbocyclic nucleotide; 1,5-anhydrohexitol nucleotide; L-nucleotides; alpha-nucleotides; modified base nucleotide; phosphorodithioate linkage; *threo*-pentofuransyl nucleotide; acyclic 3',4'-seco nucleotide; acyclic 3,4-dihydroxybutyl nucleotide; acyclic 3,5-dihydroxypentyl nucleotide, 3'-3'-inverted nucleotide moiety; 3'-3'-inverted abasic moiety; 3'-2'-inverted nucleotide moiety; 3'-2'-inverted abasic moiety; 1,4-butanediol phosphate; 3'-phosphoramidate; hexylphosphate; aminohexyl phosphate; 3'-phosphate; 3'-phosphorothioate; phosphorodithioate; or bridging or non-bridging methylphosphonate moiety (for more details see Beigelman *et al.*, International PCT publication No. WO 97/26270, incorporated by reference herein). In yet another preferred embodiment the 3'-cap is selected from a group comprising, 4',5'-methylene nucleotide; 1-(beta-D-erythrofuransyl) nucleotide; 4'-thio nucleotide, carbocyclic nucleotide; 5'-amino-alkyl phosphate; 1,3-diamino-2-propyl phosphate, 3-aminopropyl phosphate; 6-aminohexyl phosphate; 1,2-aminododecyl phosphate; hydroxypropyl phosphate; 1,5-anhydrohexitol nucleotide; L-nucleotide; alpha-nucleotide; modified base nucleotide; phosphorodithioate; *threo*-pentofuransyl nucleotide; acyclic 3',4'-seco nucleotide; 3,4-dihydroxybutyl nucleotide; 3,5-dihydroxypentyl nucleotide, 5'-5'-inverted nucleotide moiety; 5'-5'-inverted abasic moiety; 5'-phosphoramidate; 5'-phosphorothioate; 1,4-butanediol phosphate; 5'-amino; bridging and/or non-bridging 5'-phosphoramidate, phosphorothioate and/or phosphorodithioate, bridging or non bridging methylphosphonate and 5'-mercapto moieties (for more details see Beaucage and Iyer, 1993, *Tetrahedron* 49, 1925; incorporated by reference herein). By the term "non-nucleotide" is meant any group or compound which can be incorporated into a nucleic acid chain in the place of one or more nucleotide units, including either sugar and/or phosphate substitutions, and allows the remaining bases to exhibit their enzymatic activity. The group or compound is abasic in that it does not contain a commonly recognized nucleotide base, such as adenosine, guanine, cytosine, uracil or thymine.

**[00106]** An "alkyl" group refers to a saturated aliphatic hydrocarbon, including straight-chain, branched-chain, and cyclic alkyl groups. Preferably, the alkyl group has 1 to 12

carbons. More preferably it is a lower alkyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO<sub>2</sub> or N(CH<sub>3</sub>)<sub>2</sub>, amino, or SH. The term also includes alkenyl groups which are unsaturated hydrocarbon groups containing at least one carbon-carbon double bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkenyl group has 1 to 12 carbons. More preferably it is a lower alkenyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkenyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO<sub>2</sub>, halogen, N(CH<sub>3</sub>)<sub>2</sub>, amino, or SH. The term "alkyl" also includes alkynyl groups which have an unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, including straight-chain, branched-chain, and cyclic groups. Preferably, the alkynyl group has 1 to 12 carbons. More preferably it is a lower alkynyl of from 1 to 7 carbons, more preferably 1 to 4 carbons. The alkynyl group may be substituted or unsubstituted. When substituted the substituted group(s) is preferably, hydroxyl, cyano, alkoxy, =O, =S, NO<sub>2</sub> or N(CH<sub>3</sub>)<sub>2</sub>, amino or SH.

**[00107]** Such alkyl groups may also include aryl, alkylaryl, carbocyclic aryl, heterocyclic aryl, amide and ester groups. An "aryl" group refers to an aromatic group which has at least one ring having a conjugated p electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. The preferred substituent(s) of aryl groups are halogen, trihalomethyl, hydroxyl, SH, OH, cyano, alkoxy, alkyl, alkenyl, alkynyl, and amino groups. An "alkylaryl" group refers to an alkyl group (as described above) covalently joined to an aryl group (as described above). Carbocyclic aryl groups are groups wherein the ring atoms on the aromatic ring are all carbon atoms. The carbon atoms are optionally substituted. Heterocyclic aryl groups are groups having from 1 to 3 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms are carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen, and include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolo, pyrimidyl, pyrazinyl, imidazolyl and the



like, all optionally substituted. An "amide" refers to an -C(O)-NH-R, where R is either alkyl, aryl, alkylaryl or hydrogen. An "ester" refers to an -C(O)-OR', where R is either alkyl, aryl, alkylaryl or hydrogen.

**[00108]** By "nucleotide" as used herein is as recognized in the art to include natural bases (standard), and modified bases well known in the art. Such bases are generally located at the 1' position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. The nucleotides can be unmodified or modified at the sugar, phosphate and/or base moiety, (also referred to interchangeably as nucleotide analogs, modified nucleotides, non-natural nucleotides, non-standard nucleotides and other; see for example, Usman and McSwiggen, *supra*; Eckstein *et al.*, International PCT Publication No. WO 92/07065; Usman *et al.*, International PCT Publication No. WO 93/15187; Uhlman & Peyman, *supra*) all are hereby incorporated by reference herein). There are several examples of modified nucleic acid bases known in the art and has recently been summarized by Limbach *et al.*, 1994, *Nucleic Acids Res.* 22, 2183. Some of the non-limiting examples of base modifications that can be introduced into nucleic acid molecules include, inosine, purine, pyridin-4-one, pyridin-2-one, phenyl, pseudouracil, 2, 4, 6-trimethoxy benzene, 3-methyl uracil, dihydrouridine, naphthyl, aminophenyl, 5-alkylcytidines (e.g., 5-methylcytidine), 5-alkyluridines (e.g., ribothymidine), 5-halouridine (e.g., 5-bromouridine) or 6-azapyrimidines or 6-alkylpyrimidines (e.g. 6-methyluridine), propyne, and others (Burgin *et al.*, 1996, *Biochemistry*, 35, 14090; Uhlman & Peyman, *supra*). By "modified bases" in this aspect is meant nucleotide bases other than adenine, guanine, cytosine and uracil at 1' position or their equivalents; such bases may be used at any position, for example, within the catalytic core of an enzymatic nucleic acid molecule and/or in the substrate-binding regions of the nucleic acid molecule.

**[00109]** By "abasic" is meant sugar moieties lacking a base or having other chemical groups in place of a base at the 1' position.

**[00110]** By "ribonucleotide" is meant a nucleotide with one of the bases adenine, cytosine, guanine, or uracil joined to the 1' carbon of  $\beta$ -D-ribo-furanose.

**[00111]** By "unmodified nucleoside" is meant one of the bases adenine, cytosine, guanine, uracil joined to the 1' carbon of  $\beta$ -D-ribo-furanose.

**[00112]** By "modified nucleoside" is meant any nucleotide base which contains a modification in the chemical structure of an unmodified nucleotide base, sugar and/or phosphate.

**[00113]** In connection with 2'-modified nucleotides as described for the present invention, by "amino" is meant 2'-NH<sub>2</sub> or 2'-O- NH<sub>2</sub>, which may be modified or unmodified. Such modified groups are described, for example, in Eckstein et al., U.S. Patent 5,672,695 and Matulic-Adamic et al., WO 98/28317, respectively, which are both incorporated by reference in their entireties.

**[00114]** Various modifications to nucleic acid (e.g., antisense and ribozyme) structure can be made to enhance the utility of these molecules. Such modifications will enhance shelf-life, half-life *in vitro*, stability, and ease of introduction of such oligonucleotides to the target site, e.g., to enhance penetration of cellular membranes, and confer the ability to recognize and bind to targeted cells.

**[00115]** Use of these molecules will lead to better treatment of the disease progression by affording the possibility of combination therapies (e.g., multiple ribozymes targeted to different genes, ribozymes coupled with known small molecule inhibitors, or intermittent treatment with combinations of ribozymes (including different ribozyme motifs) and/or other chemical or biological molecules). The treatment of patients with nucleic acid molecules may also include combinations of different types of nucleic acid molecules. Therapies may be devised which include a mixture of ribozymes (including different ribozyme motifs),

antisense and/or 2-5A chimera molecules to one or more targets to alleviate symptoms of a disease.

#### Administration of Nucleic Acid Molecules

**[00116]** Methods for the delivery of nucleic acid molecules are described in Akhtar *et al.*, 1992, *Trends Cell Bio.*, 2, 139; and *Delivery Strategies for Antisense Oligonucleotide Therapeutics*, ed. Akhtar, 1995 which are both incorporated herein by reference. Sullivan *et al.*, PCT WO 94/02595, further describes the general methods for delivery of enzymatic RNA molecules. These protocols may be utilized for the delivery of virtually any nucleic acid molecule. Nucleic acid molecules may be administered to cells by a variety of methods known to those familiar to the art, including, but not restricted to, encapsulation in liposomes, by iontophoresis, or by incorporation into other vehicles, such as hydrogels, cyclodextrins, biodegradable nanocapsules, and bioadhesive microspheres. For some indications, nucleic acid molecules may be directly delivered *ex vivo* to cells or tissues with or without the aforementioned vehicles. Alternatively, the nucleic acid/vehicle combination is locally delivered by direct injection or by use of a catheter, infusion pump or stent. Other routes of delivery include, but are not limited to, intravascular, intramuscular, subcutaneous or joint injection, aerosol inhalation, oral (tablet or pill form), topical, systemic, ocular, intraperitoneal and/or intrathecal delivery. More detailed descriptions of nucleic acid delivery and administration are provided in Sullivan *et al.*, *supra* and Draper *et al.*, PCT WO93/23569 which have been incorporated by reference herein.

**[00117]** The molecules of the instant invention can be used as pharmaceutical agents. Pharmaceutical agents prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state in a patient.

**[00118]** The negatively charged polynucleotides of the invention can be administered (e.g., RNA, DNA or protein) and introduced into a patient by any standard means, with or without stabilizers, buffers, and the like, to form a pharmaceutical composition. When it is desired to use a liposome delivery mechanism, standard protocols for formation of liposomes can

be followed. The compositions of the present invention may also be formulated and used as tablets, capsules or elixirs for oral administration; suppositories for rectal administration; sterile solutions; suspensions for injectable administration; and the like.

**[00119]** The present invention also includes pharmaceutically acceptable formulations of the compounds described. These formulations include salts of the above compounds, e.g., acid addition salts, for example, salts of hydrochloric, hydrobromic, acetic acid, and benzene sulfonic acid.

**[00120]** A pharmacological composition or formulation refers to a composition or formulation in a form suitable for administration, e.g., systemic administration, into a cell or patient, preferably a human. Suitable forms, in part, depend upon the use or the route of entry, for example oral, transdermal, or by injection. Such forms should not prevent the composition or formulation to reach a target cell (*i.e.*, a cell to which the negatively charged polymer is desired to be delivered to). For example, pharmacological compositions injected into the blood stream should be soluble. Other factors are known in the art, and include considerations such as toxicity and forms which prevent the composition or formulation from exerting its effect.

**[00121]** By "systemic administration" is meant *in vivo* systemic absorption or accumulation of drugs in the blood stream followed by distribution throughout the entire body. Administration routes which lead to systemic absorption include, without limitations: intravenous, subcutaneous, intraperitoneal, inhalation, oral, intrapulmonary and intramuscular. Each of these administration routes expose the desired negatively charged polymers, e.g., nucleic acids, to an accessible diseased tissue. The rate of entry of a drug into the circulation has been shown to be a function of molecular weight or size. The use of a liposome or other drug carrier comprising the compounds of the instant invention can potentially localize the drug, for example, in certain tissue types, such as the tissues of the reticular endothelial system (RES). A liposome formulation which can facilitate the

association of drug with the surface of cells, such as, lymphocytes and macrophages is also useful. This approach may provide enhanced delivery of the drug to target cells by taking advantage of the specificity of macrophage and lymphocyte immune recognition of abnormal cells, such as the cancer cells.

**[00122]** The invention also features the use of the composition comprising surface-modified liposomes containing poly (ethylene glycol) lipids (PEG-modified, or long-circulating liposomes or stealth liposomes). These formulations offer an method for increasing the accumulation of drugs in target tissues. This class of drug carriers resists opsonization and elimination by the mononuclear phagocytic system (MPS or RES), thereby enabling longer blood circulation times and enhanced tissue exposure for the encapsulated drug (Lasic *et al.* *Chem. Rev.* 1995, **95**, 2601-2627; Ishiwata *et al.*, *Chem. Pharm. Bull.* 1995, **43**, 1005-1011). Such liposomes have been shown to accumulate selectively in tumors, presumably by extravasation and capture in the neovascularized target tissues (Lasic *et al.*, *Science* 1995, **267**, 1275-1276; Oku *et al.*, 1995, *Biochim. Biophys. Acta*, **1238**, 86-90). The long-circulating liposomes enhance the pharmacokinetics and pharmacodynamics of DNA and RNA, particularly compared to conventional cationic liposomes which are known to accumulate in tissues of the MPS (Liu *et al.*, *J. Biol. Chem.* 1995, **42**, 24864-24870; Choi *et al.*, International PCT Publication No. WO 96/10391; Ansell *et al.*, International PCT Publication No. WO 96/10390; Holland *et al.*, International PCT Publication No. WO 96/10392; all of these are incorporated by reference herein). Long-circulating liposomes are also likely to protect drugs from nuclease degradation to a greater extent compared to cationic liposomes, based on their ability to avoid accumulation in metabolically aggressive MPS tissues such as the liver and spleen. All of these references are incorporated by reference herein.

**[00123]** The present invention also includes compositions prepared for storage or administration which include a pharmaceutically effective amount of the desired compounds in a pharmaceutically acceptable carrier or diluent. Acceptable carriers or diluents for

therapeutic use are well known in the pharmaceutical art, and are described, for example, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co. (A.R. Gennaro edit. 1985) hereby incorporated by reference herein. For example, preservatives, stabilizers, dyes and flavoring agents may be provided. These include sodium benzoate, sorbic acid and esters of *p*-hydroxybenzoic acid. In addition, antioxidants and suspending agents may be used.

**[00124]** A pharmaceutically effective dose is that dose required to prevent, inhibit the occurrence, or treat (alleviate a symptom to some extent, preferably all of the symptoms) of a disease state. The pharmaceutically effective dose depends on the type of disease, the composition used, the route of administration, the type of mammal being treated, the physical characteristics of the specific mammal under consideration, concurrent medication, and other factors which those skilled in the medical arts will recognize. Generally, an amount between 0.1 mg/kg and 100 mg/kg body weight/day of active ingredients is administered dependent upon potency of the negatively charged polymer.

**[00125]** The nucleic acid molecules of the present invention may also be administered to a patient in combination with other therapeutic compounds to increase the overall therapeutic effect. The use of multiple compounds to treat an indication may increase the beneficial effects while reducing the presence of side effects.

**[00126]** Alternatively, certain of the nucleic acid molecules of the instant invention (e.g., formula IV) can be expressed within cells from eukaryotic promoters (e.g., Izant and Weintraub, 1985 *Science* 229, 345; McGarry and Lindquist, 1986 *Proc. Natl. Acad. Sci. USA* 83, 399; Scanlon et al., 1991, *Proc. Natl. Acad. Sci. USA*, 88, 10591-5; Kashani-Sabet et al., 1992 *Antisense Res. Dev.*, 2, 3-15; Dropulic et al., 1992 *J. Virol*, 66, 1432-41; Weerasinghe et al., 1991 *J. Virol*, **65**, 5531-4; Ojwang et al., 1992 *Proc. Natl. Acad. Sci. USA* 89, 10802-6; Chen et al., 1992 *Nucleic Acids Res.*, 20, 4581-9; Sarver et al., 1990 *Science* 247, 1222-1225; Thompson et al., 1995 *Nucleic Acids Res.* 23, 2259; Good et al., 1997, *Gene Therapy*, 4, 45; all of the references are hereby incorporated in their

totality by reference herein). Those skilled in the art realize that any nucleic acid can be expressed in eukaryotic cells from the appropriate DNA/RNA vector. The activity of such nucleic acids can be augmented by their release from the primary transcript by a ribozyme (Draper *et al.*, PCT WO 93/23569, and Sullivan *et al.*, PCT WO 94/02595; Ohkawa *et al.*, 1992 *Nucleic Acids Symp. Ser.*, 27, 15-6; Taira *et al.*, 1991, *Nucleic Acids Res.*, 19, 5125-30; Ventura *et al.*, 1993 *Nucleic Acids Res.*, 21, 3249-55; Chowrira *et al.*, 1994 *J. Biol. Chem.* 269, 25856; all of the references are hereby incorporated in their totality by reference herein).

**[00127]** In another aspect of the invention, RNA molecules of the present invention are preferably expressed from transcription units (see for example Couture *et al.*, 1996, *TIG.*, 12, 510) inserted into DNA or RNA vectors. The recombinant vectors are preferably DNA plasmids or viral vectors. Ribozyme expressing viral vectors could be constructed based on, but not limited to, adeno-associated virus, retrovirus, adenovirus, or alphavirus. Preferably, the recombinant vectors capable of expressing the nucleic acid molecules are delivered as described above, and persist in target cells. Alternatively, viral vectors may be used that provide for transient expression of nucleic acid molecules. Such vectors might be repeatedly administered as necessary. Once expressed, the nucleic acid molecule binds to the target mRNA. Delivery of nucleic acid molecule expressing vectors could be systemic, such as by intravenous or intra-muscular administration, by administration to target cells explanted from the patient followed by reintroduction into the patient, or by any other means that would allow for introduction into the desired target cell (for a review see Couture *et al.*, 1996, *TIG.*, 12, 510).

**[00128]** In one aspect the invention features, an expression vector comprising nucleic acid sequence encoding at least one of the nucleic acid molecules of the instant invention is disclosed. The nucleic acid sequence encoding the nucleic acid molecule of the instant invention is operable linked in a manner which allows expression of that nucleic acid molecule.

**[00129]** In another aspect the invention features, the expression vector comprises: a transcription initiation region (e.g., eukaryotic pol I, II or III initiation region); b) a transcription termination region (e.g., eukaryotic pol I, II or III termination region); c) a gene encoding at least one of the nucleic acid catalyst of the instant invention; and wherein said gene is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. The vector may optionally include an open reading frame (ORF) for a protein operably linked on the 5' side or the 3'-side of the gene encoding the nucleic acid catalyst of the invention; and/or an intron (intervening sequences).

**[00130]** Transcription of the nucleic acid molecule sequences are driven from a promoter for eukaryotic RNA polymerase I (pol I), RNA polymerase II (pol II), or RNA polymerase III (pol III). Transcripts from pol II or pol III promoters will be expressed at high levels in all cells; the levels of a given pol II promoter in a given cell type will depend on the nature of the gene regulatory sequences (enhancers, silencers, etc.) present nearby. Prokaryotic RNA polymerase promoters are also used, providing that the prokaryotic RNA polymerase enzyme is expressed in the appropriate cells (Elroy-Stein and Moss, 1990 *Proc. Natl. Acad. Sci. U S A*, 87, 6743-7; Gao and Huang 1993 *Nucleic Acids Res.*, 21, 2867-72; Lieber et al., 1993 *Methods Enzymol.*, 217, 47-66; Zhou et al., 1990 *Mol. Cell. Biol.*, 10, 4529-37). Several investigators have demonstrated that nucleic acid molecules, such as ribozymes expressed from such promoters can function in mammalian cells (e.g. Kashani-Sabet et al., 1992 *Antisense Res. Dev.*, 2, 3-15; Ojwang et al., 1992 *Proc. Natl. Acad. Sci. U S A*, 89, 10802-6; Chen et al., 1992 *Nucleic Acids Res.*, 20, 4581-9; Yu et al., 1993 *Proc. Natl. Acad. Sci. U S A*, 90, 6340-4; L'Huillier et al., 1992 *EMBO J.* 11, 4411-8; Lisiewicz et al., 1993 *Proc. Natl. Acad. Sci. U. S. A.*, 90, 8000-4; Thompson et al., 1995 *Nucleic Acids Res.* 23, 2259; Sullenger & Cech, 1993, *Science*, 262, 1566). More specifically, transcription units such as the ones derived from genes encoding U6 small nuclear (snRNA), transfer RNA (tRNA) and adenovirus VA RNA are useful in generating high concentrations of



desired RNA molecules such as ribozymes in cells (Thompson *et al.*, *supra*; Couture and Stinchcomb, 1996, *supra*; Noonberg *et al.*, 1994, *Nucleic Acid Res.*, 22, 2830; Noonberg *et al.*, US Patent No. 5,624,803; Good *et al.*, 1997, *Gene Ther.* 4, 45; Beigelman *et al.*, International PCT Publication No. WO 96/18736; all of these publications are incorporated by reference herein. The above ribozyme transcription units can be incorporated into a variety of vectors for introduction into mammalian cells, including but not restricted to, plasmid DNA vectors, viral DNA vectors (such as adenovirus or adeno-associated virus vectors), or viral RNA vectors (such as retroviral or alphavirus vectors) (for a review see Couture and Stinchcomb, 1996, *supra*).

**[00131]** In yet another aspect the invention features an expression vector comprising nucleic acid sequence encoding at least one of the nucleic acid molecules of the invention, in a manner which allows expression of that nucleic acid molecule. The expression vector comprises in one embodiment; a) a transcription initiation region; b) a transcription termination region; c) a gene encoding at least one said nucleic acid molecule; and wherein said gene is operably linked to said initiation region and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In another preferred embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an open reading frame; d) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3'-end of said open reading frame; and wherein said gene is operably linked to said initiation region, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In yet another embodiment the expression vector comprises: a) a transcription initiation region; b) a transcription termination region; c) an intron; d) a gene encoding at least one said nucleic acid molecule; and wherein said gene is operably linked to said initiation region, said intron and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule. In another embodiment, the expression vector comprises: a) a transcription initiation region; b) a

transcription termination region; c) an intron; d) an open reading frame; e) a gene encoding at least one said nucleic acid molecule, wherein said gene is operably linked to the 3'-end of said open reading frame; and wherein said gene is operably linked to said initiation region, said intron, said open reading frame and said termination region, in a manner which allows expression and/or delivery of said nucleic acid molecule.

#### Examples.

**[00132]** The following are non-limiting examples showing the selection, isolation, synthesis and activity of nucleic acids of the instant invention.

**[00133]** The following examples demonstrate the selection and design of Antisense, hammerhead, DNAzyme, NCH, or G-Cleaver ribozyme molecules and binding/cleavage sites within TERT RNA.

#### Example 1: Identification of Potential Target Sites in Human TERT RNA

**[00134]** The sequence of human TERT was screened for accessible sites using a computer folding algorithm. Regions of the RNA that did not form secondary folding structures and contained potential ribozyme and/or antisense binding/cleavage sites were identified. The sequences of these cleavage sites are shown in **tables III-VII**.

#### Example 2: Selection of Enzymatic Nucleic Acid Cleavage Sites in Human TERT RNA

**[00135]** To test whether the sites predicted by the computer-based RNA folding algorithm corresponded to accessible sites in TERT RNA, 10 hammerhead ribozyme and three G-Cleaver ribozyme sites were selected for further analysis (Table VI). Ribozyme target sites were chosen by analyzing sequences of Human TERT (Nakamura *et al.*, 1997 *Science* 277, 955-959; Genbank sequence accession number: NM\_003219) and prioritizing the sites on the basis of folding. Ribozymes were designed that could bind each target and were individually analyzed by computer folding (Christoffersen *et al.*, 1994 *J. Mol. Struc. Theochem*, 311, 273; Jaeger *et al.*, 1989, *Proc. Natl. Acad. Sci. USA*, **86**, 7706) to assess

whether the ribozyme sequences fold into the appropriate secondary structure. Those ribozymes with unfavorable intramolecular interactions between the binding arms and the catalytic core were eliminated from consideration. As noted below, varying binding arm lengths can be chosen to optimize activity. Generally, at least 5 bases on each arm are able to bind to, or otherwise interact with, the target RNA.

### Example 3: Chemical Synthesis and Purification of Ribozymes for Efficient Cleavage of TERT RNA

**[00136]** Ribozymes were designed to anneal to various sites in the RNA message. The binding arms are complementary to the target site sequences described above. The ribozymes were chemically synthesized. The method of synthesis used followed the procedure for normal RNA synthesis as described above and in Usman et al., (1987 J. Am. Chem. Soc., 109, 7845), Scaringe et al., (1990 Nucleic Acids Res., 18, 5433) and Wincott et al., *supra*, and made use of common nucleic acid protecting and coupling groups, such as dimethoxytrityl at the 5'-end, and phosphoramidites at the 3'-end. The average stepwise coupling yields were >98%.

**[00137]** Ribozymes were also synthesized from DNA templates using bacteriophage T7 RNA polymerase (Milligan and Uhlenbeck, 1989, Methods Enzymol. 180, 51). Ribozymes were purified by gel electrophoresis using general methods or were purified by high pressure liquid chromatography (HPLC; See Wincott et al., *supra*; the totality of which is hereby incorporated herein by reference) and were resuspended in water. The sequences of the chemically synthesized ribozymes used in this study are shown below in **Table III-VII**.

### Example 4: Ribozyme Cleavage of TERT RNA Target *in vitro*

**[00138]** Ribozymes targeted to the human TERT RNA are designed and synthesized as described above. These ribozymes can be tested for cleavage activity *in vitro*, for example

using the following procedure. The target sequences and the nucleotide location within the TERT RNA are given in Tables III-VII.

**[00139]** *Cleavage Reactions:* Full-length or partially full-length, internally-labeled target RNA for ribozyme cleavage assay is prepared by *in vitro* transcription in the presence of [ $\alpha$ - $^{32}\text{P}$ ] CTP, passed over a G 50 Sephadex column by spin chromatography and used as substrate RNA without further purification. Alternately, substrates are 5'- $^{32}\text{P}$ -end labeled using T4 polynucleotide kinase enzyme. Assays are performed by pre-warming 15  $\mu\text{l}$  of a 2X concentration of purified ribozyme in ribozyme cleavage buffer (50 mM Tris-HCl, pH 7.5 at 37°C, 10 mM  $\text{MgCl}_2$ ) and the cleavage reaction was initiated by adding the 2X ribozyme mix to an equal volume (15  $\mu\text{l}$ ) of substrate RNA (maximum of 1-5 nM;  $5 \times 10^5$  to  $1 \times 10^7$  cpm) that was also pre-warmed in cleavage buffer. As an initial screen, assays are carried out for 1 hour at 37°C using a final concentration of either 40 nM or 1 mM ribozyme, *i.e.*, ribozyme excess. The reaction is quenched by the addition of an equal volume (30  $\mu\text{l}$ ) of 95% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol after which the sample is heated to 95°C for 2 minutes, quick chilled and loaded onto a denaturing polyacrylamide gel. Substrate RNA and the specific RNA cleavage products generated by ribozyme cleavage are visualized on an autoradiograph of the gel. The percentage of cleavage is determined by Phosphor Imager<sup>®</sup> quantitation of bands representing the intact substrate and the cleavage products.

#### Cell Culture Models

**[00140]** Various methods have been developed to assay telomerase activity *in vitro*. The most widely used method to characterize telomerase activity is the telomeric repeat amplification protocol (TRAP). TRAP utilizes RT-PCR of cellular extracts to measure telomerase activity by making the amount of PCR target dependant upon the biochemical activity of the enzyme (Kim, N. W., 1997, *Nucleic Acids Research*, 25, 2595-2597).

**[00141]** Human cell culture studies have been established to assay inhibition of telomerase activity in human carcinomas responding to various therapeutics. A human breast cancer model for studying telomerase inhibitors is described (Raymond, E., 1999, Br. J. Cancer, 80, 1332-1341). Human studies of telomerase expression as related to various other cancers are described including cervical cancer (Nakano, K., 1998, Am. J. Pathol, 153, 857-864), endometrial cancer (Kyo, S., 1999, Int. J. Cancer, 80, 60-63), meningeal carcinoma (Kleinschmidt-DeMasters, B. K., 1998, J. Neurol. Sci., 161, 124-134), lung carcinoma (Yashima, K., 1997, Cancer Reseach, 57, 2372-2377), testicular cancer in response to cisplatin (Burger, A. M., 1997, Eur. J. Cancer, 33, 638-644), and ovarian carcinoma (Counter, C. M., 1994, Proc. Natl. Acad. Sci., 91, 2900-2904).

#### Animal Models

**[00142]** A variety of animal models have been designed to assay telomerase activity *in vivo*. Inhibition of telomerase activity has been analyzed in rats via cell proliferation studies with MNU (N-methyl-N-nitrosurea) induced mammary carcinomas in response to treatment with 4-(hydroxyphenyl)retinamide (4-HPR), a known inhibitor of mammary carcinogenesis in animal models and premenopausal women (Bednarek, A., 1999, Carcinogenesis, 20, 879-883). The method of Bednarek et al. uses N-methyl-N-nitrosourea (MNU)-induced mammary carcinomas in rats to analyze the effect of telomerase inhibitors *in vivo*. MNU-induced tumors express high telomerase activity. Female virgin Sprague-Dawley rats are injected twice with MNU (50 mg/kg body weight) at days 43 and 50 days of age. Mammary tumors are allowed to grow to 4-8 mm before commencing treatment with an agent, such as 4-(hydroxyphenyl) retinamide (used by Bednarek et al.) or a nucleic acid of the invention being tested as a modulator of telomerase activity. Following treatment with an agent for 0 to 6 weeks, telomerase activity is assayed using the TRAP method on CHAPS-extracted tumor-cell protein samples. A decrease of 10% or more in telomerase activity relative to the level in tumors of untreated animals indicates an agent is a telomerase inhibitor. Additional studies have focused on the up-regulation of telomerase in transformed cell lines from animal and

human model systems (Zhang, P. B., 1998, Leuk. Res., 22, 509-516), (Chadeneau, C., 1995, Oncogene, 11, 893-898), (Greenberg, R., 1999, Oncogene, 18, 1219-1226).

### Indications

**[00143]** Particular degenerative and disease states that can be associated with telomerase expression modulation include but are not limited to:

- Cancer: Almost all human tumors have detectable telomerase activity (Shay, J. W., 1997, Eur. J. Cancer, 33, 787-791). Treatment with telomerase inhibitors may provide effective cancer therapy with minimal side effects in normal somatic cells that lack telomerase activity. The therapeutic potential exists for the treatment of a wide variety of cancer types.
- Restinosis: Telomerase inhibition in vascular smooth muscle cells may inhibit restinosis by limiting proliferation of these cells.
- Infectious disease: Telomerase inhibition in infectious cell types that express telomerase activity may provide selective antibiotic activity. Such treatment may prove especially effective in protozoan-based infection such as Giardia and Leishmaniasis.
- Transplant rejection: Telomerase inhibition in endothelial cell types may demonstrate selective immunosuppressant activity. Activation of telomerase in transplant cells could benefit grafting success through increased proliferative potential.
- Autoimmune disease: Telomerase modulation in various immune cells may prove beneficial in treating diseases such as multiple sclerosis, lupus, and AIDS.
- Age related disease: Activation of telomerase expression in cells at or nearing senescence as a result of advanced age or premature aging could benefit conditions such as macular degeneration, skin ulceration, and rheumatoid arthritis.

**[00144]** The present body of knowledge in telomerase research indicates the need for methods to assay telomerase activity and for compounds that can regulate telomerase expression for research, diagnostic, and therapeutic use.

**[00145]** Gemcytabine and cyclophosphamide are non-limiting examples of chemotherapeutic agents that can be combined with or used in conjunction with the nucleic acid molecules (e.g. ribozymes and antisense molecules) of the instant invention. Those skilled in the art will recognize that other drugs such as anti-cancer compounds and therapies can be similarly be readily combined with the nucleic acid molecules of the instant invention (e.g. ribozymes and antisense molecules) and are hence within the scope of the instant invention. Such compounds and therapies are well known in the art (see for example *Cancer: Principles and Practice of Oncology*, Volumes 1 and 2, eds Devita, V.T., Hellman, S., and Rosenberg, S.A., J.B. Lippincott Company, Philadelphia, USA; incorporated herein by reference) and include, without limitations, antifolates; fluoropyrimidines; cytarabine; purine analogs; adenosine analogs; amsacrine; topoisomerase I inhibitors; anthrapyrazoles; retinoids; antibiotics such as bleomycin, anthacyclins, mitomycin C, dactinomycin, and mithramycin; hexamethylmelamine; dacarbazine; l-asparaginase; platinum analogs; alkylating agents such as nitrogen mustard, melphalan, chlorambucil, busulfan, ifosfamide, 4-hydroperoxycyclophosphamide, nitrosoureas, thiotepa; plant derived compounds such as vinca alkaloids, epipodophyllotoxins, taxol; Tomaxifen; radiation therapy; surgery; nutritional supplements; gene therapy; radiotherapy such as 3D-CRT; immunotoxin therapy such as ricin, monoclonal antibodies herceptin; and the like. For combination therapy, the nucleic acids of the invention are prepared in one of two ways. First, the agents are physically combined in a preparation of nucleic acid and chemotherapeutic agent, such as a mixture of a nucleic acid of the invention encapsulated in liposomes and ifosfamide in a solution for intravenous administration, wherein both agents are present in a therapeutically effective concentration (e.g., ifosfamide in solution to deliver 1000-1250 mg/m<sup>2</sup>/day and liposome-associated nucleic acid of the invention in the same solution to deliver 0.1-100 mg/kg/day).

Alternatively, the agents are administered separately but simultaneously in their respective effective doses (e.g., 1000-1250 mg/m<sup>2</sup>/d ifosfamide and 0.1 to 100 mg/kg/day nucleic acid of the invention).

### Diagnostic uses

**[00146]** The nucleic acid molecules of this invention (e.g., *ribozymes*) may be used as diagnostic tools to examine genetic drift and mutations within diseased cells or to detect the presence of TERT RNA in a cell. The close relationship between ribozyme activity and the structure of the target RNA allows the detection of mutations in any region of the molecule which alters the base-pairing and three-dimensional structure of the target RNA. By using multiple ribozymes described in this invention, one may map nucleotide changes which are important to RNA structure and function *in vitro*, as well as in cells and tissues. Cleavage of target RNAs with ribozymes may be used to inhibit gene expression and define the role (essentially) of specified gene products in the progression of disease. In this manner, other genetic targets may be defined as important mediators of the disease. These experiments will lead to better treatment of the disease progression by affording the possibility of combinational therapies (e.g., multiple ribozymes targeted to different genes, ribozymes coupled with known small molecule inhibitors, or intermittent treatment with combinations of ribozymes and/or other chemical or biological molecules). Other *in vitro* uses of ribozymes of this invention are well known in the art, and include detection of the presence of mRNAs associated with TERT-related condition. Such RNA is detected by determining the presence of a cleavage product after treatment with a ribozyme using standard methodology.

**[00147]** In a specific example, ribozymes which can cleave only wild-type or mutant forms of the target RNA are used for the assay. The first ribozyme is used to identify wild-type RNA present in the sample and the second ribozyme will be used to identify mutant RNA in the sample. As reaction controls, synthetic substrates of both wild-type and mutant RNA will be cleaved by both ribozymes to demonstrate the relative ribozyme efficiencies in the



reactions and the absence of cleavage of the “non-targeted” RNA species. The cleavage products from the synthetic substrates will also serve to generate size markers for the analysis of wild-type and mutant RNAs in the sample population. Thus each analysis will require two ribozymes, two substrates and one unknown sample which will be combined into six reactions. The presence of cleavage products will be determined using an RNase protection assay so that full-length and cleavage fragments of each RNA can be analyzed in one lane of a polyacrylamide gel. For example, the cleavage reactions are performed in ribozyme cleavage buffer with a final reaction volume of 30  $\mu$ l per reaction as follows: 1) ribozyme specific for (*i.e.*, that specifically cleaves) wild-type RNA (wt ribozyme; 40 nM final reaction concentration) is incubated with wild type substrate (1-5 nM final reaction concentration) at 37°C for one hour; 2) wt ribozyme is incubated with mutant substrate (same conditions); 3) wt ribozyme (40 nM final concentration) is incubated with 50  $\mu$ g of total RNA from the individual being tested, at 37°C for one hour; 4) same as (1), only with 40 nM final concentration of ribozyme specific for mutant RNA; 5) same as (2), only with ribozyme specific for mutant RNA; and 6) same as (3), only with ribozyme specific for mutant RNA. Cleavage products are precipitated with ethanol and resuspended in 20  $\mu$ l of hybridization buffer for RNase protection with  $5 \times 10^5$  to  $1 \times 10^7$  cpm of  $^{32}$ P-labeled RNA probe. Hybridization buffer consists of the following (per reaction): 24 $\mu$ l Formamide, 2 $\mu$ l 0.6M PIPES, 2.4 $\mu$ l 5M NaCl, 0.3 $\mu$ l 0.1M EDTA, and DEPC-treated water to 30  $\mu$ l. Samples are heated at 95°C for 10 minutes, then incubated 4 hours at 55°C (hybridization temperatures may be estimated by one of skill in the art and optimized empirically for a given probe:target combination without undue experimentation). Following hybridization, hybridized sequences are digested with ribonucleases by the addition of 350  $\mu$ l of RNase digestion buffer (300 mM NaOAc, 10 mM Tris, 5 mM EDTA) followed by addition of 1  $\mu$ l of 4mg/ml RNase A and 0.4  $\mu$ l of 10u/ $\mu$ l RNase T1. Digestion is carried out for 45 minutes to 1 hour at 30°C, followed by the addition of 10  $\mu$ l of 20% SDS and 2.5  $\mu$ l of 10mg/ml Proteinase K. Samples are incubated at 37°C for 15-20 minutes followed by phenol/chloroform/isoamyl alcohol (25:24:1) extraction and precipitation with ethanol. Samples are resuspended in formamide

loading buffer, heat denatured and electrophoresed on a denaturing polyacrylamide gel. Protected cleavage products are visualized by autoradiography and quantitated by phosphorimager analysis. It is not absolutely required to quantify the results to gain insight into the expression of mutant RNAs and putative risk of the desired phenotypic changes in target cells. The expression of mRNA whose protein product is implicated in the development of the phenotype (i.e., TERT) is adequate to establish risk. If probes of comparable specific activity are used for both transcripts, then a qualitative comparison of RNA levels will be adequate and will decrease the cost of the initial diagnosis. Higher mutant form to wild-type ratios will be correlated with higher risk whether RNA levels are compared qualitatively or quantitatively.

#### Additional Uses

**[00148]** Potential usefulness of sequence-specific enzymatic nucleic acid molecules of the instant invention might have many of the same applications for the study of RNA that DNA restriction endonucleases have for the study of DNA (Nathans *et al.*, 1975 *Ann. Rev. Biochem.* 44:273). For example, the pattern of restriction fragments could be used to establish sequence relationships between two related RNAs, and large RNAs could be specifically cleaved to fragments of a size more useful for study. The ability to engineer sequence specificity of the enzymatic nucleic acid molecule is ideal for cleavage of RNAs of unknown sequence. Applicant describes the use of nucleic acid molecules to down-regulate gene expression of target genes in bacterial, microbial, fungal, viral, and eukaryotic systems including plant, or mammalian cells.

**[00149]** All patents and publications mentioned in the specification are indicative of the levels of skill of those skilled in the art to which the invention pertains. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually.

**[00150]** One skilled in the art would readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The methods and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.

**[00151]** It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. Thus, such additional embodiments are within the scope of the present invention and the following claims.

**[00152]** The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments, optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the description and the appended claims.

**[00153]** In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that

the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.

**[00154]** Other embodiments are within the following claims.

TABLE I

**Characteristics of naturally occurring ribozymes****Group I Introns**

- Size: ~150 to >1000 nucleotides.
- Requires a U in the target sequence immediately 5' of the cleavage site.
- Binds 4-6 nucleotides at the 5'-side of the cleavage site.
- Reaction mechanism: attack by the 3'-OH of guanosine to generate cleavage products with 3'-OH and 5'-guanosine.
- Additional protein cofactors required in some cases to help folding and maintenance of the active structure.
- Over 300 known members of this class. Found as an intervening sequence in *Tetrahymena thermophila* rRNA, fungal mitochondria, chloroplasts, phage T4, blue-green algae, and others.
- Major structural features largely established through phylogenetic comparisons, mutagenesis, and biochemical studies [i, ii].
- Complete kinetic framework established for one ribozyme [iii, iv, v, vi].
- Studies of ribozyme folding and substrate docking underway [vii, viii, ix].
- Chemical modification investigation of important residues well established [x, xi].
- The small (4-6 nt) binding site may make this ribozyme too non-specific for targeted RNA cleavage, however, the *Tetrahymena* group I intron has been used to repair a "defective"  $\beta$ -galactosidase message by the ligation of new  $\beta$ -galactosidase sequences onto the defective message [xii].

**RNAse P RNA (M1 RNA)**

- Size: ~290 to 400 nucleotides.
- RNA portion of a ubiquitous ribonucleoprotein enzyme.
- Cleaves tRNA precursors to form mature tRNA [xiii].
- Reaction mechanism: possible attack by  $M^{2+}$ -OH to generate cleavage products with 3'-OH and 5'-phosphate.
- RNAse P is found throughout the prokaryotes and eukaryotes. The RNA subunit has been sequenced from bacteria, yeast, rodents, and primates.
- Recruitment of endogenous RNAse P for therapeutic applications is possible through hybridization of an External Guide Sequence (EGS) to the target RNA [xiv, xv].
- Important phosphate and 2' OH contacts recently identified [xvi, xvii].

**Group II Introns**

- Size: >1000 nucleotides.
- Trans cleavage of target RNAs recently demonstrated [xviii, xix].
- Sequence requirements not fully determined.
- Reaction mechanism: 2'-OH of an internal adenosine generates cleavage products with 3'-OH and a "lariat" RNA containing a 3'-5' and a 2'-5' branch point.

- Only natural ribozyme with demonstrated participation in DNA cleavage [xx,xxi] in addition to RNA cleavage and ligation.
- Major structural features largely established through phylogenetic comparisons [xxii].
- Important 2' OH contacts beginning to be identified [xxiii]
- Kinetic framework under development [xxiv]

### Neurospora VS RNA

- Size: ~144 nucleotides.
- Trans cleavage of hairpin target RNAs recently demonstrated [xxv].
- Sequence requirements not fully determined.
- Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5'-OH ends.
- Binding sites and structural requirements not fully determined.
- Only 1 known member of this class. Found in *Neurospora* VS RNA.

### Hammerhead Ribozyme

(see text for references)

- Size: ~13 to 40 nucleotides.
- Requires the target sequence UH immediately 5' of the cleavage site.
- Binds a variable number nucleotides on both sides of the cleavage site.
- Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5'-OH ends.
- 14 known members of this class. Found in a number of plant pathogens (virusoids) that use RNA as the infectious agent.
- Essential structural features largely defined, including 2 crystal structures [xxvi,xxvii]
- Minimal ligation activity demonstrated (for engineering through *in vitro* selection) [xxviii]
- Complete kinetic framework established for two or more ribozymes [xxix].
- Chemical modification investigation of important residues well established [xxx].

### Hairpin Ribozyme

- Size: ~50 nucleotides.
- Requires the target sequence GUC immediately 3' of the cleavage site.
- Binds 4-6 nucleotides at the 5'-side of the cleavage site and a variable number to the 3'-side of the cleavage site.
- Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5'-OH ends.
- 3 known members of this class. Found in three plant pathogen (satellite RNAs of the tobacco ringspot virus, arabis mosaic virus and chicory yellow mottle virus) which uses RNA as the infectious agent.
- Essential structural features largely defined [xxxi,xxxii,xxxiii,xxxiv]
- Ligation activity (in addition to cleavage activity) makes ribozyme amenable to engineering through *in vitro* selection [xxxv]
- Complete kinetic framework established for one ribozyme [xxxvi].
- Chemical modification investigation of important residues begun [xxxvii,xxxviii].

## Hepatitis Delta Virus (HDV) Ribozym

- Size: ~60 nucleotides.
- Trans cleavage of target RNAs demonstrated [xxxix].
- Binding sites and structural requirements not fully determined, although no sequences 5' of cleavage site are required. Folded ribozyme contains a pseudoknot structure [xl].
- Reaction mechanism: attack by 2'-OH 5' to the scissile bond to generate cleavage products with 2',3'-cyclic phosphate and 5'-OH ends.
- Only 2 known members of this class. Found in human HDV.
- Circular form of HDV is active and shows increased nuclease stability [xli]

- 
- i. Michel, Francois; Westhof, Eric. Slippery substrates. *Nat. Struct. Biol.* (1994), 1(1), 5-7.
  - ii. Lisacek, Frederique; Diaz, Yolande; Michel, Francois. Automatic identification of group I intron cores in genomic DNA sequences. *J. Mol. Biol.* (1994), 235(4), 1206-17.
  - iii. Herschlag, Daniel; Cech, Thomas R.. Catalysis of RNA cleavage by the *Tetrahymena thermophila* ribozyme. 1. Kinetic description of the reaction of an RNA substrate complementary to the active site. *Biochemistry* (1990), 29(44), 10159-71.
  - iv. Herschlag, Daniel; Cech, Thomas R.. Catalysis of RNA cleavage by the *Tetrahymena thermophila* ribozyme. 2. Kinetic description of the reaction of an RNA substrate that forms a mismatch at the active site. *Biochemistry* (1990), 29(44), 10172-80.
  - v. Knitt, Deborah S.; Herschlag, Daniel. pH Dependencies of the *Tetrahymena* Ribozyme Reveal an Unconventional Origin of an Apparent pKa. *Biochemistry* (1996), 35(5), 1560-70.
  - vi. Bevilacqua, Philip C.; Sugimoto, Naoki; Turner, Douglas H.. A mechanistic framework for the second step of splicing catalyzed by the *Tetrahymena* ribozyme. *Biochemistry* (1996), 35(2), 648-58.
  - vii. Li, Yi; Bevilacqua, Philip C.; Mathews, David; Turner, Douglas H.. Thermodynamic and activation parameters for binding of a pyrene-labeled substrate by the *Tetrahymena* ribozyme: docking is not diffusion-controlled and is driven by a favorable entropy change. *Biochemistry* (1995), 34(44), 14394-9.
  - viii. Banerjee, Alok Raj; Turner, Douglas H.. The time dependence of chemical modification reveals slow steps in the folding of a group I ribozyme. *Biochemistry* (1995), 34(19), 6504-12.
  - ix. Zarrinkar, Patrick P.; Williamson, James R.. The P9.1-P9.2 peripheral extension helps guide folding of the *Tetrahymena* ribozyme. *Nucleic Acids Res.* (1996), 24(5), 854-8.
  - x. Strobel, Scott A.; Cech, Thomas R.. Minor groove recognition of the conserved G.cntdot.U pair at the *Tetrahymena* ribozyme reaction site. *Science (Washington, D. C.)* (1995), 267(5198), 675-9.
  - xi. Strobel, Scott A.; Cech, Thomas R.. Exocyclic Amine of the Conserved G.cntdot.U Pair at the Cleavage Site of the *Tetrahymena* Ribozyme Contributes to 5'-Splice Site Selection and Transition State Stabilization. *Biochemistry* (1996), 35(4), 1201-11.
  - xii. Sullenger, Bruce A.; Cech, Thomas R.. Ribozyme-mediated repair of defective mRNA by targeted trans-splicing. *Nature (London)* (1994), 371(6498), 619-22.
  - xiii. Robertson, H.D.; Altman, S.; Smith, J.D. *J. Biol. Chem.*, **247**, 5243-5251 (1972).
  - xiv. Forster, Anthony C.; Altman, Sidney. External guide sequences for an RNA enzyme. *Science (Washington, D. C., 1883-)* (1990), 249(4970), 783-6.
  - xv. Yuan, Y.; Hwang, E. S.; Altman, S. Targeted cleavage of mRNA by human RNase P. *Proc. Natl. Acad. Sci. USA* (1992) **89**, 8006-10.
  - xvi. Harris, Michael E.; Pace, Norman R.. Identification of phosphates involved in catalysis by the ribozyme RNase P RNA. *RNA* (1995), 1(2), 210-18.
  - xvii. Pan, Tao; Loria, Andrew; Zhong, Kun. Probing of tertiary interactions in RNA: 2'-hydroxyl-base contacts between the RNase P RNA and pre-tRNA. *Proc. Natl. Acad. Sci. U. S. A.* (1995), 92(26), 12510-14.
  - xviii. Pyle, Anna Marie; Green, Justin B.. Building a Kinetic Framework for Group II Intron Ribozyme Activity: Quantitation of Interdomain Binding and Reaction Rate. *Biochemistry* (1994), 33(9), 2716-25.
  - xix. Michels, William J. Jr.; Pyle, Anna Marie. Conversion of a Group II Intron into a New Multiple-Turnover Ribozyme that Selectively Cleaves Oligonucleotides: Elucidation of Reaction Mechanism and Structure/Function Relationships. *Biochemistry* (1995), 34(9), 2965-77.
  - xx. Zimmerly, Steven; Guo, Huatao; Eskes, Robert; Yang, Jian; Perlman, Philip S.; Lambowitz, Alan M.. A group II intron

- RNA is a catalytic component of a DNA endonuclease involved in intron mobility. *Cell* (Cambridge, Mass.) (1995), 83(4), 529-38.
- xxi . Griffin, Edmund A., Jr.; Qin, Zhifeng; Michels, Williams J., Jr.; Pyle, Anna Marie. Group II intron ribozymes that cleave DNA and RNA linkages with similar efficiency, and lack contacts with substrate 2'-hydroxyl groups. *Chem. Biol.* (1995), 2(11), 761-70.
- xxii . Michel, Francois; Ferat, Jean Luc. Structure and activities of group II introns. *Annu. Rev. Biochem.* (1995), 64, 435-61.
- xxiii . Abramovitz, Dana L.; Friedman, Richard A.; Pyle, Anna Marie. Catalytic role of 2'-hydroxyl groups within a group II intron active site. *Science* (Washington, D. C.) (1996), 271(5254), 1410-13.
- xxiv . Daniels, Danette L.; Michels, William J., Jr.; Pyle, Anna Marie. Two competing pathways for self-splicing by group II introns: a quantitative analysis of in vitro reaction rates and products. *J. Mol. Biol.* (1996), 256(1), 31-49.
- xxv . Guo, Hans C. T.; Collins, Richard A.. Efficient trans-cleavage of a stem-loop RNA substrate by a ribozyme derived from *Neurospora* VS RNA. *EMBO J.* (1995), 14(2), 368-76.
- xxvi . Scott, W.G., Finch, J.T., Aaron, K. The crystal structure of an all RNA hammerhead ribozyme: A proposed mechanism for RNA catalytic cleavage. *Cell*, (1995), 81, 991-1002.
- xxvii . McKay, Structure and function of the hammerhead ribozyme: an unfinished story. *RNA*, (1996), 2, 395-403.
- xxviii . Long, D., Uhlenbeck, O., Hertel, K. Ligation with hammerhead ribozymes. US Patent No. 5,633,133.
- xxix . Hertel, K.J., Herschlag, D., Uhlenbeck, O. A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. *Biochemistry*, (1994) 33, 3374-3385. Beigelman, L., *et al.*, Chemical modifications of hammerhead ribozymes. *J. Biol. Chem.*, (1995) 270, 25702-25708.
- xxx . Beigelman, L., *et al.*, Chemical modifications of hammerhead ribozymes. *J. Biol. Chem.*, (1995) 270, 25702-25708.
- xxxi . Hampel, Arnold; Tritz, Richard; Hicks, Margaret; Cruz, Phillip. 'Hairpin' catalytic RNA model: evidence for helices and sequence requirement for substrate RNA. *Nucleic Acids Res.* (1990), 18(2), 299-304.
- xxxii . Chowrira, Bharat M.; Berzal-Herranz, Alfredo; Burke, John M.. Novel guanosine requirement for catalysis by the hairpin ribozyme. *Nature* (London) (1991), 354(6351), 320-2.
- xxxiii . Berzal-Herranz, Alfredo; Joseph, Simpson; Chowrira, Bharat M.; Butcher, Samuel E.; Burke, John M.. Essential nucleotide sequences and secondary structure elements of the hairpin ribozyme. *EMBO J.* (1993), 12(6), 2567-73.
- xxxiv . Joseph, Simpson; Berzal-Herranz, Alfredo; Chowrira, Bharat M.; Butcher, Samuel E.. Substrate selection rules for the hairpin ribozyme determined by in vitro selection, mutation, and analysis of mismatched substrates. *Genes Dev.* (1993), 7(1), 130-8.
- xxxv . Berzal-Herranz, Alfredo; Joseph, Simpson; Burke, John M.. In vitro selection of active hairpin ribozymes by sequential RNA-catalyzed cleavage and ligation reactions. *Genes Dev.* (1992), 6(1), 129-34.
- xxxvi . Hegg, Lisa A.; Fedor, Martha J.. Kinetics and Thermodynamics of Intermolecular Catalysis by Hairpin Ribozymes. *Biochemistry* (1995), 34(48), 15813-28.
- xxxvii . Grasby, Jane A.; Mersmann, Karin; Singh, Mohinder; Gait, Michael J.. Purine Functional Groups in Essential Residues of the Hairpin Ribozyme Required for Catalytic Cleavage of RNA. *Biochemistry* (1995), 34(12), 4068-76.
- xxxviii . Schmidt, Sabine; Beigelman, Leonid; Karpeisky, Alexander; Usman, Nassim; Sorensen, Ulrik S.; Gait, Michael J.. Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure. *Nucleic Acids Res.* (1996), 24(4), 573-81.
- xxxix . Perrotta, Anne T.; Been, Michael D.. Cleavage of oligoribonucleotides by a ribozyme derived from the hepatitis delta virus RNA sequence. *Biochemistry* (1992), 31(1), 16-21.
- xl . Perrotta, Anne T.; Been, Michael D.. A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA. *Nature* (London) (1991), 350(6317), 434-6.
- xli . Puttaraju, M.; Perrotta, Anne T.; Been, Michael D.. A circular trans-acting hepatitis delta virus ribozyme. *Nucleic Acids Res.* (1993), 21(18), 4253-8.



**Table II: 0.2  $\mu$ mol RNA Synthesis Cycle**

Reagents	Equivalents	Amounts (microL)	Wait time (sec)
Phosphoramidites	15	31	465
SET	38.7	31	465
Acetic anhydride	655	124	5
N-methyl-imidazole	1245	124	5
TCA	700	732	10
Iodine	20.6	244	15

\* Wait time does not include contact time during delivery.

Table III: Human telomerase reverse transcriptase (TERT) Hammerhead Ribozyme and Target Sequence

nt. Position	Ribozyme Sequence			Seq ID Nos.	Substrate Sequence	Seq ID Nos.				
13	CGCAGCAG	CUGAUGAG	GCCGUUAGGC	CGAA	ACGCAGCG	2780	CGCUGCGU	C	CUGCUGCG	1
68	GCAGCGGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCGCGCG	2781	CGCGCGCU	C	CCCUGCUGC	2
90	GCAGCAGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCGCAGC	2782	CGUGCGCU	C	CCUGCUGC	3
108	CCUCGCGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUGGCUG	2783	CAGCCACU	A	CCGCGAGG	4
135	GCCGCACG	CUGAUGAG	GCCGUUAGGC	CGAA	ACGUGGCC	2784	GGCCACGU	U	CGUGCGGC	5
136	CGCCGCAC	CUGAUGAG	GCCGUUAGGC	CGAA	AACGUGGC	2785	GCCACGUU	C	GUGCGGCG	6
194	CGCGCGGA	CUGAUGAG	GCCGUUAGGC	CGAA	AGCCGCCG	2786	CGGCGGCU	U	UCCGCGCG	7
195	GCGCGCGG	CUGAUGAG	GCCGUUAGGC	CGAA	AAGCCGCC	2787	GCGGCGUU	U	CCGCGCGC	8
196	AGCGCGCG	CUGAUGAG	GCCGUUAGGC	CGAA	AAAGCCGC	2788	GCGGCUUU	C	CGCGCGCU	9
264	GGCGGAAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGGGGCG	2789	CGCCCCCU	C	CUUCCGCC	10
267	CTUGGCGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGAGGGG	2790	CCCCUCCU	U	CCGCCAGG	11
268	ACCUGGCG	CUGAUGAG	GCCGUUAGGC	CGAA	AAGGAGGG	2791	CCCUCCUU	C	CGCCAGGU	12
279	UCAGGCAG	CUGAUGAG	GCCGUUAGGC	CGAA	ACACCUGG	2792	CCAGGUGU	C	CUGCCUGA	13
351	CGAAGCGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGCCAGC	2793	GCUGGGCU	U	CGGCUUCG	14
352	GCGAAGCC	CUGAUGAG	GCCGUUAGGC	CGAA	AAGGCCAG	2794	CUGGCCUU	C	GGCUUCGC	15
357	GCAGCGCG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCCGAAG	2795	CUUCGGCU	U	CGCGCUGC	16
358	AGCAGCGC	CUGAUGAG	GCCGUUAGGC	CGAA	AAGCCGAA	2796	UUCGGCUU	C	CGCGCUGCU	17
399	UGGUGGUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGCCUCG	2797	CGAGGCCU	U	CACCACCA	18
400	CUGGUGGU	CUGAUGAG	GCCGUUAGGC	CGAA	AAGGCCUC	2798	GAGGCCUU	C	ACCACCAG	19
420	UGGGCAGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCUGCGC	2799	GCGCAGCU	A	CCUGCCCA	20
505	AGCAGGUG	CUGAUGAG	GCCGUUAGGC	CGAA	ACCAGCAC	2800	GUGCUGGU	U	CACCUGCU	21
506	CAGCAGGU	CUGAUGAG	GCCGUUAGGC	CGAA	AACCAGCA	2801	UGCUGGUU	C	ACCUGCUG	22
529	AGCACAAA	CUGAUGAG	GCCGUUAGGC	CGAA	AGCGCGCA	2802	UGCGCGCU	C	UUUGUGCU	23
531	CCAGCACACA	CUGAUGAG	GCCGUUAGGC	CGAA	AGAGCGCG	2803	CGCGCUU	U	UGUGCUGG	24
532	ACCAGCAC	CUGAUGAG	GCCGUUAGGC	CGAA	AAGAGCGC	2804	GCGCUUU	U	GUGCUGGU	25
545	GCAGCUGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCCACCA	2805	UGGUGGCU	C	CCAGCUGC	26
558	ACACCUGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGCGCAG	2806	CUGCGCCU	A	CCAGGUGU	27
582	CGAGCUGG	CUGAUGAG	GCCGUUAGGC	CGAA	ACAGCGGC	2807	GCCGCUGU	A	CCAGCUGC	28
589	GCAGCGCC	CUGAUGAG	GCCGUUAGGC	CGAA	AGCUGGUA	2808	UACCAGCU	C	GGGGCUGC	29

602	CCGGGCCU	CUGAUGAG	GCCGUUAGGC	CGAA	AGUGGCAG	2809	CUGCCACU	C	AGGCCCGG	30
626	GGGUCCAC	CUGAUGAG	GCCGUUAGGC	CGAA	AGCGUGUG	2810	CACACGCU	A	GUGGACCC	31
644	GCAUCCCA	CUGAUGAG	GCCGUUAGGC	CGAA	ACGCCUUC	2811	GAAGGCGU	C	UGGGAUGC	32
671	CCUGACGC	CUGAUGAG	GCCGUUAGGC	CGAA	AUGGUUCC	2812	GGAACCAU	A	GCGUCAGG	33
676	GCCUCCCU	CUGAUGAG	GCCGUUAGGC	CGAA	ACGCUAUG	2813	CAUAGCGU	C	AGGGAGGC	34
691	CCCAGGGG	CUGAUGAG	GCCGUUAGGC	CGAA	ACCCCGGC	2814	GCCGGGGU	C	CCCCUGGG	35
749	CAACGGCA	CUGAUGAG	GCCGUUAGGC	CGAA	ACUUCGGC	2815	GCCGAAGU	C	UGCCGUUG	36
756	UCUUGGGC	CUGAUGAG	GCCGUUAGGC	CGAA	ACGGCAGA	2816	UCUGCCGU	U	GCCCAAGA	37
808	CCUGCCCC	CUGAUGAG	GCCGUUAGGC	CGAA	ACGGGCGU	2817	ACGCCCGU	U	GGGCAGGG	38
819	GGGCCCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	ACCCUUGC	2818	GCAGGGGU	C	CUGGGCCC	39
863	CACACAGA	CUGAUGAG	GCCGUUAGGC	CGAA	ACCACGGU	2819	ACCGUGGU	U	UCUGUGUG	40
864	CCACACAG	CUGAUGAG	GCCGUUAGGC	CGAA	AACACACG	2820	CCGUGGUU	U	CUGUGUGG	41
865	ACCACACA	CUGAUGAG	GCCGUUAGGC	CGAA	AAACCACG	2821	CGUGGUUU	C	UGUGUGGU	42
876	UGGCAGGU	CUGAUGAG	GCCGUUAGGC	CGAA	ACACCACA	2822	UGUGUGUU	C	ACCUGCCA	43
906	CCUCCAAA	CUGAUGAG	GCCGUUAGGC	CGAA	AGGUGGCU	2823	AGCCACCU	C	UUUGGAGG	44
908	ACCCUCCA	CUGAUGAG	GCCGUUAGGC	CGAA	AGAGGUGG	2824	CCACCUCU	U	UGGAGGGU	45
909	CACCCUCC	CUGAUGAG	GCCGUUAGGC	CGAA	AAGAGGUG	2825	CACCUCUU	U	GGAGGGUG	46
922	GUGCCAGA	CUGAUGAG	GCCGUUAGGC	CGAA	AGCGCACC	2826	GGUGCGCU	C	UCUGGCAC	47
924	GCGUGCCA	CUGAUGAG	GCCGUUAGGC	CGAA	AGAGCGCA	2827	UGCGUCUU	C	UGGCACGC	48
939	AUGGGUGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUGGCGC	2828	GCGCCACU	C	CCACCCAU	49
948	GGCCACAG	CUGAUGAG	GCCGUUAGGC	CGAA	AUGGGUGG	2829	CCACCCAU	C	CGUGGGCC	50
981	GCGAUGUG	CUGAUGAG	GCCGUUAGGC	CGAA	AUGGGGGG	2830	CCCCCCAU	C	CACAUCGC	51
987	GUGGCCGC	CUGAUGAG	GCCGUUAGGC	CGAA	AUGUGGAU	2831	AUCCACAU	C	GCGGCCAC	52
1001	GUCCCAGG	CUGAUGAG	GCCGUUAGGC	CGAA	ACGUGGUG	2832	CACCACGU	C	CCUGGGAC	53
1016	CGGGGGAC	CUGAUGAG	GCCGUUAGGC	CGAA	AGGCGUGU	2833	ACACGCCU	U	GUCCCCCG	54
1019	CACCGGGG	CUGAUGAG	GCCGUUAGGC	CGAA	ACAAGGCG	2834	CGCCUUGU	C	CCCCGGUG	55
1029	UCUCGGCG	CUGAUGAG	GCCGUUAGGC	CGAA	ACACCGGG	2835	CCCGGUGU	A	CGCCGAGA	56
1047	AGUAGAGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUCUUG	2836	CAAGCACU	U	CCUCUACU	57
1048	GAGUAGAG	CUGAUGAG	GCCGUUAGGC	CGAA	AAGUGCUU	2837	AAGCACUU	C	CUCUACUC	58
1051	GAGGAGUA	CUGAUGAG	GCCGUUAGGC	CGAA	AGGAAGUG	2838	CACUUCUU	C	UACUCCUC	59
1053	CUGAGGAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGAGGAAG	2839	CUUCCUCU	A	CUCCUCAG	60
1056	CGCCUGAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUAGAGG	2840	CCUCUACU	C	CUCAGGCG	61
1059	UGUGGCCU	CUGAUGAG	GCCGUUAGGC	CGAA	AGGAGUAG	2841	CUACUCCU	C	AGGCGACA	62
1086	GUAGGAAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGGCCGC	2842	GCGGCCCU	C	CUUCCUAC	63

1089	UGAGUAGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGAGGGC	2843	GCCCUCCU	U	CCUACUCA	64
1090	CUGAGUAG	CUGAUGAG	GCCGUUAGGC	CGAA	AAGGAGGG	2844	CCCUCCUU	C	CUACUCAG	65
1093	GAGCUGAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGAAGGA	2845	UCCUUCUU	A	CUCAGCUC	66
1096	AGAGAGCU	CUGAUGAG	GCCGUUAGGC	CGAA	AGUAGGAA	2846	UUCUACU	C	AGCUCUCU	67
1101	GCUCACAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCUGAGU	2847	ACUCAGCU	C	UCUGAGGC	68
1103	GGGCCUCA	CUGAUGAG	GCCGUUAGGC	CGAA	AGAGCUGA	2848	UCAGCUCU	C	UGAGGCCCC	69
1127	GAGCCUCC	CUGAUGAG	GCCGUUAGGC	CGAA	AGCGCCAG	2849	CUGGCGCU	C	GGAGGCUC	70
1135	GUCUCCAC	CUGAUGAG	GCCGUUAGGC	CGAA	AGCCUCCG	2850	CGGAGGCU	C	GUGGAGAC	71
1147	CCAGAGAA	CUGAUGAG	GCCGUUAGGC	CGAA	AUGGUCUC	2851	GAGACCAU	C	UUUCUGGG	72
1149	AACCCAGA	CUGAUGAG	GCCGUUAGGC	CGAA	AGAUGGUC	2852	GACCAUCU	U	UCUGGGUU	73
1150	GAACCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	AAGAUGGU	2853	ACCAUCUU	U	CUGGGUUC	74
1151	GGAAACCCA	CUGAUGAG	GCCGUUAGGC	CGAA	AAAGAUGG	2854	CCAUCUUU	C	UGGGUUCU	75
1157	GGGCCUGG	CUGAUGAG	GCCGUUAGGC	CGAA	ACCCAGAA	2855	UUCUGGGU	U	CCAGGCCCC	76
1158	AGGGCCUG	CUGAUGAG	GCCGUUAGGC	CGAA	AACCCAGA	2856	UCUGGGUU	C	CAGGCCCU	77
1181	CCUGCGGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUCCUUG	2857	CAGGGACU	C	CCC GCAGG	78
1191	GGCGGGGC	CUGAUGAG	GCCGUUAGGC	CGAA	ACCUGGGG	2858	CCGCAGGU	U	GCCCCGCC	79
1212	UUUGCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCGCUGG	2859	CCAGCGCU	A	CUGGCAAA	80
1233	GCUCACAG	CUGAUGAG	GCCGUUAGGC	CGAA	ACAGGGGC	2860	GCCCCUGU	U	UCUGGAGC	81
1234	AGCUCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	AACAGGGG	2861	CCCCUGUU	U	CUGGAGCU	82
1235	CAGCUCCA	CUGAUGAG	GCCGUUAGGC	CGAA	AAACAGGG	2862	CCCUGUUU	C	UGGAGCUG	83
1246	UGGUUCCC	CUGAUGAG	GCCGUUAGGC	CGAA	AGCAGCUC	2863	GAGCUGCU	U	GGGAACCA	84
1269	GCACCCCC	CUGAUGAG	GCCGUUAGGC	CGAA	AGGGGCAC	2864	GUGCCCCU	A	CGGGGUGC	85
1279	GUCUUGAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCACCCC	2865	GGGGUGCU	C	CUCAAAGAC	86
1282	UGCGUCUU	CUGAUGAG	GCCGUUAGGC	CGAA	AGGAGCAC	2866	GUGCUCCU	C	AAGACGCA	87
1312	GCUGGGGU	CUGAUGAG	GCCGUUAGGC	CGAA	ACCGCAGC	2867	GCUGCGGU	C	ACCCCAGC	88
1330	CGGGCACA	CUGAUGAG	GCCGUUAGGC	CGAA	ACACCGGC	2868	GCCGGUGU	C	UGUGCCCC	89
1356	CCGCCACA	CUGAUGAG	GCCGUUAGGC	CGAA	AGCCCUUG	2869	CCAGGGCU	C	UGUGGCGG	90
1394	CACCAGGC	CUGAUGAG	GCCGUUAGGC	CGAA	ACGGGGGU	2870	ACCCCGU	C	GCCUGGUG	91
1411	UGCUGGGC	CUGAUGAG	GCCGUUAGGC	CGAA	AGCAGCUG	2871	CAGCUGCU	C	CGCCAGCA	92
1440	CGAAGCCG	CUGAUGAG	GCCGUUAGGC	CGAA	ACACCUGC	2872	GCAGGUGU	A	CGGCUUCG	93
1446	CCCGCACG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCCGUAC	2873	GUACGGCU	U	CGUGCGGG	94
1447	GCCCGCAC	CUGAUGAG	GCCGUUAGGC	CGAA	AAGCCGUA	2874	UACGGCUU	C	GUGCGGGC	95
1486	GAGCCCCA	CUGAUGAG	GCCGUUAGGC	CGAA	AGGCCUUG	2875	CCAGGCCU	C	UGGGGCUC	96
1494	UGUGCCUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCCCCAG	2876	CUGGGGCU	C	CAGGCACA	97

1515	UCCUGAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGCGGCGU	2877	ACGCCGCU	U	CCUCAGGA	98
1516	UUCUCUGAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAGCGGCG	2878	CGCCGCUU	C	CUCAGGAA	99
1519	GUGUUCCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGGAAGCG	2879	CGCUUCCU	C	AGGAACAC	100
1536	GGGAGAUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACUUCUUG	2880	CAAGAAGU	U	CAUCUCCC	101
1537	AGGAGAGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AACUUCUU	2881	AAGAAGUU	C	AUCUCCCU	102
1540	CCCAGGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUGAACUU	2882	AAGUUCAU	C	UCCCUGGG	103
1542	UCCCCAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGAUGAAC	2883	GUUCAUCU	C	CCUGGGGA	104
1564	UGCAGCGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGCUUGGC	2884	GCCAAGCU	C	UCGCUGCA	105
1566	CCUGCAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGAGCUUG	2885	CAAGCUCU	C	GCUGCAGG	106
1610	GGCAGGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGCGCAGU	2886	ACUGCGCU	U	GGCUGCGC	107
1633	ACACAGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACCCUUGG	2887	CCAGGGGU	U	GGCUGUGU	108
1642	GGGCGCGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACACAGCC	2888	GGCUGUGU	U	CCGGCCGC	109
1643	UGCGGCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AACACAGC	2889	GCUGUGUU	C	CGGCCCGCA	110
1661	CUCACGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGGUGCU	2890	AGCACCGU	C	UGCUGAG	111
1675	UUGGCCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUCUCCUC	2891	GAGGAGAU	C	CUGGCCAA	112
1686	AGUGCAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACUUGGCC	2892	GGCCAAGU	U	CCUGCACU	113
1687	CAGUGCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AACUUGGC	2893	GCCAAGUU	C	CUGCACUG	114
1710	CGACGACG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACACACUC	2894	GAGUGUGU	A	CGUCGUCG	115
1714	AGCUCGAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGUACAC	2895	GUGUACGU	C	GUCGAGCU	116
1717	AGCAGCUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGACGUA	2896	UAGGUCGU	C	GAGCUGCU	117
1726	AAAGACCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGCAGCUC	2897	GAGCUGCU	C	AGGUCUUU	118
1731	AAAAGAAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACCUGAGC	2898	GCUCAGGU	C	UUUCUUUU	119
1733	AUAAAAGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGACCUGA	2899	UCAGGUCU	U	UCUUUUUU	120
1734	CAUAAAAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGACCUCG	2900	CAGGUCUU	U	CUUUUAUG	121
1735	ACAUAAAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAAGACCU	2901	AGGUCUUU	C	UUUUUAUGU	122
1737	UGACAUAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGAAAGAC	2902	GUCUUUCU	U	UUAUGUCA	123
1738	GUGACAU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGAAAGA	2903	UCUUUCUU	U	UAUGUCAC	124
1739	CGUGACAU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAAGAAAG	2904	CUUUCUUU	U	AUGUCACG	125
1740	CCGUGACA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAAAAGAA	2905	UUUCUUUU	A	UGUCACGG	126
1744	GUCUCCGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACAUAAAA	2906	UUUUAUGU	C	ACGGAGAC	127
1758	UCUUUUUA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGUGGUC	2907	GACCACGU	U	UCAAAAGA	128
1759	UUCUUUUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AACGUGGU	2908	ACCACGUU	U	CAAAAGAA	129
1760	GUUCUUUU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAACGUGG	2909	CCACGUUU	C	AAAAGAAC	130
1774	UAGAAAAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGCCUGUU	2910	AACAGGCU	C	UUUUUCUA	131

1776	GGUAGAAA	CUGAUGAG	GCCGUUAGGC	CGAA	AGAGCCUG	2911	CAGGCUCU U	UUUCUACC	132
1777	CGGUAGAA	CUGAUGAG	GCCGUUAGGC	CGAA	AAGAGCCU	2912	AGGCUCUU U	UUCUACCG	133
1778	CCGUAGA	CUGAUGAG	GCCGUUAGGC	CGAA	AAAGAGCC	2913	GGCUCUUU U	UCUACCGG	134
1779	UCCGGUAG	CUGAUGAG	GCCGUUAGGC	CGAA	AAAAGAGC	2914	GCUCUUUU U	CUACCCGA	135
1780	UUCCGGUA	CUGAUGAG	GCCGUUAGGC	CGAA	AAAAGAG	2915	CUCUUUUU C	UACCCGGA	136
1782	UCUUCGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGAAAAAG	2916	CUUUUUU A	CCGGAAGA	137
1795	UUGCUCCA	CUGAUGAG	GCCGUUAGGC	CGAA	ACACUCUU	2917	AAGAGUGU C	UGGAGCAA	138
1806	UGCUUUGC	CUGAUGAG	GCCGUUAGGC	CGAA	ACUUGCUC	2918	GAGCAAGU U	GCAAAGCA	139
1816	CUGAUUCC	CUGAUGAG	GCCGUUAGGC	CGAA	AUGCUUUG	2919	CAAAGCAU U	GGAUUCAG	140
1822	UGCUGUCU	CUGAUGAG	GCCGUUAGGC	CGAA	AUUCCAAU	2920	AUUGGAU C	AGACAGCA	141
1833	CCUCUUC	CUGAUGAG	GCCGUUAGGC	CGAA	AGUGCUGU	2921	ACAGCACU U	GAAGAGGG	142
1860	CUGCUUCC	CUGAUGAG	GCCGUUAGGC	CGAA	ACAGCUCC	2922	GGAGCUGU C	GGAAGCAG	143
1873	UGCUGCCU	CUGAUGAG	GCCGUUAGGC	CGAA	ACCUCUGC	2923	GCAGAGGU C	AGGCAGCA	144
1883	GGCUUCCC	CUGAUGAG	GCCGUUAGGC	CGAA	AUGCUGCC	2924	GGCAGCAU C	GGGAAGCC	145
1911	GGAGUCUG	CUGAUGAG	GCCGUUAGGC	CGAA	ACGUCAGC	2925	GCUGACGU C	CAGACUCC	146
1918	AUGAAGCG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUCUGGA	2926	UCCAGACU C	CGCUUCAU	147
1923	UGGGGAUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCGGAGU	2927	ACUCCGCU U	CAUCCCCA	148
1924	UUGGGGAU	CUGAUGAG	GCCGUUAGGC	CGAA	AAGCGGAG	2928	CUCCGCUU C	AUCCCCAA	149
1927	GGCUUUGG	CUGAUGAG	GCCGUUAGGC	CGAA	AUGAAGCG	2929	CGCUUCAU C	CCCAAGCC	150
1954	AUGUUCAC	CUGAUGAG	GCCGUUAGGC	CGAA	AUCGGCCG	2930	CGGCCGAU U	GUGAACAU	151
1968	CCAGGACG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUCCAUG	2931	CAUGGACU A	CGUCGUGG	152
1972	GCUCCAC	CUGAUGAG	GCCGUUAGGC	CGAA	ACGUAGUC	2932	GACUACGU C	GUGGGAGC	153
1989	CUCUGCGG	CUGAUGAG	GCCGUUAGGC	CGAA	ACGUUCUG	2933	CAGAACGU U	CCGCAGAG	154
1990	UCUCUGCG	CUGAUGAG	GCCGUUAGGC	CGAA	AACGUUCU	2934	AGAACGUU C	CGCAGAGA	155
2015	CGAGGUGA	CUGAUGAG	GCCGUUAGGC	CGAA	ACGUCGG	2935	CCGAGCGU C	UCACCUCC	156
2017	CUCGAGGU	CUGAUGAG	GCCGUUAGGC	CGAA	AGACGCU	2936	GAGCGUCU C	ACCUCGAG	157
2022	UCACCCUC	CUGAUGAG	GCCGUUAGGC	CGAA	AGGUGAGA	2937	UCUCACCU C	GAGGGUGA	158
2040	GCACGCUG	CUGAUGAG	GCCGUUAGGC	CGAA	ACAGUGCC	2938	GGCACUGU U	CAGCGUGC	159
2041	AGCAGGCU	CUGAUGAG	GCCGUUAGGC	CGAA	AACAGUGC	2939	GCACUGUU C	AGCGUGCU	160
2050	UCGUAGUU	CUGAUGAG	GCCGUUAGGC	CGAA	AGCAGCU	2940	AGCGUGCU C	AACUACGA	161
2055	CCGCUCUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUUGAGC	2941	GCUCAACU A	CGAGCGGG	162
2080	GGCCCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGCCGGG	2942	CCCGGCCU C	CUGGGCGC	163
2091	CCAGCAC	CUGAUGAG	GCCGUUAGGC	CGAA	AGGCGCCC	2943	GGGCGCCU C	UGUGCUGG	164
2111	CCUGUGGA	CUGAUGAG	GCCGUUAGGC	CGAA	AUCGUCCA	2944	UGGACGAU A	UCCACAGG	165

2113	GCCUGUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUAUCGUC	2945	GACGAUUAU	C	CACAGGGC	166
2133	GCAGCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGGUGGC	2946	GCGCACCU	U	CGUGCUGC	167
2134	CGCAGCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAGGUGG	2947	GCGACCUU	C	GUGCUGCG	168
2175	UGACAAAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACAGCUCA	2948	UGAGCUGU	A	CUUUGUCA	169
2178	CCUUGACA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGUACAGC	2949	GCUGUACU	U	UGUCAAGG	170
2179	ACCUUGAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAGUACAG	2950	CUGUACU	U	GUCAAGGU	171
2182	UCCACCUU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACAAAGUA	2951	UACUUUGU	C	AAGGUGGA	172
2205	UGGUGUCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGGGCC	2952	GGGCGCGU	A	CGACACCA	173
2215	UCCUGGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUGGUGUC	2953	GACACCAU	C	CCCCAGGA	174
2230	ACCUCCGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGCCUGUC	2954	GACAGGCU	C	ACGGAGGU	175
2239	CUGGGCGAU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACCUCCGU	2955	ACGGAGGU	C	AUCGCCAG	176
2242	AUGCUGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUGACCUC	2956	GAGGUCAU	C	GCCAGCAU	177
2251	GGUUUGAU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUGCUGGC	2957	GCCAGCAU	C	AUCAAACC	178
2254	UGGGGUTU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUGAUGCU	2958	AGCAUCAU	C	AAACCCCA	179
2271	GCAGGCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGUGUUC	2959	GAACACGU	A	CUGCGUGC	180
2282	GGCAUACC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGCACGC	2960	GCGUGCGU	C	GGUAUGCC	181
2286	CCACGGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACCGACGC	2961	GCGUCGGU	A	UGCCGUGG	182
2296	GCCUUCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACCACGCG	2962	GCCGUGGU	C	CAGAAGGC	183
2320	GCCUUGCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGUGCCC	2963	GGGCACGU	C	CGCAAGGC	184
2331	GGCUCUUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGGCCUUG	2964	CAAGGCCU	U	CAAGAGCC	185
2332	UGGCUCUTU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAGGCCUU	2965	AAGGCCUU	C	AAGAGCCA	186
2344	AAGGUAGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGUGGCU	2966	AGCCACGU	C	UCUACCUU	187
2346	UCAAGGUA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGACGUGG	2967	CCACGUCU	C	UACCUUGA	188
2348	UGUCAAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGAGACGU	2968	AGUCUCU	A	CCUUGACA	189
2352	GGUCUGUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGGUAGAG	2969	CUCUACCU	U	GACAGACC	190
2362	UACGGCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGGUCUGU	2970	ACAGACCU	C	CAGCCGUA	191
2370	GUCGCAUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGGCUGG	2971	CCAGCCGU	A	CAUGCGAC	192
2382	GAGCCACG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACUGUGCG	2972	GCGACAGU	U	CGUGGCUC	193
2383	UGAGCCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AACUGUCG	2973	CGACAGUU	C	GUGGCUCA	194
2390	CUGCAGGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGCCACGA	2974	UCGUGGCU	C	ACCUGCAG	195
2425	UCGAUGAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGGCAUC	2975	GAUGCCGU	C	GUCAUCGA	196
2428	UGCUCGAU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGACGGC	2976	GCCGUGCU	C	AUCGAGCA	197
2431	CUCUGCUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUGACGAC	2977	GUCGUCAU	C	GAGCAGAG	198
2442	UCAGGGAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGCUCUGC	2978	GCAGAGCU	C	CUCCCTUGA	199

2445	CAUUCAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGGAGCUC	2979	GAGCUCCU	C	CCUGAAUG	200
2470	ACGU CGAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGGCCACU	2980	AGUGGCCU	C	UUCGACGU	201
2472	AGAGGU CG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGAGGCCA	2981	UGGCCUCU	U	CGACGUCU	202
2473	AAGACGUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGAGGCC	2982	GGCCUCU	C	GACGUCU	203
2479	CGUAGGAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGUCGAA	2983	UUCGACGU	C	UUCCUACG	204
2481	AGCGUAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGACGU CG	2984	CGACGUCU	U	CCUACGCU	205
2482	AAGCGUAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAGACGUC	2985	GACGUCU	C	CUACGCUU	206
2485	AUGAAGCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGGAAGAC	2986	GUCUUCCU	A	CGCUUCAU	207
2490	GGCACAU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGCGUAGG	2987	CCUACGCU	U	CAUGUGCC	208
2491	UGGCACAU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAGCGUAG	2988	CUACGCUU	C	AUGUGCCA	209
2515	UUGCCCCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUGCGCAC	2989	GUGCGCAU	C	AGGGCAA	210
2526	GGACGUAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACUUGCCC	2990	GGGCAAGU	C	CUACGUCC	211
2529	ACUGGACG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGGACUUG	2991	CAAGUCCU	A	CGUCCAGU	212
2533	UGGCACUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGUAGGA	2992	UCCUACGU	C	CAGUGCCA	213
2548	CCUGCGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUCCCCUG	2993	CAGGGGAU	C	CCGCAGGG	214
2559	AGAGGAUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGCCUGC	2994	GCAGGGCU	C	CAUCCUCU	215
2563	GUGGAGAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUGGAGCC	2995	GGCUCCAU	C	CUCUCCAC	216
2566	AGCGUGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGGAUGGA	2996	UCCAUCU	C	UCCACGCU	217
2568	GCAGCGUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGAGGAUG	2997	CAUCCUCU	C	CACGUCG	218
2578	AGGCUGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGCAGCGU	2998	AGGCUGCU	C	UGCAGCCU	219
2592	UGUCGCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGCAGAGG	2999	CCUGUGCU	A	CGGCGACA	220
2616	UCCCCGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACAGCUUG	3000	CAAGCTUGU	U	UGC GGGA	221
2617	AUCCCCGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AACAGCTU	3001	AAGCTUGU	U	GCGGGGAU	222
2626	UCCCGCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUCCCCGC	3002	GCGGGGAU	U	CGGCGGGA	223
2627	GUCCCGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUCCCCG	3003	CGGGGAU	C	GGC GGAC	224
2644	AAACGCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGCAGCCC	3004	GGGCUGCU	C	CUGCGUUU	225
2651	AUCCACCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACGCAGGA	3005	UCCUGCGU	U	UGGUGGAU	226
2652	CAUCCACC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AACGCAGG	3006	CCUGCGUU	U	GGUGGAUG	227
2663	CAACAAGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUCAUCCA	3007	UGGAUGAU	U	UCUUGUUG	228
2664	CCAACAAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAUCAUCC	3008	GGAUGAUU	U	CUUGUUGG	229
2665	ACCAACAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAAUCAUC	3009	GAUGAUUU	C	UUGUUGGU	230
2667	UCACCAAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGAAUCA	3010	UGAUUUUU	U	GUUGGUGA	231
2670	GUGUCACC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACAAGAAA	3011	UUUCUUGU	U	GGUGACAC	232
2681	GGUGAGGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AGGUGUCA	3012	UGACACCU	C	ACCUCACC	233



2686	GCGUGGGU	CUGAUGAG	GCCGUUAGGC	CGAA	AGGUGAGG	3013	CCUCACCU	C	ACCCACGC	234	
2703	UCCUGAGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGUUUUC	3014	GAAAACCU	U	CCUCAGGA	235	
2704	GUCCUGAG	CUGAUGAG	GCCGUUAGGC	CGAA	AAGGUUUU	3015	AAAACCUU	C	CUCAGGAC	236	
2707	AGGUUCCU	CUGAUGAG	GCCGUUAGGC	CGAA	AGGAAGGU	3016	ACCUUCCU	C	AGGACCCU	237	
2719	ACACCUUG	CUGAUGAG	GCCGUUAGGC	CGAA	ACCAGGGU	3017	ACCCUGGU	C	CGAGGUGU	238	
2728	UACUCAGG	CUGAUGAG	GCCGUUAGGC	CGAA	ACACCUUG	3018	CGAGGUGU	C	CCUGAGUA	239	
2736	CGCAGCCA	CUGAUGAG	GCCGUUAGGC	CGAA	ACUCAGGG	3019	CCUCAGAU	A	UGGCUGCG	240	
2754	UCUUCGCG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUUCACC	3020	GGUGAACU	U	GCGGAAGA	241	
2775	CUACAGGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUUCACC	3021	GGUGAACU	U	CCCUGUAG	242	
2776	UCUACAGG	CUGAUGAG	GCCGUUAGGC	CGAA	AAGUUCAC	3022	GUGAACUU	C	CCUGUAGA	243	
2782	UCGUUCUC	CUGAUGAG	GCCGUUAGGC	CGAA	ACAGGGAA	3023	UUCCCUUG	A	GAAGACGA	244	
2810	CUGAACAA	CUGAUGAG	GCCGUUAGGC	CGAA	AGCCUGUC	3024	GCACGGCU	U	UUGUUCAG	245	
2811	UCUGAAC	CUGAUGAG	GCCGUUAGGC	CGAA	AAGCCGUG	3025	CACGGCUU	U	UGUUCAGA	246	
2812	AUCUGAAC	CUGAUGAG	GCCGUUAGGC	CGAA	AAAGCCGU	3026	ACGGCUUU	U	GUUCAGAU	247	
2815	GGCAUCUG	CUGAUGAG	GCCGUUAGGC	CGAA	ACAAAAGC	3027	GCUUUUUG	U	CAGAUGCC	248	
2816	CGGCAUCU	CUGAUGAG	GCCGUUAGGC	CGAA	AACAAAAG	3028	CUUUUUGU	C	AGAUGCCG	249	
2836	CAGGGGAA	CUGAUGAG	GCCGUUAGGC	CGAA	AGGCCGUG	3029	CACGGCCU	A	UUCCCCUG	250	
2838	ACCAGGGG	CUGAUGAG	GCCGUUAGGC	CGAA	AUAGGCCG	3030	CGGCCU	AU	U	CCCCUGGU	251
2839	CACCAAGG	CUGAUGAG	GCCGUUAGGC	CGAA	AAUAGGCC	3031	GGCCU	AU	C	CCCUGGUG	252
2864	GGUCCGGG	CUGAUGAG	GCCGUUAGGC	CGAA	AUCCAGCA	3032	UGCUGGAU	A	CCCGGACC	253	
2892	AGCUGGAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUCCGUC	3033	GAGCGACU	A	CUCCAGCU	254	
2895	CAUAGCUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUAGUCG	3034	CGACUACU	C	CAGCUAUG	255	
2901	UCCGGGCA	CUGAUGAG	GCCGUUAGGC	CGAA	AGCUGGAG	3035	CUCCAGCU	A	UGCCCGGA	256	
2913	CUCUGAUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGUCCGG	3036	CCGGACCU	C	CAUCAGAG	257	
2917	CUGGCUCU	CUGAUGAG	GCCGUUAGGC	CGAA	AUGGAGGU	3037	ACCUCCAU	C	AGAGCCAG	258	
2927	GAAGGUGA	CUGAUGAG	GCCGUUAGGC	CGAA	ACUGGCUC	3038	GAGCCAGU	C	UCACCUUC	259	
2929	UUGAAGGU	CUGAUGAG	GCCGUUAGGC	CGAA	AGACUGGC	3039	GCCAGUCU	C	ACCUUCA	260	
2934	CGCGGUUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGUGAGA	3040	UCUCACCU	U	CAACCGCG	261	
2935	CGCGGUU	CUGAUGAG	GCCGUUAGGC	CGAA	AAGGUGAG	3041	CUCACCUU	C	AACCGCGG	262	
2946	CAGCCUUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCCGCGG	3042	CCGCGGCU	U	CAAGGCUG	263	
2947	CCAGCCUU	CUGAUGAG	GCCGUUAGGC	CGAA	AGCCGCGG	3043	CGCGGCUU	C	AAGGCUGG	264	
2969	GAGUUUG	CUGAUGAG	GCCGUUAGGC	CGAA	ACGCAUGU	3044	ACAUGCGU	C	GCAAACUC	265	
2977	ACCCCAA	CUGAUGAG	GCCGUUAGGC	CGAA	AGUUUGCG	3045	CGCAAACU	C	UUUGGGGU	266	
2979	AGACCCCA	CUGAUGAG	GCCGUUAGGC	CGAA	AGAGUUUG	3046	CAAACUCU	U	UGGGGUUCU	267	

2980	AAGACCCC	CUGAUGAG	GCCGUUAGGC	CGAA	AAGAGUUU	3047	AAACUCUU	U	GGGGUCUU	268
2986	AGCCGCAA	CUGAUGAG	GCCGUUAGGC	CGAA	ACCCCAAA	3048	UUUGGGGU	C	UUGCGGCU	269
2988	UCAGCCGC	CUGAUGAG	GCCGUUAGGC	CGAA	AGACCCCA	3049	UGGGGUCU	U	GCGGCUGA	270
3002	CAGGCUGU	CUGAUGAG	GCCGUUAGGC	CGAA	ACACUUA	3050	UGAAGUGU	C	ACAGCCUG	271
3012	AAUCCAGA	CUGAUGAG	GCCGUUAGGC	CGAA	ACAGGCUG	3051	CAGCCUGU	U	UCUGGAUU	272
3013	AAAUCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	AACAGGCU	3052	AGCCUGUU	U	CUGGAUUU	273
3014	CAAAUCCA	CUGAUGAG	GCCGUUAGGC	CGAA	AAACAGGC	3053	GCCUGUUU	C	UGGAUUUG	274
3020	CACCUGCA	CUGAUGAG	GCCGUUAGGC	CGAA	AUCCAGAA	3054	UUCUGGAU	U	UGCAGGUG	275
3021	UCACCCUG	CUGAUGAG	GCCGUUAGGC	CGAA	AAUCCAGA	3055	UCUGGAUU	U	GCAGGUGA	276
3037	ACCGUCUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGCUGUU	3056	AAACAGCCU	C	CAGACGGU	277
3058	AUCUUUA	CUGAUGAG	GCCGUUAGGC	CGAA	AUGUUGGU	3057	ACCAACAU	C	UACAAGAU	278
3060	GGAUCUUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGAUGUUG	3058	CAACAUCU	A	CAAGAUCU	279
3067	AGCAGGAG	CUGAUGAG	GCCGUUAGGC	CGAA	AUCUUGUA	3059	UACAAGAU	C	CUCCUGCU	280
3070	UGCAGCAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGAUCUU	3060	AAGAUCU	C	CUGCUGCA	281
3084	GAACCCUG	CUGAUGAG	GCCGUUAGGC	CGAA	ACGCCUGC	3061	GCAGGCGU	A	CAGGUUUC	282
3090	AUGCGUGA	CUGAUGAG	GCCGUUAGGC	CGAA	ACCUGUAC	3062	GUACAGGU	U	UCACGCAU	283
3091	CAUGCUGU	CUGAUGAG	GCCGUUAGGC	CGAA	AACCUUGA	3063	UACAGGUU	U	CACGCAUG	284
3092	ACAUGCUG	CUGAUGAG	GCCGUUAGGC	CGAA	AAACCCUGU	3064	ACAGGUUU	C	ACGCAUGU	285
3112	UGAAAUGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCUGCAG	3065	CUGCAGCU	C	CCAUUUCA	286
3117	GCUGAUGA	CUGAUGAG	GCCGUUAGGC	CGAA	AUGGGAGC	3066	GCUCCCAU	U	UCAUCAGC	287
3118	UGCUGAUG	CUGAUGAG	GCCGUUAGGC	CGAA	AUUGGAG	3067	CUCCCAUU	U	CAUCAGCA	288
3119	UUGCUGAU	CUGAUGAG	GCCGUUAGGC	CGAA	AAUUGGGA	3068	UCCCAUUU	C	AUCAGCAA	289
3122	AACUUGCU	CUGAUGAG	GCCGUUAGGC	CGAA	AUGAAAUG	3069	CAUUUCAU	C	AGCAAGUU	290
3130	UUCUUCCA	CUGAUGAG	GCCGUUAGGC	CGAA	ACUUGCUG	3070	CAGCAAGU	U	UGGAAGAA	291
3131	GUUCUUC	CUGAUGAG	GCCGUUAGGC	CGAA	AACUUGCU	3071	AGCAAGUU	U	GGAAGAAC	292
3147	GCAGGAAA	CUGAUGAG	GCCGUUAGGC	CGAA	AUGUGGGG	3072	CCCCACAU	U	UUUCCUGC	293
3148	CGCAGGAA	CUGAUGAG	GCCGUUAGGC	CGAA	AAUGUGGG	3073	CCCACAUU	U	UUUCCUGC	294
3149	GGCAGGGA	CUGAUGAG	GCCGUUAGGC	CGAA	AAUUGUGG	3074	CCACAUUU	U	UCCUGCGC	295
3150	CGGCAGG	CUGAUGAG	GCCGUUAGGC	CGAA	AAAUGUG	3075	CACAUUUU	U	CCUGCGCG	296
3151	ACGCGCAG	CUGAUGAG	GCCGUUAGGC	CGAA	AAAAUGU	3076	ACAUUUUU	C	CUGCGCGU	297
3160	UCAGAGAU	CUGAUGAG	GCCGUUAGGC	CGAA	ACGCGCAG	3077	CUGCGCGU	C	AUCUCUGA	298
3163	GUGUCAGA	CUGAUGAG	GCCGUUAGGC	CGAA	AUGACGGG	3078	CGCGUCAU	C	UCUGACAC	299
3165	CCGUGUCA	CUGAUGAG	GCCGUUAGGC	CGAA	AGAUGACG	3079	CGUCAUCU	C	UGACACGG	300
3177	AGCAGAGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGCCGUG	3080	CACGGCCU	C	CCUCUGCU	301

3181	GAGUAGCA	CUGAUGAG	GCCGUUAGGC	CGAA	AGGGAGGC	3081	GCCUCCCU	C	UGC	UACUC	302
3186	GGAUGGAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCAGAGG	3082	CCUCUGCU	A	CUCCA	UCC	303
3189	UCAGGAUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUAGCAG	3083	CUGCUACU	C	CAUCC	UGA	304
3193	GCUUUCAG	CUGAUGAG	GCCGUUAGGC	CGAA	AUGGAGUA	3084	UACUCCAU	C	CUGAA	AAGC	305
3219	CCCCCAGC	CUGAUGAG	GCCGUUAGGC	CGAA	ACAUCCCU	3085	AGGGAUGU	C	GCUGGGGG		306
3248	GGAGGGCA	CUGAUGAG	GCCGUUAGGC	CGAA	AGGGCCGG	3086	CCGGCCCU	C	UGCCCUCC		307
3255	CGGCCUCG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGGCAGA	3087	UCUGCCCU	C	CGAGGCCG		308
3288	UGAGCAGG	CUGAUGAG	GCCGUUAGGC	CGAA	AUGCUUGG	3088	CCAAGCAU	U	CCUGC	UCA	309
3289	UUGAGCAG	CUGAUGAG	GCCGUUAGGC	CGAA	AAUGCUUG	3089	CAAGCAU	C	CUGC	UCA	310
3295	GUCAGCUTU	CUGAUGAG	GCCGUUAGGC	CGAA	AGCAGGAA	3090	UUCUCUGU	C	AAGCUGAC		311
3305	ACGGUGUC	CUGAUGAG	GCCGUUAGGC	CGAA	AGUCAGCU	3091	AGCUGACU	C	GACACCGU		312
3316	ACGUAGGU	CUGAUGAG	GCCGUUAGGC	CGAA	ACACGGUG	3092	CACCGUGU	C	ACCUACGU		313
3321	GUGGCACG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGUGACA	3093	UGUCACCU	A	CGUGCCAC		314
3331	GACCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUGGCAC	3094	GUGCCACU	C	CUGGGGUC		315
3339	UCCUGAGU	CUGAUGAG	GCCGUUAGGC	CGAA	ACCCAGG	3095	CCUGGGGU	C	ACUCAGGA		316
3343	GUUGUCCU	CUGAUGAG	GCCGUUAGGC	CGAA	AGUGACCC	3096	GGGUCACU	C	AGGACAGC		317
3368	GAGCUUCC	CUGAUGAG	GCCGUUAGGC	CGAA	ACUCAGCU	3097	AGCUGAGU	C	GGAAGCUC		318
3376	GUCCCCGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCUUCCG	3098	CGGAAGCU	C	CCGGGGAC		319
3429	UGAAGUCU	CUGAUGAG	GCCGUUAGGC	CGAA	AGGGCAGU	3099	ACUGCCCU	C	AGACUUCA		320
3435	UGGUCUUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUCUGAG	3100	CUCAGACU	U	CAAGACCA		321
3436	AUGGUCUU	CUGAUGAG	GCCGUUAGGC	CGAA	AAGUCUGA	3101	UCAGACUU	C	AAGACCAU		322
3445	CAGUCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	AUGGUCUU	3102	AAGACCAU	C	CUGGACUG		323
3503	CCCGGCGU	CUGAUGAG	GCCGUUAGGC	CGAA	ACAGGGCU	3103	AGCCCUGU	C	ACGCCGGG		324
3514	GGGACGUA	CUGAUGAG	GCCGUUAGGC	CGAA	AGCCCGGC	3104	GCCGGGCU	C	UACGUCCC		325
3516	UUGGGACG	CUGAUGAG	GCCGUUAGGC	CGAA	AGAGCCCG	3105	CGGGCUCU	A	CGUCCCAG		326
3520	CUCCUCUG	CUGAUGAG	GCCGUUAGGC	CGAA	ACGUAGAG	3106	CUCUACGU	C	CCAGGGAG		327
3568	AGGCCUCA	CUGAUGAG	GCCGUUAGGC	CGAA	ACUCCAG	3107	CUGGGAGU	C	UGAGGGCU		328
3587	CUUGGCCA	CUGAUGAG	GCCGUUAGGC	CGAA	ACACUCAC	3108	GUGAGUGU	U	UGGCCGAG		329
3588	CCUCGGCC	CUGAUGAG	GCCGUUAGGC	CGAA	AACACUCA	3109	UGAGUGUU	U	GGCCGAGG		330
3606	UUCAGCCG	CUGAUGAG	GCCGUUAGGC	CGAA	ACAUGCAG	3110	CUGCAUGU	C	CGGCUGAA		331
3625	CUCAGCCG	CUGAUGAG	GCCGUUAGGC	CGAA	ACACUCAG	3111	CUGAGUGU	C	CGGCUGAG		332
3648	CUUGGCUG	CUGAUGAG	GCCGUUAGGC	CGAA	ACACUCGC	3112	GCGAGUGU	C	CAGCCAA		333
3667	GUGUGCUG	CUGAUGAG	GCCGUUAGGC	CGAA	ACACUCAG	3113	CUGAGUGU	C	CAGCACAC		334
3683	GAAGUGAA	CUGAUGAG	GCCGUUAGGC	CGAA	ACGGCAGG	3114	CCUGCCGU	C	UUCACUUC		335

3685	GGGAAGUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGACGGCA	3115	UGCCGUCU	U	CACUUCCC	336
3686	GGGAAGU	CUGAUGAG	GCCGUUAGGC	CGAA	AAGACGGC	3116	GCCGUCUU	C	ACUUCCCC	337
3690	CUGUGGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUGAAGA	3117	UCUUCACU	U	CCCCACAG	338
3691	CCUGUGGG	CUGAUGAG	GCCGUUAGGC	CGAA	AAGUGAAG	3118	CUUCACUU	C	CCCACAGG	339
3708	GUGGAGCC	CUGAUGAG	GCCGUUAGGC	CGAA	AGCGCCAG	3119	CUGGCGCU	C	GGCUCACC	340
3713	CUGGGGUG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCCGAGC	3120	GCUCGGCU	C	CACCCCAG	341
3730	GUGAGGAA	CUGAUGAG	GCCGUUAGGC	CGAA	AGCUGGCC	3121	GGCCAGCU	U	UCCUCAC	342
3731	GGUGAGGA	CUGAUGAG	GCCGUUAGGC	CGAA	AAGCUGGC	3122	GCCAGCUU	U	UCCUCACC	343
3732	UGGUGAGG	CUGAUGAG	GCCGUUAGGC	CGAA	AAAGCUGG	3123	CCAGCUUU	U	CCUCACCA	344
3733	CUGGUGAG	CUGAUGAG	GCCGUUAGGC	CGAA	AAAAGCUG	3124	CAGCUUUU	C	CUCACCAG	345
3736	CUCCUGGU	CUGAUGAG	GCCGUUAGGC	CGAA	AGGAAAAG	3125	CUUUUCCU	C	ACCAGGAG	346
3752	GGGAGUGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGCCGGGC	3126	GCCGGGCU	U	CCACUCCC	347
3753	GGGGAGUG	CUGAUGAG	GCCGUUAGGC	CGAA	AAGCCGGG	3127	CCCGGCUU	C	CACUCCCC	348
3758	UAUGUGGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGUGGAAAG	3128	CUUCCACU	C	CCCACAU	349
3766	ACUAUCC	CUGAUGAG	GCCGUUAGGC	CGAA	AUGUGGGG	3129	CCCCACAU	A	GGAUAGU	350
3772	GGAUGGAC	CUGAUGAG	GCCGUUAGGC	CGAA	AUUCUUAU	3130	AUAGGAU	A	GUCCAUC	351
3775	UGGGGAUG	CUGAUGAG	GCCGUUAGGC	CGAA	ACUAUCC	3131	GGAUAGU	C	CAU'CCCCA	352
3779	AAUCUGGG	CUGAUGAG	GCCGUUAGGC	CGAA	AUGGACUA	3132	UAGUCCAU	C	CCCAGAUU	353
3787	CAAUGGCG	CUGAUGAG	GCCGUUAGGC	CGAA	AUCUGGGG	3133	CCCCAGAU	U	CGCCAUUG	354
3788	ACAAUGGC	CUGAUGAG	GCCGUUAGGC	CGAA	AUUCUGGG	3134	CCCAGAUU	C	GCCAUUGU	355
3794	GGGUGAAC	CUGAUGAG	GCCGUUAGGC	CGAA	AUGGGCAA	3135	UUCGCCAU	U	GUUCACCC	356
3797	GAGGGGUG	CUGAUGAG	GCCGUUAGGC	CGAA	ACAAUGGC	3136	GCCAUUGU	U	CACCCCUC	357
3798	CGAGGGGU	CUGAUGAG	GCCGUUAGGC	CGAA	AACAUGG	3137	CCAUUGUU	C	ACCCCUCG	358
3805	GGCAGGGC	CUGAUGAG	GCCGUUAGGC	CGAA	AGGGUGUA	3138	UCACCCCU	C	GCCCUGCC	359
3816	AGGCAAAG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGGCAGG	3139	CCUGCCCU	C	CUUUGCCU	360
3819	GGAAGGCA	CUGAUGAG	GCCGUUAGGC	CGAA	AGGAGGGC	3140	GCCCUCUU	U	UGCCUUC	361
3820	UGGAAGGC	CUGAUGAG	GCCGUUAGGC	CGAA	AAGGAGGG	3141	CCCUCUUU	U	GCCUUCCA	362
3825	GGGGGUGG	CUGAUGAG	GCCGUUAGGC	CGAA	AGGCAAAG	3142	CUUUGCCU	U	CCACCCCC	363
3826	UGGGGGUG	CUGAUGAG	GCCGUUAGGC	CGAA	AAGGCAAA	3143	UUUGCCCU	C	CACCCCCA	364
3839	UCCACCUG	CUGAUGAG	GCCGUUAGGC	CGAA	AUGGUGGG	3144	CCCACCAU	C	CAGGUGGA	365
3873	AAUUCCCA	CUGAUGAG	GCCGUUAGGC	CGAA	AGCUCCCA	3145	UGGGAGCU	C	UGGGAUUU	366
3881	UCACUCCA	CUGAUGAG	GCCGUUAGGC	CGAA	AUJCCAG	3146	CUGGGAU	U	UGGAGUGA	367
3882	GUCACUCC	CUGAUGAG	GCCGUUAGGC	CGAA	AUUCCCA	3147	UGGGAUUU	U	GGAGUGAC	368
3907	CGCCUGUG	CUGAUGAG	GCCGUUAGGC	CGAA	ACAGGGCA	3148	UGCC'CCUGU	A	CACAGGCG	369

3940	CCACAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACCCCAU	3149	AUGGGGU C	CCUGUGG	370
3950	CCCAAUU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACCCACAG	3150	CUGUGGU C	AAAUUGG	371
3955	CUGCCCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUUUGACC	3151	GGUCAAU U	GGGGGAG	372
3977	CAGUAUU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACUCCAC	3152	GUGGGAGU A	AAUACUG	373
3982	AUAUUCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUUUUACU	3153	AGUAAAAU A	CUGAAUUAU	374
3989	AACUCAUA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUUCAGUA	3154	UACUGAAU A	UAUGAGUU	375
3991	AAACUCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AUAUUCAG	3155	CUGAAUUA A	UGAGUUUU	376
3997	AACUGAAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACUCAUAU	3156	AUAUGAGU U	UUUCAGUU	377
3998	AAACUGAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AACUCAUA	3157	UAUGAGUU U	UUCAGUUU	378
3999	AAAACUGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAACUCAU	3158	AUGAGUUU U	UCAGUUUU	379
4000	CAAAACUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAACUCA	3159	UGAGUUUU U	CAGUUUUG	380
4001	UCAAACU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAAAACUC	3160	GAGUUUUU C	AGUUUUGA	381
4005	UUUUUCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ACUGAAAA	3161	UUUUCAGU U	UGAAAAAA	382
4006	UUUUUUCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AACUGAAA	3162	UUUCAGUU U	UGAAAAAA	383
4007	UUUUUUUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	AAACUGAA	3163	UUCAGUUU U	GAAAAAAA	384

Stem Length = 8 . Core Sequence = CUGAUGAG GCCGUUAGGC CGAA

Seq1 = TERT (Homo sapiens telomerase reverse transcriptase (TERT) mRNA, 4015 bp); Nakamura *et al.*, Science 277 (5328), 955-959 (1997)

Table IV: Human telomerase reverse transcriptase (TERT) NCH Ribozyme and Target Sequence

nt. Position	Ribozyme Sequence	Seq ID Nos	Substrate Sequence	Seq ID Nos
14	GCGCAGCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IACGACGC	385	GCUGCGUC C UGUGCGC	3164
15	UGCGCAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGACGCAG	386	CUGCGUCC U GCUGCGCA	3165
18	ACGUGCGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAGGACG	387	CGUCCUGC U GCGCACGU	3166
23	UUCCACAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGCAGCA	388	UGCUGGCG A CGUGGAA	3167
34	GGGGCCAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUUCCCA	389	UGGGAAGC C CUGGCCCC	3168
35	CGGGGCCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCUUCCC	390	GGGAAGCC C UGGCCCCCG	3169
36	CCGGGGCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGCUUCC	391	GGAAGCCC U GGCCCCCG	3170
40	GUGGCCGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCAGGGC	392	GCCCUGGC C CCGGCCAC	3171
41	GGUGGCCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCAGGGG	393	CCUUGGCC C CGGCCACC	3172
42	GGGUGGCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGCCAGG	394	CCUGGCC C GGCCACCC	3173
46	GCGGGGGU CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCGGGGC	395	GCCCCGGC C ACCCCCGC	3174
47	CGCGGGGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCCTGGG	396	CCCCGGCC A CCCCCTGG	3175
49	AUCGCGGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGGCCGG	397	CCGGCCAC C CCCGCGAU	3176
50	CAUCGCGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGGCCCG	398	CGGCCACC C CCGCGAUG	3177
51	GCAUCGCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGUGGCC	399	GGCCACC C CGCGAUGC	3178
52	GGCAUCGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGUUGGC	400	GCCACCCC C GCGAUGCC	3179
60	GAGCGCGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAUCGCG	401	CGCGAUGC C GCGCGCUC	3180
67	CAGCGGGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGCGCGG	402	CCGCGGCG U CCCCCTUG	3181
69	GGCAGCGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGCGCGC	403	GCGGCGUC C CCGUGCCC	3182
70	CGGCAGCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGAGCGCG	404	CGCGUCC C CGCUGCCG	3183
71	UCGGCAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGAGCGC	405	GCGCUCCC C GCUGCCGA	3184
74	GGCUCGGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGGGGAG	406	CUCCCCGC U GCCGAGCC	3185
77	CACGGCUC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAGCGGG	407	CCCGCUGC C GAGCCGUG	3186
82	GAGCGCAC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUCGGGCA	408	UGCCGAGC C GUGCGCUC	3187
89	CAGCAGGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGCACGG	409	CCGUGCGC U CCCUGCUG	3188
91	CGCAGCAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGCGCAC	410	GUGCGCUC C CUGCUGCG	3189
92	GCGCAGCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGCGCA	411	UGCGUCC C UGUGCGC	3190
93	UGCGCAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGAGCGC	412	GCGCUCCC U GCUGCGCA	3191
96	GGCUGCGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAGGGAG	413	CUCCUGC U GCGCAGCC	3192
101	GUAGUGGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGCAGCA	414	UGCUGCGC A GCCACUAC	3193

104	GCGGUAGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGCGCA	415	UGCGCAGC	C	ACUACCGC	3194
105	CGCGGUAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCUGCGC	416	GCGCAGCC	A	CUACCGCG	3195
107	CUCGCGGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGGUGUC	417	GCAGCCAC	U	ACCGCGAG	3196
110	CACCUCGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUAGUGGC	418	GCCACUAC	C	GCGAGGUG	3197
120	CCAGCGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACCUUG	419	CGAGGUGC	U	GCCGCUGG	3198
123	UGGCCAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGCACC	420	GGUGCUGC	C	GCUGGGCA	3199
126	ACGUGGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGCAGC	421	GCUGCCGC	U	GGCCACGU	3200
130	ACGAACGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGCGG	422	CCGCUGGC	C	ACGUUCGU	3201
131	CACGAACG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCAGCG	423	CGCUGGCC	A	CGUUCGUG	3202
146	GGGCCCCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGCCGCA	424	UGCGGCGC	C	UGGGGCC	3203
147	GGGGCCCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCCCGC	425	GCGGCGCC	U	GGGGCCCC	3204
153	AGCCUUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCCAGG	426	CCUGGGGC	C	CCAGGGCU	3205
154	CAGCCUCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCCCAG	427	CUGGGGCC	C	CAGGGCUG	3206
155	CCAGCCCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCCCCA	428	UGGGGCC	C	AGGGCUGG	3207
156	GCCAGCCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGCCCC	429	GGGGCCCC	A	GGGCUGGC	3208
161	CAGCGGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCCUGGG	430	CCCAGGGC	U	GGCGGCUG	3209
168	GCUGCACC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGCCCAG	431	CUGGCGGC	U	GGUGCAGC	3210
174	CCCCGCGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACCAGC	432	GCUGGUGC	A	GCGCGGGG	3211
185	AGCCGCGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCCCCGC	433	GCGGGGAC	C	CGGCGGCU	3212
186	AAGCCGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUCCCCG	434	CGGGGACC	C	GGCGGGCU	3213
193	GCGCGGAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGCCCCG	435	CCGGCGGC	U	UUCCGCGC	3214
197	CAGCGCGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAAGCCG	436	CGGCUUUC	C	GCGCGCUG	3215
204	GGGCCACC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGCGCGG	437	CCGCGCGC	U	GGUGGCC	3216
211	AGGCACUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCACCAG	438	CUGGUGGC	C	CAGUGCCU	3217
212	CAGGCACU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCACCA	439	UGGUGGCC	C	AGUGCCUG	3218
213	CCAGGCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCCACC	440	GGUGGCC	A	GUGCCUGG	3219
218	GCACACCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACUGGG	441	CCCAGUGC	C	UGGUGUGC	3220
219	CGCACACC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCACUGG	442	CCAGUGCC	U	GGUGUGCG	3221
231	CGUCCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGGCAC	443	GUGCGUGC	C	CUGGGACG	3222
232	GCGUCCCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCACGCA	444	UGCGUGCC	C	UGGGACGC	3223
233	UGCGUCCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCACGC	445	GCGUGCCC	U	GGGACGCA	3224
241	GGCGGCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGUCCCC	446	UGGGACGC	A	CGGCCGCC	3225
246	CGGGGGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGUGCG	447	GGCACGGC	C	GCCCCCG	3226
249	CGGCGGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGCCGU	448	ACGGCGGC	C	CCCCCGCG	3227

250	GCGCGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCGGCGG	449	CGGCGGCC	C	CGGCGGCC	3228
251	GGCGGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCGGGCC	450	GGCGGCC	C	CGGCGGCC	3229
252	GGCGGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGCGGC	451	GCGGCCCC	C	GCGGCCCC	3230
253	GGGCGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGCGG	452	CGGCCCC	C	GCGGCCCC	3231
256	GAGGGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGGGGG	453	CCCCCGC	C	GCCCCCUC	3232
259	AAGGAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGCGGG	454	CCGCGCGC	C	CCCUCCUU	3233
260	GAAGAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCGGGG	455	CCGCGGCC	C	CCUCCUUC	3234
261	GGAAGAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGGGG	456	CGCGGCC	C	CUCCUUC	3235
262	CGGAAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGCGGC	457	GCGGCCCC	C	UCCUUCGG	3236
263	GCGGAAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGCGG	458	CGGCCCC	U	CCUUCGCG	3237
265	UGGCGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGGGGC	459	GCCCCCUC	C	UUCGCGCA	3238
266	CUGCGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGGGG	460	CCCCUCC	U	UCCGCCAG	3239
269	CACCGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAGGAGG	461	CCUCCUUC	C	GCCAGGUG	3240
272	GGACACU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGAAGG	462	CCUUCGCG	C	AGGUGUCC	3241
273	AGGACAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCGGAAG	463	CUUCCGCC	A	GGUGUCCU	3242
280	UUCAGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACACCTG	464	CAGGUGC	C	UGCCUGAA	3243
281	CUUCAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGACACCU	465	AGGUGUCC	U	GCCUGAAG	3244
284	CUCCUUA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGGACA	466	UGUCCUGC	C	UGAAGGAG	3245
285	GUCCUUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCAGGAC	467	GUCCUGCC	U	GAAGGAGC	3246
294	GGGCCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUCCUUC	468	GAAGGAGC	U	GGUGGCC	3247
301	AGCACUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCACCAG	469	CUGGUGGC	C	CGAGUGCU	3248
302	CAGCACUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCACCA	470	UGGUGGCC	C	GAGUGCUG	3249
309	GCCUCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACUCGG	471	CCGAGUGC	U	GCAGAGGC	3250
312	ACAGCCUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGCACU	472	AGUGCUGC	A	GAGGCUGU	3251
318	GUUCGCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUUCGC	473	GCAGAGGC	U	GUGCGAGC	3252
345	CGAAGGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACGUUC	474	GAACGUGC	U	GGCCUUCG	3253
349	AAGCGAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCAGCAC	475	GUGCUGGC	C	UUCGGCUU	3254
350	GAAGCCGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCAGCA	476	UGCUGGCC	U	UCGGCUUC	3255
356	CAGCGCGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGAAGG	477	CCUUCGGC	U	UCGCGCUG	3256
363	CGUCCAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGCGAAG	478	CUUCGCGC	U	GCUGGACG	3257
366	CCCCGUCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGCGCG	479	CGCGCUGC	U	GGACGGGG	3258
376	CCCCCGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCCCGUC	480	GACGGGGC	C	CGCGGGGG	3259
377	GCCCCGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCCCGU	481	ACGGGGCC	C	GCGGGGGC	3260
386	CUCGGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCCCCGC	482	GCGGGGGC	C	CCCCCGAG	3261



387	CCUCGGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCCCCCG	483	CGGGGGCC C CCCCAGG	3262
388	GCCUCGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGCCCCC	484	GGGGGCC C CCGAGGC	3263
389	GGCTUCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGCCCCC	485	GGGGCCCC C CCGAGGC	3264
390	AGGCCUC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGGGCCC	486	GGGGCCCC C CGAGGCCU	3265
391	AAGGCCUC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGGGGCC	487	GGGGCCCC C GAGGCCUU	3266
397	GUGGUGAA CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCUCGGG	488	CCCGAGGC C UUCACCAC	3267
398	GGUGGUGA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCCUCGG	489	CCGAGGCC U UCACCACC	3268
401	GCUGGUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAAGGCCU	490	AGGCCUUC A CCACCAGC	3269
403	ACGUCUGU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGAAGGC	491	GCCUUCAC C ACCAGCGU	3270
404	CACGUCUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGUGAAGG	492	CCUUCACC A CCAGCGUG	3271
406	CGCACGCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGGUGAA	493	UUCACCAC C AGCGUGCG	3272
407	GCGCAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGUGGUGA	494	UCACCACC A GCGUGCGC	3273
416	CAGGUAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGCACGC	495	GCGUGCGC A GCUACCUG	3274
419	GGCAGGU CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUGCGCA	496	UGCGCAGC U ACCUGCCC	3275
422	GUUGGGCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUAGCUGC	497	GCAGCUAC C UGCCCCAAC	3276
423	UGUUGGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGUAGCUG	498	CAGCUACC U GCCCAACA	3277
426	CCGUGUUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAGGUAG	499	CUACCUGC C CAACACGG	3278
427	ACCGUGUU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCAGGUA	500	UACCUUGC C AACACGGU	3279
428	CACCGUGU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCAGGU	501	ACCUGCCC A ACACGGUG	3280
431	GGUCACCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUUGGGCA	502	UGCCCCAAC A CGGUGACC	3281
439	AGUGCGUC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUCACCGU	503	ACGGUGAC C GACGCACU	3282
445	CCCCGCAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGUCGGU	504	ACCGACGC A CUGCGGGG	3283
447	UCCCCCGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGCGUUG	505	CGACGCAC U GCGGGGGA	3284
471	GCAGCAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCCCCAC	506	GUGGGGGC U GCUGCUGC	3285
474	GGCGCAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAGCCCC	507	GGGGCUGC U GCUGCCGC	3286
477	CGCGGCGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAGCAGC	508	GCUGCUGC U GCGCCCGC	3287
482	GCCCCAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGCAGCA	509	UGCUGC GC C GCGUGGGC	3288
501	GGUGAAC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICACGUUG	510	CGACGUGC U GGUUCACC	3289
507	CCAGCAGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAACCAGC	511	GCUGGUUC A CCUGCUGG	3290
509	UGCCAGCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGAACCA	512	UGGUUCAC C UGCUGGCA	3291
510	GUGCCAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGUGAAC	513	GGUUCACC U GCUGGCAC	3292
513	AGCGUGCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAGGUGA	514	UCACCUGC U GGCACGCU	3293
517	GCGCAGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCAGCAG	515	CUGCUGGC A CGCUGCGC	3294
521	GAGCGGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGUGCCA	516	UGGCACGC U GCGCGCUC	3295

528	GCACAAAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGCGCAG	517	CUGCGCGC	U	CUUUGUGC	3296
530	CAGACAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGCGCGC	518	GCGCGCUC	U	UUGUGCUG	3297
537	GAGCCACC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACAAAG	519	CUUUGUC	U	GGUGGCUC	3298
544	CAGCUGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACCCAG	520	UUGUGGC	U	CCCAGCUG	3299
546	CGCAGCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGCCACC	521	GGUGGCUC	C	CAGCUGCG	3300
547	GCGCAGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGCCAC	522	GUGGCUC	C	AGCUGCGC	3301
548	GGCGCAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGCCA	523	UGGCUC	A	GCUGCGC	3302
551	GUAGGGCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGGGAG	524	CUCCAGC	U	GCGCCUAC	3303
556	ACCUGGUA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGCGCU	525	AGCUGCGC	C	UACCAGGU	3304
557	CACCUGGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGCGAGC	526	GCUGCGCC	U	ACCAGGUG	3305
560	GCACACCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUAGGCGC	527	GCGCCUAC	C	AGGUGUGC	3306
561	CGCACACC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGAGGCG	528	CGCCUACC	A	GGUGUGCG	3307
573	ACAGCGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGGCAC	529	GUGCGGGC	C	GCCGCUGU	3308
576	GGUACAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGCCCG	530	CGGCGCGC	C	GCUGUACC	3309
579	GCUGGUAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGCGGC	531	GCCGCGC	U	GUACCAGC	3310
584	GCCGAGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUACAGCG	532	CGCUGUAC	C	AGCUCGGC	3311
585	CGCCGAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUACAGC	533	GCUGUACC	A	GCUCGGCG	3312
588	CAGCGCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGGUAC	534	GUACCAGC	U	CGGCGCUG	3313
595	UGAGUGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGCCGAG	535	CUCGGCGC	U	GCCACUCA	3314
598	GCCUGAGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACGGGCC	536	GGCGCUGC	C	ACUCAGGC	3315
599	GGCCUGAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCAGCGC	537	GCGCUGCC	A	CUCAGGCC	3316
601	CGGGCCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGGCAGC	538	GCUGCCAC	U	CAGGCCCG	3317
603	GCCGGGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGUGGCA	539	UGCCACUC	A	GGCCCGGC	3318
607	GGGGGCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUAGU	540	ACUCAGGC	C	CGGCCCCC	3319
608	CGGGGGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCUGAG	541	CUCAGGCC	C	GGCCCCCG	3320
612	GUGGGCGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGGGCC	542	GGCCCCGC	C	CCCCGCCAC	3321
613	UGUGGGCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCGGGC	543	GCCCCGGC	C	CCGCCACA	3322
614	GUGUGGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCCGGG	544	CCCCGGCC	C	CGCCACAC	3323
615	CGUGUGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGCCGG	545	CCGGCCCC	C	GCCACACG	3324
618	UAGCGUGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGGGGC	546	GCCCCCGC	C	ACACGCUA	3325
619	CUAGCGUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCGGGGG	547	CCCCCGCC	A	CACGCUAG	3326
621	CACUAGCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGGCGGG	548	CCGCGCAC	A	CGCUAGUG	3327
625	GGUCCACU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGUGUGG	549	CCACACGC	U	AGUGGACC	3328
633	GCCUUCGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCCACUA	550	UAGUGGAC	C	CCGAAGGC	3329

634	CGCCUUCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGUCCACU	551	AGUGGACC C CGAAGGCG	3330
635	ACGCCUUC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGUCCAC	552	GUGGACCC C GAAGGCGU	3331
645	CGCAUCCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IACGCCUU	553	AAGGCGUC U GGGAUUGC	3332
661	UGGUUCCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCGUUUC	554	GAACGGGC C UGGAACCA	3333
662	AUGGUUCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCOCGUU	555	AACGGGCC U GGAACCAU	3334
668	GACGCUAU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUUCCAGG	556	CCUGGAAC C AUAGCGUC	3335
669	UGACGCUA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGUCCAG	557	CUGGAACC A UAGCGUCA	3336
677	GGCCUCCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IACGCUAU	558	AUAGCGUC A GGGAGGCC	3337
685	GGGACCCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCUCCCU	559	AGGGAGGC C GGGGUCCC	3338
692	GCCCAGGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IACCCCGG	560	CCGGGGUC C CCCUGGGC	3339
693	GGCCCAGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGACCCCG	561	CGGGGUCC C CCUGGGCC	3340
694	AGGCCCAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGACCCC	562	GGGUUCCC C CUGGGCCU	3341
695	CAGGCCCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGACCCC	563	GGGUUCCC C UGGGCCUG	3342
696	GCAGGCCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGGACCC	564	GGUCCCCC U GGGCCUCG	3343
701	GGCUGGCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCAGGG	565	CCCUGGGC C UGCCAGCC	3344
702	GGCUGGCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCCAGG	566	CCUGGGCC U GCCAGCCC	3345
705	CCGGGGCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAGGCCC	567	GGGCCUCG C AGCCCCGG	3346
706	CCCGGGGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCAGGCC	568	GGCCUGCC A GCCCCGGG	3347
709	GCACCCGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUGGCAG	569	CUGCCAGC C CCGGUGC	3348
710	GCACCCGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCUGGCA	570	UGCCAGCC C CGGGUGCG	3349
711	UCGCACCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGCUGGC	571	GCCAGCCC C GGGUGCGA	3350
734	GCUGGCAC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICOCGCCG	572	GCGGGGGC A GUGCCAGC	3351
739	CUUCGGCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICACUGCC	573	GGCAGUGC C AGCCGAAG	3352
740	ACUUCGGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCACUGC	574	GCAGUGCC A GCCGAAGU	3353
743	CAGACUUC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUGGCAC	575	GUGCCAGC C GAAGUCUG	3354
750	GCAACGGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IACUUCGG	576	CCGAAGUC U GCCGUUGC	3355
753	UGGGCAAC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAGACUU	577	AAGUCUGC C GUUGCCCA	3356
759	GCCUCUUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAACGGC	578	GCCGUUGC C CAAGAGGC	3357
760	GGCCUCUU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCAACGG	579	CCGUUGCC C AAGAGGCC	3358
761	GGGCCUCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGCAACG	580	CGUUGCCC A AGAGGCC	3359
768	CACGCCUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCUCUUG	581	CAAGAGGC C CAGGCGUG	3360
769	CCACGCCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCCUCUU	582	AAGAGGCC C AGGCGUGG	3361
770	GCCACGCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGCCUCU	583	AGAGGCC A GGCUGGCC	3362
781	UCAGGGGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGCCACG	584	CGUGGCGC U GCCCCUGA	3363

784	GGCUCAGG	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGCGCC	585	GGCGCUGC	C	CCUGAGCC	3364
785	CGGCUCAG	CUGAUGAG	GCCGUUAGGC	CGAA	IGCAGCGC	586	GCGCUGCC	C	CUGAGCCG	3365
786	CCGGCUCA	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCAGCG	587	GCGUGCCC	C	UGAGCCGG	3366
787	UCCGGCUC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCAGCG	588	GCUGCCCC	U	GAGCCGGA	3367
792	UCCGCUCC	CUGAUGAG	GCCGUUAGGC	CGAA	IUCAGGG	589	CCCUGAGC	C	GGAGCGGA	3368
804	GCCCAACG	CUGAUGAG	GCCGUUAGGC	CGAA	ICGUCCGC	590	GCGGACGC	C	CGUUGGGC	3369
805	UGCCCAAC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGUUCCG	591	CGGACGCC	C	GUUGGGCA	3370
813	AGGACCCC	CUGAUGAG	GCCGUUAGGC	CGAA	ICCCAACG	592	CGUUGGGC	A	GGGUUCCU	3371
820	UGGGCCCC	CUGAUGAG	GCCGUUAGGC	CGAA	IACCCUG	593	CAGGGGUC	C	UGGGCCCC	3372
821	GUGGGCCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGACCCCU	594	AGGGGUCC	U	GGGCCCAC	3373
826	CCCGGGUG	CUGAUGAG	GCCGUUAGGC	CGAA	ICCCAGGA	595	UCCUGGGC	C	CACCCGGG	3374
827	GCCCGGGU	CUGAUGAG	GCCGUUAGGC	CGAA	IGCCAGG	596	CCUGGGCC	C	ACCCGGGC	3375
828	UGCCCGGG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCCCAG	597	CUGGGCCC	A	CCCGGGCA	3376
830	CCUGCCCC	CUGAUGAG	GCCGUUAGGC	CGAA	IUGGGCCC	598	GGGCCCCAC	C	CGGGCAGG	3377
831	UCCUGCCC	CUGAUGAG	GCCGUUAGGC	CGAA	IUGGGCCC	599	GGCCACC	C	GGGCAGGA	3378
836	ACGGUCC	CUGAUGAG	GCCGUUAGGC	CGAA	ICCGGGU	600	ACCCGGGC	A	GGACGGU	3379
849	GGUCACUC	CUGAUGAG	GCCGUUAGGC	CGAA	IUCCACGC	601	GCGUGGAC	C	GAGUGACC	3380
857	GAACCCAC	CUGAUGAG	GCCGUUAGGC	CGAA	IUCACUCG	602	CGAGUGAC	C	GUGGUUUC	3381
866	CACCACAC	CUGAUGAG	GCCGUUAGGC	CGAA	IAAACCAC	603	GUGGUUUC	U	GUGUGGUG	3382
877	CUGGCAGG	CUGAUGAG	GCCGUUAGGC	CGAA	IACACCAC	604	GUGGUGUC	A	CCUGCCAG	3383
879	GUCUGGCA	CUGAUGAG	GCCGUUAGGC	CGAA	IUGACACC	605	GGUGUCAC	C	UGCCAGAC	3384
880	GGUCUGGC	CUGAUGAG	GCCGUUAGGC	CGAA	IGUGACAC	606	GUGUCACC	U	GCCAGACC	3385
883	GCGGGUCU	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGGUGA	607	UCACCCUG	C	AGACCCGC	3386
884	GGCGGGUC	CUGAUGAG	GCCGUUAGGC	CGAA	IGCAGGUG	608	CACCUGCC	A	GACCCGCC	3387
888	CUUCGGCG	CUGAUGAG	GCCGUUAGGC	CGAA	IUCUGGCA	609	UGCCAGAC	C	CGCCGAAG	3388
889	UCUUCGGC	CUGAUGAG	GCCGUUAGGC	CGAA	IGUCUGGC	610	GCCAGACC	C	GCCGAAGA	3389
892	GUUCUCUC	CUGAUGAG	GCCGUUAGGC	CGAA	ICGGGUCU	611	AGACCCGC	C	GAAGAAGC	3390
901	AAAGAGGU	CUGAUGAG	GCCGUUAGGC	CGAA	ICUUCUUC	612	GAAGAAGC	C	ACCUCUUU	3391
902	CAAAGAGG	CUGAUGAG	GCCGUUAGGC	CGAA	IGCUUCUU	613	AAGAAGCC	A	CCUCUUUG	3392
904	UCCAAAGA	CUGAUGAG	GCCGUUAGGC	CGAA	IUGGCUUC	614	GAAGCCAC	C	UCUUUGGA	3393
905	CUCCAAAG	CUGAUGAG	GCCGUUAGGC	CGAA	IGUGGCUU	615	AAGCCACC	U	CUUUGGAG	3394
907	CCCUCCAA	CUGAUGAG	GCCGUUAGGC	CGAA	IAGGUGGC	616	GCCACCUC	U	UUGGAGGG	3395
921	UGCCAGAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICGCACCC	617	GGGUGGCG	U	CUCUGGCA	3396
923	CGUGCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	IAGCGCAC	618	GUGCGCUC	U	CUGGCACG	3397

925	CGCGUGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1AGAGCGC	619	GCGCUCUC	U	GGCACGCG	3398
929	GUGGCGCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1CCAGAGA	620	UCUCUGGC	A	CGCGCCAC	3399
935	GUGGGAGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1CGCGUGC	621	GCACGGGC	C	ACUCCAC	3400
936	GGUGGGAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GCGCGUG	622	CACGCGCC	A	CUCCAC	3401
938	UGGUGGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1UGGCGCG	623	CGCGCCAC	U	CCCACCCA	3402
940	GAUGGGUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1AGUGGCG	624	CGCCACUC	C	CACCCAUC	3403
941	GAUGGGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GAGUGGC	625	GCCACUCC	C	ACCAUCC	3404
942	CGAUGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GGAGUGG	626	CCACUCCC	A	CCCAUCCG	3405
944	CACGGAUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1UGGGAGU	627	ACUCCAC	C	CAUCCGUG	3406
945	CCACGGAU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GUGGGAG	628	CUCCAC	C	AUCCGUGG	3407
946	CCCACGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GGUGGGA	629	UCCACCC	A	UCCGUGGG	3408
949	CGGCCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1AUGGGUG	630	CACCAUC	C	GUGGGCCG	3409
956	GUGCUGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1CCCACGG	631	CCGUGGGC	C	GCCAGCAC	3410
959	GUGGUGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1CGGCCCA	632	UGGGCCGC	C	AGCACCC	3411
960	CGUGGUGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GCGGCC	633	GGGCCGCC	A	GCACCAG	3412
963	CCGCGUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1CUGGCCG	634	CCGCCAGC	A	CCACGCCG	3413
965	GCCCCGGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1UGCUGGC	635	GCCAGCAC	C	ACGCGGGC	3414
966	GGCCCCGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GUGCUGG	636	CCAGCAC	A	CGCGGGCC	3415
974	GGAUGGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1CCCGCGU	637	ACGCGGC	C	CCCCAUCC	3416
975	UGGAUGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GCCCCGG	638	CGCGGGCC	C	CCCAUCCA	3417
976	GUGGAUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GGCCCCG	639	GCGGGCCC	C	CCAUCCAC	3418
977	UGUGGAUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GGGCCCG	640	CGGGCCCC	C	CAUCCACA	3419
978	AUGUGGAU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GGGGCCC	641	GGGCCCCC	C	AUCCACAU	3420
979	GAUGUGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GGGGGCC	642	GGCCCCC	A	UCCACAUC	3421
982	CGCGAUGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1AUGGGGG	643	CCCCCAUC	C	ACAUCGGG	3422
983	CCGCGAUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GAUGGGG	644	CCCCAUCC	A	CAUCGCGG	3423
985	GGCCCGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1UGGAUGG	645	CCAUCCAC	A	UCGCGGCC	3424
993	GACGUGGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1CCGCGAU	646	AUCGGGC	C	ACCACGUC	3425
994	GGACGUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GCCCGCA	647	UCGCGGCC	A	CCACGUCC	3426
996	AGGGACGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1UGGCCCG	648	GCGGCCAC	C	ACGUCCCU	3427
997	CAGGACG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GUGGCCG	649	CGGCCACC	A	CGUCCUG	3428
1002	UGUCCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1ACGUGGU	650	ACCACGUC	C	CUGGGACA	3429
1003	GUGUCCCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GACGUGG	651	CCACGUCC	C	UGGGACAC	3430
1004	CGUGUCCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	1GGACGUG	652	CACGUCCC	U	GGGACACG	3431

1010	ACAAGGCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCCAGG	653	CCUGGGAC	A	CGCCUUGU	3432
1014	GGGGACAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGUCC	654	GGACACGC	C	UUGUCCCC	3433
1015	GGGGGACA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCGUGUC	655	GACACGCC	U	UGUCCCCC	3434
1020	ACACCGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACAAGGC	656	GCCUUGUC	C	CCCGGUGU	3435
1021	UACACCGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGACAAGG	657	CCUUGUCC	C	CCGGUGUA	3436
1022	GUACACCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGACAAG	658	CUUGUCCC	C	CGGUGUAC	3437
1023	CGUACACC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGACAA	659	UUGUCCCC	C	GGUGUACG	3438
1033	UUGGUCUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGUACAC	660	GUGUACGC	C	GAGACCAA	3439
1039	AAGUGCUU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCUGGGC	661	GCCGAGAC	C	AAGCACUU	3440
1040	GAAGUGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUCUCGG	662	CCGAGACC	A	AGCACUUC	3441
1044	AGAGGAAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUUGGUC	663	GACCAAGC	A	CUUCCUCU	3442
1046	GUAGAGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGCUUGG	664	CCAAGCAC	U	UCCUCUAC	3443
1049	GGAGUAGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAGUGCU	665	AGCACUUC	C	UCUACUCC	3444
1050	AGGAGUAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAAGUGC	666	GCACUUC	U	CUACUCCU	3445
1052	UGAGGAGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGGAAGU	667	ACUUCUUC	U	ACUCCUCA	3446
1055	GCCUGAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUAGAGGA	668	UCCUCUAC	U	CCUCAGGC	3447
1057	UCGCCUGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGUAGAG	669	CUCUACUC	C	UCAGGCGA	3448
1058	GUCGCCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGUAGA	670	UCUACUCC	U	CAGGCGAC	3449
1060	UUGUCGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGGAGUA	671	UACUCCUC	A	GGCGACAA	3450
1067	CUGCUCCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCGCCUG	672	CAGGCGAC	A	AGGAGCAG	3451
1074	GCCGCAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUCCUUG	673	CAAGGAGC	A	GCUGCGGC	3452
1077	AGGGCCGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGCUCC	674	GGAGCAGC	U	GCGGCCCU	3453
1083	GGAAGGAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGCAGC	675	GCUGCGGC	C	CUCCUUC	3454
1084	AGGAAGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCGCAG	676	CUGCGGCC	C	UCCUUCUU	3455
1085	UAGGAAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGC'CGCA	677	UGCGGCC	U	CCUUCCUA	3456
1087	AGUAGGAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGGGCCG	678	CGGCCUUC	C	UUCCUACU	3457
1088	GAGUAGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGGGCC	679	GGCCUUC	U	UCCUACUC	3458
1091	GCUGAGUA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAGGAGG	680	CCUCCUUC	C	UACUCAGC	3459
1092	AGCUGAGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGAAGGAG	681	CUCCUUC	U	ACUCAGCU	3460
1095	GAGAGCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUAGGAAG	682	CUUCCUAC	U	CAGCUCUC	3461
1097	CAGAGAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGUAGGA	683	UCCUACUC	A	GCUCUCUG	3462
1100	CCUCAGAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGAGUA	684	UACUCAGC	U	CUCUGAGG	3463
1102	GGCCUCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGCUGAG	685	CUCAGCUC	U	CUGAGGCC	3464
1104	UGGGCCUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGAGCUG	686	CAGCUCUC	U	GAGGCCCA	3465

1110	UCAGGCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUCAGA	687	UCUGAGGC	C	CAGCCUGA	3466
1111	GUCAGGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCUCAG	688	CUGAGGCC	C	AGCCUGAC	3467
1112	AGUCAGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCCUCA	689	UGAGGCC	A	GCCUGACU	3468
1115	GCCAGUCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGGGCC	690	GGCCCCAGC	C	UGACUGGC	3469
1116	CGCCAGUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCUGGGC	691	GCCCCAGCC	U	GACUGGGC	3470
1120	CGAGCGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCAGGCU	692	AGCCUGAC	U	GGCGCUCG	3471
1126	AGCCUCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGCCAGU	693	ACUGGCGC	U	CGGAGGCU	3472
1134	UCUCCACG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUCCCGA	694	UCGGAGGC	U	CGUGGAGA	3473
1144	AGAAAGAU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCUCCAC	695	GUGGAGAC	C	AUCUUUCU	3474
1145	CAGAAAGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUCUCCA	696	UGGAGACC	A	UCUUUCUG	3475
1148	ACCCAGAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAUGGUCU	697	AGACCAUC	U	UUCUGGGU	3476
1152	UGGAACCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAAGAUG	698	CAUCUUUC	U	GGGUUCCA	3477
1159	CAGGGCCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAACCCAG	699	CUGGGUUC	C	AGGCCCCUG	3478
1160	CCAGGGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAACCCA	700	UGGGUUC	A	GGCCCCUG	3479
1164	GCAUCCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUGAA	701	UUCCAGGC	C	CUGGAUGC	3480
1165	GGCAUCCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCUGGA	702	UCCAGGCC	C	UGGAUGCC	3481
1166	UGGCAUCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCCUGG	703	CCAGGCC	U	GGAUGCCA	3482
1173	GAGUCCCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAUCCAG	704	CUGGAUGC	C	AGGACUC	3483
1174	GGAGUCCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCAUCCA	705	UGGAUGCC	A	GGGACUCC	3484
1180	CUGGGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCCUGG	706	CCAGGGAC	U	CCCCGCAG	3485
1182	ACUUGCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGUCCCU	707	AGGGACUC	C	CCGCAGGU	3486
1183	AACCUCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGUCCC	708	GGGACUCC	C	CGCAGGUU	3487
1184	CAACCUCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGAGUCC	709	GGACUCCC	C	GCAGGUUG	3488
1187	GGGCAACC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGGGAG	710	CUCCCCGC	A	GGUUGCCC	3489
1194	GCAGGCGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAAACCU	711	CAGGUUGC	C	CCGCCUGC	3490
1195	GGCAGCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCAACCU	712	AGGUUGCC	C	CGCCUGCC	3491
1196	GGCAGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCAACC	713	GGUUGCCC	C	GCCUGCCC	3492
1199	CUGGGGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGGGCA	714	UGCCCCGC	C	UGCCCCAG	3493
1200	GUUGGGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCGGGGC	715	GCCCCCGC	U	GCCCCCAGC	3494
1203	AGCGCUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGGCGG	716	CCGCCUGC	C	CCAGCGCU	3495
1204	UAGCGCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCAGGCG	717	CGCCUGCC	C	CAGCGCUA	3496
1205	GUAGCGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCAGGC	718	GCCUGCCC	C	AGCGCUAC	3497
1206	AGUAGCGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGCAGG	719	CCUGCCCC	A	GCGCUACU	3498
1211	UUGCCAGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGUGGG	720	CCCAGCGC	U	ACUGGCAA	3499

1214	CAUUGCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUAGCGCU	721	AGCGCUAC U GGCAAAUG	3500
1218	GCCGCAUU CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCAGUAG	722	CUACUGGC A AAUGCGGC	3501
1227	GAACAGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCGCAUU	723	AAUGCGGC C CCUGUUUC	3502
1228	AGAAACAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCCGCAU	724	AUGCGGCC C CUGUUUCU	3503
1229	CAGAAACA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGCCGCA	725	UGCGGCC C UGUUUUCUG	3504
1230	CCAGAAC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGGCCGC	726	GCGGCCCC U GUUUCUGG	3505
1236	GCAGCUCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAAACAGG	727	CCUGUUUC U GGAGCUGC	3506
1242	UCCCAAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUCCAGA	728	UCUGGAGC U GCUUGGGA	3507
1245	GGUUCCCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAGCUCC	729	GGAGCUGC U UGGGAACC	3508
1253	CUGCGCGU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUUCCCAA	730	UUGGGAAC C ACGCGCAG	3509
1254	ACUGCGCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGUUCCCA	731	UGGGAACC A CGCGCAGU	3510
1260	AGGGGCAC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGCGUGG	732	CCACGCGC A GUGCCCCU	3511
1265	CCCCUAGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICACUGCG	733	CGCAGUGC C CCUACGGG	3512
1266	CCCCGUAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCACUGC	734	GCAGUGCC C CUACGGGG	3513
1267	ACCCCGUA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGCACUG	735	CAGUGCCC C UACGGGGU	3514
1268	CACCCCGU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGGCACU	736	AGUGCCCC U ACGGGUG	3515
1278	UCUUGAGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICACCCCG	737	CGGGGUGC U CCUCAAGA	3516
1280	CGUCUUGA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGCACCC	738	GGGUGCUC C UCAAGACG	3517
1281	GGUCUUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGAGCAC	739	GGUGCUCC U CAAGACGC	3518
1283	GUGCGUCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGGAGCA	740	UGCUCUC A AGACGCAC	3519
1290	GCGGGCAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGUCUUG	741	CAAGACGC A CUGCCCCG	3520
1292	CAGCGGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGCGUCU	742	AGACGCAC U GCCCGCUG	3521
1295	UCGCAGCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAGUGCG	743	CGCACUGC C CGCUGCGA	3522
1296	CUCGCAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCAGUGC	744	GCACUGCC C GCUGCGAG	3523
1299	CAGCUCGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGGGCAG	745	CUGCCCCG U GCGAGCUG	3524
1306	GUGACCGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUCGCAG	746	CUGCGAGC U GCGGUCAC	3525
1313	UGCUGGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IACCGCAG	747	CUGGGGUC A CCCCAGCA	3526
1315	GCUCUGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGACCGC	748	GCGGUCAC C CCAGCAGC	3527
1316	GGCUGCUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGUGACCG	749	CGGUCACC C CAGCAGCC	3528
1317	CGGCUGCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGUGACC	750	GGUCACCC C AGCAGCCG	3529
1318	CCGCUGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGUGAC	751	GUCACCCC A GCAGCCGG	3530
1321	ACACCGGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUGGGGU	752	ACCCAGC A GCCGGUGU	3531
1324	CAGACACC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUGCUGG	753	CCAGCAGC C GGUGUCUG	3532
1331	CCGGGCAC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IACACCGG	754	CCGGUGUC U GUGCCCCG	3533



1336	UUCUCCG	CUGAUGAG	GCCGUUAGGC	CGAA	ICACAGAC	755	GUCUGUGC	C	CGGGAGAA	3534
1337	CUUCUCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGCACAGA	756	UCUGUGCC	C	GGGAGAAG	3535
1347	AGCCUUG	CUGAUGAG	GCCGUUAGGC	CGAA	ICUUCUCC	757	GGAGAAGC	C	CCAGGGCU	3536
1348	GAGCCUG	CUGAUGAG	GCCGUUAGGC	CGAA	IGCUUCUC	758	GAGAAGCC	C	CAGGGCUC	3537
1349	AGAGCCCU	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCUCUC	759	AGAAGCCC	C	AGGGCUCU	3538
1350	CAGAGCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGGCUC	760	GAAGCCCC	A	GGGCUCUG	3539
1355	CGCCACAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICCCUGGG	761	CCCAGGGC	U	CUGUGGGC	3540
1357	GCCGCCAC	CUGAUGAG	GCCGUUAGGC	CGAA	IAGCCUCG	762	CAGGGCUC	U	GUGGCGGC	3541
1366	UCCUCGG	CUGAUGAG	GCCGUUAGGC	CGAA	ICCGCCAC	763	GUGGCGGC	C	CCCGAGGA	3542
1367	CUCCUCG	CUGAUGAG	GCCGUUAGGC	CGAA	IGCCGCCA	764	UGGCGGCC	C	CCGAGGAG	3543
1368	CUCCUCG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCGGCC	765	GGCGGCC	C	CGAGGAGG	3544
1369	UCCUCCUC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGGCCGC	766	GCGGCCCC	C	GAGGAGGA	3545
1382	GGGUCUC	CUGAUGAG	GCCGUUAGGC	CGAA	IUCCUCCU	767	AGGAGGAC	A	CAGACCCC	3546
1384	CGGGGUC	CUGAUGAG	GCCGUUAGGC	CGAA	IUGUCCUC	768	GAGGACAC	A	GACCCCCG	3547
1388	GGACGGG	CUGAUGAG	GCCGUUAGGC	CGAA	IUCUGUGU	769	ACACAGAC	C	CCCGUCGC	3548
1389	GGGACGG	CUGAUGAG	GCCGUUAGGC	CGAA	IGUCUGUG	770	CACAGACC	C	CCGUCGCC	3549
1390	AGGCGAG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGUCUGU	771	ACAGACCC	C	CGUCGCCU	3550
1391	CAGGCGAC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGGUCUG	772	CAGACCCC	C	GUCGCCUG	3551
1397	CUGCACC	CUGAUGAG	GCCGUUAGGC	CGAA	ICGACGGG	773	CCCGUCGC	C	UGGUGCAG	3552
1398	GCUGACC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGACGG	774	CCGUGGCC	U	GGUGCAGC	3553
1404	GGAGCAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICACCAGG	775	CCUGGUGC	A	GCUGCUC	3554
1407	GGCGGAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGCACC	776	GGUGCAGC	U	GCUCCGCC	3555
1410	GCUGGGG	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGCUGC	777	GCAGCUGC	U	CCGCCAGC	3556
1412	GUGCUGG	CUGAUGAG	GCCGUUAGGC	CGAA	IAGCAGCU	778	AGCUGCUC	C	GCCAGCAC	3557
1415	GCUGUGCU	CUGAUGAG	GCCGUUAGGC	CGAA	ICGGAGCA	779	UGCUCCGC	C	AGCACAGC	3558
1416	UGCUGUG	CUGAUGAG	GCCGUUAGGC	CGAA	IGCGGAGC	780	GCUCCGCC	A	GCACAGCA	3559
1419	GGCUGUG	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGGCGG	781	CCGCCAGC	A	CAGCAGCC	3560
1421	GGGGCUG	CUGAUGAG	GCCGUUAGGC	CGAA	IUGCUGGC	782	GCCAGCAC	A	GCAGCCCC	3561
1424	CCAGGGG	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGUGCU	783	AGCACAGC	A	GCCCCUGG	3562
1427	CUGCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGCUGU	784	ACAGCAGC	C	CCUGGCAG	3563
1428	CCUGCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	IGCUGCUG	785	CAGCAGCC	C	CUGGCAGG	3564
1429	ACUGCCA	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCUGCU	786	AGCAGCCC	C	UGGCAGGU	3565
1430	CACCUCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGGCUGC	787	GCAGCCCC	U	GGCAGGUG	3566
1434	CGUACACC	CUGAUGAG	GCCGUUAGGC	CGAA	ICCAGGGG	788	CCCCUGGC	A	GGUGUACG	3567

1445	CCGCACGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGUACA	789	UGUACGGC	U	UCGUGCGG	3568
1456	CGCAGGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGGCAC	790	GUGCGGGC	C	UGCCUGCG	3569
1457	GCGCAGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCGGCA	791	UGCGGGCC	U	GCCUGCGC	3570
1460	CCGGCGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGGCCC	792	GGGCCUGC	C	UGC GCCCG	3571
1461	GCCGGCGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCAGGCC	793	GGCCUGCC	U	GCGCCCGC	3572
1466	CACCAGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICG CAGGC	794	GCCUGCGC	C	GGCUGGUG	3573
1470	GGGGCACC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGCGC	795	GCGCCGGC	U	GGUGCCCC	3574
1476	GGCCUGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACCAGC	796	GCUGGUGC	C	CCCAGGCC	3575
1477	AGGCCUUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCACCAG	797	CUGGUGCC	C	CCAGGCCU	3576
1478	GAGGCCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCACCA	798	UGGUGCCC	C	CAGGCCUC	3577
1479	AGAGGCCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGCACC	799	GGUGCCCC	C	AGGCCUCU	3578
1480	CAGAGGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGGCAC	800	GUGCCCCC	A	GGCCUCUG	3579
1484	GCCCCAGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUGGGG	801	CCCCAGGC	C	UCUGGGGC	3580
1485	AGCCCCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCUGGG	802	CCCAGGCC	U	CUGGGGCU	3581
1487	GGAGCCCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGGCCUG	803	CAGGCCUC	U	GGGGCUCC	3582
1493	GUGCCUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCCCAGA	804	UCUGGGGC	U	CCAGGCAC	3583
1495	UUGUGCCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGCCCCA	805	UGGGGCUC	C	AGGCACAA	3584
1496	GUUGUGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGCCCC	806	GGGGCUCC	A	GGCACAAAC	3585
1500	GUUCGUUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUGGAG	807	CUCCAGGC	A	CAACGAAC	3586
1502	GCGUUCGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGCCUGG	808	CCAGGCAC	A	ACGAACGC	3587
1511	GAGGAAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGUUCGU	809	ACGAACGC	C	GCUUCUCU	3588
1514	CCUGAGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGCGUU	810	AACGCCGC	U	UCCUCAGG	3589
1517	GUUCCUGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAGCGGC	811	GCCGCUUC	C	UCAGGAAC	3590
1518	UGUUCUUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAAGCGG	812	CCGCUUCC	U	CAGGAACA	3591
1520	GGUGUUCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGGAAGC	813	GCUUCUCC	A	GGAACACC	3592
1526	CUUCUUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUUCUUGA	814	UCAGGAAC	A	CCAAGAAAG	3593
1528	AACUUCUU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGUUCUU	815	AGGAACAC	C	AAGAAGUU	3594
1529	GAACUUCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUGUUCU	816	GGAACACC	A	AGAAGUUC	3595
1538	CAGGAGAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAACUUCU	817	AGAAGUUC	A	UCUCCUUG	3596
1541	CCCCAGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAUGAACU	818	AGUUCAUU	U	CCCUGGGG	3597
1543	UUCGCCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGAUGAA	819	UUCAUCUC	C	CUGGGGAA	3598
1544	CUUCCCCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGAUGA	820	UCAUCUCC	C	UGGGGAAG	3599
1545	GUUCGCCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGAGAUG	821	CAUCUCCC	U	GGGGAAGC	3600
1554	GCUUGGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUUCCCC	822	GGGGAAGC	A	UGCCAAGC	3601

1558	GAGAGCUU	CUGAUGAG	GCCGUUAGGC	CGAA	ICAUGCUU	823	AAGCAUGC	C	AAGCUCUC	3602
1559	CGAGAGCU	CUGAUGAG	GCCGUUAGGC	CGAA	IGCAUGCU	824	AGCAUGCC	A	AGCUCUCG	3603
1563	GCAGCGAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICUUGGCA	825	UGCCAAGC	U	CUCGCUCG	3604
1565	CUGCAGCG	CUGAUGAG	GCCGUUAGGC	CGAA	IAGCUUGG	826	CCAAGCUC	U	CGCUGCAG	3605
1569	GCUCCUGC	CUGAUGAG	GCCGUUAGGC	CGAA	ICGAGAGC	827	GCUCUCGC	U	GCAGGAGC	3606
1572	UCAGCUCC	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGCGAG	828	CUCGCUCG	A	GGAGCUGA	3607
1578	UCCACGUC	CUGAUGAG	GCCGUUAGGC	CGAA	ICUCCUCG	829	GCAGGAGC	U	GACGUGGA	3608
1604	CCAAGCGC	CUGAUGAG	GCCGUUAGGC	CGAA	IUCCCGCA	830	UGC CGGAC	U	GCGCUUGG	3609
1609	CGCAGCCA	CUGAUGAG	GCCGUUAGGC	CGAA	ICGAGUC	831	GACUGCGC	U	UGGCUCGC	3610
1614	UCCUGCGC	CUGAUGAG	GCCGUUAGGC	CGAA	ICCAAGCG	832	CGCUUGGC	U	GCGCAGGA	3611
1619	UGGGCUCC	CUGAUGAG	GCCGUUAGGC	CGAA	ICGAGCC	833	GGCUGCGC	A	GGAGCCCA	3612
1625	AACCCUCG	CUGAUGAG	GCCGUUAGGC	CGAA	ICUCCUCG	834	GCAGGAGC	C	CAGGGUUU	3613
1626	CAACCCCU	CUGAUGAG	GCCGUUAGGC	CGAA	IGCUCCUG	835	CAGGAGCC	C	AGGGGUUG	3614
1627	CCAACCCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCUCCU	836	AGGAGCCC	A	GGGGUUGG	3615
1637	CGGAACAC	CUGAUGAG	GCCGUUAGGC	CGAA	ICCAACCC	837	GGGUUGGC	U	GUGUCCCG	3616
1644	CUGCGGCC	CUGAUGAG	GCCGUUAGGC	CGAA	IAACACAG	838	CUGUGUUC	C	GGCCGCAG	3617
1648	UGCUCUGC	CUGAUGAG	GCCGUUAGGC	CGAA	ICCGGAAC	839	GUUCCGGC	C	GCAGAGCA	3618
1651	CGGUGCUC	CUGAUGAG	GCCGUUAGGC	CGAA	ICGGCCGG	840	CCGGCCGC	A	GAGCACCG	3619
1656	GCAGACGG	CUGAUGAG	GCCGUUAGGC	CGAA	ICUCUGCG	841	CGCAGAGC	A	CCGUCUGC	3620
1658	ACGCAGAC	CUGAUGAG	GCCGUUAGGC	CGAA	IUGCUCUG	842	CAGAGCAC	C	GUCUGCGU	3621
1662	CCUCACGC	CUGAUGAG	GCCGUUAGGC	CGAA	IACGGUGC	843	GCACCCGUC	U	GCGUGAGG	3622
1676	CUTUGGCC	CUGAUGAG	GCCGUUAGGC	CGAA	IAUCUCCU	844	AGGAGAUC	C	UGGCCAAG	3623
1677	ACUUGGCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGAUCUCC	845	GGAGAUCU	U	GGCCAAGU	3624
1681	AGGAACUU	CUGAUGAG	GCCGUUAGGC	CGAA	ICCAGGAU	846	AUCCUGGC	C	AAGUCCU	3625
1682	CAGGAACU	CUGAUGAG	GCCGUUAGGC	CGAA	IGCCAGGA	847	UCCUGGCC	A	AGUCCUG	3626
1688	CCAGUGCA	CUGAUGAG	GCCGUUAGGC	CGAA	IAACUUGG	848	CCAAGUUC	C	UGCACUGG	3627
1689	GCCAGUGC	CUGAUGAG	GCCGUUAGGC	CGAA	IGAACUUG	849	CAAGUUCU	U	GCACUGGC	3628
1692	UCAGCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGGAAC	850	GUUCCUGC	A	CUGGCUGA	3629
1694	CAUCAGCC	CUGAUGAG	GCCGUUAGGC	CGAA	IUGCAGGA	851	UCCUGCAC	U	GGCUGAUG	3630
1698	CACUCAUC	CUGAUGAG	GCCGUUAGGC	CGAA	ICCAGUGC	852	GCACUGGC	U	GAUGAGUG	3631
1722	ACCUGAGC	CUGAUGAG	GCCGUUAGGC	CGAA	ICUCGACG	853	CGUCGAGC	U	GCUCAGGU	3632
1725	AAGACCUG	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGCUCG	854	CGAGCUGC	U	CAGGUCUU	3633
1727	GAAAGACC	CUGAUGAG	GCCGUUAGGC	CGAA	IAGCAGCU	855	AGCUGCUC	A	GGUCUUUC	3634
1732	UAAAAGAA	CUGAUGAG	GCCGUUAGGC	CGAA	IACCUGAG	856	CUCAGGUC	U	UUCUUUUA	3635

1736	GACAUAAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAAGACC	857	GGUCUUUC	U	UUUAUGUC	3636
1745	GGUCUCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACAUA AAA	858	UUUAUGUC	A	CGGAGACC	3637
1753	UGAAACGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCUCCGU	859	ACGGAGAC	C	ACGUUUA	3638
1754	UUGAAACG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUUCUCCG	860	CGGAGACC	A	CGUUUCA	3639
1761	UGUUCUUU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAAACGUG	861	CACGUUUC	A	AAAGAACA	3640
1769	AAAGAGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUUUUUUU	862	AAAAGAAC	A	GGCUCUUU	3641
1773	AGAAAAAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUUUC	863	GAACAGGC	U	CUUUUUU	3642
1775	GUAGAAAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGCCUGU	864	ACAGGUC	U	UUUUCUAC	3643
1781	CUUCCGGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAAAAAGA	865	UCUUUUUC	U	ACCGGAAG	3644
1784	ACUCUUCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUAGAAAA	866	UUUUCUAC	C	GGAAGAGU	3645
1796	CUUGCUCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACACUCU	867	AGAGUGUC	U	GGAGCAAG	3646
1802	UUGCAACU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUCCAGA	868	UCUGGAGC	A	AGUUGCAA	3647
1809	CAAUUCUU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAAACUTG	869	CAAGUUGC	A	AAGCAUUG	3648
1814	GAUUCCAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUUUGCA	870	UGCAAAGC	A	UUGGAAUC	3649
1823	GUGCUGUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAUUCCAA	871	UUGGAAUC	A	GACAGCAC	3650
1827	UCAAGUGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCUGAUU	872	AAUCAGAC	A	GCACUUGA	3651
1830	UCUUCAAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGUCUG	873	CAGACAGC	A	CUUGAAGA	3652
1832	CCUCUUCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGCUGUC	874	GACAGCAC	U	UGAAGAGG	3653
1845	CCCGCAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACCCUC	875	GAGGGUGC	A	GCUGCGGG	3654
1848	GUUCCCGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGCACC	876	GGUGCAGC	U	GCGGGAGC	3655
1857	CUUCCGAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUCCCGC	877	GCGGGAGC	U	GUCGGAAG	3656
1867	CUGACCUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUUCCGA	878	UCGGAAGC	A	GAGGUCAG	3657
1874	AUGCUGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACCUCUG	879	CAGAGGUC	A	GGCAGCAU	3658
1878	CCCGAUGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUAGAC	880	GGUCAGGC	A	GCAUCGGG	3659
1881	CUUCCCGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGCCUG	881	CAGGCAGC	A	UCGGGAAG	3660
1891	GCGGGCCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUUCUCC	882	CGGGAAGC	C	AGGCCCCG	3661
1892	GGCGGGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCUUCCC	883	GGGAAGCC	A	GGCCCCGC	3662
1896	GCAGGGCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUUGCU	884	AGCCAGGC	C	CGCCCCUG	3663
1897	AGCAGGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCUGGC	885	GCCAGGCC	C	GCCCUGCU	3664
1900	GUCAGCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGGCCU	886	AGGCCCCG	C	CUGCUGAC	3665
1901	CGUCAGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCGGGCC	887	GGCCCCGC	C	UGCUGACG	3666
1902	ACGUCAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCGGGC	888	GCCCGCCC	U	GCUGACGU	3667
1905	UGGACGUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGGGCG	889	CGCCUUGC	U	GACGUCCA	3668
1912	CGGAGUCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACGUCAG	890	CUGACGUC	C	AGACUCCG	3669

1913	GCGGAGUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGACGUCA	891	UGACGUCC	A	GACUCCGC	3670
1917	UGAAGCGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCUGGAC	892	GUCCAGAC	U	CCGUUCA	3671
1919	GAUGAAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGUCUGG	893	CCAGACUC	C	GUUCAUC	3672
1922	GGGGAUGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGAGUC	894	GACUCCGC	U	UCAUCCCC	3673
1925	CUUGGGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAGCGGA	895	UCCGCUUC	A	UCCCCAAG	3674
1928	AGGCUUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAUGAAGC	896	GUUCAUC	C	CCAAGCCU	3675
1929	CAGGCUUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAUGAAG	897	CUUCAUC	C	CAAGCCUG	3676
1930	UCAGGCUU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGAUGAA	898	UUCAUCCC	C	AAGCCUGA	3677
1931	GUCAGGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGAUGA	899	UCAUCCCC	A	AGCCUGAC	3678
1935	GCCCCGUCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUUGGGG	900	CCCCAAGC	C	UGACGGGC	3679
1936	AGCCCGUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCUUGGG	901	CCCAAGCC	U	GACGGGCU	3680
1944	UCGGCCGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCCGUCA	902	UGACGGGC	U	GCGGCCGA	3681
1950	UCACAAUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGCAGC	903	GCUGCGGC	C	GAUUGUGA	3682
1961	GUAGUCCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUUCACAA	904	UUGUGAAC	A	UGGACUAC	3683
1967	CACGACGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCCAUGU	905	ACAUGGAC	U	ACGUUGUG	3684
1981	AACGUUCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUCCCAC	906	GUGGGAGC	C	AGAACGUU	3685
1982	GAACGUUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCUCCCA	907	UGGGAGCC	A	GAACGUUC	3686
1991	UUCUCUGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAACGUUC	908	GAACGUUC	C	GCAGAGAA	3687
1994	CUUUCUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGAACG	909	CGUCCGC	A	GAGAAAAG	3688
2008	AGACGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCCUCUU	910	AAGAGGC	C	GAGCGUCU	3689
2016	UCGAGGUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACGCU	911	CGAGCGUC	U	CACCUCCA	3690
2018	CCUCGAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGACGCU	912	AGCGUCUC	A	CCUCGAGG	3691
2020	ACCCUCCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGAGACG	913	CGUCUCAC	C	UCGAGGGU	3692
2021	CACCCUUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUGAGAC	914	GUCUCACC	U	CGAGGGUG	3693
2035	CUGAACAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUUCAC	915	GUGAAGGC	A	CUGUUCAG	3694
2037	CGCUGAAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGCCUUC	916	GAAGGCAC	U	GUUCAGCG	3695
2042	GAGCAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAACAGUG	917	CACUGUUC	A	GCGUGCUC	3696
2049	CGUAGUUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACGCUG	918	CAGCGUGC	U	CAACUACG	3697
2051	CUCGUAGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGCACGC	919	GCGUGCUC	A	ACUACGAG	3698
2054	CCGCUUGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUUGAGCA	920	UGCUCAAC	U	ACGAGCGG	3699
2072	GAGGCCGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGCCCGG	921	CGCGCGGC	C	CCGGCCUC	3700
2073	GGAGGCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCGCCGC	922	GCGGCGCC	C	CGGCCUCC	3701
2074	AGGAGGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCGCCG	923	CGGCGCCC	C	GGCCUCCU	3702
2078	GCCCAGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGGGGC	924	GCCCCGGC	C	UCCUGGGC	3703

2079	CGCCAGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCGGGG	925	CCCCGGCC U CCUGGGCG	3704
2081	GGCGCCCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGGCCG	926	CGGCCUCC C UGGCGGCC	3705
2082	AGGCGCCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGGCCG	927	CGGCCUCC U GGGCGCCU	3706
2089	AGCACAGA CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGCCAG	928	CUGGGCGC C UCUGUGCU	3707
2090	CAGCACAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCGCCA	929	UGGGCGCC U CUGUGCUG	3708
2092	CCCAGCAC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGCGCC	930	GGCGCCUC U GUGCUGGG	3709
2097	CCAGGCCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICACAGAG	931	CUCUGUGC U GGGCCUGG	3710
2102	AUCGUCCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCAGCA	932	UGCUGGGC C UGGACGAU	3711
2103	UAUCGUCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCCAGC	933	GCUGGGCC U GGACGAUA	3712
2114	GGCCUCGU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAUUCGU	934	ACGAUAUC C ACAGGGCC	3713
2115	AGGCCUCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGAUAUCG	935	CGAUAUCC A CAGGGCCU	3714
2117	CCAGGCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGGAUUA	936	AUAUCCAC A GGGCCUGG	3715
2122	GUGCGCCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCUGUG	937	CACAGGGC C UGGCGCAC	3716
2123	GGUGCGCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCCUCGU	938	ACAGGGCC U GGCACACC	3717
2129	CACGAAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGCCAG	939	CCUGGGC A CCUUCGUG	3718
2131	AGCACGAA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGGCCA	940	UGGCGCAC C UUCGUGCU	3719
2132	CAGCACGA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGUGCGC	941	GGCGCACC U UCGUGCUG	3720
2139	GCACACGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICACGAAG	942	CUUCGUGC U GCGUGUGC	3721
2152	GGUUCUCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCCGCAC	943	GUGCGGGC C CAGGACCC	3722
2153	CGGGUCCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCCGCA	944	UGCGGGCC C AGGACCCG	3723
2154	GCGGUUCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCCCGC	945	GCGGGCCC A GGACCCGC	3724
2159	AGGCGGCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUCCUGG	946	CCCAGGAC C CGCCGCCU	3725
2160	CAGCGGCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGUCCUG	947	CCAGGACC C GCCGCCUG	3726
2163	GCUCAGGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGGUCC	948	GGACCCGC C GCCUGAGC	3727
2166	ACAGCUCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGGCGG	949	CCCGCCGC C UGAGCUGU	3728
2167	UACAGCUC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCGCGG	950	CGGCCGCC U GAGCUGUA	3729
2172	CAAAGUAC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUCAGC	951	GCCUGAGC U GUACUUG	3730
2177	CUUGACAA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUACAGCU	952	AGCUGUAC U UUGUCAAG	3731
2183	AUCCACCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IACAAAGU	953	ACUUUGUC A AGGUGGAU	3732
2210	GGGGAUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUCGUACG	954	CGUACGAC A CCAUCCCC	3733
2212	UGGGGGAU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGUCGUA	955	UACGACAC C AUCCCCCA	3734
2213	CUGGGGGA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGUCUGU	956	ACGACACC A UCCCCCAG	3735
2216	GUCCUGGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAUUGUGU	957	ACACCAUC C CCCAGGAC	3736
2217	UGUCCUGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGAUGGUG	958	CACCAUCC C CCAGGACA	3737

2218	CUGUCCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGAUGGU	959	ACCAUCCC	C	CAGGACAG	3738		
2219	CCUGUCCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGAUGG	960	CCAUCCCC	C	AGGACAGG	3739		
2220	GCCUGUCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGGAUG	961	CAUCCCCC	A	GGACAGGC	3740		
2225	CGUGAGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCCUGGG	962	CCCAGGAC	A	GGCUCACG	3741		
2229	CCUCCGUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUGUCC	963	GGACAGGC	U	CACGGAGG	3742		
2231	GACCUCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGCCUGU	964	ACAGGCUC	A	CGGAGGUC	3743		
2240	GCUGGGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACCUCGG	965	CGGAGGUC	A	UCGCCACG	3744		
2245	AUGAUGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGAUGAC	966	GUCAUGGC	C	AGCAUCAU	3745		
2246	GAUGAUGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCGAUGA	967	UCAUGGCC	A	GCAUCAUC	3746		
2249	UUUGAUGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGGCGA	968	UCGCCAGC	A	UCAUCAAA	3747		
2252	GGGUUUGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAUGCUGG	969	CCAGCAUC	A	UCAAAACCC	3748		
2255	CUGGGGUU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAUGAUGC	970	GCAUCAUC	A	AACCCACG	3749		
2259	UGUUCUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUUUGAUG	971	CAUCAAA	C	CCAGAACA	3750		
2260	GUGUUCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUUUGAU	972	AUCAAA	ACC	C	CAGAAACAC	3751	
2261	CGUGUUCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGUUUGA	973	UCAAA	ACC	C	AGAACACG	3752	
2262	ACGUGUUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGUUG	974	CAA	ACC	C	A	GAACACGU	3753
2267	GCAGUACG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUUCUGGG	975	CCCAGAAC	A	CGUACUGC	3754		
2273	ACGCACGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUACGUGU	976	ACACGUAC	U	GCGUGCGU	3755		
2290	UGGACCCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAUACCG	977	CGGU	AUGC	C	GUGGUCCA	3756	
2297	GGCCUUCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACCACGG	978	CCGUGGUC	C	AGAAGGCC	3757		
2298	CGGCCUUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGACCACG	979	CGUGGUCC	A	GAAGGCCG	3758		
2305	CCAUGGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUUCUG	980	CAGAAGGC	C	GCCCAUGG	3759		
2308	UGCCCAUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGCCUU	981	AAGGCCGC	C	CAUGGGCA	3760		
2309	GUGCCCAU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCGGCCU	982	AGGCCGCC	C	AUGGGCAC	3761		
2310	CGUGCCCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCGGCC	983	GGCGCCCC	A	UGGGCACG	3762		
2316	UGCGGACG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCCAUGG	984	CCAUGGGC	A	CGUCCGCA	3763		
2321	GGCCUUGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACGUGCC	985	GGCACGUC	C	GCAAGGCC	3764		
2324	GAAGGCCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGACGU	986	ACGUCCGC	A	AGGCCUUC	3765		
2329	CUCUUGAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUUGCG	987	CGCAAGGC	C	UUCAAGAG	3766		
2330	GCUCUUGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCUUGC	988	GCAAGGCC	U	UCAAGAGC	3767		
2333	GUGGCUCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAGGCCU	989	AGGCCUUC	A	AGAGCCAC	3768		
2339	AGAGACGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUCUUGA	990	UCAAGAGC	C	ACGUCUCU	3769		
2340	UAGAGACG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCUCUUG	991	CAAGAGCC	A	CGUCUCUA	3770		
2345	CAAGGUAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACGUGGC	992	GCCACGUC	U	CUACCUUG	3771		

2347	GUCAAGGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGACGUG	993	CACGUCUC	U	ACCUUGAC	3772
2350	UCUGUCAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUAGAGAC	994	GUCUCUAC	C	UUGACAGA	3773
2351	GUCUGUCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUAAGAGA	995	UCUCUACC	U	UGACAGAC	3774
2356	UGGAGGUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUAAGGU	996	ACCUUGAC	A	GACCUCCA	3775
2360	CGGCUUGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCUGUCA	997	UGACAGAC	C	UCCAGCCG	3776
2361	ACGGCUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUCUGUC	998	GACAGACC	U	CCAGCCGU	3777
2363	GUACGGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGGUCUG	999	CAGACCUC	C	AGCCGUAC	3778
2364	UGUACGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGGUCU	1000	AGACCUCC	A	GCCGUACA	3779
2367	GCAUGUAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGGAGG	1001	CCUCCAGC	C	GUACAUGC	3780
2372	CUGUCGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUACGGCU	1002	AGCCGUAC	A	UGCGACAG	3781
2379	CCACGAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCGCAUG	1003	CAUGCGAC	A	GUUCGUGG	3782
2389	UGCAGGUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCACGAA	1004	UUCGUGGC	U	CACCUGCA	3783
2391	CCUGCAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGCCACG	1005	CGUGGCUC	A	CCUGCAGG	3784
2393	CUCCUGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGAGCCA	1006	UGGCUCAC	C	UGCAGGAG	3785
2394	UCUCCUGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUGAGCC	1007	GGCUCACC	U	GCAGGAGA	3786
2397	UGGUUCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGGUGA	1008	UCACCUGC	A	GGAGACCA	3787
2404	AGCGGGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCUCCUG	1009	CAGGAGAC	C	AGCCCCGU	3788
2405	CAGCGGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUCUCCU	1010	AGGAGACC	A	GCCCCGUG	3789
2408	CCUCACGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGGUCU	1011	AGACCAGC	C	CGCUGAGG	3790
2409	CCCUACAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCUGGUC	1012	GACCAGCC	C	GCUGAGGG	3791
2412	CAUCCUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGGCUG	1013	CAGCCCCG	U	GAGGGAUG	3792
2422	AUGACGAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAUCCCU	1014	AGGGAUGC	C	GUCGUCAU	3793
2429	CUGCUUGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACGACGG	1015	CCGUCCGUC	A	UCGAGCAG	3794
2436	AGGAGCUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUCGAUG	1016	CAUCGAGC	A	GAGCUCCU	3795
2441	CAGGAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUCUGCU	1017	AGCAGAGC	U	CCUCCUG	3796
2443	UUCAGGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGCUCUG	1018	CAGAGCUC	C	UCCCCUGAA	3797
2444	AUUCAGGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGCUCU	1019	AGAGCUCC	U	CCCUGAAU	3798
2446	UCAUUCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGGAGCU	1020	AGCUCCUC	C	CUGAAUGA	3799
2447	CUCAUUA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGGAGC	1021	GUCCUCC	C	UGAAUGAG	3800
2448	CCUCAUUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGAGGAG	1022	CUCCUCCC	U	GAUUGAGG	3801
2458	CCACUGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUCAU	1023	AAUGAGGC	C	AGCAGUGG	3802
2459	GCCACUGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCUCAU	1024	AUGAGGCC	A	GCAGUGGC	3803
2462	GAGGCCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGGCCU	1025	AGGCCAGC	A	GUGGCCUC	3804
2468	GUCCAAGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCAUCG	1026	GCAGUGGC	C	UCUUCGAC	3805



2469	CGUCGAAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCACUG	1027	CAGUGGCC	U	CUUCGACG	3806
2471	GACGUCGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGGCCAC	1028	GUGGCCUC	U	UCGACGUC	3807
2480	GCGUAGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACGUUGA	1029	UGGACGUC	U	UCCUACGC	3808
2483	GAAGCGUA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGACAGU	1030	ACGUCUUC	C	UACGCUUC	3809
2484	UGAAGCGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAAGACG	1031	CGUCUUC	U	ACGCUUCA	3810
2489	GCACAUGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGUAGGA	1032	UCCUACGC	U	UCAUGUGC	3811
2492	GUGGCACA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAGGGUA	1033	UACGCUUC	A	UGUGCCAC	3812
2498	GGCGUGGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACAUGA	1034	UCAUGUGC	C	ACCACGCC	3813
2499	CGGCGUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCACAUG	1035	CAUGUGCC	A	CCACGCCG	3814
2501	CACGGCGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGGCACA	1036	UGUGCCAC	C	ACGCCGUG	3815
2502	GCACGGCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGGCAC	1037	GUGCCACC	A	CGCCGUGC	3816
2506	AUGCGCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGUGGUG	1038	CACCACGC	C	GUGCGCAU	3817
2513	GCCCCUGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGCACGG	1039	CCGUGCGC	A	UCAGGGGC	3818
2516	CUUGCCCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAUGCGCA	1040	UGCGCAUC	A	GGGGCAAG	3819
2522	GUAGGACU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCCUGA	1041	UCAGGGGC	A	AGUCCUAC	3820
2527	UGGACGUA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACUUGCC	1042	GGCAAGUC	C	UACGUCCA	3821
2528	CUGGACGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGACUUGC	1043	GCAAGUCC	U	ACGUCCAG	3822
2534	CUGGCACU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACGUAGG	1044	CCUACGUC	C	AGUGCCAG	3823
2535	CCUGGCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGACGUAG	1045	CUACGUCC	A	GUGCCAGG	3824
2540	GAUCCCCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACUGGA	1046	UCCAGUGC	C	AGGGGAUC	3825
2541	GGAUCCCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCACUGG	1047	CCAGUGCC	A	GGGGAUCC	3826
2549	GCCCCUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAUCCCCU	1048	AGGGGAUC	C	CGCAGGGC	3827
2550	AGCCUUGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAUCCCC	1049	GGGGAUCC	C	GCAGGGCU	3828
2553	UGGAGCCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGGGAUC	1050	GAUCCCGC	A	GGGCUCCA	3829
2558	GAGGAUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCCUGCG	1051	CGCAGGGC	U	CCAUCCUC	3830
2560	GAGAGGAU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGCCUGG	1052	CAGGGCUC	C	AUCCUCUC	3831
2561	GGAGAGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGCCCU	1053	AGGGCUCC	A	UCCUCUCC	3832
2564	CGUGGAGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAUGGAGC	1054	GUCCCAUC	C	UCUCCACG	3833
2565	GCGUGGAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAUGGAG	1055	CUCCAUCC	U	CUCCACGC	3834
2567	CAGCGUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGGAUGG	1056	CCAUCCUC	U	CCACGCUG	3835
2569	AGCAGCGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAGAGGAU	1057	AUCCUCUC	C	ACGUGCUU	3836
2570	GAGCAGCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGAGGA	1058	UCCUCUCC	A	CGCUGCUC	3837
2574	UGCAGAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGUGGAG	1059	CUCCACGC	U	GCUCUGCA	3838
2577	GGCUGCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGCGUG	1060	CACGCUGC	U	CUGCAGCC	3839

2579	CAGGCUGC	CUGAUGAG	GCCGUUAGGC	CGAA	IAGCAGCG	1061	CGCUGCUC	U	GCAGCCUG	3840
2582	GCACAGGC	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGAGCA	1062	UGCUCUGC	A	GCCUGUGC	3841
2585	GUAGCACA	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGCAGA	1063	UCUGCAGC	C	UGUGCUC	3842
2586	CGUAGCAC	CUGAUGAG	GCCGUUAGGC	CGAA	IGCUGCAG	1064	CUGCAGCC	U	GUGCUCAG	3843
2591	GUCGCCGU	CUGAUGAG	GCCGUUAGGC	CGAA	ICACAGGC	1065	GCCUGUGC	U	ACGGCGAC	3844
2600	GUUCUCCA	CUGAUGAG	GCCGUUAGGC	CGAA	IUCGCCGU	1066	ACGGCGAC	A	UGGAGAAC	3845
2609	AAACAGCU	CUGAUGAG	GCCGUUAGGC	CGAA	IUUCUCCA	1067	UGGAGAAC	A	AGCUGUUU	3846
2613	CCGCAAAC	CUGAUGAG	GCCGUUAGGC	CGAA	ICUUGUUC	1068	GAACAAGC	U	GUUUGCGG	3847
2640	GCAGGAGC	CUGAUGAG	GCCGUUAGGC	CGAA	ICCCGUCC	1069	GGACGGGC	U	GCUCCUGC	3848
2643	AACGCAGG	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGCCCG	1070	CGGGCUGC	U	CCUGCGUU	3849
2645	CAAAACGC	CUGAUGAG	GCCGUUAGGC	CGAA	IAGCAGCC	1071	GGCUGCUC	C	UGCGUUUG	3850
2646	CCAAACGC	CUGAUGAG	GCCGUUAGGC	CGAA	IAGCAGC	1072	GCUGCUCU	U	GCGUUUGG	3851
2666	CACCAACA	CUGAUGAG	GCCGUUAGGC	CGAA	IAAAUCAU	1073	AUGAUUUC	U	UGUUGGUG	3852
2677	AGGUGAGG	CUGAUGAG	GCCGUUAGGC	CGAA	IUCACCAA	1074	UUGGUGAC	A	CCUCACCU	3853
2679	UGAGGUGA	CUGAUGAG	GCCGUUAGGC	CGAA	IUGUCACC	1075	GGUGACAC	C	UCACCUCA	3854
2680	GUGAGGUG	CUGAUGAG	GCCGUUAGGC	CGAA	IGUGUCAC	1076	GUGACACC	U	CACCUCAC	3855
2682	GGGUGAGG	CUGAUGAG	GCCGUUAGGC	CGAA	IAGGUGUC	1077	GACACCUC	A	CCUCACCC	3856
2684	GUGGGUGA	CUGAUGAG	GCCGUUAGGC	CGAA	IUGAGGUG	1078	CACCUCAC	C	UCACCCAC	3857
2685	CGUGGGUG	CUGAUGAG	GCCGUUAGGC	CGAA	IUGAGGU	1079	ACCUCACC	U	CACCCACG	3858
2687	CGGUGGG	CUGAUGAG	GCCGUUAGGC	CGAA	IAGGUGAG	1080	CUCACCUC	A	CCCACGGC	3859
2689	UUCGCGUG	CUGAUGAG	GCCGUUAGGC	CGAA	IUGAGGUG	1081	CACCUCAC	C	CACGCGAA	3860
2690	UUUCGCGU	CUGAUGAG	GCCGUUAGGC	CGAA	IGUGAGGU	1082	ACCUCACC	C	ACGCGAAA	3861
2691	UUUUCGCG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGUGAGG	1083	CCUCACCC	A	CGCGAAAA	3862
2701	CUGAGGAA	CUGAUGAG	GCCGUUAGGC	CGAA	IUUUUCGC	1084	GGGAAAAC	C	UUCCUCAG	3863
2702	CCUGAGGA	CUGAUGAG	GCCGUUAGGC	CGAA	IGUUUUCG	1085	CGAAAACC	U	UCCUCAGG	3864
2705	GGUCCUGA	CUGAUGAG	GCCGUUAGGC	CGAA	IAAGGUUU	1086	AAACCUUC	C	UCAGGACC	3865
2706	GGGUCCUG	CUGAUGAG	GCCGUUAGGC	CGAA	IGAAGGUU	1087	AACCUUCC	U	CAGGACCC	3866
2708	CAGGUUCC	CUGAUGAG	GCCGUUAGGC	CGAA	IAGGAAGG	1088	CCUUCUCC	A	GGACCCUG	3867
2713	CGGACCAG	CUGAUGAG	GCCGUUAGGC	CGAA	IUCUCUGAG	1089	CUCAGGAC	C	CUGGUCCG	3868
2714	UCGGACCA	CUGAUGAG	GCCGUUAGGC	CGAA	IGUCCUGA	1090	UCAGGACC	C	UGGUCCGA	3869
2715	CUCGGACC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGUCCUG	1091	CAGGACCC	U	GGUCCGAG	3870
2720	GACACCUU	CUGAUGAG	GCCGUUAGGC	CGAA	IACCAGGG	1092	CCCUGGUC	C	GAGGUGUC	3871
2729	AUACUCAG	CUGAUGAG	GCCGUUAGGC	CGAA	IACACCUU	1093	GAGGUGUC	C	CUGAGUAU	3872
2730	CAUACUCA	CUGAUGAG	GCCGUUAGGC	CGAA	IGACACCU	1094	AGGUGUCC	C	UGAGUAUG	3873

2731	CCAUACUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGACACC	1095	GGUGUCCC	U	GAGUAUGG	3874
2741	CACCACGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCAUACU	1096	AGUAUGGC	U	GCGUGGUG	3875
2753	CUUCCGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUUCACCA	1097	UGGUGAAC	U	UGCGGAAG	3876
2764	UUCACCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCUUCCG	1098	CGGAAGAC	A	GUGGUGAA	3877
2774	UACAGGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUUCACCA	1099	UGGUGAAC	U	UCCCUGUA	3878
2777	UUCUACAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAGUUCA	1100	UGAACUUC	C	CUGUAGAA	3879
2778	CUUCUACA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAGUUUC	1101	GAACUUC	C	UGUAGAAG	3880
2779	UCUUCUAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGAAGUU	1102	AACUUC	U	GUAGAAGA	3881
2794	CCACCCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUUGUC	1103	GACGAGGC	C	CUGGGUGG	3882
2795	GCCACCCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCUUGU	1104	ACGAGGCC	C	UGGGUGGC	3883
2796	UGCCACCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCCUUG	1105	CGAGGCC	U	GGGUGGCA	3884
2804	AAAGCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCACCCCA	1106	UGGGUGGC	A	CGGCUUUU	3885
2809	UGAACAAA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGUGCC	1107	GGCACGGC	U	UUUGUUCA	3886
2817	CCGGCAUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAACAAAA	1108	UUUGUUC	A	GAUGCCCG	3887
2823	CGUGGGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAUCUGA	1109	UCAGAUGC	C	GGCCCACG	3888
2827	AGGCCGUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGGCAU	1110	AUGCCGGC	C	CACGGCCU	3889
2828	UAGGCCGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCGGCA	1111	UGCCGGCC	C	ACGGCCUA	3890
2829	AUAGGCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCCGGC	1112	GCCGGCCC	A	CGGCCUAU	3891
2834	GGGGAUA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGUGGG	1113	CCCACGGC	C	UAUCCCC	3892
2835	AGGGAAU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCGUGG	1114	CCACGGCC	U	AUCCCCU	3893
2840	GCACCAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAUAGGC	1115	GCCUAUUC	C	CCUGGUGC	3894
2841	CGCACCCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAAUAGG	1116	CCUAUUC	C	CUGGUGCG	3895
2842	CCGCACCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGAUAG	1117	CUAUUC	C	UGGUGCGG	3896
2843	GCCGCACC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGAUA	1118	UAUUC	U	GGUGCGC	3897
2852	CAGCAGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGCACC	1119	GGUGCGGC	C	UGCUGCUG	3898
2853	CCAGCAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCGCAC	1120	GUGCGGCC	U	GCUGCUGG	3899
2856	UAUCCAGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGGCCG	1121	CGGCCUGC	U	GCUGGAUA	3900
2859	GGUAUCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGCAGG	1122	CCUGCUGC	U	GGAUACCC	3901
2866	AGGUCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUAUCCAG	1123	CUGGAUAC	C	CGGACCCU	3902
2867	CAGGGUCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUAUCCA	1124	UGGAUACC	C	GGACCCUG	3903
2872	ACCUCCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCCGGGU	1125	ACCCGGAC	C	CUGGAGGU	3904
2873	CACCUCCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUCCGGG	1126	CCCGGACC	C	UGGAGGUG	3905
2874	GCACCUCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGUCCGG	1127	CCGGACCC	U	GGAGGUGC	3906
2883	AGUCGCUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACCUCC	1128	GGAGGUGC	A	GAGCGACU	3907

2891	GCUGGAGU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUUCGUCU	1129	AGAGCGAC U ACUCCAGC	3908
2894	AUAGCUGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUAGUCGC	1130	GGACUAC U CCAGCUAU	3909
2896	GCAUAGCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGUAGUC	1131	GACUACUC C AGCUAUGC	3910
2897	GGCAUAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGAGUAGU	1132	ACUACUCC A GCUAUGCC	3911
2900	CCGGGCAU CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUGGAGU	1133	ACUCCAGC U AUGCCCGG	3912
2905	GAGGUCCG CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICAUAGCU	1134	AGCUAUGC C CGGACCUC	3913
2906	GGAGGUCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCAUAGC	1135	GCUAUGCC C GGACCUC	3914
2911	CUGAUGGA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUCCGGGC	1136	GCCCGGAC C UCCAUCAG	3915
2912	UCUGAUGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGUCCGGG	1137	CCCGGACC U CCAUCAGA	3916
2914	GCUCUGAU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGGUCCG	1138	CGGACCUC C AUCAGAGC	3917
2915	GGCUCUGA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGAGGUCC	1139	GGACCUCC A UCAGAGCC	3918
2918	ACUGGCUC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAUAGGAG	1140	CUCCAU C A GAGCCAGU	3919
2923	GUGAGACU CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUCUGAU	1141	AUCAGAGC C AGUCUCAC	3920
2924	GGUGAGAC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCUCUGA	1142	UCAGAGCC A GUCUCACC	3921
2928	UGAAGGUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IACUGGCU	1143	AGCCAGUC U CACCUUCA	3922
2930	GUUGAAGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGACUGG	1144	CCAGUCUC A CCUUCAAC	3923
2932	CGGUUGAA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGAGACU	1145	AGUCUCAC C UUCAACCG	3924
2933	GCGGUUGA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGUGAGAC	1146	GUCUCACC U UCAACCGC	3925
2936	GCCGCGGU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAAAGGUA	1147	UCACCUUC A ACCGCGC	3926
2939	GAAGCCGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUUGAAGG	1148	CCUUCAAC C GCGGCUUC	3927
2945	AGCCUUUA CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCGCGGU	1149	ACCGCGGC U UCAAGGCU	3928
2948	CCCAGCCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAAAGCCGC	1150	GCGGCUUC A AGGCUGGG	3929
2953	IUCCUCCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCUUGAA	1151	UUCAAGGC U GGGAGGAA	3930
2963	GCGACGCA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUUCCUCC	1152	GGAGGAAC A UGCGUCGC	3931
2972	AAAGAGUU CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGACGCA	1153	UGCGUCGC A AACUCUUU	3932
2976	CCCCAAAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUUUGCGA	1154	UCGCAAA C U CUUUGGGG	3933
2978	GACCCCAA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGUUUGC	1155	GCAAAUC U UUGGGGUC	3934
2987	CAGCCGGA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IACCCCAA	1156	UUGGGGUC U UGCGGCUG	3935
2994	GACACUUC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCGCAAG	1157	CUUGCGGC U GAAGUGUC	3936
3003	ACAGGCUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IACACUUC	1158	GAAGUGUC A CAGCCUGU	3937
3005	AAACAGGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGACACU	1159	AGUGUCAC A GCCUGUUU	3938
3008	CAGAAACA CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUGUGAC	1160	GUCACAGC C UGUUUUCG	3939
3009	CCAGAAAC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCUGUGA	1161	UCACAGCC U GUUUCUGG	3940
3015	GCAAAUCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAAACAGG	1162	CCUGUUUC U GGAUUUGC	3941

3024	UGUUCACC	CUGAUGAG	GCCGUUAGGC	CGAA	ICAAAUCC	1163	GGAUUUGC	A	GGUGAACA	3942
3032	CUGGAGGC	CUGAUGAG	GCCGUUAGGC	CGAA	IUUCACCU	1164	AGGUGAAC	A	GCCUCCAG	3943
3035	CGUCUGGA	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGUUA	1165	UGAACAGC	C	UCCAGACG	3944
3036	CCGUCUGG	CUGAUGAG	GCCGUUAGGC	CGAA	IGUGUUC	1166	GAACAGCC	U	CCAGACGG	3945
3038	CACCGUCU	CUGAUGAG	GCCGUUAGGC	CGAA	IAGGUCUG	1167	ACAGCCUC	C	AGACGGUG	3946
3039	ACACCGUC	CUGAUGAG	GCCGUUAGGC	CGAA	IGAGGCUG	1168	CAGCCUCC	A	GACGGUGU	3947
3050	GAUGUUGG	CUGAUGAG	GCCGUUAGGC	CGAA	ICACACCG	1169	CGGUGGC	A	CCAACAUC	3948
3052	UAGAUGUU	CUGAUGAG	GCCGUUAGGC	CGAA	IUGCACAC	1170	GUGUGCAC	C	ACAUCUA	3949
3053	GUAGAUGU	CUGAUGAG	GCCGUUAGGC	CGAA	IGUGCACA	1171	UGUGCACC	A	ACAUCUAC	3950
3056	CUTUGUAGA	CUGAUGAG	GCCGUUAGGC	CGAA	IUUGGUGC	1172	GCACCAAC	A	UCUACAAG	3951
3059	GAUCUUGU	CUGAUGAG	GCCGUUAGGC	CGAA	IAUGUUGG	1173	CCAACAUC	U	ACAAGAUC	3952
3062	GAGGAUCU	CUGAUGAG	GCCGUUAGGC	CGAA	IUAGAUGU	1174	ACAUCUAC	A	AGAUCUC	3953
3068	CAGCAGGA	CUGAUGAG	GCCGUUAGGC	CGAA	IAUCUUGU	1175	ACAAGAUC	C	UCCUGCUG	3954
3069	GCAGCAGG	CUGAUGAG	GCCGUUAGGC	CGAA	IGAUCUUG	1176	CAAGAUC	U	CCUGCUGC	3955
3071	CUGCAGCA	CUGAUGAG	GCCGUUAGGC	CGAA	IAGGAUCU	1177	AGAUCUC	C	UGCUGCAG	3956
3072	CCUGCAGC	CUGAUGAG	GCCGUUAGGC	CGAA	IGAGGAUC	1178	GAUCCUCC	U	GCUGCAGG	3957
3075	ACGCCUGC	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGGAGG	1179	CCUCCUGC	U	GCAGGCGU	3958
3078	UGUACGCC	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGCAGG	1180	CCUGCUGC	A	GGCGUACA	3959
3086	GUGAAACC	CUGAUGAG	GCCGUUAGGC	CGAA	IUACGCCU	1181	AGGCGUAC	A	GGUUUCAC	3960
3093	CACAUGCG	CUGAUGAG	GCCGUUAGGC	CGAA	IAAACCCUG	1182	CAGGUUUC	A	CGCAUGUG	3961
3097	AGCACACA	CUGAUGAG	GCCGUUAGGC	CGAA	ICGUGAAA	1183	UUUCACGC	A	UGUGUGCU	3962
3105	GGAGCUGC	CUGAUGAG	GCCGUUAGGC	CGAA	ICACACAU	1184	AUGUGUGC	U	GCAGCUC	3963
3108	AUGGGAGC	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGCACA	1185	UGUGCUGC	A	GCUCCCAU	3964
3111	GAAAUUGG	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGCAGC	1186	GCUGCAGC	U	CCCAUUUC	3965
3113	AUGAAUUG	CUGAUGAG	GCCGUUAGGC	CGAA	IAGCUGCA	1187	UGCAGCUC	C	CAUUUCAU	3966
3114	GAUGAAAU	CUGAUGAG	GCCGUUAGGC	CGAA	IGAGCUGC	1188	GCAGCUC	C	AUUUCAUC	3967
3115	UGAUGAAA	CUGAUGAG	GCCGUUAGGC	CGAA	IGGAGCUG	1189	CAGCUC	A	UUUCAUCA	3968
3120	CUUGCUGA	CUGAUGAG	GCCGUUAGGC	CGAA	IAAAUGGG	1190	CCCAUUC	A	UCAGCAAG	3969
3123	AAACUUGC	CUGAUGAG	GCCGUUAGGC	CGAA	IAUGAAAU	1191	AUUUCAUC	A	GCAAGUUU	3970
3126	UCCAAACU	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGAUGA	1192	UCAUCAGC	A	AGUUUGGA	3971
3140	AAAUUGG	CUGAUGAG	GCCGUUAGGC	CGAA	IUUCUUC	1193	GGAAGAAC	C	CCACAUUU	3972
3141	AAAAUGUG	CUGAUGAG	GCCGUUAGGC	CGAA	IGUUCUUC	1194	GAAGAACC	C	CACAUUUU	3973
3142	AAAAAUGU	CUGAUGAG	GCCGUUAGGC	CGAA	IGGUUCUU	1195	AAGAACC	C	ACAUUUUU	3974
3143	AAAAAUG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGGUUCU	1196	AGAACC	A	CAUUUUUC	3975

3145	AGGAAAA	CUGAUGAG	GCCGUUAGGC	CGAA	IUGGGGUU	1197	AACCCAC	A	UUUUUCCU	3976
3152	GACGCGCA	CUGAUGAG	GCCGUUAGGC	CGAA	IAAAAAUG	1198	CAUUUUUC	C	UGCGGUC	3977
3153	UGACGCGC	CUGAUGAG	GCCGUUAGGC	CGAA	IGAAAAAU	1199	AUUUUUCC	U	GCGGCUA	3978
3161	GUCAGAGA	CUGAUGAG	GCCGUUAGGC	CGAA	IACGCGCA	1200	UGC	GCGUC	A UCUCUGAC	3979
3164	CGUGUCAG	CUGAUGAG	GCCGUUAGGC	CGAA	IAUGACGC	1201	GCGUCAUC	U	CUGACACG	3980
3166	GCCGUGUC	CUGAUGAG	GCCGUUAGGC	CGAA	IAUGAGAC	1202	GUCAUCUC	U	GACACGGC	3981
3170	GGAGGCCG	CUGAUGAG	GCCGUUAGGC	CGAA	IUCAGAGA	1203	UCUCUGAC	A	CGGCCUCC	3982
3175	CAGAGGGA	CUGAUGAG	GCCGUUAGGC	CGAA	ICCGUGUC	1204	GACACGGC	C	UCCUCUG	3983
3176	GCAGAGGG	CUGAUGAG	GCCGUUAGGC	CGAA	IGCCGUGU	1205	ACACGGCC	U	CCCUCUGC	3984
3178	UAGCAGAG	CUGAUGAG	GCCGUUAGGC	CGAA	IAGGCCGU	1206	ACGGCCUC	C	CUCUGCUA	3985
3179	GUAGCAGA	CUGAUGAG	GCCGUUAGGC	CGAA	IGAGGCCG	1207	CGGCCUCC	C	UCUGCUAC	3986
3180	AGUAGCAG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGAGGCC	1208	GGCCUCCC	U	CUGCUACU	3987
3182	GGAGUAGC	CUGAUGAG	GCCGUUAGGC	CGAA	IAGGGAGG	1209	CCUCCUCU	U	GCUACUCC	3988
3185	GAUGGAGU	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGAGGG	1210	CCCUCUGC	U	ACUCCAU	3989
3188	CAGGAUGG	CUGAUGAG	GCCGUUAGGC	CGAA	IUAGCAGA	1211	UCUGCUAC	U	CCAUCUUG	3990
3190	UUCAGGAU	CUGAUGAG	GCCGUUAGGC	CGAA	IAGUAGCA	1212	UGC	UACUC C AUCCUGAA		3991
3191	UUUCAGGA	CUGAUGAG	GCCGUUAGGC	CGAA	IGAGUAGC	1213	GCUACUCC	A	UCCUGAAA	3992
3194	GGUUUUA	CUGAUGAG	GCCGUUAGGC	CGAA	IAUGGAGU	1214	ACUCCAUC	C	UGAAAGCC	3993
3195	UGGUUUUC	CUGAUGAG	GCCGUUAGGC	CGAA	IGAUGGAG	1215	CUCCAUC	U	GAAAGCCA	3994
3202	GCGUUCUU	CUGAUGAG	GCCGUUAGGC	CGAA	IUUUCAG	1216	CUGAAAGC	C	AAGAACGC	3995
3203	UGCGUUCU	CUGAUGAG	GCCGUUAGGC	CGAA	IGUUUUA	1217	UGAAAGCC	A	AGAACGCA	3996
3211	GACAUCCC	CUGAUGAG	GCCGUUAGGC	CGAA	ICGUUCUU	1218	AAGAACGC	A	GGAUGUC	3997
3222	UGGCCCCC	CUGAUGAG	GCCGUUAGGC	CGAA	ICGACAUC	1219	GAUGUCGC	U	GGGGGCCA	3998
3229	GCGCCUUU	CUGAUGAG	GCCGUUAGGC	CGAA	ICCCCCAG	1220	CUGGGGGC	C	AAGGGCG	3999
3230	GGCGCCCU	CUGAUGAG	GCCGUUAGGC	CGAA	IGCCCCCA	1221	UGGGGGCC	A	AGGGCGCC	4000
3238	GGGCCGCG	CUGAUGAG	GCCGUUAGGC	CGAA	ICGCCCUU	1222	AAGGGCGC	C	GCCGGCCC	4001
3241	AGAGGGCC	CUGAUGAG	GCCGUUAGGC	CGAA	ICGGCGCC	1223	GGCGCCGC	C	GGCCCUU	4002
3245	GGGCAGAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICGGCGGG	1224	CGGCCGGC	C	CUCUGCCC	4003
3246	AGGGCAGA	CUGAUGAG	GCCGUUAGGC	CGAA	IGCCGGCG	1225	CGCCGGCC	C	UCUGCCCU	4004
3247	GAGGGCAG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCCGGC	1226	GCCGGGCC	U	CUGCCCU	4005
3249	CGGAGGGC	CUGAUGAG	GCCGUUAGGC	CGAA	IAGGGCCG	1227	CGGCCCU	U	GCCCUCCG	4006
3252	CCUCGGAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGAGGG	1228	CCUCUGC	C	CUCCGAGG	4007
3253	GCCUCGGA	CUGAUGAG	GCCGUUAGGC	CGAA	IGCAGAGG	1229	CCUCUGCC	C	UCCGAGGC	4008
3254	GGCCUCGG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCAGAG	1230	CUCUGCCC	U	CCGAGGCC	4009

3256	ACGGCCUC	CUGAUGAG	GCCGUUAGGC	CGAA	IAGGCGAG	1231	CUGCCCCUC	C	GAGGCCGU	4010
3262	CACUGCAC	CUGAUGAG	GCCGUUAGGC	CGAA	ICCUUGGA	1232	UCCGAGGC	C	GUGCAGUG	4011
3267	ACAGCCAC	CUGAUGAG	GCCGUUAGGC	CGAA	ICACGGCC	1233	GGCCGUGC	A	GUGGCUGU	4012
3273	GGUGGCAC	CUGAUGAG	GCCGUUAGGC	CGAA	ICACUGC	1234	GCAGUGGC	U	GUGCCACC	4013
3278	UGCUUGGU	CUGAUGAG	GCCGUUAGGC	CGAA	ICACAGCC	1235	GGCUGUGC	C	ACCAAGCA	4014
3279	AUGCJUUG	CUGAUGAG	GCCGUUAGGC	CGAA	IGCACAGC	1236	GCUGUGCC	A	CCAAGCAU	4015
3281	GA AUGCUU	CUGAUGAG	GCCGUUAGGC	CGAA	IUGGCACA	1237	UGUGCCAC	C	AAGCAUUC	4016
3282	GGAAUGCU	CUGAUGAG	GCCGUUAGGC	CGAA	IUGGCGAC	1238	GUGCCACC	A	AGCAUUC	4017
3286	AGCAGGAA	CUGAUGAG	GCCGUUAGGC	CGAA	ICUUGGUG	1239	CACCAAGC	A	UUCCUGCU	4018
3290	CUUGAGCA	CUGAUGAG	GCCGUUAGGC	CGAA	IAAUGCUU	1240	AAGCAUUC	C	UGCUC AAG	4019
3291	GUUGAGC	CUGAUGAG	GCCGUUAGGC	CGAA	IGRAUGCU	1241	AGCAUUC	U	GCUCAAGC	4020
3294	UCAGCUUG	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGGAU	1242	AUCCUGC	U	CAAGCUGA	4021
3296	AGUCAGCU	CUGAUGAG	GCCGUUAGGC	CGAA	IAGCAGGA	1243	UCCUGCUC	A	AGCUGACU	4022
3300	GUCGAGUC	CUGAUGAG	GCCGUUAGGC	CGAA	ICUUGAGC	1244	GCUCAAGC	U	GACUCGAC	4023
3304	CGGUGUC	CUGAUGAG	GCCGUUAGGC	CGAA	IUCAGCUU	1245	AAGCUGAC	U	CGACACCG	4024
3309	UGACACGG	CUGAUGAG	GCCGUUAGGC	CGAA	IUCGAGUC	1246	GACUCGAC	A	CCGUGUCA	4025
3311	GGUGACAC	CUGAUGAG	GCCGUUAGGC	CGAA	IUGUCGAG	1247	CUCGACAC	C	GUGUCACC	4026
3317	CACGUAGG	CUGAUGAG	GCCGUUAGGC	CGAA	IACACGGU	1248	ACCGUGUC	A	CCUACGUG	4027
3319	GGCACGUA	CUGAUGAG	GCCGUUAGGC	CGAA	IUGACACG	1249	CGUGUCAC	C	UACGUGCC	4028
3320	UGGCACGU	CUGAUGAG	GCCGUUAGGC	CGAA	IUGACAC	1250	GUGUCACC	U	ACGUGCCA	4029
3327	CCAGGAGU	CUGAUGAG	GCCGUUAGGC	CGAA	ICACGUAG	1251	CUACGUGC	C	ACUCCUGG	4030
3328	CCCAGGAG	CUGAUGAG	GCCGUUAGGC	CGAA	IGCACGUA	1252	UACGUGCC	A	CUCCUGGG	4031
3330	ACCCAGG	CUGAUGAG	GCCGUUAGGC	CGAA	IUGGCACG	1253	CGUGCCAC	U	CCUGGGGU	4032
3332	UGACCCCA	CUGAUGAG	GCCGUUAGGC	CGAA	IAGUGGCA	1254	UGCCACUC	C	UGGGGUCA	4033
3333	GUGACCCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGAGUGGC	1255	GCCACUCC	U	GGGGUCAC	4034
3340	GUCCUGAG	CUGAUGAG	GCCGUUAGGC	CGAA	IACCCAG	1256	CUGGGGUC	A	CUCAGGAC	4035
3342	CUGUCCUG	CUGAUGAG	GCCGUUAGGC	CGAA	IUGACCCC	1257	GGGUCAC	U	CAGGACAG	4036
3344	GGCUGUCC	CUGAUGAG	GCCGUUAGGC	CGAA	IAGUGACC	1258	GGUCACUC	A	GGACAGCC	4037
3349	GUCUGGGC	CUGAUGAG	GCCGUUAGGC	CGAA	IUCCUGAG	1259	CUCAGGAC	A	GCCCAGAC	4038
3352	UGCGUCUG	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGUCCU	1260	AGGACAGC	C	CAGACGCA	4039
3353	CUGCGUCU	CUGAUGAG	GCCGUUAGGC	CGAA	IGCUGUCC	1261	GGACAGCC	C	AGACGCAG	4040
3354	GCUGCGUC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCUGUC	1262	GACAGCCC	A	GACGCAGC	4041
3360	GACUCAGC	CUGAUGAG	GCCGUUAGGC	CGAA	ICGUCUGG	1263	CCAGACGC	A	GCUGAGUC	4042
3363	UCCGACUC	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGCGUC	1264	GACGCAGC	U	GAGUCGGA	4043

3375	UCCCCGGG	CUGAUGAG	GCCGUUAGGC	CGAA	ICUUCCGA	1265	UCGGAAGC	U	CCCCGGGA	4044
3377	CGUCCCCG	CUGAUGAG	GCCGUUAGGC	CGAA	IAGCUUCC	1266	GGAAGCUC	C	CGGGGACG	4045
3378	UCGUCCCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGAGCUUC	1267	GAAGCUCC	C	GGGGACGA	4046
3390	GGGCAGUC	CUGAUGAG	GCCGUUAGGC	CGAA	ICGUUCGUC	1268	GACGACGC	U	GACUGCCC	4047
3394	UCCAGGGC	CUGAUGAG	GCCGUUAGGC	CGAA	IUCAGCGU	1269	ACGCUGAC	U	GCCCUGGA	4048
3397	GCCUCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGUCAG	1270	CUGACUGC	C	CUGGAGGC	4049
3398	GGCCUCCA	CUGAUGAG	GCCGUUAGGC	CGAA	IGCAGUCA	1271	UGACUGCC	C	UGGAGGCC	4050
3399	CGGCCUCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCAGUC	1272	GACUGCCC	U	GGAGGCCG	4051
3406	UUGGCUGC	CUGAUGAG	GCCGUUAGGC	CGAA	ICCUCCAG	1273	CUGGAGGC	C	GCAGCCAA	4052
3409	GGGUUGGC	CUGAUGAG	GCCGUUAGGC	CGAA	ICGGCCUC	1274	GAGGCCGC	A	GCCAAACC	4053
3412	GCCGGGUU	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGCGGC	1275	GCCGCAGC	C	AACCCGGC	4054
3413	UGCCGGGU	CUGAUGAG	GCCGUUAGGC	CGAA	IGCUGCGG	1276	CCGCAGCC	A	ACCCGGCA	4055
3416	CAGUGCUG	CUGAUGAG	GCCGUUAGGC	CGAA	IUUGGCUG	1277	CAGCCAAC	C	CGGCACUG	4056
3417	GCAGUGCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGUUGGCU	1278	AGCCAACC	C	GGCACUGC	4057
3421	GAGGGCAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICCGGGUU	1279	AACCCGGC	A	CUGCCCUC	4058
3423	CUGAGGGC	CUGAUGAG	GCCGUUAGGC	CGAA	IUGCCGGG	1280	CCCGGCAC	U	GCCCUACG	4059
3426	AGUCUGAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGUGCC	1281	GGCACUGC	C	CUCAGACU	4060
3427	AAGUCUGA	CUGAUGAG	GCCGUUAGGC	CGAA	IGCAGUGC	1282	GCACUGCC	C	UCAGACUU	4061
3428	GAAGUCUG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCAGUG	1283	CACUGCCC	U	CAGACUUC	4062
3430	UUGAAGUC	CUGAUGAG	GCCGUUAGGC	CGAA	IAGGCAG	1284	CUGCCCUC	A	GACUUCAA	4063
3434	GGUCUUGA	CUGAUGAG	GCCGUUAGGC	CGAA	IUCUGAGG	1285	CCUCAGAC	U	UCAAGACC	4064
3437	GAUGGUCU	CUGAUGAG	GCCGUUAGGC	CGAA	IAAGUCUG	1286	CAGACUUC	A	AGACCAUC	4065
3442	UCCAGGAU	CUGAUGAG	GCCGUUAGGC	CGAA	IUCUUGAA	1287	UUCAAGAC	C	AUCCUGGA	4066
3443	GUCCAGGA	CUGAUGAG	GCCGUUAGGC	CGAA	IGUCUUGA	1288	UCAAGACC	A	UCCUGGAC	4067
3446	UCAGUCCA	CUGAUGAG	GCCGUUAGGC	CGAA	IAUGGUCU	1289	AGACCAUC	C	UGGACUGA	4068
3447	AUCAGUCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGAUGGUC	1290	GACCAUCC	U	GGACUGAU	4069
3452	UGGCCAUC	CUGAUGAG	GCCGUUAGGC	CGAA	IUCCAGGA	1291	UCCUGGAC	U	GAUGGCCA	4070
3459	GGGGGGGU	CUGAUGAG	GCCGUUAGGC	CGAA	ICCAUCAG	1292	CUGAUGGC	C	ACCCGCCC	4071
3460	UGGGCGGG	CUGAUGAG	GCCGUUAGGC	CGAA	IGCCAUCA	1293	UGAUGGCC	A	CCCGCCCA	4072
3462	UGUGGGCG	CUGAUGAG	GCCGUUAGGC	CGAA	IUGGCCAU	1294	AUGGCCAC	C	CGCCCCACA	4073
3463	CUGUGGGC	CUGAUGAG	GCCGUUAGGC	CGAA	IGUGGCCA	1295	UGGCCACC	C	GCCCCACG	4074
3466	UGGCUUGU	CUGAUGAG	GCCGUUAGGC	CGAA	ICGGGUGG	1296	CCACCCGC	C	CACAGCCA	4075
3467	CUGGCUGU	CUGAUGAG	GCCGUUAGGC	CGAA	IGCGGGUG	1297	CACCCGCC	C	ACAGCCAG	4076
3468	CCUGGCUG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCGGGU	1298	ACCCGCCC	A	CAGCCAGG	4077



3470	GGCCUUGC	CUGAUGAG	GCCGUUAGGC	CGAA	IUGGGCGG	1299	CCGCCCCAC	A	GCCAGGCC	4078
3473	CUCGGCCU	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGUGGG	1300	CCCACAGC	C	AGGCCGAG	4079
3474	UCUCGGCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGCUGUGG	1301	CCACAGCC	A	GGCCGAGA	4080
3478	CUGCUCUC	CUGAUGAG	GCCGUUAGGC	CGAA	ICUUGGCU	1302	AGCCAGGC	C	GAGAGCAG	4081
3485	CUGGUGUC	CUGAUGAG	GCCGUUAGGC	CGAA	ICUCUCGG	1303	CCGAGAGC	A	GACACCCAG	4082
3489	GCUGCUGG	CUGAUGAG	GCCGUUAGGC	CGAA	IUCUGCUC	1304	GAGCAGAC	A	CCAGCAGC	4083
3491	GGGUCUGU	CUGAUGAG	GCCGUUAGGC	CGAA	IUGUCUGC	1305	GCAGACAC	C	AGCAGCCC	4084
3492	AGGGCUGC	CUGAUGAG	GCCGUUAGGC	CGAA	IGUGUCUG	1306	CAGACACC	A	GCAGCCCU	4085
3495	GACAGGGC	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGGUGU	1307	ACACCAGC	A	GCCCUGUC	4086
3498	CGUGACAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICUGCUGG	1308	CCAGCAGC	C	CUGUCACG	4087
3499	GGUGAGCA	CUGAUGAG	GCCGUUAGGC	CGAA	IGCUGCUG	1309	CAGCAGCC	C	UGUCACGC	4088
3500	GGGUGAC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCUGCU	1310	AGCAGCCC	U	GUCACGCC	4089
3504	GCCC GGCG	CUGAUGAG	GCCGUUAGGC	CGAA	IACAGGGC	1311	GCCCUGUC	A	CGCCGGGC	4090
3508	UAGAGCCC	CUGAUGAG	GCCGUUAGGC	CGAA	ICGUGACA	1312	UGUCACGC	C	GGGCUCUA	4091
3513	GGACGUAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICCCGGCG	1313	CGCCGGGC	U	CUACGUCC	4092
3515	UGGGACGU	CUGAUGAG	GCCGUUAGGC	CGAA	IAGCCCGG	1314	CGGGGUCU	U	ACGUCCCA	4093
3521	CCUCCCUU	CUGAUGAG	GCCGUUAGGC	CGAA	IACGUAGA	1315	UCUACGUC	C	CAGGGAGG	4094
3522	CCCUCCCU	CUGAUGAG	GCCGUUAGGC	CGAA	IGACGUAG	1316	CUACGUCC	C	AGGGAGGG	4095
3523	UCCCUCCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGACGUA	1317	UACGUCCC	A	GGGAGGGA	4096
3540	UGGGUGUG	CUGAUGAG	GCCGUUAGGC	CGAA	ICCGCCCC	1318	GGGGCGGC	C	CACACCCA	4097
3541	CUGGGUGU	CUGAUGAG	GCCGUUAGGC	CGAA	IGCCGCCC	1319	GGGCGGCC	C	ACACCCAG	4098
3542	CCUGGGUG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCGGCC	1320	GGCGGCCC	A	CACCCAGG	4099
3544	GGCCUGGG	CUGAUGAG	GCCGUUAGGC	CGAA	IUGGGCCG	1321	CGGCCCCAC	A	CCCAGGCC	4100
3546	CGGGCCUG	CUGAUGAG	GCCGUUAGGC	CGAA	IUGUGGGC	1322	GCCACAC	C	CAGGCCCG	4101
3547	GCGGGCCU	CUGAUGAG	GCCGUUAGGC	CGAA	IGUGUGGG	1323	CCCACACC	C	AGGCCCGC	4102
3548	UGCGGGCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGUGUGG	1324	CCACACCC	A	GGCCCCGCA	4103
3552	GCGGUGGG	CUGAUGAG	GCCGUUAGGC	CGAA	ICCUUGGU	1325	ACCCAGGC	C	CGCACCGC	4104
3553	AGCGGUGC	CUGAUGAG	GCCGUUAGGC	CGAA	IGCCUGGG	1326	CCCAGGCC	C	GCACCGCU	4105
3556	CCCAGCGG	CUGAUGAG	GCCGUUAGGC	CGAA	ICGGGCCU	1327	AGGCCCGC	A	CCGCUGGG	4106
3558	CUCCCCAGC	CUGAUGAG	GCCGUUAGGC	CGAA	IUGCGGGC	1328	GCCCGCAC	C	GCUGGGAG	4107
3561	AGACUCCC	CUGAUGAG	GCCGUUAGGC	CGAA	ICGGUGCG	1329	CGCACCGC	U	GGGAGUCU	4108
3569	CAGGCCUC	CUGAUGAG	GCCGUUAGGC	CGAA	IACUCCCA	1330	UGGGAGUC	U	GAGGCCUG	4109
3575	CUACAUCA	CUGAUGAG	GCCGUUAGGC	CGAA	ICCUACAGA	1331	UCUGAGGC	C	UGAGUGAG	4110
3576	ACUCACUC	CUGAUGAG	GCCGUUAGGC	CGAA	IGCCUCAG	1332	CUGAGGCC	U	GAGUGAGU	4111

3592	CAGGCCUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCAAACA	1333	UGUUUGGC	C	GAGGCCUG	4112	
3598	GACAUGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUCCGC	1334	GCCGAGGC	C	UGCAUGUC	4113	
3599	GGACAUGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCUCGG	1335	CCGAGGCC	U	GCAUGUCC	4114	
3602	GCCGGACA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGGCCU	1336	AGGCCUGC	A	UGUCCGGC	4115	
3607	CUUCAGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACAUGCA	1337	UGCAUGUC	C	GGCUGAAG	4116	
3611	CAGCCUUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGGACA	1338	UGUCCGGC	U	GAAGGCUG	4117	
3618	GGACACUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUUCAG	1339	CUGAAGGC	U	GAGUGUCC	4118	
3626	CCUCAGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACACUCA	1340	UGAGUGUC	C	GGCUGAGG	4119	
3630	CAGGCCUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGGACA	1341	UGUCCGGC	U	GAGGCCUG	4120	
3636	CUCGCUCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUACAG	1342	GCUGAGGC	C	UGAGCGAG	4121	
3637	ACUCGCUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCCUCAG	1343	CUGAGGCC	U	GAGCGAGU	4122	
3649	CCUUGGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACACUCG	1344	CGAGUGUC	C	AGCCAAGG	4123	
3650	CCCUUGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGACACUC	1345	GAGUGUCC	A	GCCAAGGG	4124	
3653	CAGCCCUU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGGACA	1346	UGUCCAGC	C	AAGGGCUG	4125	
3654	UCAGCCCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCUGGAC	1347	GUCCAGCC	A	AGGCUGA	4126	
3660	GGACACUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCCUUGG	1348	CCAAGGCC	U	GAGUGUCC	4127	
3668	GGUGUGCU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACACUCA	1349	UGAGUGUC	C	AGCACACC	4128	
3669	AGGUGUGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGACACUC	1350	GAGUGUCC	A	GCACACCU	4129	
3672	GGCAGGUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICUGGACA	1351	UGUCCAGC	A	CACCUGCC	4130	
3674	ACGGCAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGCUGGA	1352	UCCAGCAC	A	CCUGCCGU	4131	
3676	AGACGGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGUGCUG	1353	CAGCACAC	C	UGCCGUCU	4132	
3677	AAGACGGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUGUGCU	1354	AGCACACC	U	GCCGUCUU	4133	
3680	GUGAAGAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGGUGU	1355	ACACCUGC	C	GUCUUCAC	4134	
3684	GGAAGUGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACGGCAG	1356	CUGCCGUC	U	UCACUUC	4135	
3687	UGGGGAAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAGACGG	1357	CCGUCUUC	A	CUUCCCCA	4136	
3689	UGUGGGGA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGAAGAC	1358	GUCUUCAC	U	UCCCCACA	4137	
3692	GCCUGUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAGUGAA	1359	UUCACUUC	C	CCACAGGC	4138	
3693	AGCCUGUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGAAGUGA	1360	UCACUUC	C	CACAGGCU	4139	
3694	CAGCCUGU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGAAGUG	1361	CACUUC	CCC	C	ACAGGCUG	4140
3695	CCAGCCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGGAAGU	1362	ACUUC	CCCC	A	CAGGCUGG	4141
3697	CGCCAGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGGGGAA	1363	UUCCCCAC	A	GGCUGGGC	4142	
3701	CGAGCGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCUUGGG	1364	CCACAGGC	U	GGGCGUCG	4143	
3707	UGGAGCCG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICGCCAGC	1365	GCUGGCGC	U	CGGCUCCA	4144	
3712	UGGGGUGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICCGAGCG	1366	CGCUCGGC	U	CCACCCCCA	4145	

3714	CCUGGGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGCCGAG	1367	CUCGGCUC C ACCCCAGG	4146
3715	CCCUGGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGCCGA	1368	UCGGCUC A CCCAGGG	4147
3717	GGCCUUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGGAGCC	1369	GGCUCAC C CCAGGGCC	4148
3718	UGGCCUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGGAGC	1370	GCUCCACC C CAGGGCCA	4149
3719	CUGGCCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGUGGAG	1371	CUCCACCC C AGGGCCAG	4150
3720	GCUGGCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGUGGA	1372	UCCACCCC A GGGCCAGC	4151
3725	GAAAAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICCUGGG	1373	CCCAGGC C AGUUUUC	4152
3726	GGAAAAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCCUGG	1374	CCAGGGC A GCUUUUC	4153
3729	UGAGGAA CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUGGCC	1375	GGGCCAG U UUUCCUCA	4154
3734	CCUGGUA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAAAAGC	1376	AGCUUUC C UCACCAGG	4155
3735	UCCUGGU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGAAGC	1377	GCUUUUC U CACCAGG	4156
3737	GUCCUGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGAAAA	1378	UUUUCUC A CCAGGAGC	4157
3739	GGCUCUC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGAGGA	1379	UUCUCAC C AGGAGCCC	4158
3740	CGGGCUC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGAGGA	1380	UCCUCAC A GGAGCCC	4159
3746	GGAAGCC CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICUCCUG	1381	CCAGGAG C CGGUUCC	4160
3747	UGGAAGC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCUCUG	1382	CAGGAGC C GGUUCCA	4161
3751	GGAGUGA CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGGGCU	1383	AGCCCGC U UCCACUC	4162
3754	UGGGGAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGCCCG	1384	CGGCUUC C ACUCCCA	4163
3755	GUGGGAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGAAGCC	1385	CGGCUUC A CUCCCCAC	4164
3757	AUGUGGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGGAAGC	1386	GCUUCCAC U CCCACAU	4165
3759	CUAUGUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGUGGA	1387	UUCACUC C CCACAUAG	4166
3760	CCUAUG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAGUGGA	1388	UCCACUC C CACAUAGG	4167
3761	UCCUAGU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGAGUG	1389	CCACUCC C ACAUAGGA	4168
3762	UUCCUAG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGAGUG	1390	CACUCCC A CAUAGGA	4169
3764	UAUCCUA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IUGGGGAG	1391	CUCCCCAC A UAGGAUA	4170
3776	CUGGGGAU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IACUAUUC	1392	GAUAGUC C AUCCCCAG	4171
3777	UCUGGGA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IACUAUUC	1393	AUAGUCC A UCCCCAGA	4172
3780	GAUUGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAUAGACU	1394	AGUCCAUC C CCAGAUUC	4173
3781	CGAAUCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGAUGGAC	1395	GUCCAUC C CAGAUUCG	4174
3782	GCGAUCU CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGAUGGA	1396	UCCAUC C AGAUUCGC	4175
3783	GGCGAUC CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGGGAGG	1397	CCAUC C A GAUUCGC	4176
3791	UGAACAAU CUGAUGAG <u>GCCGUUAGGC</u> CGAA ICGAAUCU	1398	AGAUUGC C AUUGUCA	4177
3792	GUGAACAA CUGAUGAG <u>GCCGUUAGGC</u> CGAA IGCAAUC	1399	GAUUCGC A UUGUUCAC	4178
3799	GCGAGGG CUGAUGAG <u>GCCGUUAGGC</u> CGAA IAACAAUG	1400	CAUUGUUC A CCCUCGC	4179

3801	GGGCGAG	CUGAUGAG	GCCGUUAGGC	CGAA	IUGAACAA	1401	UUGUUCAC	C	CCUCGCC	4180
3802	AGGGCGAG	CUGAUGAG	GCCGUUAGGC	CGAA	IGUGAACAA	1402	UGUUCACC	C	CUCGCCCU	4181
3803	CAGGGCGA	CUGAUGAG	GCCGUUAGGC	CGAA	IGGUGAAC	1403	GUUCACCC	C	UCGCCCUUG	4182
3804	GCAGGGCG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGGUGAA	1404	UUCACCCC	U	CGCCCUUGC	4183
3808	GAGGGCAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICGAGGGG	1405	CCCCUCGC	C	CUGCCCUUC	4184
3809	GGAGGGCA	CUGAUGAG	GCCGUUAGGC	CGAA	IGCGAGGG	1406	CCCUCGCC	C	UGCCCUCC	4185
3810	AGGAGGGC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCGAGG	1407	CCUCGCC	U	GCCCUCCU	4186
3813	CAAAGGAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICAGGGCG	1408	GGCCUUGC	C	CUCUUUG	4187
3814	GCAAAGGA	CUGAUGAG	GCCGUUAGGC	CGAA	IGCAGGGC	1409	GCCUUGCC	C	UCCUUUGC	4188
3815	GGCAAAGG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGCAGGG	1410	CCCUGCCC	U	CCUUUGCC	4189
3817	AAGGCAAA	CUGAUGAG	GCCGUUAGGC	CGAA	IAGGCGAG	1411	CUGCCCUUC	C	UUUGCCUU	4190
3818	GAAGGCAA	CUGAUGAG	GCCGUUAGGC	CGAA	IGAGGGCA	1412	UGCCCUCC	U	UUGCCUUUC	4191
3823	GGGUGGAA	CUGAUGAG	GCCGUUAGGC	CGAA	ICAAAGGA	1413	UCCUUUGC	C	UUCCACCC	4192
3824	GGGUGGGA	CUGAUGAG	GCCGUUAGGC	CGAA	IGCAAAGG	1414	CCUUUGCC	U	UCCACCCC	4193
3827	GUGGGGU	CUGAUGAG	GCCGUUAGGC	CGAA	IAAGGCAA	1415	UUGCCUUC	C	ACCCCCAC	4194
3828	GGUGGGGG	CUGAUGAG	GCCGUUAGGC	CGAA	IGAAGGCA	1416	UGCCUUC	A	CCCCACC	4195
3830	AUGGUGGG	CUGAUGAG	GCCGUUAGGC	CGAA	IUGGAAGG	1417	CCUCCAC	C	CCCACCAU	4196
3831	GAUGGUGG	CUGAUGAG	GCCGUUAGGC	CGAA	IGUGGAAG	1418	CUUCCACC	C	CCACCAUC	4197
3832	GGAUGGUG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGUGGAA	1419	UUCCACCC	C	CACCAUCC	4198
3833	UGGAUGGU	CUGAUGAG	GCCGUUAGGC	CGAA	IGGGUGGA	1420	UCCACCCC	C	ACCAUCCA	4199
3834	CUGGAUGG	CUGAUGAG	GCCGUUAGGC	CGAA	IGGGGUGG	1421	CCACCCC	A	CCAUCCAG	4200
3836	ACCUGGAU	CUGAUGAG	GCCGUUAGGC	CGAA	IUGGGGGU	1422	ACCCCCAC	C	AUCCAGGU	4201
3837	CACCUGGA	CUGAUGAG	GCCGUUAGGC	CGAA	IGUGGGGG	1423	CCCCCACC	A	UCCAGGUG	4202
3840	CUCCACCU	CUGAUGAG	GCCGUUAGGC	CGAA	IAUGGUGG	1424	CCACCAUC	C	AGGUGGAG	4203
3841	UCUCCACC	CUGAUGAG	GCCGUUAGGC	CGAA	IGAUGGUG	1425	CACCAUCC	A	GGUGGAGA	4204
3851	CUUCUCAG	CUGAUGAG	GCCGUUAGGC	CGAA	IUCUCCAC	1426	GUGGAGAC	C	CUGAGAAG	4205
3852	CCUUCUCA	CUGAUGAG	GCCGUUAGGC	CGAA	IGUCUCCA	1427	UGGAGACC	C	UGAGAAGG	4206
3853	UCCUUCUC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGUCUCC	1428	GGAGACCC	U	GAGAAGGA	4207
3863	GUCCCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	IUCCUUCU	1429	AGAAGGAC	C	CUGGGAGC	4208
3864	AGCUCCCA	CUGAUGAG	GCCGUUAGGC	CGAA	IGUCCUUC	1430	GAAGGACC	C	UGGGAGCU	4209
3865	GAGCUCCC	CUGAUGAG	GCCGUUAGGC	CGAA	IGGUCCUU	1431	AAGGACCC	U	GGGAGCTUC	4210
3872	AUUCCCAG	CUGAUGAG	GCCGUUAGGC	CGAA	ICUCCCGAG	1432	CUGGGAGC	U	CUGGGAAU	4211
3874	AAAUUCCC	CUGAUGAG	GCCGUUAGGC	CGAA	IAGCUCCC	1433	GGGAGCTUC	U	GGGAAUUU	4212
3891	ACACCUUU	CUGAUGAG	GCCGUUAGGC	CGAA	IUCACUCC	1434	GGAGUGAC	C	AAAGGUGU	4213

3892	CACACCUU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUCACUC	1435	GAGUGACC	A	AAGGUGUG	4214
3902	GUGUACAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACACCU	1436	AGGUGUGC	C	CUGUACAC	4215
3903	UGUGUACA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGCACACC	1437	GGUGUGCC	C	UGUACACA	4216
3904	CUGUGUAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGCACAC	1438	GUGUGCCC	U	GUACACAG	4217
3909	CUCGCCUG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUACAGGG	1439	CCCUGUAC	A	CAGGCCGAG	4218
3911	UCCUCGCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGUACAG	1440	CUGUACAC	A	GCGAGGA	4219
3921	AGGUGCAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUCCUCGC	1441	GCGAGGAC	C	CUGCACCU	4220
3922	CAGGUGCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUCCUCG	1442	CGAGGACC	C	UGCACCUG	4221
3923	CCAGGUGC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGUCCUC	1443	GAGGACCC	U	GCACCUUG	4222
3926	CAUCCAGG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICAGGGUC	1444	GACCCUGC	A	CCUGGAUG	4223
3928	CCCAUCCA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUGCAGGG	1445	CCCUGCAC	C	UGGAUGGG	4224
3929	CCCCAUCC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGUGCAGG	1446	CCUGCACC	U	GGAUGGGG	4225
3941	ACCCACAG	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACCCCCA	1447	UGGGGGUC	C	CUGUGGGU	4226
3942	GACCCACA	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGACCCCC	1448	GGGGGUCC	C	UGUGGGUC	4227
3943	UGACCCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IGGACCCC	1449	GGGUUCCC	U	GUGGGUCA	4228
3951	CCCCAAUU	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IACCCACA	1450	UGUGGGUC	A	AAUUGGGG	4229
3968	ACUCCCCAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	ICACCCUCC	1451	GGAGGUGC	U	GUGGGAGU	4230
3984	AUAUAUUC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IUAUUUUA	1452	UAAAAUAC	U	GAUAUAU	4231
4002	UUCAAAAC	CUGAUGAG	<u>GCCGUUAGGC</u>	CGAA	IAAAAACU	1453	AGUUUUUC	A	GUUUUGAA	4232

Stem Length = 8 . Core Sequence = CUGAUGAG GCCGUUAGGC CGAA, I = Inosine nucleotide

Seq1 = TERT (Homo sapiens telomerase reverse transcriptase (TERT) mRNA, 4015 bp); Nakamura *et al.*, Science 277 (5328), 955-959 (1997)

**Table V: Human telomerase reverse transcriptase (TERT) G-Cleaver Ribozyme and Target Sequence**

nt. Position	Substrate Sequence	Seq ID Nos	Ribozyme Sequence	
16	GCUGCGUCCU G CUGCG	1454	CGCAG UGAUGGCAUGCACUAUGCGCG AGGACGCAGC	4233
19	GCGUCCUGCU G CGCAC	1455	GUGCG UGAUGGCAUGCACUAUGCGCG AGCAGGACGC	4234
21	GUCCUGCUGC G CACGU	1456	ACGUG UGAUGGCAUGCACUAUGCGCG GCAGCAGGAC	4235
53	GGCCACCCCC G CGAUG	1457	CAUCG UGAUGGCAUGCACUAUGCGCG GGGGGUGGCC	4236
55	CCACCCCCGC G AUGCC	1458	GGCAU UGAUGGCAUGCACUAUGCGCG GCGGGGUGG	4237
58	CCCCCGCGAU G CCGCG	1459	CGCGG UGAUGGCAUGCACUAUGCGCG AUCGCGGGGG	4238
61	CCGCGAUGCC G CGCGC	1460	GCGCG UGAUGGCAUGCACUAUGCGCG GGCAUCGCGG	4239
63	GCGAUGCCGC G CGCUC	1461	GAGCG UGAUGGCAUGCACUAUGCGCG GCGGCAUCGC	4240
65	GAUGCCGCGC G CUCCC	1462	GGGAG UGAUGGCAUGCACUAUGCGCG GCGCGGCAUC	4241
72	CGCGCUCCCC G CUGCC	1463	GGCAG UGAUGGCAUGCACUAUGCGCG GGGGAGCGCG	4242
75	GUCCCCGCU G CCGAG	1464	CUCGG UGAUGGCAUGCACUAUGCGCG AGCGGGGAGC	4243
78	CCCCGUGCC G AGCCG	1465	CGGCU UGAUGGCAUGCACUAUGCGCG GGCAGCGGGG	4244
85	GCCGAGCCGU G CGCUC	1466	GAGCG UGAUGGCAUGCACUAUGCGCG ACGGCUCGGC	4245
87	CGAGCCGUGC G CUCCC	1467	GGGAG UGAUGGCAUGCACUAUGCGCG GCACGGCUCG	4246
94	UGCGCUCCCU G CUGCG	1468	CGCAG UGAUGGCAUGCACUAUGCGCG AGGGAGCGCA	4247
97	GUCCCCGCU G CGCAG	1469	CUGCG UGAUGGCAUGCACUAUGCGCG AGCAGGGAGC	4248
99	UCCUGCUGC G CAGCC	1470	GGCUG UGAUGGCAUGCACUAUGCGCG GCAGCAGGGA	4249
111	AGCCACUACC G CGAGG	1471	CCUCG UGAUGGCAUGCACUAUGCGCG GGUAGUGGCU	4250
113	CCACUACCGC G AGGUG	1472	CACCU UGAUGGCAUGCACUAUGCGCG GCGGUAGUGG	4251
118	ACCGCGAGGU G CUGCC	1473	GGCAG UGAUGGCAUGCACUAUGCGCG ACCUCGCGGU	4252
121	GCGAGGUGCU G CCGCU	1474	AGCGG UGAUGGCAUGCACUAUGCGCG AGCACCUCGC	4253
124	AGGUGCUGCC G CUGGC	1475	GCCAG UGAUGGCAUGCACUAUGCGCG GGCAGCACCU	4254
139	CCACGUUCGU G CGGCG	1476	CGCCG UGAUGGCAUGCACUAUGCGCG ACGAACGUGG	4255
144	UUCGUGCGGC G CCUGG	1477	CCAGG UGAUGGCAUGCACUAUGCGCG GCCGCACGAA	4256
172	GGCGGUGGU G CAGCG	1478	CGCUG UGAUGGCAUGCACUAUGCGCG ACCAGCCGCC	4257
177	CUGGUGCAGC G CGGGG	1479	CCCCG UGAUGGCAUGCACUAUGCGCG GCUGCACCAG	4258
198	GCGGCUUCC G CGCGC	1480	GCGCG UGAUGGCAUGCACUAUGCGCG GGAAGCCGC	4259
200	GGCUUCCGC G CGCUG	1481	CAGCG UGAUGGCAUGCACUAUGCGCG GCGGAAAGCC	4260
202	CUUCCGCGC G CUGGU	1482	ACCAG UGAUGGCAUGCACUAUGCGCG GCGCGAAAG	4261
216	GUGGCCAGU G CCUGG	1483	CCAGG UGAUGGCAUGCACUAUGCGCG ACUGGGCCAC	4262
223	AGUGCCUGGU G UCGU	1484	ACGCA UGAUGGCAUGCACUAUGCGCG ACCAGGCACU	4263
225	UGCCUGGUGU G CGUGC	1485	GCACG UGAUGGCAUGCACUAUGCGCG ACACCAGGCA	4264
229	UGGUGUGCGU G CCCUG	1486	CAGGG UGAUGGCAUGCACUAUGCGCG ACGCACACCA	4265
239	GCCCUGGGAC G CACGG	1487	CCGUG UGAUGGCAUGCACUAUGCGCG GUCCAGGGC	4266
247	ACGCACGGCC G CCCCC	1488	GGGGG UGAUGGCAUGCACUAUGCGCG GGCCGUGCGU	4267
254	GCCGCCCCC G CCGCC	1489	GGCGG UGAUGGCAUGCACUAUGCGCG GGGGGCGGC	4268
257	GCCCCCGCC G CCCCC	1490	GGGGG UGAUGGCAUGCACUAUGCGCG GGCGGGGGC	4269
270	CCUCCUCC G CCAGG	1491	CCUGG UGAUGGCAUGCACUAUGCGCG GGAAGAGGG	4270
277	UCCGCCAGGU G UCCUG	1492	CAGGA UGAUGGCAUGCACUAUGCGCG ACCUGGCGGA	4271
282	CAGGUGUCCU G CCUGA	1493	UCAGG UGAUGGCAUGCACUAUGCGCG AGGACACCUG	4272
286	UGUCCUGCCU G AAGGA	1494	UCCUU UGAUGGCAUGCACUAUGCGCG AGGCAGGACA	4273

303	CUGGUGGCCC G AGUGC	1495	GCACU UGAUGGCAUGCACUAUGCGCG	GGGCCACCAG	4274
307	UGGCCCAGAGU G CUGCA	1496	UGCAG UGAUGGCAUGCACUAUGCGCG	ACUCGGGCCA	4275
310	CCCGAGUGCU G CAGAG	1497	CUCUG UGAUGGCAUGCACUAUGCGCG	AGCACUCGGG	4276
319	UGCAGAGGCU G UCGA	1498	UCGCA UGAUGGCAUGCACUAUGCGCG	AGCCUCUGCA	4277
321	CAGAGGCUGU G CGAGC	1499	GCUCG UGAUGGCAUGCACUAUGCGCG	ACAGCCUCUG	4278
323	GAGGCUGUGC G AGCGC	1500	GCGCU UGAUGGCAUGCACUAUGCGCG	GCACAGCCUC	4279
327	CUGUGCGAGC G CGGCG	1501	CGCCG UGAUGGCAUGCACUAUGCGCG	GCUCGCACAG	4280
332	CGAGCGCGGC G CGAAG	1502	CUUCG UGAUGGCAUGCACUAUGCGCG	GCCGCGCUCG	4281
334	AGCGCGGCGC G AAGAA	1503	UUCUU UGAUGGCAUGCACUAUGCGCG	GCGCCGCGCU	4282
343	CGAAGAACGU G CUGGC	1504	GCCAG UGAUGGCAUGCACUAUGCGCG	ACGUUCUUCG	4283
359	CUUCGGCUUC G CGCUG	1505	CAGCG UGAUGGCAUGCACUAUGCGCG	GAAGCCGAAG	4284
361	UCGGCUUCGC G CUGCU	1506	AGCAG UGAUGGCAUGCACUAUGCGCG	GCGAAGCCGA	4285
364	GCUUCGCGCU G CUGGA	1507	UCCAG UGAUGGCAUGCACUAUGCGCG	AGCGCGAAGC	4286
378	GACGGGGCCC G CGGGG	1508	CCCCG UGAUGGCAUGCACUAUGCGCG	GGGCCCCGUC	4287
392	GGGCCCCCCC G AGGCC	1509	GGCCU UGAUGGCAUGCACUAUGCGCG	GGGGGGGCC	4288
412	CCACCAGCGU G CGCAG	1510	CUGCG UGAUGGCAUGCACUAUGCGCG	ACGUCGUGG	4289
414	ACCAGCGUGC G CAGCU	1511	AGCUG UGAUGGCAUGCACUAUGCGCG	GCACGUGGU	4290
424	GCAGCUACCU G CCCAA	1512	UUGGG UGAUGGCAUGCACUAUGCGCG	AGGUAGCUGC	4291
436	CCAACACGGU G ACCGA	1513	UCGGU UGAUGGCAUGCACUAUGCGCG	ACCGUGUUGG	4292
440	CACGGUGACC G ACGCA	1514	UGCGU UGAUGGCAUGCACUAUGCGCG	GGUCACCGUG	4293
443	GGUGACCGAC G CACUG	1515	CAGUG UGAUGGCAUGCACUAUGCGCG	GUCGGUCACC	4294
448	CCGACGCACU G CGGGG	1516	CCCCG UGAUGGCAUGCACUAUGCGCG	AGUGCGUCGG	4295
472	CGUGGGGGCU G CUGCU	1517	AGCAG UGAUGGCAUGCACUAUGCGCG	AGCCCCACG	4296
475	GGGGGCUGCU G CUGCG	1518	CGCAG UGAUGGCAUGCACUAUGCGCG	AGCAGCCCC	4297
478	GGCUGCUGCU G CGCCG	1519	CGGCG UGAUGGCAUGCACUAUGCGCG	AGCAGAGCC	4298
480	CUGCUGCUGC G CCGCG	1520	CGCGG UGAUGGCAUGCACUAUGCGCG	GCAGCAGCAG	4299
483	CUGCUGCGCC G CGUGG	1521	CCACG UGAUGGCAUGCACUAUGCGCG	GGCGCAGCAG	4300
491	CCGCGUGGGC G ACGAC	1522	GUCGU UGAUGGCAUGCACUAUGCGCG	GCCCACGCGG	4301
494	CGUGGGCGAC G ACGUG	1523	CACGU UGAUGGCAUGCACUAUGCGCG	GUCGCCACG	4302
499	GCGACGACGU G CUGGU	1524	ACCAG UGAUGGCAUGCACUAUGCGCG	ACGUCGUCGC	4303
511	UGGUUACCU G CUGGC	1525	GCCAG UGAUGGCAUGCACUAUGCGCG	AGGUGAACCA	4304
519	CUGCUGGCAC G CUGCG	1526	CGCAG UGAUGGCAUGCACUAUGCGCG	GUGCCAGCAG	4305
522	CUGGCACGCU G CGCGC	1527	GCGCG UGAUGGCAUGCACUAUGCGCG	AGCGUGCCAG	4306
524	GGCACGCUGC G CGCUC	1528	GAGCG UGAUGGCAUGCACUAUGCGCG	GCAGCGUGCC	4307
526	CACGCUGCGC G CUCUU	1529	AAGAG UGAUGGCAUGCACUAUGCGCG	GCGCAGCGUG	4308
533	CGCGCUCUUU G UGUG	1530	CAGCA UGAUGGCAUGCACUAUGCGCG	AAAGAGCGCG	4309
535	CGCUCUUUGU G CUGGU	1531	ACCAG UGAUGGCAUGCACUAUGCGCG	ACAAAGAGCG	4310
552	GCUCCCAGCU G CGCCU	1532	AGGCG UGAUGGCAUGCACUAUGCGCG	AGCUGGGAGC	4311
554	UCCCAGCUGC G CCUAC	1533	GUAGG UGAUGGCAUGCACUAUGCGCG	GCAGCUGGGA	4312
565	CCUACCAGGU G UGCGG	1534	CCGCA UGAUGGCAUGCACUAUGCGCG	ACCUGGUAGG	4313
567	UACCAGGUGU G CGGGC	1535	GCCCG UGAUGGCAUGCACUAUGCGCG	ACACCUGGUA	4314
574	UGUGCGGGCC G CCGCU	1536	AGCGG UGAUGGCAUGCACUAUGCGCG	GGCCCGACA	4315
577	GCGGGCCGCC G CUGUA	1537	UACAG UGAUGGCAUGCACUAUGCGCG	GGCGGCCCGC	4316
580	GGCCGCCGCU G UACCA	1538	UGGUA UGAUGGCAUGCACUAUGCGCG	AGCGGCGGCC	4317
593	CCAGCUCGGC G CUGCC	1539	GGCAG UGAUGGCAUGCACUAUGCGCG	GCCGAGCUGG	4318
596	GCUCGGCGCU G CCACU	1540	AGUGG UGAUGGCAUGCACUAUGCGCG	AGCGCCGAGC	4319
616	CCCGGCCCCC G CCACA	1541	UGUGG UGAUGGCAUGCACUAUGCGCG	GGGGGCCGGG	4320

623	CCCGCCACAC G CUAGU	1542	ACUAG UGAUGGCAUGCACUAUGCGCG	GUGUGGCGGG	4321
636	AGUGGACCCC G AAGGC	1543	GCCUU UGAUGGCAUGCACUAUGCGCG	GGGGUCCACU	4322
651	CGUCUGGGAU G CGAAC	1544	GUUCG UGAUGGCAUGCACUAUGCGCG	AUCCAGACG	4323
653	UCUGGGAUGC G AACGG	1545	CCGUU UGAUGGCAUGCACUAUGCGCG	GCAUCCAGAG	4324
703	CCCUGGGCCU G CCAGC	1546	GCUGG UGAUGGCAUGCACUAUGCGCG	AGGCCAGGG	4325
716	AGCCCCGGGU G CGAGG	1547	CCUCG UGAUGGCAUGCACUAUGCGCG	ACCCGGGGCU	4326
718	CCCCGGGUGC G AGGAG	1548	CUCCU UGAUGGCAUGCACUAUGCGCG	GCACCCGGGG	4327
726	GCGAGGAGGC G CGGGG	1549	CCCCG UGAUGGCAUGCACUAUGCGCG	GCCUCCUCGC	4328
737	CGGGGGCAGU G CCAGC	1550	GCUGG UGAUGGCAUGCACUAUGCGCG	ACUGCCCCCG	4329
744	AGUGCCAGCC G AAGUC	1551	GACUU UGAUGGCAUGCACUAUGCGCG	GGCUGGCACU	4330
751	GCCGAAGUCU G CCGUU	1552	AACGG UGAUGGCAUGCACUAUGCGCG	AGACUUCGGC	4331
757	GUCUGCCGUU G CCCAA	1553	UUGGG UGAUGGCAUGCACUAUGCGCG	AACGGCAGAC	4332
779	CAGGCGUGGC G CUGCC	1554	GGCAG UGAUGGCAUGCACUAUGCGCG	GCCACGCCUG	4333
782	GCGUGGCGCU G CCCC	1555	AGGGG UGAUGGCAUGCACUAUGCGCG	AGCGCCACGC	4334
788	CGCUGCCCCU G AGCCG	1556	CGGCU UGAUGGCAUGCACUAUGCGCG	AGGGGCAGCG	4335
802	CGGAGCGGAC G CCCGU	1557	ACGGG UGAUGGCAUGCACUAUGCGCG	GUCCGCUCCG	4336
841	CGGGCAGGAC G CGUGG	1558	CCACG UGAUGGCAUGCACUAUGCGCG	GUCCUGCCCC	4337
850	CGCGUGGACC G AGUGA	1559	UCACU UGAUGGCAUGCACUAUGCGCG	GGUCCACGCG	4338
854	UGGACCGAGU G ACCGU	1560	ACGGU UGAUGGCAUGCACUAUGCGCG	ACUCGGUCCA	4339
867	CGUGGUUUCU G UGUGG	1561	CCACA UGAUGGCAUGCACUAUGCGCG	AGAAACCACG	4340
869	UGGUUUCUGU G UGGUG	1562	CACCA UGAUGGCAUGCACUAUGCGCG	ACAGAAACCA	4341
874	UCUGUGUGGU G UCACC	1563	GGUGA UGAUGGCAUGCACUAUGCGCG	ACCACACAGA	4342
881	GGUGUCACCU G CCAGA	1564	UCUGG UGAUGGCAUGCACUAUGCGCG	AGGUGACACC	4343
890	UGCCAGACCC G CCGAA	1565	UUCGG UGAUGGCAUGCACUAUGCGCG	GGGUCUGGCA	4344
893	CAGACCCGCC G AAGAA	1566	UUCUU UGAUGGCAUGCACUAUGCGCG	GGCGGGUCUG	4345
917	UUUGGAGGGU G CGCUC	1567	GAGCG UGAUGGCAUGCACUAUGCGCG	ACCCUCCAAA	4346
919	UGGAGGGUGC G CUCUC	1568	GAGAG UGAUGGCAUGCACUAUGCGCG	GCACCCUCCA	4347
931	UCUCUGGCAC G CGCCA	1569	UGGCG UGAUGGCAUGCACUAUGCGCG	GUGCCAGAGA	4348
933	UCUGGCACGC G CCACU	1570	AGUGG UGAUGGCAUGCACUAUGCGCG	GCGUGCCAGA	4349
957	UCCGUGGGCC G CCAGC	1571	GCUGG UGAUGGCAUGCACUAUGCGCG	GGCCCACGGA	4350
968	CCAGCACAC G CGGGC	1572	GCCCG UGAUGGCAUGCACUAUGCGCG	GUGGUGCUGG	4351
988	CAUCCACAUC G CGGCC	1573	GGCCG UGAUGGCAUGCACUAUGCGCG	GAUGUGGAUG	4352
1012	CCUGGGACAC G CCUUG	1574	CAAGG UGAUGGCAUGCACUAUGCGCG	GUGUCCAGG	4353
1017	GACACGCCUU G UCCCC	1575	GGGGA UGAUGGCAUGCACUAUGCGCG	AAGGCUGUC	4354
1027	GUCCCCCGGU G UACGC	1576	GCGUA UGAUGGCAUGCACUAUGCGCG	ACCGGGGGAC	4355
1031	CCCGGUGUAC G CCGAG	1577	CUCGG UGAUGGCAUGCACUAUGCGCG	GUACACCGGG	4356
1034	GGUGUACGCC G AGACC	1578	GGUCU UGAUGGCAUGCACUAUGCGCG	GGCGUACACC	4357
1064	CUCCUCAGGC G ACAAG	1579	CUUGU UGAUGGCAUGCACUAUGCGCG	GCCUGAGGAG	4358
1078	AGGAGCAGCU G CGGCC	1580	GGCCG UGAUGGCAUGCACUAUGCGCG	AGCUGCUCCU	4359
1105	UCAGCUCUCU G AGGCC	1581	GGCCU UGAUGGCAUGCACUAUGCGCG	AGAGAGCUGA	4360
1117	GGCCCAGCCU G ACUGG	1582	CCAGU UGAUGGCAUGCACUAUGCGCG	AGGCUGGGCC	4361
1124	CCUGACUGGC G CUCGG	1583	CCGAG UGAUGGCAUGCACUAUGCGCG	GCCAGUCAGG	4362
1171	GGCCUGGAU G CCAGG	1584	CCUGG UGAUGGCAUGCACUAUGCGCG	AUCCAGGGCC	4363
1185	GGGACUCCCC G CAGGU	1585	ACCUG UGAUGGCAUGCACUAUGCGCG	GGGGAGUCCC	4364
1192	CCCGCAGGUU G CCCC	1586	CGGGG UGAUGGCAUGCACUAUGCGCG	AACCUCCGGG	4365
1197	AGGUUGCCCC G CCUGC	1587	GCAGG UGAUGGCAUGCACUAUGCGCG	GGGGCAACCU	4366
1201	UGCCCCGCCU G CCCCA	1588	UGGGG UGAUGGCAUGCACUAUGCGCG	AGGCGGGGCA	4367



1209	CUGCCCCAGC G CUACU	1589	AGUAG UGAUGGCAUGCACUAUGCGCG	GCUGGGGCAG	4368
1222	ACUGGCAAU G CGGCC	1590	GGCCG UGAUGGCAUGCACUAUGCGCG	AUUUGCCAGU	4369
1231	UGCGGCCCU G UUUCU	1591	AGAAA UGAUGGCAUGCACUAUGCGCG	AGGGGCCGCA	4370
1243	UUCUGGAGCU G CUUGG	1592	CCAAG UGAUGGCAUGCACUAUGCGCG	AGCUCAGAA	4371
1256	UGGGAACCAC G CGCAG	1593	CUGCG UGAUGGCAUGCACUAUGCGCG	GUGGUUCCCA	4372
1258	GGAACCACGC G CAGUG	1594	CACUG UGAUGGCAUGCACUAUGCGCG	GCGUGGUUCC	4373
1263	CACGCGCAGU G CCCC	1595	AGGGG UGAUGGCAUGCACUAUGCGCG	ACUGCGCUG	4374
1276	CCUACGGGGU G CUCCU	1596	AGGAG UGAUGGCAUGCACUAUGCGCG	ACCCCGUAGG	4375
1288	UCCUCAAGAC G CACUG	1597	CAGUG UGAUGGCAUGCACUAUGCGCG	GUCUUGAGGA	4376
1293	AAGACGCACU G CCCGC	1598	GCGGG UGAUGGCAUGCACUAUGCGCG	AGUGCGUCU	4377
1297	CGCACUGCCC G CUGCG	1599	CGCAG UGAUGGCAUGCACUAUGCGCG	GGGCAGUGCG	4378
1300	ACUGCCCGCU G CGAGC	1600	GCUCG UGAUGGCAUGCACUAUGCGCG	AGCGGGCAGU	4379
1302	UGCCCGCUGC G AGCUG	1601	CAGCU UGAUGGCAUGCACUAUGCGCG	GCAGCGGGCA	4380
1307	GCUGCGAGCU G CGGUC	1602	GACCG UGAUGGCAUGCACUAUGCGCG	AGCUCGCAGC	4381
1328	AGCAGCCGGU G UCUGU	1603	ACAGA UGAUGGCAUGCACUAUGCGCG	ACCGGCUGCU	4382
1332	GCCGGUGUCU G UGCC	1604	GGGCA UGAUGGCAUGCACUAUGCGCG	AGACACCGGC	4383
1334	CGGUGUCUGU G CCCGG	1605	CCGGG UGAUGGCAUGCACUAUGCGCG	ACAGACCCG	4384
1358	CCAGGGCUCU G UGGCG	1606	CGCCA UGAUGGCAUGCACUAUGCGCG	AGAGCCUGG	4385
1370	GGCGGCCCC G AGGAG	1607	CUCCU UGAUGGCAUGCACUAUGCGCG	GGGGGCCGCC	4386
1395	GACCCCGUC G CCUGG	1608	CCAGG UGAUGGCAUGCACUAUGCGCG	GACGGGGUC	4387
1402	GUCGCCUGGU G CAGCU	1609	AGCUG UGAUGGCAUGCACUAUGCGCG	ACCAGGCGAC	4388
1408	UGGUGCAGCU G CUCCG	1610	CGGAG UGAUGGCAUGCACUAUGCGCG	AGCUGACCA	4389
1413	CAGCUGCUCC G CCAGC	1611	GCUGG UGAUGGCAUGCACUAUGCGCG	GGAGCAGCUG	4390
1438	CCUGGCAGGU G UACGG	1612	CCGUA UGAUGGCAUGCACUAUGCGCG	ACCUGCCAGG	4391
1450	ACGGCUUCGU G CGGGC	1613	GCCCG UGAUGGCAUGCACUAUGCGCG	ACGAAGCCGU	4392
1458	GUGCGGGCCU G CCUGC	1614	GCAGG UGAUGGCAUGCACUAUGCGCG	AGGCCCGCAC	4393
1462	GGGCCUGCCU G CGCCG	1615	CGGCG UGAUGGCAUGCACUAUGCGCG	AGGCAAGGCC	4394
1464	GCCUGCCUGC G CCGGC	1616	GCCGG UGAUGGCAUGCACUAUGCGCG	GCAGGCAGGC	4395
1474	GCCGGCUGGU G CCCCC	1617	GGGGG UGAUGGCAUGCACUAUGCGCG	ACCAGCCGGC	4396
1505	CAGGCACAAC G AACGC	1618	GCGUU UGAUGGCAUGCACUAUGCGCG	GUUGUGCCUG	4397
1509	CACAACGAAC G CCGCU	1619	AGCGG UGAUGGCAUGCACUAUGCGCG	GUUCGUUGUG	4398
1512	AACGAACGCC G CUUCC	1620	GGAAG UGAUGGCAUGCACUAUGCGCG	GGCGUUCGU	4399
1556	GGGGAAGCAU G CCAAG	1621	CUUGG UGAUGGCAUGCACUAUGCGCG	AUGCUUCCCC	4400
1567	CCAAGCUCUC G CUGCA	1622	UGCAG UGAUGGCAUGCACUAUGCGCG	GAGAGCUUGG	4401
1570	AGCUCUCGCU G CAGGA	1623	UCCUG UGAUGGCAUGCACUAUGCGCG	AGCGAGAGCU	4402
1579	UGCAGGAGCU G ACGUG	1624	CACGU UGAUGGCAUGCACUAUGCGCG	AGCUCCUGCA	4403
1591	CGUGGAAGAU G AGCGU	1625	ACGCU UGAUGGCAUGCACUAUGCGCG	AUCUCCACG	4404
1597	AGAUGAGCGU G CGGGA	1626	UCCCG UGAUGGCAUGCACUAUGCGCG	ACGCUCAUCU	4405
1605	GUGCGGGACU G CGCUU	1627	AAGCG UGAUGGCAUGCACUAUGCGCG	AGUCCCGCAC	4406
1607	GCGGGACUGC G CUUGG	1628	CCAAG UGAUGGCAUGCACUAUGCGCG	GCAGUCCGCG	4407
1615	GCGCUUGGCU G CGCAG	1629	CUGCG UGAUGGCAUGCACUAUGCGCG	AGCCAAGCGC	4408
1617	GCUUGGCUGC G CAGGA	1630	UCCUG UGAUGGCAUGCACUAUGCGCG	GCAGCCAAGC	4409
1638	GGGGUUGGCU G UGUUC	1631	GAACA UGAUGGCAUGCACUAUGCGCG	AGCCAACCCC	4410
1640	GGUUGGCGU G UCCG	1632	CGGAA UGAUGGCAUGCACUAUGCGCG	ACAGCCAACC	4411
1649	UGUUCGGGCC G CAGAG	1633	CUCUG UGAUGGCAUGCACUAUGCGCG	GGCCGGAACA	4412
1663	AGCACCGUCU G CGUGA	1634	UCACG UGAUGGCAUGCACUAUGCGCG	AGACGGUGCU	4413
1667	CCGUCUGCGU G AGGAG	1635	CUCCU UGAUGGCAUGCACUAUGCGCG	ACGCAGACGG	4414

1690	CCAAGUCCU G CACUG	1636	CAGUG UGAUGGCAUGCACUAUGCGCG AGGAACUUGG	4415
1699	UGCACUGGCU G AUGAG	1637	CUCAU UGAUGGCAUGCACUAUGCGCG AGCCAGUGCA	4416
1702	ACUGGCUGAU G AGUGU	1638	ACACU UGAUGGCAUGCACUAUGCGCG AUCAGCCAGU	4417
1706	GCUGAUGAGU G UGUAC	1639	GUACA UGAUGGCAUGCACUAUGCGCG ACUCAUCAGC	4418
1708	UGAUGAGUGU G UACGU	1640	ACGUA UGAUGGCAUGCACUAUGCGCG ACACUCAUCA	4419
1718	GUACGUCGUC G AGCUG	1641	CAGCU UGAUGGCAUGCACUAUGCGCG GACGACGUAC	4420
1723	UCGUCGAGCU G CUCAG	1642	CUGAG UGAUGGCAUGCACUAUGCGCG AGCUCGACGA	4421
1742	UUUCUUUAU G UCACG	1643	CGUGA UGAUGGCAUGCACUAUGCGCG AUAAAAGAAA	4422
1793	CCGGAAGAGU G UCUGG	1644	CCAGA UGAUGGCAUGCACUAUGCGCG ACUCUCCGG	4423
1807	GGAGCAAGUU G CAAAG	1645	CUUUG UGAUGGCAUGCACUAUGCGCG AACUUGCUC	4424
1834	GACAGCACUU G AAGAG	1646	CUCUU UGAUGGCAUGCACUAUGCGCG AAGUGCUGUC	4425
1843	UGAAGAGGGU G CAGCU	1647	AGCUG UGAUGGCAUGCACUAUGCGCG ACCUCUUCA	4426
1849	GGGUGCAGCU G CGGGA	1648	UCCCG UGAUGGCAUGCACUAUGCGCG AGCUGACCC	4427
1858	UGC GGGAGCU G UC GGA	1649	UCCGA UGAUGGCAUGCACUAUGCGCG AGCUCCCGCA	4428
1898	AGCCAGGCCC G CCCUG	1650	CAGGG UGAUGGCAUGCACUAUGCGCG GGGCCUGGCU	4429
1903	GGCCCGCCCU G CUGAC	1651	GUCAG UGAUGGCAUGCACUAUGCGCG AGGGCGGGCC	4430
1906	CCGCCCUGCU G ACGUC	1652	GACGU UGAUGGCAUGCACUAUGCGCG AGCAGGGCGG	4431
1920	UCCAGACUCC G CUUCA	1653	UGAAG UGAUGGCAUGCACUAUGCGCG GGAGUCUGGA	4432
1937	CCCCAAGCCU G ACGGG	1654	CCCGU UGAUGGCAUGCACUAUGCGCG AGGCUUGGGG	4433
1945	CUGACGGGCU G CGGCC	1655	GGCCG UGAUGGCAUGCACUAUGCGCG AGCCCGUCAG	4434
1951	GGCUGCGGCC G AUUGU	1656	ACAAU UGAUGGCAUGCACUAUGCGCG GGCCCGAGCC	4435
1955	GCGGCCGAUU G UGAAC	1657	GUUCA UGAUGGCAUGCACUAUGCGCG AAUCGGCCGC	4436
1957	GGCCGAUUGU G AACAU	1658	AUGUU UGAUGGCAUGCACUAUGCGCG ACAUCGGCC	4437
1992	AGAACGUUCC G CAGAG	1659	CUCUG UGAUGGCAUGCACUAUGCGCG GGAACGUUCU	4438
2009	AAAGAGGGCC G AGCGU	1660	ACGCU UGAUGGCAUGCACUAUGCGCG GGCCUCUUU	4439
2023	GUCUCACCUC G AGGGU	1661	ACCCU UGAUGGCAUGCACUAUGCGCG GAGGUGAGAC	4440
2029	CCUCGAGGGU G AAGGC	1662	GCCUU UGAUGGCAUGCACUAUGCGCG ACCCUCGAGG	4441
2038	UGAAGGCACU G UUCAG	1663	CUGAA UGAUGGCAUGCACUAUGCGCG AGUGCCUUCA	4442
2047	UGUUCAGCGU G CUCAA	1664	UUGAG UGAUGGCAUGCACUAUGCGCG ACGUGAACA	4443
2057	GCUCAACUAC G AGCGG	1665	CCGCU UGAUGGCAUGCACUAUGCGCG GUAGUUGAGC	4444
2065	ACGAGCGGGC G CGGCG	1666	CGCCG UGAUGGCAUGCACUAUGCGCG GCCCGCUCGU	4445
2070	CGGGCGCGGC G CCCC	1667	CGGGG UGAUGGCAUGCACUAUGCGCG GCCGCGCCG	4446
2087	CCUCCUGGGC G CCUCU	1668	AGAGG UGAUGGCAUGCACUAUGCGCG GCCCAGGAGG	4447
2093	GGGCGCCUCU G UGCUG	1669	CAGCA UGAUGGCAUGCACUAUGCGCG AGAGGCGCCC	4448
2095	GCGCCUCUGU G CUGGG	1670	CCCAG UGAUGGCAUGCACUAUGCGCG ACAGAGGCGC	4449
2108	GGGCCUGGAC G AUAUC	1671	GAUUA UGAUGGCAUGCACUAUGCGCG GUCCAGGCCC	4450
2127	AGGGCCUGGC G CACCU	1672	AGGUG UGAUGGCAUGCACUAUGCGCG GCCAGGCCU	4451
2137	GCACCUUCGU G CUGCG	1673	CGCAG UGAUGGCAUGCACUAUGCGCG ACGAAGGUGC	4452
2140	CCUUCGUGCU G CGUGU	1674	ACACG UGAUGGCAUGCACUAUGCGCG AGCACGAAGG	4453
2144	CGUGCUGCGU G UGCGG	1675	CCGCA UGAUGGCAUGCACUAUGCGCG ACGCAGCACG	4454
2146	UGCUGCGUGU G CGGGC	1676	GCCCG UGAUGGCAUGCACUAUGCGCG ACACGCAGCA	4455
2161	CCCAGGACCC G CCGCC	1677	GGCGG UGAUGGCAUGCACUAUGCGCG GGGUCCUGGG	4456
2164	AGGACCCGCC G CCUGA	1678	UCAGG UGAUGGCAUGCACUAUGCGCG GGCGGUCCU	4457
2168	CCCGCCGCCU G AGCUG	1679	CAGCU UGAUGGCAUGCACUAUGCGCG AGGCGGCGGG	4458
2173	CGCCUGAGCU G UACUU	1680	AAGUA UGAUGGCAUGCACUAUGCGCG AGCUCAGGCG	4459
2180	GCUGUACUUU G UCAAG	1681	CUUGA UGAUGGCAUGCACUAUGCGCG AAAGUACAGC	4460
2192	CAAGGUGGAU G UGACG	1682	CGUCA UGAUGGCAUGCACUAUGCGCG AUCCACCUUG	4461

2194	AGGUGGAUGU G ACGGG	1683	CCCGU UGAUGGCAUGCACUAUGCGCG	ACAUCCACCU	4462
2201	UGUGACGGGC G CGUAC	1684	GUACG UGAUGGCAUGCACUAUGCGCG	GCCCGUCACA	4463
2207	GGGCGCGUAC G ACACC	1685	GGUGU UGAUGGCAUGCACUAUGCGCG	GUACGCGCCC	4464
2243	GGAGGUCAUC G CCAGC	1686	GCUGG UGAUGGCAUGCACUAUGCGCG	GAUGACCUC	4465
2274	AACACGUACU G CGUGC	1687	GCACG UGAUGGCAUGCACUAUGCGCG	AGUACGUGUU	4466
2278	CGUACUGCGU G CGUCG	1688	CGACG UGAUGGCAUGCACUAUGCGCG	ACGCAGUACG	4467
2288	GCGUCGGUAU G CCGUG	1689	CACGG UGAUGGCAUGCACUAUGCGCG	AUACCGACGC	4468
2306	CCAGAAGGCC G CCCAU	1690	AUGGG UGAUGGCAUGCACUAUGCGCG	GGCCUUCUGG	4469
2322	GGGCACGUCC G CAAGG	1691	CCUUG UGAUGGCAUGCACUAUGCGCG	GGACGUGCCC	4470
2353	UCUCUACCUU G ACAGA	1692	UCUGU UGAUGGCAUGCACUAUGCGCG	AAGGUAGAGA	4471
2374	AGCCGUACAU G CGACA	1693	UGUCG UGAUGGCAUGCACUAUGCGCG	AUGUACGGCU	4472
2376	CCGUACAUGC G ACAGU	1694	ACUGU UGAUGGCAUGCACUAUGCGCG	GCAUGUACGG	4473
2395	UGGCUCACCU G CAGGA	1695	UCCUG UGAUGGCAUGCACUAUGCGCG	AGGUGAGCCA	4474
2410	AGACCAGCCC G CUGAG	1696	CUCAG UGAUGGCAUGCACUAUGCGCG	GGGCUUGUCU	4475
2413	CCAGCCCGCU G AGGGA	1697	UCCCU UGAUGGCAUGCACUAUGCGCG	AGCGGGCUGG	4476
2420	GCUGAGGGAU G CCGUC	1698	GACGG UGAUGGCAUGCACUAUGCGCG	AUCCUCAGC	4477
2432	CGUCGUCAUC G AGCAG	1699	CUGCU UGAUGGCAUGCACUAUGCGCG	GAUACGACG	4478
2449	GCUCCUCCCU G AAUGA	1700	UCAUU UGAUGGCAUGCACUAUGCGCG	AGGGAGGAGC	4479
2453	CUCCUGAAU G AGGCC	1701	GGCCU UGAUGGCAUGCACUAUGCGCG	AUUCAGGGAG	4480
2474	UGGCCUCUUC G ACGUC	1702	GACGU UGAUGGCAUGCACUAUGCGCG	GAAGAGGCCA	4481
2487	GUCUCCUAC G CUUCA	1703	UGAAG UGAUGGCAUGCACUAUGCGCG	GUAGGAAGAC	4482
2494	UACGCUUCAU G UGCCA	1704	UGGCA UGAUGGCAUGCACUAUGCGCG	AUGAAGCGUA	4483
2496	CGCUUCAUGU G CCACC	1705	GGUGG UGAUGGCAUGCACUAUGCGCG	ACAUGAAGCG	4484
2504	GUGCCACCAC G CCGUG	1706	CACGG UGAUGGCAUGCACUAUGCGCG	GUGGUGGCAC	4485
2509	ACCACGCCGU G CGCAU	1707	AUGCG UGAUGGCAUGCACUAUGCGCG	ACGGCGUGGU	4486
2511	CACGCCGUGC G CAUCA	1708	UGAUG UGAUGGCAUGCACUAUGCGCG	GCACGGCGUG	4487
2538	UACGUCCAGU G CCAGG	1709	CCUGG UGAUGGCAUGCACUAUGCGCG	ACUGGACGUA	4488
2551	AGGGGAUCCC G CAGGG	1710	CCUG UGAUGGCAUGCACUAUGCGCG	GGGAUCCCU	4489
2572	UCCUCUCCAC G CUGCU	1711	AGCAG UGAUGGCAUGCACUAUGCGCG	GUGGAGAGGA	4490
2575	UCUCCACGCU G CUCUG	1712	CAGAG UGAUGGCAUGCACUAUGCGCG	AGCGUGGAGA	4491
2580	ACGCUGCUCU G CAGCC	1713	GGCUG UGAUGGCAUGCACUAUGCGCG	AGAGCAGCGU	4492
2587	UCUGCAGCCU G UGCUA	1714	UAGCA UGAUGGCAUGCACUAUGCGCG	AGGCUGCAGA	4493
2589	UGCAGCCUGU G CUACG	1715	CGUAG UGAUGGCAUGCACUAUGCGCG	ACAGGCUCA	4494
2597	GUGCUACGGC G ACAUG	1716	CAUGU UGAUGGCAUGCACUAUGCGCG	GCCGUAGCAC	4495
2614	AGAACAAGCU G UUUGC	1717	GCAAA UGAUGGCAUGCACUAUGCGCG	AGCUUGUUCU	4496
2618	CAAGCUGUUU G CGGGG	1718	CCCCG UGAUGGCAUGCACUAUGCGCG	AAACAGCUUG	4497
2641	GGGACGGGCU G CUCCU	1719	AGGAG UGAUGGCAUGCACUAUGCGCG	AGCCCGUCCC	4498
2647	GGCUGCUCCU G CGUUU	1720	AAACG UGAUGGCAUGCACUAUGCGCG	AGGAGCAGCC	4499
2660	UUUGGUGGAU G AUUUC	1721	GAAAU UGAUGGCAUGCACUAUGCGCG	AUCCACCAA	4500
2668	AUGAUUUCUU G UUGGU	1722	ACCAA UGAUGGCAUGCACUAUGCGCG	AAGAAUCAU	4501
2674	UCUUGUUGGU G ACACC	1723	GGUGU UGAUGGCAUGCACUAUGCGCG	ACCAACAAGA	4502
2693	CCUCACCCAC G CGAAA	1724	UUUCG UGAUGGCAUGCACUAUGCGCG	GUGGGUGAGG	4503
2695	UCACCCACGC G AAAAC	1725	GUUUU UGAUGGCAUGCACUAUGCGCG	GCGUGGGUGA	4504
2721	ACCCUGGUCC G AGGUG	1726	CACCU UGAUGGCAUGCACUAUGCGCG	GGACCAGGGU	4505
2726	GGUCCGAGGU G UCCCU	1727	AGGGA UGAUGGCAUGCACUAUGCGCG	ACCUCGGACC	4506
2732	AGGUGUCCCU G AGUAU	1728	AUACU UGAUGGCAUGCACUAUGCGCG	AGGGACACCU	4507
2742	GAGUAUGGCU G CGUGG	1729	CCACG UGAUGGCAUGCACUAUGCGCG	AGCCAUAUC	4508

2749	GCUGCGUGGU G AACUU	1730	AAGUU UGAUGGCAUGCACUAUGCGCG ACCACGCAGC	4509
2755	UGGUGAACUU G CGGAA	1731	UUCCG UGAUGGCAUGCACUAUGCGCG AAGUUCACCA	4510
2770	AGACAGUGGU G AACUU	1732	AAGUU UGAUGGCAUGCACUAUGCGCG ACCACUGUCU	4511
2780	GAACUUCCCU G UAGAA	1733	UUCUA UGAUGGCAUGCACUAUGCGCG AGGGAAGUUC	4512
2789	UGUAGAAGAC G AGGCC	1734	GGCCU UGAUGGCAUGCACUAUGCGCG GUCUUCUACA	4513
2813	CACGGCUUUU G UUCAG	1735	CUGAA UGAUGGCAUGCACUAUGCGCG AAAAGCCGUG	4514
2821	UUGUUCAGAU G CCGGC	1736	GCCGG UGAUGGCAUGCACUAUGCGCG AUCUGAACAA	4515
2847	UUCCCCUGGU G CGGCC	1737	GGCCG UGAUGGCAUGCACUAUGCGCG ACCAGGGGAA	4516
2854	GGUGCGGCCU G CUGCU	1738	AGCAG UGAUGGCAUGCACUAUGCGCG AGGCCGCACC	4517
2857	GCGGCCUGCU G CUGGA	1739	UCCAG UGAUGGCAUGCACUAUGCGCG AGCAGGCCGC	4518
2881	CCCUGGAGGU G CAGAG	1740	CUCUG UGAUGGCAUGCACUAUGCGCG ACCUCCAGGG	4519
2888	GGUGCAGAGC G ACUAC	1741	GUAGU UGAUGGCAUGCACUAUGCGCG GCUCUGCACC	4520
2903	CUCCAGCUAU G CCCGG	1742	CCGGG UGAUGGCAUGCACUAUGCGCG AUAGCUGGAG	4521
2940	ACCUUCAACC G CGGCU	1743	AGCCG UGAUGGCAUGCACUAUGCGCG GGUUGAAGGU	4522
2965	GGAGGAACAU G CGUCG	1744	CGACG UGAUGGCAUGCACUAUGCGCG AUGUCCUCC	4523
2970	AACAUGCUGC G CAAAC	1745	GUUUG UGAUGGCAUGCACUAUGCGCG GACGCAUGUU	4524
2989	UUGGGGUCUU G CGGCU	1746	AGCCG UGAUGGCAUGCACUAUGCGCG AAGACCCCAA	4525
2995	UCUUGCGGCU G AAGUG	1747	CACUU UGAUGGCAUGCACUAUGCGCG AGCCGCAAGA	4526
3000	CGGCUGAAGU G UCACA	1748	UGUGA UGAUGGCAUGCACUAUGCGCG ACUUCAGCCG	4527
3010	GUCACAGCCU G UUUCU	1749	AGAAA UGAUGGCAUGCACUAUGCGCG AGGCUGUGAC	4528
3022	UUCUGGAUUU G CAGGU	1750	ACCUG UGAUGGCAUGCACUAUGCGCG AAUCCAGAA	4529
3028	AUUUGCAGGU G AACAG	1751	CUGUU UGAUGGCAUGCACUAUGCGCG ACCUGCAAU	4530
3046	UCCAGACGGU G UGCAC	1752	GUGCA UGAUGGCAUGCACUAUGCGCG ACCGUCUGGA	4531
3048	CAGACGGUGU G CACCA	1753	UGGUG UGAUGGCAUGCACUAUGCGCG ACACCUCUG	4532
3073	AGAUCUCCU G CUGCA	1754	UGCAG UGAUGGCAUGCACUAUGCGCG AGGAGGAUCU	4533
3076	UCCUCCUGCU G CAGGC	1755	GCCUG UGAUGGCAUGCACUAUGCGCG AGCAGGAGGA	4534
3095	CAGGUUUCAC G CAUGU	1756	ACAUG UGAUGGCAUGCACUAUGCGCG GUGAAACCUG	4535
3099	UUUCACGAU G UGUGC	1757	GCACA UGAUGGCAUGCACUAUGCGCG AUGCGUGAAA	4536
3101	UCACGCAUGU G UGCUG	1758	CAGCA UGAUGGCAUGCACUAUGCGCG ACAUGCGUGA	4537
3103	ACGCAUGUGU G CUGCA	1759	UGCAG UGAUGGCAUGCACUAUGCGCG ACACAUGCGU	4538
3106	CAUGUGUGCU G CAGCU	1760	AGCUG UGAUGGCAUGCACUAUGCGCG AGCACACAUG	4539
3154	CAUUUUUCCU G CGCGU	1761	ACGCG UGAUGGCAUGCACUAUGCGCG AGGAAAAAUG	4540
3156	UUUUUCCUGC G CGUCA	1762	UGACG UGAUGGCAUGCACUAUGCGCG GCAGGAAAAA	4541
3167	CGUCAUCUCU G ACACG	1763	CGUGU UGAUGGCAUGCACUAUGCGCG AGAGAUGACG	4542
3183	GCCUCCUCU G CUACU	1764	AGUAG UGAUGGCAUGCACUAUGCGCG AGAGGGAGGC	4543
3196	ACUCCAUCCU G AAAGC	1765	GCUUU UGAUGGCAUGCACUAUGCGCG AGGAUGGAGU	4544
3209	AGCCAAGAAC G CAGGG	1766	CCUG UGAUGGCAUGCACUAUGCGCG GUUCUUGGCU	4545
3217	ACGCAGGGAU G UGCU	1767	AGCGA UGAUGGCAUGCACUAUGCGCG AUCCUGCGU	4546
3220	CAGGGAUGUC G CUGGG	1768	CCCAG UGAUGGCAUGCACUAUGCGCG GACAUCCUG	4547
3236	GGCCAAGGGC G CCGCC	1769	GGCCG UGAUGGCAUGCACUAUGCGCG GCCUUGGCC	4548
3239	CAAGGGCGCC G CCGGC	1770	GCCGG UGAUGGCAUGCACUAUGCGCG GGCGCCUUG	4549
3250	CCGGCCCUCU G CCCUC	1771	GAGGG UGAUGGCAUGCACUAUGCGCG AGAGGGCCGG	4550
3257	UCUGCCCUC G AGGCC	1772	GGCCU UGAUGGCAUGCACUAUGCGCG GGAGGGCAGA	4551
3265	CCGAGGCCGU G CAGUG	1773	CACUG UGAUGGCAUGCACUAUGCGCG ACGGCCUCGG	4552
3274	UGCAGUGGCU G UGCCA	1774	UGGCA UGAUGGCAUGCACUAUGCGCG AGCCACUGCA	4553
3276	CAGUGGCUGU G CCACC	1775	GGUGG UGAUGGCAUGCACUAUGCGCG ACAGCCACUG	4554
3292	AAGCAUCCU G CUCAA	1776	UUGAG UGAUGGCAUGCACUAUGCGCG AGGAAUGCUU	4555

3301	UGCUC AAGCU G ACUCG	1777	CGAGU UGAUGGCAUGCACUAUGCGCG	AGCUUGAGCA	4556
3306	AAGCUGACUC G ACACC	1778	GGUGU UGAUGGCAUGCACUAUGCGCG	GAGUCAGCUU	4557
3314	UCGACACCGU G UCACC	1779	GGUGA UGAUGGCAUGCACUAUGCGCG	ACGGUGUCGA	4558
3325	UCACCUACGU G CCACU	1780	AGUGG UGAUGGCAUGCACUAUGCGCG	ACGUAGGUGA	4559
3358	CAGCCCAGAC G CAGCU	1781	AGCUG UGAUGGCAUGCACUAUGCGCG	GUCUGGGCUG	4560
3364	AGACGCAGCU G AGUCG	1782	CGACU UGAUGGCAUGCACUAUGCGCG	AGCUGCGUCU	4561
3385	UCCCCGGGAC G ACGCU	1783	AGCGU UGAUGGCAUGCACUAUGCGCG	GUGCCCCGGA	4562
3388	CGGGGACGAC G CUGAC	1784	GUCAG UGAUGGCAUGCACUAUGCGCG	GUCGUCCCCG	4563
3391	GGACGACGCU G ACUGC	1785	GCAGU UGAUGGCAUGCACUAUGCGCG	AGCGUCGUCC	4564
3395	GACGCUGACU G CCCUG	1786	CAGGG UGAUGGCAUGCACUAUGCGCG	AGUCAGCGUC	4565
3407	CCUGGAGGCC G CAGCC	1787	GGCUG UGAUGGCAUGCACUAUGCGCG	GGCCUCCAGG	4566
3424	ACCCGGCACU G CCCUC	1788	GAGGG UGAUGGCAUGCACUAUGCGCG	AGUGCCGGGU	4567
3453	AUCCUGGACU G AUGGC	1789	GCCAU UGAUGGCAUGCACUAUGCGCG	AGUCCAGGAU	4568
3464	AUGGCCACCC G CCCAC	1790	GUGGG UGAUGGCAUGCACUAUGCGCG	GGGUGGCCAU	4569
3479	CAGCCAGGCC G AGAGC	1791	GCUCU UGAUGGCAUGCACUAUGCGCG	GGCCUGGCUG	4570
3501	CAGCAGCCCU G UCACG	1792	CGUGA UGAUGGCAUGCACUAUGCGCG	AGGGCUGCUG	4571
3506	GCCCUGUCAC G CCGGG	1793	CCCGG UGAUGGCAUGCACUAUGCGCG	GUGACAGGGC	4572
3554	ACCCAGGCC G CACCG	1794	CGGUG UGAUGGCAUGCACUAUGCGCG	GGGCCUGGGU	4573
3559	GGCCCGCACC G CUGGG	1795	CCCAG UGAUGGCAUGCACUAUGCGCG	GGUGCGGGCC	4574
3570	CUGGGAGUCU G AGGCC	1796	GGCCU UGAUGGCAUGCACUAUGCGCG	AGACUCCAG	4575
3577	UCUGAGGCCU G AGUGA	1797	UCACU UGAUGGCAUGCACUAUGCGCG	AGGCCUCAGA	4576
3581	AGGCCUGAGU G AGUGU	1798	ACACU UGAUGGCAUGCACUAUGCGCG	ACUCAGGCCU	4577
3585	CUGAGUGAGU G UUUGG	1799	CCAAA UGAUGGCAUGCACUAUGCGCG	ACUCACUCAG	4578
3593	GUGUUUGGCC G AGGCC	1800	GGCCU UGAUGGCAUGCACUAUGCGCG	GGCCAAACAC	4579
3600	GCCGAGGCCU G CAUGU	1801	ACAUG UGAUGGCAUGCACUAUGCGCG	AGGCCUCGGC	4580
3604	AGGCCUGCAU G UCCGG	1802	CCGGA UGAUGGCAUGCACUAUGCGCG	AUGCAGGCCU	4581
3612	AUGUCCGGCU G AAGGC	1803	GCCUU UGAUGGCAUGCACUAUGCGCG	AGCCGGACAU	4582
3619	GCUGAAGGCU G AGUGU	1804	ACACU UGAUGGCAUGCACUAUGCGCG	AGCCUUCAGC	4583
3623	AAGGCUGAGU G UCCGG	1805	CCGGA UGAUGGCAUGCACUAUGCGCG	ACUCAGCCUU	4584
3631	GUGUCCGGCU G AGGCC	1806	GGCCU UGAUGGCAUGCACUAUGCGCG	AGCCGGACAC	4585
3638	GCUGAGGCCU G AGCGA	1807	UCGCU UGAUGGCAUGCACUAUGCGCG	AGGCCUCAGC	4586
3642	AGGCCUGAGC G AGUGU	1808	ACACU UGAUGGCAUGCACUAUGCGCG	GCUCAGGCCU	4587
3646	CUGAGCGAGU G UCCAG	1809	CUGGA UGAUGGCAUGCACUAUGCGCG	ACUCGCUCAG	4588
3661	GCCAAGGGCU G AGUGU	1810	ACACU UGAUGGCAUGCACUAUGCGCG	AGCCCUUGGC	4589
3665	AGGGCUGAGU G UCCAG	1811	CUGGA UGAUGGCAUGCACUAUGCGCG	ACUCAGCCCU	4590
3678	CAGCACACCU G CCGUC	1812	GACGG UGAUGGCAUGCACUAUGCGCG	AGGUGUGCUG	4591
3705	ACAGGCUGGC G CUCGG	1813	CCGAG UGAUGGCAUGCACUAUGCGCG	GCCAGCCUGU	4592
3789	CCCCAGAUUC G CCAUU	1814	AAUGG UGAUGGCAUGCACUAUGCGCG	GAAUCUGGGG	4593
3795	AUUCGCCAUU G UUCAC	1815	GUGAA UGAUGGCAUGCACUAUGCGCG	AAUGGCGAAU	4594
3806	UUCACCCUC G CCCUG	1816	CAGGG UGAUGGCAUGCACUAUGCGCG	GAGGGGUGAA	4595
3811	CCCUCGCCC G CCCUC	1817	GAGGG UGAUGGCAUGCACUAUGCGCG	AGGGCGAGGG	4596
3821	GCCCUCUUU G CCUUC	1818	GAAGG UGAUGGCAUGCACUAUGCGCG	AAAGGAGGGC	4597
3854	UGGAGACCCU G AGAAG	1819	CUUCU UGAUGGCAUGCACUAUGCGCG	AGGGUCUCCA	4598
3888	AAUUUGGAGU G ACCAA	1820	UUGGU UGAUGGCAUGCACUAUGCGCG	ACUCCAAAUU	4599
3898	GACCAAAGGU G UGCCC	1821	GGGCA UGAUGGCAUGCACUAUGCGCG	ACCUUUGGUC	4600
3900	CCAAAGGUGU G CCCUG	1822	CAGGG UGAUGGCAUGCACUAUGCGCG	ACACCUUUGG	4601
3905	GGUGUGCCCU G UACAC	1823	GUGUA UGAUGGCAUGCACUAUGCGCG	AGGGCACACC	4602

3915	GUACACAGGC G AGGAC	1824	GUCCU UGAUGGCAUGCACUAUGCGCG GCCUGUGUAC	4603
3924	CGAGGACCCU G CACCU	1825	AGGUG UGAUGGCAUGCACUAUGCGCG AGGGUCCUCG	4604
3944	GGGGGUCCU G UGGGU	1826	ACCCA UGAUGGCAUGCACUAUGCGCG AGGGACCCCC	4605
3966	GGGGGGAGGU G CUGUG	1827	CACAG UGAUGGCAUGCACUAUGCGCG ACCUCCCCC	4606
3969	GGGAGGUGCU G UGGGA	1828	UCCCA UGAUGGCAUGCACUAUGCGCG AGCACCUC	4607
3985	GUAAAAUACU G AAUAU	1829	AUAU UGAUGGCAUGCACUAUGCGCG AGUAUUUAC	4608
3993	CUGAAUAUAU G AGUUU	1830	AAACU UGAUGGCAUGCACUAUGCGCG AUAUAUUCAG	4609
4008	UUUCAGUUUU G AAAAA	1831	UUUUU UGAUGGCAUGCACUAUGCGCG AAAACUGAAA	4610

Seq1 = TERT (Homo sapiens telomerase reverse transcriptase (TERT) mRNA, 4015 bp); Nakamura *et al.*, Science 277 (5328), 955-959 (1997)

Input Sequence = TERT. Cut Site = YG/M or UG/U.

Stem Length = 5/10. Core Sequence = UGAUG GCAUGCACUAUGC GCG

**Table VI: Human telomerase reverse transcriptase (TERT) DNzyme and Target Sequence**

nt. Position	DNzyme Sequence	Seq. ID Nos	Substrate	Seq. ID Nos
9	CAGGACGC GGCTAGCTACAACGA AGCGCTGC	1832	GCAGCGCU G GCGUCCUG	4611
11	AGCAGGAC GGCTAGCTACAACGA GCAGCGCT	1833	AGCGCUGC G GUCCUGCU	4612
16	TGCGCAGC GGCTAGCTACAACGA AGGACGCA	1834	UGCGUCCU G GCUGCGCA	4613
19	ACGTGCGC GGCTAGCTACAACGA AGCAGGAC	1835	GUCCUGCU G GCGCACGU	4614
21	CCACGTGC GGCTAGCTACAACGA GCAGCAGG	1836	CCUGCUGC G GCACGUGG	4615
23	TCCCACGT GGCTAGCTACAACGA GCGCAGCA	1837	UGCUGCGC A ACGUGGGA	4616
25	CTTCCCAC GGCTAGCTACAACGA GTGCGCAG	1838	CUGCGCAC G GUGGGAAG	4617
32	GCCAGGGC GGCTAGCTACAACGA TTCCCACG	1839	CGUGGGAA G GCCCUGGC	4618
38	GCCGGGGC GGCTAGCTACAACGA CAGGGCTT	1840	AAGCCUG G GCCCCGGC	4619
44	GGGGTGGC GGCTAGCTACAACGA CGGGGCCA	1841	UGGCCCG G GCCACCC	4620
47	GCGGGGGT GGCTAGCTACAACGA GGCCGGGG	1842	CCCCGGCC A ACCCCCGC	4621
53	GGCATCGC GGCTAGCTACAACGA GGGGGTGG	1843	CCACCCCG G GCGAUGCC	4622
56	CGCGGCAT GGCTAGCTACAACGA CGCGGGGG	1844	CCCCCGCG A AUGCCGCG	4623
58	CGCGCGGC GGCTAGCTACAACGA ATCGCGGG	1845	CCCGCGAU G GCCGCGCG	4624
61	GAGCGCGC GGCTAGCTACAACGA GGCATCGC	1846	GCGAUGCC G GCGCGCUC	4625
63	GGGAGCGC GGCTAGCTACAACGA GCGGCATC	1847	GAUGCCCG G GCGCUGCC	4626
65	CGGGGAGC GGCTAGCTACAACGA GCGCGGCA	1848	UGCCGCGC G GCUGCCCG	4627
72	TCGGCAGC GGCTAGCTACAACGA GGGGAGCG	1849	CGCUGCCC G GCUGCCGA	4628
75	GGCTCGGC GGCTAGCTACAACGA AGCGGGGA	1850	UCCCCGCU G GCCGAGCC	4629
80	CGCACGGC GGCTAGCTACAACGA TCGGCAGC	1851	GCUGCCGA G GCCGUGCG	4630
83	GAGCGCAC GGCTAGCTACAACGA GGCTCGGC	1852	GCCGAGCC G GUGCGCUC	4631
85	GGGAGCGC GGCTAGCTACAACGA ACGGCTCG	1853	CGAGCCGU G GCGCUGCC	4632
87	CAGGGAGC GGCTAGCTACAACGA GCACGGCT	1854	AGCCGUGC G GCUGCCUG	4633
94	TGCGCAGC GGCTAGCTACAACGA AGGGAGCG	1855	CGCUGCCU G GCUGCGCA	4634
97	GGTGCGC GGCTAGCTACAACGA AGCAGGGA	1856	UCCCUGCU G GCGCAGCC	4635
99	GTGGCTGC GGCTAGCTACAACGA GCAGCAGG	1857	CCUGCUGC G GCAGCCAC	4636
102	GTAGTGGC GGCTAGCTACAACGA TGCGCAGC	1858	GCUGCGCA G GCCACUAC	4637
105	GCGGTAGT GGCTAGCTACAACGA GGCTGCGC	1859	GCGCAGCC A ACUACCGC	4638
108	CTCGCGGT GGCTAGCTACAACGA AGTGGCTG	1860	CAGCCACU A ACCGCGAG	4639
111	CACCTCGC GGCTAGCTACAACGA GGTAGTGG	1861	CCACUACC G GCGAGGUG	4640
116	GGCAGCAC GGCTAGCTACAACGA CTCGCGGT	1862	ACCGCGAG G GUGCUGCC	4641
118	GCGGCAGC GGCTAGCTACAACGA ACCTCGCG	1863	CGCGAGGU G GCUGCCGC	4642
121	CCAGCGGC GGCTAGCTACAACGA AGCACCTC	1864	GAGGUGCU G GCCGUGG	4643
124	TGGCCAGC GGCTAGCTACAACGA GGCAGCAC	1865	GUGCUGCC G GCUGGCCA	4644
128	AACGTGGC GGCTAGCTACAACGA CAGCGGCA	1866	UGCCGUG G GCCACGUU	4645
131	ACGAACGT GGCTAGCTACAACGA GGCCAGCG	1867	CGCUGGCC A ACGUUCGU	4646
133	GCACGAAC GGCTAGCTACAACGA GTGGCCAG	1868	CUGGCCAC G GUUCGUGC	4647
137	CGCCGCAC GGCTAGCTACAACGA GAACGTGG	1869	CCACGUUC G GUGCGGCG	4648
139	GGCGCCGC GGCTAGCTACAACGA ACGAACGT	1870	ACGUUCGU G GCGGCGCC	4649
142	CCAGGCGC GGCTAGCTACAACGA CGCACGAA	1871	UUCGUGCG G GCGCCUGG	4650
144	CCCCAGGC GGCTAGCTACAACGA GCCGCACG	1872	CGUGCGGC G GCCUGGGG	4651

151	CCTGGGGC GGCTAGCTACAACGA CCCAGGCG	1873	CGCCUGGG G GCCCCAGG	4652
159	CCGCCAGC GGCTAGCTACAACGA CCTGGGGC	1874	GCCCCAGG G GCUGGCGG	4653
163	CCAGCCGC GGCTAGCTACAACGA CAGCCCTG	1875	CAGGGCUG G GCGGCUGG	4654
166	GCACCAGC GGCTAGCTACAACGA CGCCAGCC	1876	GGCUGGCG G GCUGGUGC	4655
170	CGCTGCAC GGCTAGCTACAACGA CAGCCGCC	1877	GGCGGCUG G GUGCAGCG	4656
172	CGCGCTGC GGCTAGCTACAACGA ACCAGCCG	1878	CGGCUGGU G GCAGCGCG	4657
175	CCCCGCGC GGCTAGCTACAACGA TGCACCAG	1879	CUGGUGCA G GCGCGGGG	4658
177	GTCCCCGC GGCTAGCTACAACGA GCTGCACC	1880	GGUGCAGC G GCGGGGAC	4659
183	CGCCGGGT GGCTAGCTACAACGA CCCC GCGC	1881	GCGCGGGG A ACCCGGCG	4660
188	AAAGCCGC GGCTAGCTACAACGA CGGGTCCC	1882	GGGACCCG G GCGGCUUU	4661
191	CGGAAAGC GGCTAGCTACAACGA CGCCGGGT	1883	ACCCGGCG G GCUUCCG	4662
198	CAGCGCGC GGCTAGCTACAACGA GGAAAGCC	1884	GGCUUCC G GCGCGCUG	4663
200	ACCAGCGC GGCTAGCTACAACGA GCGGAAAG	1885	CUUCCGC G GCGCUGGU	4664
202	CCACCAGC GGCTAGCTACAACGA GCGCGGAA	1886	UUCGCGC G GCUGGUGG	4665
206	TGGGCCAC GGCTAGCTACAACGA CAGCGCGC	1887	GCGCGCUG G GUGGCCCA	4666
209	CACTGGGC GGCTAGCTACAACGA CACCAGCG	1888	CGCUGGUG G GCCCAGUG	4667
214	CCAGGCAC GGCTAGCTACAACGA TGGGCCAC	1889	GUGGCCCA G GUGCCUGG	4668
216	CACCAGGC GGCTAGCTACAACGA ACTGGGCC	1890	GGCCCAGU G GCCUGGUG	4669
221	ACGCACAC GGCTAGCTACAACGA CAGGCACT	1891	AGUGCCUG G GUGUGCGU	4670
223	GCACGCAC GGCTAGCTACAACGA ACCAGGCA	1892	UGCCUGGU G GUGCGUGC	4671
225	GGGCACGC GGCTAGCTACAACGA ACACCAGG	1893	CCUGGUGU G GCGUGCCC	4672
227	CAGGGCAC GGCTAGCTACAACGA GCACACCA	1894	UGGUGUGC G GUGCCCUG	4673
229	CCCAGGGC GGCTAGCTACAACGA ACGCACAC	1895	GUGUGCGU G GCCCUGGG	4674
237	CCGTGCGT GGCTAGCTACAACGA CCCAGGGC	1896	GCCCUGGG A ACGCACGG	4675
239	GGCCGTGC GGCTAGCTACAACGA GTCCAGG	1897	CCUGGGAC G GCACGGCC	4676
241	GCGGCCGT GGCTAGCTACAACGA GCGTCCCA	1898	UGGGACGC A ACGGCCGC	4677
244	GGGGCGGC GGCTAGCTACAACGA CGTGCGTC	1899	GACGCACG G GCCGCCCC	4678
247	CGGGGGGC GGCTAGCTACAACGA GGCCGTGC	1900	GCACGGCC G GCCCCCCG	4679
254	GGGGCGGC GGCTAGCTACAACGA GGGGGGCG	1901	CGCCCCC G GCCGCCCC	4680
257	GAGGGGGC GGCTAGCTACAACGA GGCGGGGG	1902	CCCCCGCC G GCCCCUC	4681
270	CACCTGGC GGCTAGCTACAACGA GGAAGGAG	1903	CUCCUCC G GCCAGGUG	4682
275	CAGGACAC GGCTAGCTACAACGA CTGGCGGA	1904	UCCGCCAG G GUGUCCUG	4683
277	GGCAGGAC GGCTAGCTACAACGA ACCTGGCG	1905	CGCCAGGU G GUCCUGCC	4684
282	CTTCAGGC GGCTAGCTACAACGA AGGACACC	1906	GGUGUCCU G GCCUGAAG	4685
292	CCACCAGC GGCTAGCTACAACGA TCCTTCAG	1907	CUGAAGGA G GCUGGUGG	4686
296	CGGGCCAC GGCTAGCTACAACGA CAGCTCCT	1908	AGGAGCUG G GUGGCCCG	4687
299	ACTCGGGC GGCTAGCTACAACGA CACCAGCT	1909	AGCUGGUG G GCCCGAGU	4688
305	TGCAGCAC GGCTAGCTACAACGA TCGGGCCA	1910	UGGCCCCA G GUGCUGCA	4689
307	TCTGCAGC GGCTAGCTACAACGA ACTCGGGC	1911	GCCCAGU G GCUGCAGA	4690
310	GCCTCTGC GGCTAGCTACAACGA AGCACTCG	1912	CGAGUGCU G GCAGAGGC	4691
316	CGCACAGC GGCTAGCTACAACGA CTCTGCAG	1913	CUGCAGAG G GCUGGCG	4692
319	GCTCGCAC GGCTAGCTACAACGA AGCCTCTG	1914	CAGAGGCU G GUGCGAGC	4693
321	GCGCTCGC GGCTAGCTACAACGA ACAGCCTC	1915	GAGGCUGU G GCGAGCGC	4694
325	CGCCGCGC GGCTAGCTACAACGA TCGCACAG	1916	CUGUGCGA G GCGCGCG	4695
327	CGCGCCGC GGCTAGCTACAACGA GCTCGCAC	1917	GUGCGAGC G GCGGCGCG	4696
330	CTTCGCGC GGCTAGCTACAACGA CGCGCTCG	1918	CGAGCGCG G GCGCGAAG	4697
332	TTCTTCGC GGCTAGCTACAACGA GCCGCGCT	1919	AGCGCGGC G GCGAAGAA	4698



339	CAGCACGT GGCTAGCTACAACGA TCTTCGCG	1920	CGCGAAGA A ACGUGCUG	4699
341	GCCAGCAC GGCTAGCTACAACGA GTTCTTCG	1921	CGAAGAAC G GUGCUGGC	4700
343	AGGCCAGC GGCTAGCTACAACGA ACGTTCTT	1922	AAGAACGU G GCUGGCCU	4701
347	CCGAAGGC GGCTAGCTACAACGA CAGCACGT	1923	ACGUGCUG G GCCUUCGG	4702
354	CGCGAAGC GGCTAGCTACAACGA CGAAGGCC	1924	GGCCUUCG G GCUUCGCG	4703
359	AGCAGCGC GGCTAGCTACAACGA GAAGCCGA	1925	UCGGCUUC G GCGCUGCU	4704
361	CCAGCAGC GGCTAGCTACAACGA GCGAAGCC	1926	GGCUUCGC G GCUGCUGG	4705
364	CGTCCAGC GGCTAGCTACAACGA AGCGCGAA	1927	UUCGCGCU G GCUGGACG	4706
369	GGCCCCGT GGCTAGCTACAACGA CCAGCAGC	1928	GCUGCUGG A ACGGGGCC	4707
374	CCGCGGGC GGCTAGCTACAACGA CCCGTCCA	1929	UGGACGGG G GCCCGCGG	4708
378	GCCCCCGC GGCTAGCTACAACGA GGGCCCCG	1930	CGGGGCCC G GCGGGGGC	4709
384	GGGGGGGC GGCTAGCTACAACGA CCCC CGCG	1931	CCGCGGGG G GCCCCCCC	4710
395	GTGAAGGC GGCTAGCTACAACGA CTCGGGGG	1932	CCCCCGAG G GCCUUCAC	4711
401	CTGGTGGT GGCTAGCTACAACGA GAAGGCCT	1933	AGGCCUUC A ACCACCAG	4712
404	ACGCTGGT GGCTAGCTACAACGA GGTGAAGG	1934	CCUUCACC A ACCAGCGU	4713
408	GCGCACGC GGCTAGCTACAACGA TGGTGGTG	1935	CACCACCA G GCGUGCGC	4714
410	CTGCGCAC GGCTAGCTACAACGA GCTGGTGG	1936	CCACCAGC G GUGCGCAG	4715
412	AGCTGCGC GGCTAGCTACAACGA ACGCTGGT	1937	ACCAGCGU G GCGCAGCU	4716
414	GTAGCTGC GGCTAGCTACAACGA GCACGCTG	1938	CAGCGUGC G GCAGCUAC	4717
417	CAGGTAGC GGCTAGCTACAACGA TGCGCACG	1939	CGUGCGCA G GCUACCUG	4718
420	GGGCAAGT GGCTAGCTACAACGA AGCTGCGC	1940	GCGCAGCU A ACCUGCCC	4719
424	TGTTGGGC GGCTAGCTACAACGA AGGTAGCT	1941	AGCUACCU G GCCCAACA	4720
429	CACCGTGT GGCTAGCTACAACGA TGGGCAGG	1942	CCUGCCCA A ACACGGUG	4721
431	GTCACCGT GGCTAGCTACAACGA GTTGGGCA	1943	UGCCCAAC A ACGGUGAC	4722
434	TCGGTCAC GGCTAGCTACAACGA CGTGTGG	1944	CCAACACG G GUGACCGA	4723
437	GCGTCGGT GGCTAGCTACAACGA CACCGTGT	1945	ACACGGUG A ACCGACGC	4724
441	CAGTGCGT GGCTAGCTACAACGA CGGTCACC	1946	GGUGACCG A ACGCACUG	4725
443	CGCAGTGC GGCTAGCTACAACGA GTCGGTCA	1947	UGACCGAC G GCACUGCG	4726
445	CCCGCAGT GGCTAGCTACAACGA GCGTCGGT	1948	ACCGACGC A ACUGCGGG	4727
448	TCCCCCGC GGCTAGCTACAACGA AGTGCGTC	1949	GACGCACU G GCGGGGGA	4728
456	CGCCCCGC GGCTAGCTACAACGA TCCCCCGC	1950	GCGGGGGA G GCGGGGCG	4729
461	CCCCACGC GGCTAGCTACAACGA CCCGCTCC	1951	GGAGCGGG G GCGUGGGG	4730
463	GCCCCCAC GGCTAGCTACAACGA GCCCGCT	1952	AGCGGGGC G GUGGGGGC	4731
469	GCAGCAGC GGCTAGCTACAACGA CCCACGC	1953	GCGUGGGG G GCUGCUGC	4732
472	GCAGCAGC GGCTAGCTACAACGA AGCCCCCA	1954	UGGGGGCU G GCUGCUGC	4733
475	GGCGCAGC GGCTAGCTACAACGA AGCAGCCC	1955	GGGCUGCU G GCUGCGCC	4734
478	CGCGGCGC GGCTAGCTACAACGA AGCAGCAG	1956	CUGCUGCU G GCGCCGCG	4735
480	CACGCGGC GGCTAGCTACAACGA GCAGCAGC	1957	GCUGCUGC G GCCGCGUG	4736
483	GCCCACGC GGCTAGCTACAACGA GGCGCAGC	1958	GCUGCGCC G GCGUGGGC	4737
485	TCGCCCAC GGCTAGCTACAACGA GCGGCGCA	1959	UGCGCCGC G GUGGGCGA	4738
489	GTCGTCGC GGCTAGCTACAACGA CCACGCGG	1960	CCGCGUGG G GCGACGAC	4739
492	CACGTCGT GGCTAGCTACAACGA CGCCCACG	1961	CGUGGGCG A ACGACGUG	4740
495	CAGCACGT GGCTAGCTACAACGA CGTCGCCC	1962	GGGCGACG A ACGUGCUG	4741
497	ACCAGCAC GGCTAGCTACAACGA GTCGTCGC	1963	GCGACGAC G GUGCUGGU	4742
499	GAACCAGC GGCTAGCTACAACGA ACGTCGTC	1964	GACGACGU G GCUGGUUC	4743
503	AGGTGAAC GGCTAGCTACAACGA CAGCACGT	1965	ACGUGCUG G GUUACCU	4744
507	CAGCAGGT GGCTAGCTACAACGA GAACCAGC	1966	GCUGGUUC A ACCUGCUG	4745

511	GTGCCAGC GGCTAGCTACAACGA AGGTGAAC	1967	GUUCACCU G GCUGGCAC	4746
515	CAGCGTGC GGCTAGCTACAACGA CAGCAGGT	1968	ACCUGCUG G GCACGCUG	4747
517	CGCAGCGT GGCTAGCTACAACGA GCCAGCAG	1969	CUGCUGGC A ACGCUGCG	4748
519	CGCGCAGC GGCTAGCTACAACGA GTGCCAGC	1970	GCUGGCAC G GCUGCGCG	4749
522	GAGCGCGC GGCTAGCTACAACGA AGCGTGCC	1971	GGCACGCU G GCGCGCUC	4750
524	AAGAGCGC GGCTAGCTACAACGA GCAGCGTG	1972	CACGCUGC G GCGCUCUU	4751
526	CAAAGAGC GGCTAGCTACAACGA GCGCAGCG	1973	CGCUGCGC G GCUCUUUG	4752
533	ACCAGCAC GGCTAGCTACAACGA AAAGAGCG	1974	CGCUCUUU G GUGCUGGU	4753
535	CCACCAGC GGCTAGCTACAACGA ACAAAGAG	1975	CUCUUUGU G GCUGGUGG	4754
539	GGAGCCAC GGCTAGCTACAACGA CAGCACAA	1976	UUGUGCUG G GUGGCUC	4755
542	CTGGGAGC GGCTAGCTACAACGA CACCAGCA	1977	UGCUGGUG G GCUCCAC	4756
549	GGCGCAGC GGCTAGCTACAACGA TGGGAGCC	1978	GGCUCCCA G GCUGCGCC	4757
552	GTAGGCGC GGCTAGCTACAACGA AGCTGGGA	1979	UCCCAGCU G GCGCCUAC	4758
554	TGGTAGGC GGCTAGCTACAACGA GCAGCTGG	1980	CCAGCUGC G GCCUACCA	4759
558	CACCTGGT GGCTAGCTACAACGA AGGCGCAG	1981	CUGCGCCU A ACCAGGUG	4760
563	CCGCACAC GGCTAGCTACAACGA CTGGTAGG	1982	CCUACCAG G GUGUGCGG	4761
565	GCCCGCAC GGCTAGCTACAACGA ACCTGGTA	1983	UACCAGGU G GUGCGGGC	4762
567	CGGCCCGC GGCTAGCTACAACGA ACACCTGG	1984	CCAGGUGU G GCGGGCCG	4763
571	GCGGCGGC GGCTAGCTACAACGA CCGCACAC	1985	GUGUGCGG G GCCGCCGC	4764
574	ACAGCGGC GGCTAGCTACAACGA GGCCCGCA	1986	UGCGGGCC G GCCGCUGU	4765
577	GGTACAGC GGCTAGCTACAACGA GGCGGCC	1987	GGGCCGCC G GCUGUACC	4766
580	GCTGGTAC GGCTAGCTACAACGA AGCGGCGG	1988	CCGCCGCU G GUACCAGC	4767
582	GAGCTGGT GGCTAGCTACAACGA ACAGCGGC	1989	GCCGCUGU A ACCAGCUC	4768
586	CGCCGAGC GGCTAGCTACAACGA TGGTACAG	1990	CUGUACCA G GCUCGGCG	4769
591	GGCAGCGC GGCTAGCTACAACGA CGAGCTGG	1991	CCAGCUCG G GCGCUGCC	4770
593	GTGGCAGC GGCTAGCTACAACGA GCCGAGCT	1992	AGCUCGGC G GCUGCCAC	4771
596	TGAGTGGC GGCTAGCTACAACGA AGCGCCGA	1993	UCGGCGCU G GCCACUCA	4772
599	GCCTGAGT GGCTAGCTACAACGA GGCAGCGC	1994	GCGCUGCC A ACUCAGGC	4773
605	GGCCGGGC GGCTAGCTACAACGA CTGAGTGG	1995	CCACUCAG G GCCCGGCC	4774
610	GCGGGGGC GGCTAGCTACAACGA CGGGCCTG	1996	CAGGCCCG G GCCCCCGC	4775
616	CGTGTGGC GGCTAGCTACAACGA GGGGGCCG	1997	CGGCCCCC G GCCACACG	4776
619	TAGCGTGT GGCTAGCTACAACGA GGCGGGGG	1998	CCCCCGCC A ACACGCUA	4777
621	ACTAGCGT GGCTAGCTACAACGA GTGGCGGG	1999	CCCGCCAC A ACGCUAGU	4778
623	CCACTAGC GGCTAGCTACAACGA GTGTGGCG	2000	CGCCACAC G GCUAGUGG	4779
627	GGTCCAC GGCTAGCTACAACGA TAGCGTGT	2001	ACACGCUA G GUGGACCC	4780
631	TTCGGGGT GGCTAGCTACAACGA CCACTAGC	2002	GCUAGUGG A ACCCCGAA	4781
640	CCAGACGC GGCTAGCTACAACGA CTTTCGGG	2003	CCCCGAAG G GCGUCUGG	4782
642	TCCAGAC GGCTAGCTACAACGA GCCTTCGG	2004	CCGAAGGC G GUCUGGGA	4783
649	GTTCGCAT GGCTAGCTACAACGA CCCAGACG	2005	CGUCUGGG A AUGCGAAC	4784
651	CCGTTCGC GGCTAGCTACAACGA ATCCAGA	2006	UCUGGGAU G GCGAACGG	4785
655	AGGCCCGT GGCTAGCTACAACGA TCGCATCC	2007	GGAUGCGA A ACGGGCCU	4786
659	TTCCAGGC GGCTAGCTACAACGA CCGTTCGC	2008	GCGAACGG G GCCUGGAA	4787
666	GCTATGGT GGCTAGCTACAACGA TCCAGGCC	2009	GGCCUGGA A ACCAUAGC	4788
669	GACGCTAT GGCTAGCTACAACGA GGTTCAG	2010	CUGGAACC A AUAGCGUC	4789
672	CCTGACGC GGCTAGCTACAACGA TATGGTTC	2011	GAACCAUA G GCGUCAGG	4790
674	TCCCTGAC GGCTAGCTACAACGA GCTATGGT	2012	ACCAUAGC G GUCAGGGA	4791
683	ACCCCGGC GGCTAGCTACAACGA CTCCCTGA	2013	UCAGGGAG G GCCGGGGU	4792

689	AGGGGGAC GGCTAGCTACAACGA CCCGGCCT	2014	AGGCCGGG G GUCCCCCU	4793
699	TGGCAGGC GGCTAGCTACAACGA CCAGGGGG	2015	CCCCUGG G GCCUGCCA	4794
703	GGGCTGGC GGCTAGCTACAACGA AGGCCCAG	2016	CUGGGCCU G GCCAGCCC	4795
707	CCCGGGGC GGCTAGCTACAACGA TGGCAGGC	2017	GCCUGCCA G GCCCCGGG	4796
714	CCTCGCAC GGCTAGCTACAACGA CCGGGGCT	2018	AGCCCCGG G GUGCGAGG	4797
716	CTCCTCGC GGCTAGCTACAACGA ACCCGGGG	2019	CCCCGGGU G GCGAGGAG	4798
724	CCCCGCGC GGCTAGCTACAACGA CTCCTCGC	2020	GCGAGGAG G GCGCGGGG	4799
726	GCCCCGCG GGCTAGCTACAACGA GCCTCCTC	2021	GAGGAGGC G GCGGGGGC	4800
732	GGCACTGC GGCTAGCTACAACGA CCCC GCGC	2022	GCGCGGGG G GCAGUGCC	4801
735	GCTGGCAC GGCTAGCTACAACGA TGCCCCCG	2023	CGGGGGCA G GUGCCAGC	4802
737	CGGCTGGC GGCTAGCTACAACGA ACTGCCCC	2024	GGGGCAGU G GCCAGCCG	4803
741	ACTTCGGC GGCTAGCTACAACGA TGGCACTG	2025	CAGUGCCA G GCCGAAGU	4804
747	CGGCAGAC GGCTAGCTACAACGA TTCGGCTG	2026	CAGCCGAA G GUCUGCCG	4805
751	GCAACGGC GGCTAGCTACAACGA AGACTTCG	2027	CGAAGUCU G GCCGUUGC	4806
754	TGGGCAAC GGCTAGCTACAACGA GGCAGACT	2028	AGUCUGCC G GUUGCCCA	4807
757	TCTTGGGC GGCTAGCTACAACGA AACGGCAG	2029	CUGCCGUU G GCCCAAGA	4808
766	GCCTGGGC GGCTAGCTACAACGA CTCTTGGG	2030	CCCAAGAG G GCCCAGGC	4809
772	CGCCACGC GGCTAGCTACAACGA CTGGGCCT	2031	AGGCCCAG G GCGUGGCG	4810
774	AGCGCCAC GGCTAGCTACAACGA GCCTGGGC	2032	GCCCAGGC G GUGGCGCU	4811
777	GGCAGCGC GGCTAGCTACAACGA CACGCCTG	2033	CAGGCGUG G GCGCUGCC	4812
779	GGGGCAGC GGCTAGCTACAACGA GCCACGCC	2034	GGCGUGGC G GCUGCCCC	4813
782	TCAGGGGC GGCTAGCTACAACGA AGCGCCAC	2035	GUGGCGCU G GCCCCUGA	4814
790	GCTCCGGC GGCTAGCTACAACGA TCAGGGGC	2036	GCCCCUGA G GCCGGAGC	4815
796	GCGTCCGC GGCTAGCTACAACGA TCCGGCTC	2037	GAGCCGGA G GCGGACGC	4816
800	ACGGGCGT GGCTAGCTACAACGA CCGCTCCG	2038	CGGAGCGG A ACGCCCGU	4817
802	CAACGGGC GGCTAGCTACAACGA GTCCGCTC	2039	GAGCGGAC G GCCCGUUG	4818
806	TGCCCAAC GGCTAGCTACAACGA GGGCGTCC	2040	GGACGCCC G GUUGGGCA	4819
811	ACCCCTGC GGCTAGCTACAACGA CCAACGGG	2041	CCCGUUGG G GCAGGGGU	4820
817	CCCAGGAC GGCTAGCTACAACGA CCCTGCCC	2042	GGGCAGGG G GUCCUGGG	4821
824	GGGTGGGC GGCTAGCTACAACGA CCAGGACC	2043	GGUCCUGG G GCCCAGCC	4822
828	GCCCGGGT GGCTAGCTACAACGA GGGCCCAG	2044	CUGGGCCC A ACCCGGGC	4823
834	CGTCTGCG GGCTAGCTACAACGA CCGGGTGG	2045	CCACCCGG G GCAGGACG	4824
839	CCACGCGT GGCTAGCTACAACGA CCTGCCCC	2046	CGGGCAGG A ACGCGUGG	4825
841	GTCCACGC GGCTAGCTACAACGA GTCCTGCC	2047	GGCAGGAC G GCGUGGAC	4826
843	CGGTCCAC GGCTAGCTACAACGA GCGTCTG	2048	CAGGACGC G GUGGACCG	4827
847	CACTCGGT GGCTAGCTACAACGA CCACGCGT	2049	ACGCGUGG A ACCGAGUG	4828
852	ACGGTCAC GGCTAGCTACAACGA TCGGTCCA	2050	UGGACCGA G GUGACCGU	4829
855	ACCACGGT GGCTAGCTACAACGA CACTCGGT	2051	ACCGAGUG A ACCGUGGU	4830
858	GAAACCAC GGCTAGCTACAACGA GGTCACTC	2052	GAGUGACC G GUGGUUUC	4831
861	ACAGAAAC GGCTAGCTACAACGA CACGGTCA	2053	UGACCGUG G GUUUCUGU	4832
867	CACCACAC GGCTAGCTACAACGA AGAAACCA	2054	UGGUUUCU G GUGUGGUG	4833
869	GACACCAC GGCTAGCTACAACGA ACAGAAAC	2055	GUUUCUGU G GUGGUGUC	4834
872	GGTGACAC GGCTAGCTACAACGA CACACAGA	2056	UCUGUGUG G GUGUCACC	4835
874	CAGGTGAC GGCTAGCTACAACGA ACCACACA	2057	UGUGUGGU G GUCACCUG	4836
877	TGGCAGGT GGCTAGCTACAACGA GACACCAC	2058	GUGGUGUC A ACCUGCCA	4837
881	GGTCTGGC GGCTAGCTACAACGA AGGTGACA	2059	UGUCACCU G GCCAGACC	4838
886	CGGCGGGT GGCTAGCTACAACGA CTGGCAGG	2060	CCUGCCAG A ACCCGCCG	4839

890	TCTTCGGC GGCTAGCTACAACGA GGGTCTGG	2061	CCAGACCC G GCCGAAGA	4840
899	GAGGTGGC GGCTAGCTACAACGA TTCTTCGG	2062	CCGAAGAA G GCCACCUC	4841
902	AAAGAGGT GGCTAGCTACAACGA GGCTTCTT	2063	AAGAAGCC A ACCUCUUU	4842
915	GAGCGCAC GGCTAGCTACAACGA CCTCCAAA	2064	UUUGGAGG G GUGCGCUC	4843
917	GAGAGCGC GGCTAGCTACAACGA ACCCTCCA	2065	UGGAGGGU G GCGCUCUC	4844
919	CAGAGAGC GGCTAGCTACAACGA GCACCCTC	2066	GAGGGUGC G GCUCUCUG	4845
927	GCGCGTGC GGCTAGCTACAACGA CAGAGAGC	2067	GCUCUCUG G GCACGCGC	4846
929	TGGCGCGT GGCTAGCTACAACGA GCCAGAGA	2068	UCUCUGGC A ACGCGCCA	4847
931	AGTGGCGC GGCTAGCTACAACGA GTGCCAGA	2069	UCUGGCAC G GCGCCACU	4848
933	GGAGTGGC GGCTAGCTACAACGA GCGTGCCA	2070	UGGCACGC G GCCACUCC	4849
936	GTGGGAGT GGCTAGCTACAACGA GCGCGGTG	2071	CACGCGCC A ACUCCCAC	4850
942	GGATGGGT GGCTAGCTACAACGA GGGAGTGG	2072	CCACUCCC A ACCCAUCC	4851
946	CCACGGAT GGCTAGCTACAACGA GGGTGGGA	2073	UCCCACCC A AUCCGUGG	4852
950	CGGCCAC GGCTAGCTACAACGA GGATGGGT	2074	ACCCAUCC G GUGGGCCG	4853
954	CTGCGGGC GGCTAGCTACAACGA CCACGGAT	2075	AUCCGUGG G GCCGCCAG	4854
957	GTGCTGGC GGCTAGCTACAACGA GGCCACG	2076	CGUGGGCC G GCCAGCAC	4855
961	CGTGGTGC GGCTAGCTACAACGA TGGCGGCC	2077	GGCCGCCA G GCACCACG	4856
963	CGCGTGGT GGCTAGCTACAACGA GCTGGCGG	2078	CCGCCAGC A ACCACGCG	4857
966	GCCCGCGT GGCTAGCTACAACGA GGTGCTGG	2079	CCAGCACC A ACGCGGGC	4858
968	GGGCCCGC GGCTAGCTACAACGA GTGGTGCT	2080	AGCACCAC G GCGGGCCC	4859
972	TGGGGGGC GGCTAGCTACAACGA CCGCGTGG	2081	CCACGCGG G GCCCCCCA	4860
979	ATGTGGAT GGCTAGCTACAACGA GGGGGGCC	2082	GGCCCCC A AUCCACAU	4861
983	CGCGATGT GGCTAGCTACAACGA GGATGGGG	2083	CCCCAUCC A ACAUCGCG	4862
985	GCCGCGAT GGCTAGCTACAACGA GTGGATGG	2084	CCAUCCAC A AUCGCGGC	4863
988	GTGGCCGC GGCTAGCTACAACGA GATGTGGA	2085	UCCACAUC G GCGGCCAC	4864
991	GTGGTGGC GGCTAGCTACAACGA CGCGATGT	2086	ACAUCGCG G GCCACCAC	4865
994	GACGTGGT GGCTAGCTACAACGA GGCCGCGA	2087	UCGCGGCC A ACCACGUC	4866
997	AGGGACGT GGCTAGCTACAACGA GGTGGCCG	2088	CGGCCACC A ACGUCCCU	4867
999	CCAGGGAC GGCTAGCTACAACGA GTGGTGGC	2089	GCCACCAC G GUCCCUUG	4868
1008	AGGCGTGT GGCTAGCTACAACGA CCCAGGGA	2090	UCCCUGGG A ACACGCCU	4869
1010	CAAGGCGT GGCTAGCTACAACGA GTCCAGG	2091	CCUGGGAC A ACGCCUUG	4870
1012	GACAAGGC GGCTAGCTACAACGA GTGTCCCA	2092	UGGGACAC G GCCUUGUC	4871
1017	CGGGGGAC GGCTAGCTACAACGA AAGGCGTG	2093	CACGCCUU G GUCCCCCG	4872
1025	GCGTACAC GGCTAGCTACAACGA CGGGGGAC	2094	GUCCCCCG G GUGUACGC	4873
1027	CGGCGTAC GGCTAGCTACAACGA ACCGGGGG	2095	CCCCCGGU G GUACGCCG	4874
1029	CTCGGCGT GGCTAGCTACAACGA ACACGGGG	2096	CCCGGUGU A ACGCCGAG	4875
1031	GTCTCGGC GGCTAGCTACAACGA GTACACCG	2097	CGGUGUAC G GCCGAGAC	4876
1037	TGCTTGGT GGCTAGCTACAACGA CTCGGCGT	2098	ACGCCGAG A ACCAAGCA	4877
1042	GGAAGTGC GGCTAGCTACAACGA TTGGTCTC	2099	GAGACCAA G GCACUCC	4878
1044	GAGGAAGT GGCTAGCTACAACGA GCTTGGTC	2100	GACCAAGC A ACUCCUC	4879
1053	TGAGGAGT GGCTAGCTACAACGA AGAGGAAG	2101	CUUCCUCU A ACUCCUCA	4880
1062	CTTGTCGC GGCTAGCTACAACGA CTGAGGAG	2102	CUCCUCAG G GCGACAAG	4881
1065	CTCCTTGT GGCTAGCTACAACGA CGCCTGAG	2103	CUCAGGCG A ACAAGGAG	4882
1072	GCAGCTGC GGCTAGCTACAACGA TCCTTGTC	2104	GACAAGGA G GCAGCUGC	4883
1075	GCCGCAGC GGCTAGCTACAACGA TGCTCCTT	2105	AAGGAGCA G GCUGCGGC	4884
1078	AGGGCCGC GGCTAGCTACAACGA AGCTGCTC	2106	GAGCAGCU G GCGGCCCCU	4885
1081	AGGAGGGC GGCTAGCTACAACGA CGCAGCTG	2107	CAGCUGCG G GCCCUCCU	4886

1093	AGCTGAGT GGCTAGCTACAACGA AGGAAGGA	2108	UCCUCCU A ACUCAGCU	4887
1098	CAGAGAGC GGCTAGCTACAACGA TGAGTAGG	2109	CCUACUCA G GCUCUCUG	4888
1108	GGCTGGGC GGCTAGCTACAACGA CTCAGAGA	2110	UCUCUGAG G GCCCAGCC	4889
1113	AGTCAGGC GGCTAGCTACAACGA TGGGCCTC	2111	GAGGCCCA G GCCUGACU	4890
1118	GCGCCAGT GGCTAGCTACAACGA CAGGCTGG	2112	CCAGCCUG A ACUGGCGC	4891
1122	CCGAGCGC GGCTAGCTACAACGA CAGTCAGG	2113	CCUGACUG G GCGCUCGG	4892
1124	CTCCGAGC GGCTAGCTACAACGA GCCAGTCA	2114	UGACUGGC G GCUCGGAG	4893
1132	CCACGAGC GGCTAGCTACAACGA CTCCGAGC	2115	GCUCGGAG G GCUCGUGG	4894
1136	GTCTCCAC GGCTAGCTACAACGA GAGCCTCC	2116	GGAGGCUC G GUGGAGAC	4895
1142	AAGATGGT GGCTAGCTACAACGA CTCCACGA	2117	UCGUGGAG A ACCAUCUU	4896
1145	AGAAAGAT GGCTAGCTACAACGA GGTCTCCA	2118	UGGAGACC A AUCUUUCU	4897
1155	CCTGGAAC GGCTAGCTACAACGA CCAGAAAG	2119	CUUUCUGG G GUUCCAGG	4898
1162	TCCAGGGC GGCTAGCTACAACGA CTGGAACC	2120	GGUUCAG G GCCCUGGA	4899
1169	CCTGGCAT GGCTAGCTACAACGA CCAGGGCC	2121	GGCCUGG A AUGCCAGG	4900
1171	TCCCTGGC GGCTAGCTACAACGA ATCCAGGG	2122	CCCUGGAU G GCCAGGGA	4901
1178	CGGGGAGT GGCTAGCTACAACGA CCCTGGCA	2123	UGCCAGG A ACUCCCCG	4902
1185	CAACCTGC GGCTAGCTACAACGA GGGGAGTC	2124	GACUCCCC G GCAGGUUG	4903
1189	GGGGCAAC GGCTAGCTACAACGA CTGCGGGG	2125	CCCCGCAG G GUUGCCCC	4904
1192	GGCGGGGC GGCTAGCTACAACGA AACCTGCG	2126	CGCAGGUU G GCCCCGCC	4905
1197	GGGCAGGC GGCTAGCTACAACGA GGGGCAAC	2127	GUUGCCCC G GCCUGCCC	4906
1201	GCTGGGGC GGCTAGCTACAACGA AGGCGGGG	2128	CCCCGCCU G GCCCCAGC	4907
1207	AGTAGCGC GGCTAGCTACAACGA TGGGGCAG	2129	CUGCCCCA G GCGCUACU	4908
1209	CCAGTAGC GGCTAGCTACAACGA GCTGGGGC	2130	GCCCCAGC G GCUACUGG	4909
1212	TTGCCAGT GGCTAGCTACAACGA AGCGCTGG	2131	CCAGCGCU A ACUGGCAA	4910
1216	GCAATTGC GGCTAGCTACAACGA CAGTAGCG	2132	CGCUACUG G GCAAUUGC	4911
1220	GGCCGCAT GGCTAGCTACAACGA TTGCCAGT	2133	ACUGGCAA A AUGCGGCC	4912
1222	GGGGCCGC GGCTAGCTACAACGA ATTTGCCA	2134	UGGCAAAU G GCGGCCCC	4913
1225	ACAGGGGC GGCTAGCTACAACGA CGCATTTG	2135	CAAAUGCG G GCCCCUGU	4914
1231	CCAGAAAC GGCTAGCTACAACGA AGGGGCCG	2136	CGGCCCCU G GUUUCUGG	4915
1240	CAAGCAGC GGCTAGCTACAACGA TCCAGAAA	2137	UUUCUGGA G GCUCUUG	4916
1243	TCCAAGC GGCTAGCTACAACGA AGTCCAG	2138	CUGGAGCU G GCUUGGGA	4917
1251	CGCGTGGT GGCTAGCTACAACGA TCCAAGC	2139	GCUUGGGA A ACCACGCG	4918
1254	CTGCGCGT GGCTAGCTACAACGA GGTTCCTCA	2140	UGGGAACC A ACGCGCAG	4919
1256	CACTGCGC GGCTAGCTACAACGA GTGGTTCC	2141	GGAACCAC G GCGCAGUG	4920
1258	GGCACTGC GGCTAGCTACAACGA GCGTGGTT	2142	AACCACGC G GCAGUGCC	4921
1261	AGGGGCAC GGCTAGCTACAACGA TGCGCGTG	2143	CACGCGCA G GUGCCCCU	4922
1263	GTAGGGGC GGCTAGCTACAACGA ACTGCGCG	2144	CGCGCAGU G GCCCCUAC	4923
1269	CACCCCGT GGCTAGCTACAACGA AGGGGCAC	2145	GUGCCCCU A ACGGGGUG	4924
1274	AGGAGCAC GGCTAGCTACAACGA CCCGTAGG	2146	CCUACGGG G GUGCUCCU	4925
1276	TGAGGAGC GGCTAGCTACAACGA ACCCCGTA	2147	UACGGGGU G GCUCCUCA	4926
1286	CAGTGCGT GGCTAGCTACAACGA CTTGAGGA	2148	UCCUCAAG A ACGCACUG	4927
1288	GGCAGTGC GGCTAGCTACAACGA GTCTTGAG	2149	CUCAAGAC G GCACUGCC	4928
1290	CGGGCAGT GGCTAGCTACAACGA GCGTCTTG	2150	CAAGACGC A ACUGCCCG	4929
1293	CAGCGGGC GGCTAGCTACAACGA AGTGCCTC	2151	GACGCACU G GCCCGCUG	4930
1297	CTCGCAGC GGCTAGCTACAACGA GGGCAGTG	2152	CACUGCCC G GCUCGAG	4931
1300	CAGCTCGC GGCTAGCTACAACGA AGCGGGCA	2153	UGCCCGCU G GCGAGCUG	4932
1304	ACCGCAGC GGCTAGCTACAACGA TCGCAGCG	2154	CGCUGCGA G GCUCGGU	4933

1307	GTGACCGC GGCTAGCTACAACGA AGCTCGCA	2155	UGCGAGCU G GCGGUCAC	4934
1310	GGGGTGAC GGCTAGCTACAACGA CGCAGCTC	2156	GAGCUGCG G GUCACCCC	4935
1313	GCTGGGGT GGCTAGCTACAACGA GACCGCAG	2157	CUGCGGUC A ACCCCAGC	4936
1319	CCGGCTGC GGCTAGCTACAACGA TGGGGTGA	2158	UCACCCCA G GCAGCCGG	4937
1322	ACACCGGC GGCTAGCTACAACGA TGCTGGGG	2159	CCCCAGCA G GCCGGUGU	4938
1326	ACAGACAC GGCTAGCTACAACGA CGGCTGCT	2160	AGCAGCCG G GUGUCUGU	4939
1328	GCACAGAC GGCTAGCTACAACGA ACCGGCTG	2161	CAGCCGGU G GUCUGUGC	4940
1332	CCGGGCAC GGCTAGCTACAACGA AGACACCG	2162	CGGUGUCU G GUGCCCGG	4941
1334	TCCCGGGC GGCTAGCTACAACGA ACAGACAC	2163	GUGUCUGU G GCCCGGGA	4942
1345	CCTGGGGC GGCTAGCTACAACGA TTCTCCCG	2164	CGGGAGAA G GCCCCAGG	4943
1353	CACAGAGC GGCTAGCTACAACGA CCTGGGGC	2165	GCCCCAGG G GCUCUGUG	4944
1358	GCCGCCAC GGCTAGCTACAACGA AGAGCCCT	2166	AGGGCUCU G GUGGCGGC	4945
1361	GGGGCCGC GGCTAGCTACAACGA CACAGAGC	2167	GCUCUGUG G GCGGCCCC	4946
1364	TCGGGGGC GGCTAGCTACAACGA CGCCACAG	2168	CUGUGGCG G GCCCCCGA	4947
1380	GTCTGTGT GGCTAGCTACAACGA CCTCCTCC	2169	GGAGGAGG A ACACAGAC	4948
1382	GGGTCTGT GGCTAGCTACAACGA GTCCTCCT	2170	AGGAGGAC A ACAGACCC	4949
1386	ACGGGGGT GGCTAGCTACAACGA CTGTGTCC	2171	GGACACAG A ACCCCCGU	4950
1392	CAGGCGAC GGCTAGCTACAACGA GGGGGTCT	2172	AGACCCCG G GUCGCCUG	4951
1395	CACGAGGC GGCTAGCTACAACGA GACGGGGG	2173	CCCCCGUC G GCCUGGUG	4952
1400	AGTGTCAC GGCTAGCTACAACGA CAGGCGAC	2174	GUCGCCUG G GUGCAGCU	4953
1402	GCAGCTGC GGCTAGCTACAACGA ACCAGGCG	2175	CGCCUGGU G GCAGCUGC	4954
1405	GGAGCAGC GGCTAGCTACAACGA TGCACCAG	2176	CUGGUGCA G GCUGCUC	4955
1408	GGCGGAGC GGCTAGCTACAACGA AGTGTCAC	2177	GUGCAGCU G GCUCGCC	4956
1413	GTGCTGGC GGCTAGCTACAACGA GGAGCAGC	2178	GCUGCUC G GCCAGCAC	4957
1417	TGCTGTGC GGCTAGCTACAACGA TGGCGGAG	2179	CUCCGCCA G GCACAGCA	4958
1419	GCTGTGT GGCTAGCTACAACGA GCTGGCGG	2180	CCGCCAGC A ACAGCAGC	4959
1422	GGGGCTGC GGCTAGCTACAACGA TGTGCTGG	2181	CCAGCACA G GCAGCCCC	4960
1425	CCAGGGGC GGCTAGCTACAACGA TGCTGTGC	2182	GCACAGCA G GCCCCUGG	4961
1432	ACACCTGC GGCTAGCTACAACGA CAGGGGCT	2183	AGCCCCUG G GCAGGUGU	4962
1436	CCGTACAC GGCTAGCTACAACGA CTGCCAGG	2184	CCUGGCAG G GUGUACGG	4963
1438	AGCCGTAC GGCTAGCTACAACGA ACCTGCCA	2185	UGGCAGGU G GUACGGCU	4964
1440	GAAGCCGT GGCTAGCTACAACGA ACACCTGC	2186	GCAGGUGU A ACGGCUUC	4965
1443	CACGAAGC GGCTAGCTACAACGA CGTACACC	2187	GGUGUACG G GCUUCGUG	4966
1448	GCCCGCAC GGCTAGCTACAACGA GAAGCCGT	2188	ACGGCUUC G GUGCGGGC	4967
1450	AGGCCCGC GGCTAGCTACAACGA ACGAAGCC	2189	GGCUUCGU G GCGGGCCU	4968
1454	AGGCAGGC GGCTAGCTACAACGA CCGCACGA	2190	UCGUGCGG G GCCUGCCU	4969
1458	GCGCAGGC GGCTAGCTACAACGA AGGCCCGC	2191	GCGGGCCU G GCCUGCGC	4970
1462	GCCGGCGC GGCTAGCTACAACGA AGGCAGGC	2192	GCCUGCCU G GCGCCGGC	4971
1464	CAGCCGGC GGCTAGCTACAACGA GCAGGCAG	2193	CUGCCUGC G GCCGGCUG	4972
1468	GCACCAGC GGCTAGCTACAACGA CGGCGCAG	2194	CUGCGCCG G GCUGGUGC	4973
1472	GGGGGCAC GGCTAGCTACAACGA CAGCCGGC	2195	GCCGGCUG G GUGCCCCC	4974
1474	CTGGGGGC GGCTAGCTACAACGA ACCAGCCG	2196	CGGCUGGU G GCCCCAG	4975
1482	CCAGAGGC GGCTAGCTACAACGA CTGGGGGC	2197	GCCCCCAG G GCCUCUGG	4976
1491	CCTGGAGC GGCTAGCTACAACGA CCCAGAGG	2198	CCUCUGGG G GCUCCAGG	4977
1498	CGTTGTGC GGCTAGCTACAACGA CTGGAGCC	2199	GGCUCCAG G GCACAACG	4978
1500	TTCGTTGT GGCTAGCTACAACGA GCCTGGAG	2200	CUCCAGGC A ACAACGAA	4979
1503	GCGTTCGT GGCTAGCTACAACGA TGTGCCTG	2201	CAGGCACA A ACGAACGC	4980

1507	AGCGGCGT GGCTAGCTACAACGA TCGTTGTG	2202	CACAACGA A ACGCCGCU	4981
1509	GAAGCGGC GGCTAGCTACAACGA GTTCGTTG	2203	CAACGAAC G GCCGCUUC	4982
1512	GAGGAAGC GGCTAGCTACAACGA GCGTTCG	2204	CGAACGCC G GCUUCCUC	4983
1524	CTTGGTGT GGCTAGCTACAACGA TCCTGAGG	2205	CCUCAGGA A ACACCAAG	4984
1526	TTCTTGGT GGCTAGCTACAACGA GTTCCTGA	2206	UCAGGAAC A ACCAAGAA	4985
1534	AGATGAAC GGCTAGCTACAACGA TTCTTGGT	2207	ACCAAGAA G GUUCAUCU	4986
1538	AGGGAGAT GGCTAGCTACAACGA GAACTTCT	2208	AGAAGUUC A AUCUCCCU	4987
1552	TGGCATGC GGCTAGCTACAACGA TTCCCCAG	2209	CUGGGGAA G GCAUGCCA	4988
1554	CTTGGCAT GGCTAGCTACAACGA GCTTCCCC	2210	GGGGAAGC A AUGCCAAG	4989
1556	AGCTTGGC GGCTAGCTACAACGA ATGCTTCC	2211	GGAAGCAU G GCCAAGCU	4990
1561	GCGAGAGC GGCTAGCTACAACGA TTGGCATG	2212	CAUGCCAA G GCUCUCGC	4991
1567	CCTGCAGC GGCTAGCTACAACGA GAGAGCTT	2213	AAGCUCUC G GCUCGAGG	4992
1570	GCTCCTGC GGCTAGCTACAACGA AGCGAGAG	2214	CUCUCGCU G GCAGGAGC	4993
1576	ACGTCAGC GGCTAGCTACAACGA TCCTGCAG	2215	CUGCAGGA G GCUGACGU	4994
1580	TTCCACGT GGCTAGCTACAACGA CAGCTCCT	2216	AGGAGCUG A ACGUGGAA	4995
1582	TCTTCCAC GGCTAGCTACAACGA GTCAGCTC	2217	GAGCUGAC G GUGGAAGA	4996
1589	ACGCTCAT GGCTAGCTACAACGA CTTCCACG	2218	CGUGGAAG A AUGAGCGU	4997
1593	CCGCACGC GGCTAGCTACAACGA TCATCTTC	2219	GAAGAUGA G GCGUGCGG	4998
1595	TCCCGCAC GGCTAGCTACAACGA GCTCATCT	2220	AGAUGAGC G GUGCGGGA	4999
1597	AGTCCCGC GGCTAGCTACAACGA ACGCTCAT	2221	AUGAGCGU G GCGGGACU	5000
1602	AGCGCAGT GGCTAGCTACAACGA CCCGCACG	2222	CGUGCGGG A ACUGCGCU	5001
1605	CCAAGCGC GGCTAGCTACAACGA AGTCCCGC	2223	GCGGGACU G GCGCUUGG	5002
1607	AGCCAAGC GGCTAGCTACAACGA GCAGTCCC	2224	GGGACUGC G GCUUGGCU	5003
1612	TGCGCAGC GGCTAGCTACAACGA CAAGCGCA	2225	UGCGCUUG G GCUGCGCA	5004
1615	TCCTGCGC GGCTAGCTACAACGA AGCCAAGC	2226	GCUUGGCU G GCGCAGGA	5005
1617	GCTCCTGC GGCTAGCTACAACGA GCAGCCAA	2227	UUGGCUGC G GCAGGAGC	5006
1623	CCCTGGGC GGCTAGCTACAACGA TCCTGCGC	2228	GCGCAGGA G GCCCAGGG	5007
1631	CAGCCAAC GGCTAGCTACAACGA CCCTGGGC	2229	GCCCAGGG G GUUGGCUG	5008
1635	AACACAGC GGCTAGCTACAACGA CAACCCCT	2230	AGGGGUUG G GCUGUGUU	5009
1638	CGGAACAC GGCTAGCTACAACGA AGCCAACC	2231	GGUUGGCU G GUGUCCG	5010
1640	GCCGGAAC GGCTAGCTACAACGA ACAGCCAA	2232	UUGGCUGU G GUUCCGGC	5011
1646	TCTGCGGC GGCTAGCTACAACGA CGGAACAC	2233	GUGUCCG G GCCGCAGA	5012
1649	TGCTCTGC GGCTAGCTACAACGA GGCCGGAA	2234	UUCCGGCC G GCAGAGCA	5013
1654	GACGGTGC GGCTAGCTACAACGA TCTGCGGC	2235	GCCGCAGA G GCACCGUC	5014
1656	CAGACGGT GGCTAGCTACAACGA GCTCTGCG	2236	CGCAGAGC A ACCGUCUG	5015
1659	ACGCAGAC GGCTAGCTACAACGA GGTGCTCT	2237	AGAGCACC G GUCUGCGU	5016
1663	CCTCACGC GGCTAGCTACAACGA AGACGGTG	2238	CACCGUCU G GCGUGAGG	5017
1665	CTCCTCAC GGCTAGCTACAACGA GCAGACGG	2239	CCGUCUGC G GUGAGGAG	5018
1673	GCCAGGAT GGCTAGCTACAACGA CTCCTCAC	2240	GUGAGGAG A AUCCUGGC	5019
1679	AACTTGGC GGCTAGCTACAACGA CAGGATCT	2241	AGAUCUG G GCCAAGUU	5020
1684	GCAGGAAC GGCTAGCTACAACGA TTGGCCAG	2242	CUGGCCAA G GUUCCUGC	5021
1690	GCCAGTGC GGCTAGCTACAACGA AGGAACCT	2243	AAGUCCU G GCACUGGC	5022
1692	CAGCCAGT GGCTAGCTACAACGA GCAGGAAC	2244	GUUCCUGC A ACUGGCUG	5023
1696	TCATCAGC GGCTAGCTACAACGA CAGTGCAG	2245	CUGCACUG G GCUGAUGA	5024
1700	ACACTCAT GGCTAGCTACAACGA CAGCCAGT	2246	ACUGGCUG A AUGAGUGU	5025
1704	GTACACAC GGCTAGCTACAACGA TCATCAGC	2247	GCUGAUGA G GUGUGUAC	5026
1706	ACGTACAC GGCTAGCTACAACGA ACTCATCA	2248	UGAUGAGU G GUGUACGU	5027

1708	CGACGTAC GGCTAGCTACAACGA AACTCAT	2249	AUGAGUGU G GUACGUCG	5028
1710	GACGACGT GGCTAGCTACAACGA ACACACTC	2250	GAGUGUGU A ACGUCGUC	5029
1712	TCGACGAC GGCTAGCTACAACGA GTACACAC	2251	GUGUGUAC G GUCGUCGA	5030
1715	AGCTCGAC GGCTAGCTACAACGA GACGTACA	2252	UGUACGUC G GUCGAGCU	5031
1720	TGAGCAGC GGCTAGCTACAACGA TCGACGAC	2253	GUCGUCGA G GCUCUCA	5032
1723	ACCTGAGC GGCTAGCTACAACGA AGCTCGAC	2254	GUCGAGCU G GCUCAGGU	5033
1729	AGAAAGAC GGCTAGCTACAACGA CTGAGCAG	2255	CUGCUCAG G GUCUUUCU	5034
1740	CGTGACAT GGCTAGCTACAACGA AAAAGAAA	2256	UUUCUUUU A AUGUCACG	5035
1742	TCCGTGAC GGCTAGCTACAACGA ATAAAAGA	2257	UCUUUUAU G GUCACGGA	5036
1745	GTCTCCGT GGCTAGCTACAACGA GACATAAA	2258	UUUAUGUC A ACGGAGAC	5037
1751	AACGTGGT GGCTAGCTACAACGA CTCCGTGA	2259	UCACGGAG A ACCACGUU	5038
1754	TGAAACGT GGCTAGCTACAACGA GGTCTCCG	2260	CGGAGACC A ACGUUUCA	5039
1756	TTTGAAAC GGCTAGCTACAACGA GTGGTCTC	2261	GAGACCAC G GUUUCAAA	5040
1767	GAGCCTGT GGCTAGCTACAACGA TCTTTTGA	2262	UCAAAGA A ACAGGCUC	5041
1771	AAAAGAGC GGCTAGCTACAACGA CTGTTCTT	2263	AAGAACAG G GCUCUUUU	5042
1782	CTTCCGGT GGCTAGCTACAACGA AGAAAAAG	2264	CUUUUUCU A ACCGGAAG	5043
1791	CCAGACAC GGCTAGCTACAACGA TCTTCCGG	2265	CCGGAAGA G GUGUCUGG	5044
1793	CTCCAGAC GGCTAGCTACAACGA ACTCTTCC	2266	GGAAGAGU G GUCUGGAG	5045
1800	CAACTTGC GGCTAGCTACAACGA TCCAGACA	2267	UGUCUGGA G GCAAGUUG	5046
1804	TTTGCAAC GGCTAGCTACAACGA TTGCTCCA	2268	UGGAGCAA G GUUGCAA	5047
1807	TGCTTTGC GGCTAGCTACAACGA AACTTGCT	2269	AGCAAGUU G GCAAAGCA	5048
1812	TCCAATGC GGCTAGCTACAACGA TTTGCAAC	2270	GUUGCAA G GCAUUGGA	5049
1814	ATTCCAAT GGCTAGCTACAACGA GCTTTGCA	2271	UGCAAAGC A AUUGGAU	5050
1820	TGTCTGAT GGCTAGCTACAACGA TCCAATGC	2272	GCAUUGGA A AUCAGACA	5051
1825	AGTGCTGT GGCTAGCTACAACGA CTGATTCC	2273	GGAUCAG A ACAGCACU	5052
1828	TCAAGTGC GGCTAGCTACAACGA TGTCTGAT	2274	AUCAGACA G GCACUUGA	5053
1830	CTTCAAGT GGCTAGCTACAACGA GCTGTCTG	2275	CAGACAGC A ACUUGAAG	5054
1841	AGCTGCAC GGCTAGCTACAACGA CCTCTTCA	2276	UGAAGAGG G GUGCAGCU	5055
1843	GCAGCTGC GGCTAGCTACAACGA ACCCTCTT	2277	AAGAGGGU G GCAGCUGC	5056
1846	CCCGCAGC GGCTAGCTACAACGA TGCACCCT	2278	AGGGUGCA G GCUGCGGG	5057
1849	GCTCCCGC GGCTAGCTACAACGA AGCTGCAC	2279	GUGCAGCU G GCGGGAGC	5058
1855	CCGACAGC GGCTAGCTACAACGA TCCCGCAG	2280	CUGC GGGA G GCUGUCGG	5059
1858	CTCCGAC GGCTAGCTACAACGA AGCTCCCG	2281	CGGGAGCU G GUCGGAAG	5060
1865	ACCTCTGC GGCTAGCTACAACGA TTCCGACA	2282	UGUCGGAA G GCAGAGGU	5061
1871	TGCCTGAC GGCTAGCTACAACGA CTCTGCTT	2283	AAGCAGAG G GUCAGGCA	5062
1876	GATGCTGC GGCTAGCTACAACGA CTGACCTC	2284	GAGGUCAG G GCAGCAUC	5063
1879	CCCGATGC GGCTAGCTACAACGA TGCCTGAC	2285	GUCAGGCA G GCAUCGGG	5064
1881	TTCCCGAT GGCTAGCTACAACGA GCTGCCTG	2286	CAGGCAGC A AUCGGGAA	5065
1889	GGCCTGGC GGCTAGCTACAACGA TTCCCGAT	2287	AUCGGGAA G GCCAGGCC	5066
1894	GGGCGGGC GGCTAGCTACAACGA CTGGCTTC	2288	GAAGCCAG G GCCCGCCC	5067
1898	AGCAGGGC GGCTAGCTACAACGA GGGCCTGG	2289	CCAGGCCC G GCCUGCU	5068
1903	ACGTCAGC GGCTAGCTACAACGA AGGGCGGG	2290	CCCGCCCU G GCUGACGU	5069
1907	CTGGACGT GGCTAGCTACAACGA CAGCAGGG	2291	CCCUGCUG A ACGUCCAG	5070
1909	GTCTGGAC GGCTAGCTACAACGA GTCAGCAG	2292	CUGCUGAC G GUCCAGAC	5071
1915	AGCGGAGT GGCTAGCTACAACGA CTGGACGT	2293	ACGUCCAG A ACUCCGU	5072
1920	GATGAAGC GGCTAGCTACAACGA GGAGTCTG	2294	CAGACUCC G GCUUCAUC	5073
1925	TTGGGGAT GGCTAGCTACAACGA GAAGCGGA	2295	UCCGCUUC A AUCCCAA	5074



1933	CGTCAGGC GGCTAGCTACAACGA TTGGGGAT	2296	AUCCCCAA G GCCUGACG	5075
1938	CAGCCCGT GGCTAGCTACAACGA CAGGCTTG	2297	CAAGCCUG A ACGGGCUG	5076
1942	GCCGCAGC GGCTAGCTACAACGA CCGTCAGG	2298	CCUGACGG G GCUGCGGC	5077
1945	TCGGCCGC GGCTAGCTACAACGA AGCCCGTC	2299	GACGGGCU G GCGGCCGA	5078
1948	CAATCGGC GGCTAGCTACAACGA CGCAGCCC	2300	GGGUGCG G GCCGAUUG	5079
1952	TTCACAAT GGCTAGCTACAACGA CGGCCGCA	2301	UGCGGCCG A AUUGUGAA	5080
1955	ATGTTTAC GGCTAGCTACAACGA AATCGGCC	2302	GGCCGAUU G GUGAACAU	5081
1959	GTCCATGT GGCTAGCTACAACGA TCACAATC	2303	GAUUGUGA A ACAUGGAC	5082
1961	TAGTCCAT GGCTAGCTACAACGA GTTCACAA	2304	UUGUGAAC A AUGGACUA	5083
1965	GACGTAGT GGCTAGCTACAACGA CCATGTTT	2305	GAACAUGG A ACUACGUC	5084
1968	CACGACGT GGCTAGCTACAACGA AGTCCATG	2306	CAUGGACU A ACGUCGUG	5085
1970	CCCACGAC GGCTAGCTACAACGA GTAGTCCA	2307	UGGACUAC G GUCGUGGG	5086
1973	GCTCCAC GGCTAGCTACAACGA GACGTAGT	2308	ACUACGUC G GUGGGAGC	5087
1979	GTTCTGGC GGCTAGCTACAACGA TCCCACGA	2309	UCGUGGGA G GCCAGAAC	5088
1985	CGGAACGT GGCTAGCTACAACGA TCTGGCTC	2310	GAGCCAGA A ACGUCCG	5089
1987	TGCGGAAC GGCTAGCTACAACGA GTTCTGGC	2311	GCCAGAAC G GUUCCGCA	5090
1992	TTCTCTGC GGCTAGCTACAACGA GGAACGTT	2312	AACGUUCC G GCAGAGAA	5091
2006	CGCTCGGC GGCTAGCTACAACGA CCTCTTTT	2313	AAAAGAGG G GCCGAGCG	5092
2011	TGAGACGC GGCTAGCTACAACGA TCGGCCCT	2314	AGGGCCGA G GCGUCUCA	5093
2013	GGTGAGAC GGCTAGCTACAACGA GCTCGGCC	2315	GGCCGAGC G GUCUCACC	5094
2018	CTCGAGGT GGCTAGCTACAACGA GAGACGCT	2316	AGCGUCUC A ACCUCGAG	5095
2027	GCCTTCAC GGCTAGCTACAACGA CCTCGAGG	2317	CCUCGAGG G GUGAAGGC	5096
2033	AACAGTGC GGCTAGCTACAACGA CTTACCCC	2318	GGGUGAAG G GCACUGUU	5097
2035	TGAACAGT GGCTAGCTACAACGA GCCTTCAC	2319	GUGAAGGC A ACUGUUCA	5098
2038	CGCTGAAC GGCTAGCTACAACGA AGTGCCTT	2320	AAGGCACU G GUUCAGCG	5099
2043	GAGCACGC GGCTAGCTACAACGA TGAACAGT	2321	ACUGUUCA G GCGUGCUC	5100
2045	TTGAGCAC GGCTAGCTACAACGA GCTGAACA	2322	UGUUCAGC G GUGUCUAA	5101
2047	AGTTGAGC GGCTAGCTACAACGA ACGCTGAA	2323	UUCAGCGU G GCUCAACU	5102
2052	CTCGTAGT GGCTAGCTACAACGA TGAGCACG	2324	CGUGCUCA A ACUACGAG	5103
2055	CCGCTCGT GGCTAGCTACAACGA AGTTGAGC	2325	GCUCAACU A ACGAGCGG	5104
2059	GCGCCCGC GGCTAGCTACAACGA TCGTAGTT	2326	AACUACGA G GCGGGCGC	5105
2063	CGCCGCGC GGCTAGCTACAACGA CCGCTCGT	2327	ACGAGCGG G GCGCGGCG	5106
2065	GGCGCCGC GGCTAGCTACAACGA GCCCGCTC	2328	GAGCGGGC G GCGGCGCC	5107
2068	CGGGGCGC GGCTAGCTACAACGA CGCGCCCG	2329	CGGGCGCG G GCGCCCCG	5108
2070	GCCGGGGC GGCTAGCTACAACGA GCCGCGCC	2330	GGCGCGGC G GCCCCGCG	5109
2076	CAGGAGGC GGCTAGCTACAACGA CGGGGCGC	2331	GCGCCCCG G GCCUCCUG	5110
2085	AGAGGCGC GGCTAGCTACAACGA CCAGGAGG	2332	CCUCCUGG G GCGCCUCU	5111
2087	ACAGAGGC GGCTAGCTACAACGA GCCCAGGA	2333	UCCUGGGC G GCCUCUGU	5112
2093	CCCAGCAC GGCTAGCTACAACGA AGAGGCGC	2334	GCGCCUCU G GUGCUGGG	5113
2095	GGCCCAGC GGCTAGCTACAACGA ACAGAGGC	2335	GCCUCUGU G GCUGGGCC	5114
2100	GTCCAGGC GGCTAGCTACAACGA CCAGCACA	2336	UGUGCUGG G GCCUGGAC	5115
2106	GATATCGT GGCTAGCTACAACGA CCAGGCCC	2337	GGGCCUGG A ACGAUUUC	5116
2109	GTGGATAT GGCTAGCTACAACGA CGTCCAGG	2338	CCUGGACG A AUAUCCAC	5117
2111	CTGTGGAT GGCTAGCTACAACGA ATCGTCCA	2339	UGGACGAU A AUCCACAG	5118
2115	GGCCCTGT GGCTAGCTACAACGA GGATATCG	2340	CGAUUACC A ACAGGGCC	5119
2120	CGCCAGGC GGCTAGCTACAACGA CCTGTGGA	2341	UCCACAGG G GCCUGGCG	5120
2125	AGGTGCGC GGCTAGCTACAACGA CAGGCCCT	2342	AGGGCCUG G GCGCACCU	5121

2127	GAAGGTGC GGCTAGCTACAACGA GCCAGGCC	2343	GGCCUGGC G GCACCUUC	5122
2129	ACGAAGGT GGCTAGCTACAACGA GCGCCAGG	2344	CCUGGCGC A ACCUUCGU	5123
2135	CGCAGCAC GGCTAGCTACAACGA GAAGGTGC	2345	GCACCUUC G GUGCUGCG	5124
2137	CACGCAGC GGCTAGCTACAACGA ACGAAGGT	2346	ACCUUCGU G GCUGCGUG	5125
2140	GCACACGC GGCTAGCTACAACGA AGCACGAA	2347	UUCGUGCU G GCGUGUGC	5126
2142	CCGCACAC GGCTAGCTACAACGA GCAGCACG	2348	CGUGCUGC G GUGUGCGG	5127
2144	GCCCCCAC GGCTAGCTACAACGA ACGCAGCA	2349	UGCUGCGU G GUGCGGGC	5128
2146	GGGCCCCG GGCTAGCTACAACGA ACACGCAG	2350	CUGCGUGU G GCGGGCCC	5129
2150	TCCTGGGC GGCTAGCTACAACGA CCGCACAC	2351	GUGUGCGG G GCCCAGGA	5130
2157	CGGCGGGT GGCTAGCTACAACGA CCTGGGCC	2352	GGCCCAGG A ACCCGCCG	5131
2161	CAGGCGGC GGCTAGCTACAACGA GGGTCCTG	2353	CAGGACCC G GCCGCCUG	5132
2164	GCTCAGGC GGCTAGCTACAACGA GGCGGGTC	2354	GACCCGCC G GCCUGAGC	5133
2170	AGTACAGC GGCTAGCTACAACGA TCAGGCGG	2355	CCGCCUGA G GCUGUACU	5134
2173	CAAAGTAC GGCTAGCTACAACGA AGCTCAGG	2356	CCUGAGCU G GUACUUUG	5135
2175	GACAAAGT GGCTAGCTACAACGA ACAGCTCA	2357	UGAGCUGU A ACUUUGUC	5136
2180	ACCTTGAC GGCTAGCTACAACGA AAAGTACA	2358	UGUACUUU G GUCAAGGU	5137
2186	ACATCCAC GGCTAGCTACAACGA CTTGACAA	2359	UUGUCAAG G GUGGAUGU	5138
2190	CGTCACAT GGCTAGCTACAACGA CCACCTTG	2360	CAAGGUGG A AUGUGACG	5139
2192	CCCGTCAC GGCTAGCTACAACGA ATCCACCT	2361	AGGUGGAU G GUGACGGG	5140
2195	GCGCCCGT GGCTAGCTACAACGA CACATCCA	2362	UGGAUGUG A ACGGGCGC	5141
2199	GTACGCGC GGCTAGCTACAACGA CCGTCACA	2363	UGUGACGG G GCGCGUAC	5142
2201	TCGTACGC GGCTAGCTACAACGA GCCCGTCA	2364	UGACGGGC G GCGUACGA	5143
2203	TGTCGTAC GGCTAGCTACAACGA GCGCCCGT	2365	ACGGGCGC G GUACGACA	5144
2205	GGTGTCGT GGCTAGCTACAACGA ACGCGCCC	2366	GGGCGCGU A ACGACACC	5145
2208	GATGGTGT GGCTAGCTACAACGA CGTACGCG	2367	CGCGUACG A ACACCAUC	5146
2210	GGGATGGT GGCTAGCTACAACGA GTCGTACG	2368	CGUACGAC A ACCAUCCC	5147
2213	TGGGGGAT GGCTAGCTACAACGA GGTGTCGT	2369	ACGACACC A AUCCCCA	5148
2223	GAGCCTGT GGCTAGCTACAACGA CCTGGGGG	2370	CCCCCAGG A ACAGGCUC	5149
2227	CCGTGAGC GGCTAGCTACAACGA CTGTCTCTG	2371	CAGGACAG G GCUCACGG	5150
2231	ACCTCCGT GGCTAGCTACAACGA GAGCCTGT	2372	ACAGGCUC A ACGGAGGU	5151
2237	GCGATGAC GGCTAGCTACAACGA CTCCGTGA	2373	UCACGGAG G GUCAUCGC	5152
2240	CTGGCGAT GGCTAGCTACAACGA GACCTCCG	2374	CGGAGGUC A AUCGCCAG	5153
2243	ATGCTGGC GGCTAGCTACAACGA GATGACCT	2375	AGGUCAUC G GCCAGCAU	5154
2247	GATGATGC GGCTAGCTACAACGA TGGCGATG	2376	CAUCGCCA G GCAUCAUC	5155
2249	TTGATGAT GGCTAGCTACAACGA GCTGGCGA	2377	UCGCCAGC A AUCAUCAA	5156
2252	GGTTTGAT GGCTAGCTACAACGA GATGCTGG	2378	CCAGCAUC A AUCAAACC	5157
2257	TCTGGGGT GGCTAGCTACAACGA TTGATGAT	2379	AUCAUCAA A ACCCCAGA	5158
2265	GTACGTGT GGCTAGCTACAACGA TCTGGGGT	2380	ACCCCAGA A ACACGUAC	5159
2267	CAGTACGT GGCTAGCTACAACGA GTTCTGGG	2381	CCCAGAAC A ACGUACUG	5160
2269	CGCAGTAC GGCTAGCTACAACGA GTGTTCTG	2382	CAGAACAC G GUACUGCG	5161
2271	CACGCAGT GGCTAGCTACAACGA ACGTGTTC	2383	GAACACGU A ACUGCGUG	5162
2274	ACGCACGC GGCTAGCTACAACGA AGTACGTG	2384	CACGUACU G GCGUGCGU	5163
2276	CGACGCAC GGCTAGCTACAACGA GCAGTACG	2385	CGUACUGC G GUGCGUCG	5164
2278	ACCGACGC GGCTAGCTACAACGA ACGCAGTA	2386	UACUGCGU G GCGUCGGU	5165
2280	ATACCGAC GGCTAGCTACAACGA GCACGCAG	2387	CUGCGUGC G GUCGGUUAU	5166
2284	CGGCATAC GGCTAGCTACAACGA CGACGCAC	2388	GUGCGUCG G GUAUGCCG	5167
2286	CACGGCAT GGCTAGCTACAACGA ACCGACGC	2389	GCGUCGGU A AUGCCGUG	5168

2288	ACCACGGC GGCTAGCTACAACGA ATACCGAC	2390	GUCGGUUAU G GCCGUGGU	5169
2291	TGGACCAC GGCTAGCTACAACGA GGCATACC	2391	GGUAUGCC G GUGGUCCA	5170
2294	TTCTGGAC GGCTAGCTACAACGA CACGGCAT	2392	AUGCCGUG G GUCCAGAA	5171
2303	TGGGCGGC GGCTAGCTACAACGA CTTCTGGA	2393	UCCAGAAG G GCCGCCCA	5172
2306	CCATGGGC GGCTAGCTACAACGA GGCCTTCT	2394	AGAAGGCC G GCCCAUGG	5173
2310	GTGCCCAT GGCTAGCTACAACGA GGGCGGCC	2395	GGCCGCCC A AUGGGCAC	5174
2314	GGACGTGC GGCTAGCTACAACGA CCATGGGC	2396	GCCCAUGG G GCACGUCC	5175
2316	GCGGACGT GGCTAGCTACAACGA GCCCATGG	2397	CCAUGGGC A ACGUCCGC	5176
2318	TTGCGGAC GGCTAGCTACAACGA GTGCCCAT	2398	AUGGGCAC G GUCCGCAA	5177
2322	GGCCTTGC GGCTAGCTACAACGA GGACGTGC	2399	GCACGUCC G GCAAGGCC	5178
2327	TTGAAGGC GGCTAGCTACAACGA CTTGCGGA	2400	UCCGCAAG G GCCUUCAA	5179
2337	GACGTGGC GGCTAGCTACAACGA TCTTGAAG	2401	CUUCAAGA G GCCACGUC	5180
2340	AGAGACGT GGCTAGCTACAACGA GGCTCTTG	2402	CAAGAGCC A ACGUCUCU	5181
2342	GTAGAGAC GGCTAGCTACAACGA GTGGCTCT	2403	AGAGCCAC G GUCUCUAC	5182
2348	GTCAAGGT GGCTAGCTACAACGA AGAGACGT	2404	ACGUCUCU A ACCUUGAC	5183
2354	AGGTCTGT GGCTAGCTACAACGA CAAGGTAG	2405	CUACCUUG A ACAGACCU	5184
2358	CTGGAGGT GGCTAGCTACAACGA CTGTCAAG	2406	CUUGACAG A ACCUCCAG	5185
2365	TGTACGGC GGCTAGCTACAACGA TGGAGGTC	2407	GACCUCCA G GCCGUACA	5186
2368	GCATGTAC GGCTAGCTACAACGA GGCTGGAG	2408	CUCCAGCC G GUACAUGC	5187
2370	TCGCATGT GGCTAGCTACAACGA ACGGCTGG	2409	CCAGCCGU A ACAUGCGA	5188
2372	TGTCGCAT GGCTAGCTACAACGA GTACGGCT	2410	AGCCGUAC A AUGCGACA	5189
2374	ACTGTGCG GGCTAGCTACAACGA ATGTACGG	2411	CCGUACAU G GCGACAGU	5190
2377	CGAACTGT GGCTAGCTACAACGA CGCATGTA	2412	UACAUGCG A ACAGUUCG	5191
2380	CCACGAAC GGCTAGCTACAACGA TGTCGCAT	2413	AUGCGACA G GUUCGUGG	5192
2384	TGAGCCAC GGCTAGCTACAACGA GAACTGTC	2414	GACAGUUC G GUGGCUCA	5193
2387	AGGTGAGC GGCTAGCTACAACGA CACGAACT	2415	AGUUCGUG G GCUCACCU	5194
2391	CTGCAGGT GGCTAGCTACAACGA GAGCCACG	2416	CGUGGCUC A ACCUGCAG	5195
2395	TCTCCTGC GGCTAGCTACAACGA AGGTGAGC	2417	GCUCACCU G GCAGGAGA	5196
2402	GGGTGGT GGCTAGCTACAACGA CTCCTGCA	2418	UGCAGGAG A ACCAGCCC	5197
2406	CAGCGGGC GGCTAGCTACAACGA TGGTCTCC	2419	GGAGACCA G GCCCGCUG	5198
2410	CCCTCAGC GGCTAGCTACAACGA GGGCTGGT	2420	ACCAGCCC G GCUGAGGG	5199
2418	GACGGCAT GGCTAGCTACAACGA CCCTCAGC	2421	GCUGAGGG A AUGCCGUC	5200
2420	ACGACGGC GGCTAGCTACAACGA ATCCCTCA	2422	UGAGGGAU G GCCGUCGU	5201
2423	ATGACGAC GGCTAGCTACAACGA GGCATCCC	2423	GGGAUGCC G GUCGUCAU	5202
2426	TCGATGAC GGCTAGCTACAACGA GACGGCAT	2424	AUGCCGUC G GUCAUCGA	5203
2429	TGCTCGAT GGCTAGCTACAACGA GACGACGG	2425	CCGUCGUC A AUCGAGCA	5204
2434	AGCTCTGC GGCTAGCTACAACGA TCGATGAC	2426	GUCAUCGA G GCAGAGCU	5205
2439	GGAGGAGC GGCTAGCTACAACGA TCTGCTCG	2427	CGAGCAGA G GCUCCUCC	5206
2451	GGCCTCAT GGCTAGCTACAACGA TCAGGGAG	2428	CUCCUGA A AUGAGGCC	5207
2456	CTGCTGGC GGCTAGCTACAACGA CTCATTCA	2429	UGAAUGAG G GCCAGCAG	5208
2460	GCCACTGC GGCTAGCTACAACGA TGGCCTCA	2430	UGAGGCCA G GCAGUGGC	5209
2463	GAGGCCAC GGCTAGCTACAACGA TGCTGGCC	2431	GGCCAGCA G GUGGCCUC	5210
2466	GAAGAGGC GGCTAGCTACAACGA CACTGCTG	2432	CAGCAGUG G GCCUCUUC	5211
2475	GAAGACGT GGCTAGCTACAACGA CGAAGAGG	2433	CCUCUUCG A ACGUCUUC	5212
2477	AGGAAGAC GGCTAGCTACAACGA GTCGAAGA	2434	UCUUCGAC G GUCUCCU	5213
2485	TGAAGCGT GGCTAGCTACAACGA AGGAAGAC	2435	GUCUCCU A ACGCUUCA	5214
2487	CATGAAGC GGCTAGCTACAACGA GTAGGAAG	2436	CUUCCUAC G GCUUCAUG	5215

2492	TGGCACAT GGCTAGCTACAACGA GAAGCGTA	2437	UACGCUUC A AUGUGCCA	5216
2494	GGTGGCAC GGCTAGCTACAACGA ATGAAGCG	2438	CGCUUCAU G GUGCCACC	5217
2496	GTGGTGGC GGCTAGCTACAACGA ACATGAAG	2439	CUUCAUGU G GCCACCAC	5218
2499	GGCGTGGT GGCTAGCTACAACGA GGCACATG	2440	CAUGUGCC A ACCACGCC	5219
2502	CACGGCGT GGCTAGCTACAACGA GGTGGCAC	2441	GUGCCACC A ACGCCGUG	5220
2504	CGCACGGC GGCTAGCTACAACGA GTGGTGGC	2442	GCCACCAC G GCCGUGCG	5221
2507	ATGCGCAC GGCTAGCTACAACGA GGCCTGGT	2443	ACCACGCC G GUGCGCAU	5222
2509	TGATGCGC GGCTAGCTACAACGA ACGGCGTG	2444	CACGCCGU G GCGCAUCA	5223
2511	CCTGATGC GGCTAGCTACAACGA GCACGGCG	2445	CGCCGUGC G GCAUCAGG	5224
2513	CCCCTGAT GGCTAGCTACAACGA GCGCACGG	2446	CCGUGCGC A AUCAGGGG	5225
2520	GGACTTGC GGCTAGCTACAACGA CCCTGATG	2447	CAUCAGGG G GCAAGUCC	5226
2524	CGTAGGAC GGCTAGCTACAACGA TTGCCCT	2448	AGGGGCAA G GUCCUACG	5227
2529	CTGGACGT GGCTAGCTACAACGA AGGACTTG	2449	CAAGUCCU A ACGUCCAG	5228
2531	CACTGGAC GGCTAGCTACAACGA GTAGGACT	2450	AGUCCUAC G GUCCAGUG	5229
2536	CCTGGCAC GGCTAGCTACAACGA TGGACGTA	2451	UACGUCCA G GUGCCAGG	5230
2538	CCCCTGGC GGCTAGCTACAACGA ACTGGACG	2452	CGUCCAGU G GCCAGGGG	5231
2546	TGCGGGAT GGCTAGCTACAACGA CCCCTGGC	2453	GCCAGGGG A AUCCCGCA	5232
2551	AGCCCTGC GGCTAGCTACAACGA GGGATCCC	2454	GGGAUCCC G GCAGGGCU	5233
2556	GATGGAGC GGCTAGCTACAACGA CCTGCGGG	2455	CCCGCAGG G GCUCCAUC	5234
2561	GAGAGGAT GGCTAGCTACAACGA GGAGCCCT	2456	AGGGCUCC A AUCCUCUC	5235
2570	AGCAGCGT GGCTAGCTACAACGA GGAGAGGA	2457	UCCUCUCC A ACGCUGCU	5236
2572	AGAGCAGC GGCTAGCTACAACGA GTGGAGAG	2458	CUCUCCAC G GCUGCUCU	5237
2575	TGCAGAGC GGCTAGCTACAACGA AGCGTGGA	2459	UCCACGCU G GCUCUGCA	5238
2580	CAGGCTGC GGCTAGCTACAACGA AGAGCAGC	2460	GCUGCUCU G GCAGCCUG	5239
2583	GCACAGGC GGCTAGCTACAACGA TGCAGAGC	2461	GCUCUGCA G GCCUGUGC	5240
2587	CGTAGCAC GGCTAGCTACAACGA AGGCTGCA	2462	UGCAGCCU G GUGCUACG	5241
2589	GCCGTAGC GGCTAGCTACAACGA ACAGGCTG	2463	CAGCCUGU G GCUACGGC	5242
2592	GTCGCCGT GGCTAGCTACAACGA AGCACAGG	2464	CCUGUGCU A ACGGCGAC	5243
2595	CATGTCGC GGCTAGCTACAACGA CGTAGCAC	2465	GUGCUACG G GCGACAUG	5244
2598	CTCCATGT GGCTAGCTACAACGA CGCCGTAG	2466	CUACGGCG A ACAUGGAG	5245
2600	TTCTCCAT GGCTAGCTACAACGA GTCGCCGT	2467	ACGGCGAC A AUGGAGAA	5246
2607	CAGCTTGT GGCTAGCTACAACGA TCTCCATG	2468	CAUGGAGA A ACAAGCUG	5247
2611	CAAACAGC GGCTAGCTACAACGA TTGTTCTC	2469	GAGAACAA G GCUGUUUG	5248
2614	CCGCAAAC GGCTAGCTACAACGA AGCTTGTT	2470	AACAAGCU G GUUUGCGG	5249
2618	ATCCCCGC GGCTAGCTACAACGA AAACAGCT	2471	AGCUGUUU G GCGGGGAU	5250
2624	CGCCGAAT GGCTAGCTACAACGA CCCCGBAA	2472	UUGCGGGG A AUUCGGCG	5251
2629	CGTCCCGC GGCTAGCTACAACGA CGAATCCC	2473	GGGAUUCG G GCGGGACG	5252
2634	CAGCCCGT GGCTAGCTACAACGA CCCGCCGA	2474	UCGGCGGG A ACGGGCUG	5253
2638	GGAGCAGC GGCTAGCTACAACGA CCGTCCCG	2475	CGGGACGG G GCUGCUCC	5254
2641	GCAGGAGC GGCTAGCTACAACGA AGCCCGTC	2476	GACGGGCU G GCUCCUGC	5255
2647	CCAAACGC GGCTAGCTACAACGA AGGAGCAG	2477	CUGCUCU G GCGUUUGG	5256
2649	CACCAAAC GGCTAGCTACAACGA GCAGGAGC	2478	GCUCCUGC G GUUUGGUG	5257
2654	TCATCCAC GGCTAGCTACAACGA CAAACGCA	2479	UGCGUUUG G GUGGAUGA	5258
2658	GAAATCAT GGCTAGCTACAACGA CCACCAAA	2480	UUUGGUGG A AUGAUUUC	5259
2661	CAAGAAAT GGCTAGCTACAACGA CATCCACC	2481	GGUGGAUG A AUUUCUUG	5260
2668	TCACCAAC GGCTAGCTACAACGA AAGAAATC	2482	GAUUUCUU G GUUGGUGA	5261
2672	GGTGTAC GGCTAGCTACAACGA CAACAAGA	2483	UCUUGUUG G GUGACACC	5262

2675	TGAGGTGT GGCTAGCTACAACGA CACCAACA	2484	UGUUGGUG A ACACCUC A	5263
2677	GGTGAGGT GGCTAGCTACAACGA GTCACCAA	2485	UUGGUGAC A ACCUCACC	5264
2682	GGTGAGGT GGCTAGCTACAACGA GAGGTGTC	2486	GACACCUC A ACCUCACC	5265
2687	GCGTGGGT GGCTAGCTACAACGA GAGGTGAG	2487	CUCACCUC A ACCCAGC	5266
2691	TTTCGCGT GGCTAGCTACAACGA GGGTGAGG	2488	CCUCACCC A ACGCGAAA	5267
2693	GTTTTTCG G GCTAGCTACAACGA GTGGGTGA	2489	UCACCCAC G GCGAAAAC	5268
2699	AGGAAGGT GGCTAGCTACAACGA TTTCGCGT	2490	ACGCGAAA A ACCUCCU	5269
2711	ACCAGGGT GGCTAGCTACAACGA CCTGAGGA	2491	UCCUCAGG A ACCCUGU	5270
2717	CCTCGGAC GGCTAGCTACAACGA CAGGGTCC	2492	GGACCCUG G GUCCGAGG	5271
2724	AGGGACAC GGCTAGCTACAACGA CTCGGACC	2493	GGUCCGAG G GUGUCCU	5272
2726	TCAGGGAC GGCTAGCTACAACGA ACCTCGGA	2494	UCCGAGGU G GUCCUGA	5273
2734	AGCCATAC GGCTAGCTACAACGA TCAGGGAC	2495	GUCCUGA G GUAUGGU	5274
2736	GCAGCCAT GGCTAGCTACAACGA ACTCAGGG	2496	CCCUGAGU A AUGGCUGC	5275
2739	CACGCAGC GGCTAGCTACAACGA CATACTCA	2497	UGAGUAUG G GCUGCGUG	5276
2742	CACCACGC GGCTAGCTACAACGA AGCCATAC	2498	GUAUGGU G GCGUGGUG	5277
2744	TTCACCAC GGCTAGCTACAACGA GCAGCCAT	2499	AUGGCUGC G GUGGUGAA	5278
2747	AAGTTCAC GGCTAGCTACAACGA CACGCAGC	2500	GCUGCGUG G GUGAACUU	5279
2751	CCGCAAGT GGCTAGCTACAACGA TCACCACG	2501	CGUGGUGA A ACUUGCGG	5280
2755	TCTTCCGC GGCTAGCTACAACGA AAGTTCAC	2502	GUGAACUU G GCGGAAGA	5281
2762	ACCACTGT GGCTAGCTACAACGA CTTCCGCA	2503	UGCAGGAG A ACAGUGU	5282
2765	TTCACCAC GGCTAGCTACAACGA TGTCTTCC	2504	GGAAGACA G GUGGUGAA	5283
2768	AAGTTCAC GGCTAGCTACAACGA CACTGTCT	2505	AGACAGUG G GUGAACUU	5284
2772	AGGGAAGT GGCTAGCTACAACGA TCACCACT	2506	AGUGGUGA A ACUUCCU	5285
2780	TCTTCTAC GGCTAGCTACAACGA AGGGAAGT	2507	ACUUCCU G GUAGAAGA	5286
2787	GGCCTCGT GGCTAGCTACAACGA CTTCTACA	2508	UGUAGAAG A ACGAGGCC	5287
2792	CCCAGGGC GGCTAGCTACAACGA CTCGTCTT	2509	AAGACGAG G GCCCUGGG	5288
2799	CGTGCCAC GGCTAGCTACAACGA CCAGGGCC	2510	GGCCUGG G GUGGCACG	5289
2802	AGCCGTGC GGCTAGCTACAACGA CACCCAGG	2511	CCUGGGUG G GCACGGCU	5290
2804	AAAGCCGT GGCTAGCTACAACGA GCCACCCA	2512	UGGGUGGC A ACGGCUUU	5291
2807	ACAAAAGC GGCTAGCTACAACGA CGTGCCAC	2513	GUGGCACG G GCUUUUGU	5292
2813	ATCTGAAC GGCTAGCTACAACGA AAAAGCCG	2514	CGGCUUUU G GUUCAGAU	5293
2819	GCCGGCAT GGCTAGCTACAACGA CTGAACAA	2515	UUGUUCAG A AUGCCGGC	5294
2821	GGGCCGGC GGCTAGCTACAACGA ATCTGAAC	2516	GUUCAGAU G GCCGGCCC	5295
2825	CCGTGGGC GGCTAGCTACAACGA CGGCATCT	2517	AGAUGCCG G GCCACGG	5296
2829	TAGGCCGT GGCTAGCTACAACGA GGGCCGGC	2518	GCCGGCCC A ACGGCCUA	5297
2832	GAATAGGC GGCTAGCTACAACGA CGTGGGCC	2519	GGCCACG G GCCUAUUC	5298
2836	AGGGGAAT GGCTAGCTACAACGA AGGCCGTG	2520	CACGGCCU A AUUCCCCU	5299
2845	GGCCGCAC GGCTAGCTACAACGA CAGGGGAA	2521	UUCCCCUG G GUGCGGCC	5300
2847	CAGGCCGC GGCTAGCTACAACGA ACCAGGGG	2522	CCCCUGGU G GCGGCCUG	5301
2850	CAGCAGGC GGCTAGCTACAACGA CGCACCAG	2523	CUGGUGCG G GCCUGCUG	5302
2854	CCAGCAGC GGCTAGCTACAACGA AGGCCGCA	2524	UGCGGCCU G GCUGCUGG	5303
2857	TATCCAGC GGCTAGCTACAACGA AGCAGGCC	2525	GGCCUGCU G GCUGGAUA	5304
2862	CCGGGTAT GGCTAGCTACAACGA CCAGCAGC	2526	GCUGCUGG A AUACCCGG	5305
2864	GTCCGGGT GGCTAGCTACAACGA ATCCAGCA	2527	UGCUGGAU A ACCCGGAC	5306
2870	TCCAGGGT GGCTAGCTACAACGA CCGGGTAT	2528	AUACCCGG A ACCCUGGA	5307
2879	CTCTGCAC GGCTAGCTACAACGA CTCCAGGG	2529	CCCUGGAG G GUGCAGAG	5308
2881	CGCTCTGC GGCTAGCTACAACGA ACCTCCAG	2530	CUGGAGGU G GCAGAGCG	5309

2886	G TAGTCGC GGCTAGCTACAACGA TCTGCACC	2531	GGUGCAGA G GCGACUAC	5310
2889	GGAGTAGT GGCTAGCTACAACGA CGCTCTGC	2532	GCAGAGCG A ACUACUCC	5311
2892	GCTGGAGT GGCTAGCTACAACGA AGTCGCTC	2533	GAGCGACU A ACUCCAGC	5312
2898	GGCATAGC GGCTAGCTACAACGA TGGAGTAG	2534	CUACUCCA G GCUAUGCC	5313
2901	CCGGGCAT GGCTAGCTACAACGA AGCTGGAG	2535	CUCCAGCU A AUGCCCGG	5314
2903	GTCCGGGC GGCTAGCTACAACGA ATAGCTGG	2536	CCAGCUAU G GCCCGGAC	5315
2909	ATGGAGGT GGCTAGCTACAACGA CCGGGCAT	2537	AUGCCCGG A ACCUCCAU	5316
2915	GCTCTGAT GGCTAGCTACAACGA GGAGGTCC	2538	GGACCUCC A AUCAGAGC	5317
2921	AGACTGGC GGCTAGCTACAACGA TCTGATGG	2539	CCAUCAGA G GCCAGUCU	5318
2925	GGTGAGAC GGCTAGCTACAACGA TGGCTCTG	2540	CAGAGCCA G GUCUCACC	5319
2930	TTGAAGGT GGCTAGCTACAACGA GAGACTGG	2541	CCAGUCUC A ACCUUCAA	5320
2937	GCCGCGGT GGCTAGCTACAACGA TGAAGGTG	2542	CACCUUCA A ACCGCGGC	5321
2940	GAAGCCGC GGCTAGCTACAACGA GGTGGAAG	2543	CUUCAACC G GCGGCUUC	5322
2943	CTTGAAGC GGCTAGCTACAACGA CGCGTTTG	2544	CAACCGCG G GCUUCAAG	5323
2951	CTCCCAGC GGCTAGCTACAACGA CTTGAAGC	2545	GCUUCAAG G GCUGGGAG	5324
2961	ACGCATGT GGCTAGCTACAACGA TCCTCCCA	2546	UGGGAGGA A ACAUGCGU	5325
2963	CGACGCAT GGCTAGCTACAACGA GTTCCTCC	2547	GGAGGAAC A AUGCGUCG	5326
2965	TGCGACGC GGCTAGCTACAACGA ATGTTCTT	2548	AGGAACAU G GCGUCGCA	5327
2967	TTTGCGAC GGCTAGCTACAACGA GCATGTTT	2549	GAACAUGC G GUCGCAA	5328
2970	GAGTTTGC GGCTAGCTACAACGA GACGCATG	2550	CAUGCGUC G GCAAACUC	5329
2974	CAAAGAGT GGCTAGCTACAACGA TTGCGACG	2551	CGUCGCAA A ACUCUUUG	5330
2984	CGCAAGAC GGCTAGCTACAACGA CCCAAAGA	2552	UCUUUGGG G GUCUUGCG	5331
2989	TCAGCCGC GGCTAGCTACAACGA AAGACCCC	2553	GGGGUCUU G GCGGCUGA	5332
2992	ACTTCAGC GGCTAGCTACAACGA CGCAAGAC	2554	GUCUUGCG G GCUGAAGU	5333
2998	TGTGACAC GGCTAGCTACAACGA TTCAGCCG	2555	CGGCUGAA G GUGUCACA	5334
3000	GCTGTGAC GGCTAGCTACAACGA ACTTCAGC	2556	GCUGAAGU G GUCACAGC	5335
3003	CAGGCTGT GGCTAGCTACAACGA GACACTTC	2557	GAAGUGUC A ACAGCCUG	5336
3006	AAACAGGC GGCTAGCTACAACGA TGTGACAC	2558	GUGUCACA G GCCUGUUU	5337
3010	CCAGAAAC GGCTAGCTACAACGA AGGCTGTG	2559	CACAGCCU G GUUUCUGG	5338
3018	CTGCAAAT GGCTAGCTACAACGA CCAGAAAC	2560	GUUUCUGG A AUUUGCAG	5339
3022	TCACCTGC GGCTAGCTACAACGA AAATCCAG	2561	CUGGAUUU G GCAGGUGA	5340
3026	CTGTTTAC GGCTAGCTACAACGA CTGCAAAT	2562	AUUUGCAG G GUGAACAG	5341
3030	GAGGCTGT GGCTAGCTACAACGA TCACCTGC	2563	GCAGGUGA A ACAGCCUC	5342
3033	CTGGAGGC GGCTAGCTACAACGA TGTTCACC	2564	GGUGAACA G GCCUCCAG	5343
3041	CACACCGT GGCTAGCTACAACGA CTGGAGGC	2565	GCCUCCAG A ACGGUGUG	5344
3044	GTGCACAC GGCTAGCTACAACGA CGTCTGGA	2566	UCCAGACG G GUGUGCAC	5345
3046	TGGTGCAC GGCTAGCTACAACGA ACCGTCTG	2567	CAGACGGU G GUGCACCA	5346
3048	GTTGGTGC GGCTAGCTACAACGA ACACCGTC	2568	GACGGUGU G GCACCAAC	5347
3050	ATGTTGGT GGCTAGCTACAACGA GCACACCG	2569	CGGUGUGC A ACCAACAU	5348
3054	GTAGATGT GGCTAGCTACAACGA TGGTGCAC	2570	GUGCACCA A ACAUCUAC	5349
3056	TTGTAGAT GGCTAGCTACAACGA GTTGGTGC	2571	GCACCAAC A AUCUACAA	5350
3060	GATCTTGT GGCTAGCTACAACGA AGATGTTG	2572	CAACAUCU A ACAAGAUC	5351
3065	AGGAGGAT GGCTAGCTACAACGA CTTGTAGA	2573	UCUACAAG A AUCCUCCU	5352
3073	CCTGCAGC GGCTAGCTACAACGA AGGAGGAT	2574	AUCCUCCU G GCUGCAGG	5353
3076	ACGCTGTC GGCTAGCTACAACGA AGCAGGAG	2575	CUCCUGCU G GCAGGCGU	5354
3080	CTGTACGC GGCTAGCTACAACGA CTGCAGCA	2576	UGCUGCAG G GCGUACAG	5355
3082	ACCTGTAC GGCTAGCTACAACGA GCCTGCAG	2577	CUGCAGGC G GUACAGGU	5356

3084	AAACCTGT GGCTAGCTACAACGA ACGCCTGC	2578	GCAGGCGU A ACAGGUUU	5357
3088	CGTGAAAC GGCTAGCTACAACGA CTGTACGC	2579	GCGUACAG G GUUUCACG	5358
3093	ACATGCGT GGCTAGCTACAACGA GAAACCTG	2580	CAGGUUUC A ACGCAUGU	5359
3095	ACACATGC GGCTAGCTACAACGA GTGAAACC	2581	GGUUUCAC G GCAUGUGU	5360
3097	GCACACAT GGCTAGCTACAACGA GCGTGAAA	2582	UUUCACGC A AUGUGUGC	5361
3099	CAGCACAC GGCTAGCTACAACGA ATGCGTGA	2583	UCACGCAU G GUGUGCUG	5362
3101	TGCAGCAC GGCTAGCTACAACGA ACATGCGT	2584	ACGCAUGU G GUGCUGCA	5363
3103	GCTGCAGC GGCTAGCTACAACGA ACACATGC	2585	GCAUGUGU G GCUGCAGC	5364
3106	GGAGCTGC GGCTAGCTACAACGA AGCACACA	2586	UGUGUGCU G GCAGCUCC	5365
3109	ATGGGAGC GGCTAGCTACAACGA TGCAGCAC	2587	GUGCUGCA G GCUCCCAU	5366
3115	GATGAAAT GGCTAGCTACAACGA GGGAGCTG	2588	CAGCUCCC A AUUUCAUC	5367
3120	TTGCTGAT GGCTAGCTACAACGA GAAATGGG	2589	CCCAUUUC A AUCAGCAA	5368
3124	AAACTTGC GGCTAGCTACAACGA TGATGAAA	2590	UUUCAUCA G GCAAGUUU	5369
3128	TTCCAAAC GGCTAGCTACAACGA TTGCTGAT	2591	AUCAGCAA G GUUUGGAA	5370
3138	TGTGGGGT GGCTAGCTACAACGA TCTTCCAA	2592	UUGGAAGA A ACCCCACA	5371
3143	AAAAATGT GGCTAGCTACAACGA GGGGTTCT	2593	AGAACCCC A ACAUUUUU	5372
3145	GGAAAAAT GGCTAGCTACAACGA GTGGGGTT	2594	AACCCAC A AUUUUCC	5373
3154	TGACGCGC GGCTAGCTACAACGA AGGAAAAA	2595	UUUUUCCU G GCGCGUCA	5374
3156	GATGACGC GGCTAGCTACAACGA GCAGGAAA	2596	UUUCCUGC G GCGUCAUC	5375
3158	GAGATGAC GGCTAGCTACAACGA GCGCAGGA	2597	UCCUGCGC G GUCAUCUC	5376
3161	TCAGAGAT GGCTAGCTACAACGA GACGCGCA	2598	UGCGCGUC A AUCUCUGA	5377
3168	GGCCGTGT GGCTAGCTACAACGA CAGAGATG	2599	CAUCUCUG A ACACGGCC	5378
3170	GAGCCGT GGCTAGCTACAACGA GTCAGAGA	2600	UCUCUGAC A ACGGCCUC	5379
3173	AGGGAGGC GGCTAGCTACAACGA CGTGTCAG	2601	CUGACACG G GCCUCCCU	5380
3183	GGAGTAGC GGCTAGCTACAACGA AGAGGGAG	2602	CUCCUCU G GCUACUCC	5381
3186	GATGGAGT GGCTAGCTACAACGA AGCAGAGG	2603	CCUCUGCU A ACUCCAUC	5382
3191	TTCAGGAT GGCTAGCTACAACGA GGAGTAGC	2604	GCUACUCC A AUCCUGAA	5383
3200	TTCTTGGC GGCTAGCTACAACGA TTTCAGGA	2605	UCCUGAAA G GCCAAGAA	5384
3207	CCCTGCGT GGCTAGCTACAACGA TCTTGGCT	2606	AGCCAAGA A ACGCAGGG	5385
3209	ATCCCTGC GGCTAGCTACAACGA GTTCTTGG	2607	CCAAGAAC G GCAGGGAU	5386
3215	AGCGACAT GGCTAGCTACAACGA CCCTGCGT	2608	ACGCAGGG A AUGUCGCU	5387
3217	CCAGCGAC GGCTAGCTACAACGA ATCCCTGC	2609	GCAGGGAU G GUCGUGG	5388
3220	CCCCAGC GGCTAGCTACAACGA GACATCCC	2610	GGGAUGUC G GCUGGGGG	5389
3227	CCCTTGGC GGCTAGCTACAACGA CCCCAGCG	2611	CGCUGGGG G GCCAAGGG	5390
3234	GGCGGCGC GGCTAGCTACAACGA CCTTGGCC	2612	GGCCAAGG G GCGCCGCC	5391
3236	CCGGCGGC GGCTAGCTACAACGA GCCCTTGG	2613	CCAAGGGC G GCCGCCGG	5392
3239	GGGCCGGC GGCTAGCTACAACGA GCGGCCCT	2614	AGGGCGCC G GCCGGCCC	5393
3243	CAGAGGGC GGCTAGCTACAACGA CGGCGGCG	2615	CGCCGCCG G GCCCUCUG	5394
3250	CGGAGGGC GGCTAGCTACAACGA AGAGGGCC	2616	GGCCUCU G GCCCUCCG	5395
3260	TGCACGGC GGCTAGCTACAACGA CTCGAGG	2617	CCUCCGAG G GCCGUGCA	5396
3263	CACTGCAC GGCTAGCTACAACGA GGCCTCGG	2618	CCGAGGCC G GUGCAGUG	5397
3265	GCCACTGC GGCTAGCTACAACGA ACGGCCTC	2619	GAGGCCGU G GCAGUGGC	5398
3268	ACAGCCAC GGCTAGCTACAACGA TGCACGGC	2620	GCCGUGCA G GUGGCUGU	5399
3271	GGCACAGC GGCTAGCTACAACGA CACTGCAC	2621	GUGCAGUG G GCUGUGCC	5400
3274	GGTGGCAC GGCTAGCTACAACGA AGCCACTG	2622	CAGUGGCU G GUGCCACC	5401
3276	TTGGTGGC GGCTAGCTACAACGA ACAGCCAC	2623	GUGGCUGU G GCCACCAA	5402
3279	TGCTTGGT GGCTAGCTACAACGA GGCACAGC	2624	GCUGUGCC A ACCAAGCA	5403

3284	AGGAATGC GGCTAGCTACAACGA TTGGTGGC	2625	GCCACCAA G GCAUCCU	5404
3286	GCAGGAAT GGCTAGCTACAACGA GCTTGGTG	2626	CACCAAGC A AUUCCUGC	5405
3292	GCTTGAGC GGCTAGCTACAACGA AGGAATGC	2627	GCAUCCU G GCUCAAGC	5406
3298	GAGTCAGC GGCTAGCTACAACGA TTGAGCAG	2628	CUGCUCAA G GCUGACUC	5407
3302	TGTCGAGT GGCTAGCTACAACGA CAGCTTGA	2629	UCAAGCUG A ACUCGACA	5408
3307	CACGGTGT GGCTAGCTACAACGA CGAGTCAG	2630	CUGACUCG A ACACCGUG	5409
3309	GACACGGT GGCTAGCTACAACGA GTCGAGTC	2631	GACUCGAC A ACCGUGUC	5410
3312	GGTGACAC GGCTAGCTACAACGA GGTGTCGA	2632	UCGACACC G GUGUCACC	5411
3314	TAGGTGAC GGCTAGCTACAACGA ACGGTGTC	2633	GACACCGU G GUCACCUA	5412
3317	ACGTAGGT GGCTAGCTACAACGA GACACGGT	2634	ACCGUGUC A ACCUACGU	5413
3321	TGGCACGT GGCTAGCTACAACGA AGGTGACA	2635	UGUCACCU A ACGUGCCA	5414
3323	AGTGGCAC GGCTAGCTACAACGA GTAGGTGA	2636	UCACCUAC G GUGCCACU	5415
3325	GGAGTGGC GGCTAGCTACAACGA ACGTAGGT	2637	ACCUACGU G GCCACUCC	5416
3328	CCAGGAGT GGCTAGCTACAACGA GGCACGTA	2638	UACGUGCC A ACUCCUGG	5417
3337	TGAGTGAC GGCTAGCTACAACGA CCCAGGAG	2639	CUCCUGGG G GUCACUCA	5418
3340	TCCTGAGT GGCTAGCTACAACGA GACCCCAG	2640	CUGGGGUC A ACUCAGGA	5419
3347	TGGGCTGT GGCTAGCTACAACGA CCTGAGTG	2641	CACUCAGG A ACAGCCCA	5420
3350	GTCTGGGC GGCTAGCTACAACGA TGTCCTGA	2642	UCAGGACA G GCCCAGAC	5421
3356	AGCTGCGT GGCTAGCTACAACGA CTGGGCTG	2643	CAGCCCAG A ACGCAGCU	5422
3358	TCAGCTGC GGCTAGCTACAACGA GTCTGGGC	2644	GCCCAGAC G GCAGCUGA	5423
3361	GACTCAGC GGCTAGCTACAACGA TCGTCTG	2645	CAGACGCA G GCUGAGUC	5424
3366	CTTCCGAC GGCTAGCTACAACGA TCAGCTGC	2646	GCAGCUGA G GUCGGAAG	5425
3373	CCGGGAGC GGCTAGCTACAACGA TTCCGACT	2647	AGUCGGAA G GCUCCCGG	5426
3383	AGCGTCGT GGCTAGCTACAACGA CCCCGGGA	2648	UCCCGGGG A ACGACGCU	5427
3386	GTCAGCGT GGCTAGCTACAACGA CGTCCCCG	2649	CGGGGACG A ACGCUGAC	5428
3388	CAGTCAGC GGCTAGCTACAACGA GTCGTCCC	2650	GGGACGAC G GCUGACUG	5429
3392	AGGGCAGT GGCTAGCTACAACGA CAGCGTCG	2651	CGACGCUG A ACUGCCCU	5430
3395	TCCAGGGC GGCTAGCTACAACGA AGTCAGCG	2652	CGCUGACU G GCCCUGGA	5431
3404	GCTGCGGC GGCTAGCTACAACGA CTCCAGGG	2653	CCCUGGAG G GCCGCAGC	5432
3407	TTGGCTGC GGCTAGCTACAACGA GGCCTCCA	2654	UGGAGGCC G GCAGCCAA	5433
3410	GGGTTGGC GGCTAGCTACAACGA TGCGGCCT	2655	AGGCCGCA G GCCAACCC	5434
3414	TGCCGGGT GGCTAGCTACAACGA TGGCTGCG	2656	CGCAGCCA A ACCCGGCA	5435
3419	GGCAGTGC GGCTAGCTACAACGA CGGGTTGG	2657	CCAACCCG G GCACUGCC	5436
3421	AGGGCAGT GGCTAGCTACAACGA GCCGGGTT	2658	AACCCGGC A ACUGCCCU	5437
3424	CTGAGGGC GGCTAGCTACAACGA AGTGCCGG	2659	CCGGCACU G GCCCUCAG	5438
3432	CTGAAGT GGCTAGCTACAACGA CTGAGGGC	2660	GCCCUCAG A ACUUCAAG	5439
3440	AGGATGGT GGCTAGCTACAACGA CTTGAAGT	2661	ACUUCAAG A ACCAUCCU	5440
3443	TCCAGGAT GGCTAGCTACAACGA GGTCTTGA	2662	UCAAGACC A AUCCUGGA	5441
3450	CCATCAGT GGCTAGCTACAACGA CCAGGATG	2663	CAUCCUGG A ACUGAUGG	5442
3454	GTGGCCAT GGCTAGCTACAACGA CAGTCCAG	2664	CUGGACUG A AUGGCCAC	5443
3457	CGGGTGGC GGCTAGCTACAACGA CATCAGTC	2665	GACUGAUG G GCCACCCG	5444
3460	GGGCGGGT GGCTAGCTACAACGA GGCCATCA	2666	UGAUGGCC A ACCCGCCC	5445
3464	CTGTGGGC GGCTAGCTACAACGA GGGTGGCC	2667	GGCCACCC G GCCCACAG	5446
3468	CTGGCTGT GGCTAGCTACAACGA GGGCGGGT	2668	ACCCGCCC A ACAGCCAG	5447
3471	GGCCTGGC GGCTAGCTACAACGA TGTGGGCG	2669	CGCCACA G GCCAGGCC	5448
3476	CTCTCGGC GGCTAGCTACAACGA CTGGCTGT	2670	ACAGCCAG G GCCGAGAG	5449
3483	GTGTCTGC GGCTAGCTACAACGA TCTCGGCC	2671	GGCCGAGA G GCAGACAC	5450



3487	GCTGGTGT GGCTAGCTACAACGA CTGCTCTC	2672	GAGAGCAG A ACACCAGC	5451
3489	CTGCTGGT GGCTAGCTACAACGA GTCTGCTC	2673	GAGCAGAC A ACCAGCAG	5452
3493	AGGGCTGC GGCTAGCTACAACGA TGGTGTCT	2674	AGACACCA G GCAGCCCU	5453
3496	GACAGGGC GGCTAGCTACAACGA TGCTGGTG	2675	CACCAGCA G GCCCUGUC	5454
3501	GGCGTGAC GGCTAGCTACAACGA AGGGCTGC	2676	GCAGCCCU G GUCACGCC	5455
3504	CCCGCGT GGCTAGCTACAACGA GACAGGGC	2677	GCCCUGUC A ACGCCGGG	5456
3506	AGCCCGGC GGCTAGCTACAACGA GTGACAGG	2678	CCUGUCAC G GCCGGGCU	5457
3511	CGTAGAGC GGCTAGCTACAACGA CCGGCGTG	2679	CACGCCGG G GCUCUACG	5458
3516	TGGGACGT GGCTAGCTACAACGA AGAGCCCG	2680	CGGGCUCU A ACGUCCCA	5459
3518	CCTGGGAC GGCTAGCTACAACGA GTAGAGCC	2681	GGCUCUAC G GUCCCAGG	5460
3535	TGGGCCGC GGCTAGCTACAACGA CCTCCCT	2682	AGGGAGGG G GCGGCCCA	5461
3538	GTGTGGGC GGCTAGCTACAACGA CGCCCTC	2683	GAGGGGCG G GCCCACAC	5462
3542	CTGGGTGT GGCTAGCTACAACGA GGGCCGCC	2684	GGCGGCC A ACACCAG	5463
3544	GCCTGGGT GGCTAGCTACAACGA GTGGCCG	2685	CGGCCAC A ACCCAGGC	5464
3550	GTGCGGGC GGCTAGCTACAACGA CTGGGTGT	2686	ACACCAG G GCCCGCAC	5465
3554	AGCGGTGC GGCTAGCTACAACGA GGGCCTGG	2687	CCAGGCC G GCACCGCU	5466
3556	CCAGCGGT GGCTAGCTACAACGA GCGGCCT	2688	AGGCCGC A ACCGUGG	5467
3559	CTCCAGC GGCTAGCTACAACGA GGTGCGG	2689	CCCGCAC G GCUGGGAG	5468
3566	CCTCAGAC GGCTAGCTACAACGA TCCAGCG	2690	CGCUGGA G GUCUGAGG	5469
3573	ACTCAGGC GGCTAGCTACAACGA CTCAGACT	2691	AGUCUGAG G GCCUGAGU	5470
3579	AACTCAC GGCTAGCTACAACGA TCAGGCCT	2692	AGGCCUGA G GUGAGUGU	5471
3583	CCAAACAC GGCTAGCTACAACGA TCACTCAG	2693	CUGAGUGA G GUGUUUGG	5472
3585	GGCCAAAC GGCTAGCTACAACGA ACTCACTC	2694	GAGUGAGU G GUUUGGCC	5473
3590	GCCTCGGC GGCTAGCTACAACGA CAAACACT	2695	AGUUUUG G GCCGAGGC	5474
3596	ATGCAGGC GGCTAGCTACAACGA CTCGGCCA	2696	UGGCCGAG G GCCUGCAU	5475
3600	GGACATGC GGCTAGCTACAACGA AGGCCTCG	2697	CGAGGCCU G GCAUGUCC	5476
3602	CCGGACAT GGCTAGCTACAACGA GCAGGCCT	2698	AGGCCUGC A AUGUCCGG	5477
3604	AGCCGGAC GGCTAGCTACAACGA ATGCAGGC	2699	GCCUGCAU G GUCCGGCU	5478
3609	CCTTCAGC GGCTAGCTACAACGA CGGACATG	2700	CAUGUCCG G GCUGAAGG	5479
3616	CACTCAGC GGCTAGCTACAACGA CTTAGCC	2701	GGCUGAAG G GCUGAGUG	5480
3621	CCGGACAC GGCTAGCTACAACGA TCAGCCTT	2702	AAGGCUGA G GUGUCCGG	5481
3623	AGCCGGAC GGCTAGCTACAACGA ACTCAGCC	2703	GGCUGAGU G GUCCGGCU	5482
3628	GCCTCAGC GGCTAGCTACAACGA CGGACACT	2704	AGUGUCCG G GCUGAGGC	5483
3634	GCTCAGGC GGCTAGCTACAACGA CTCAGCCG	2705	CGGCUGAG G GCCUGAGC	5484
3640	AACTCGC GGCTAGCTACAACGA TCAGGCCT	2706	AGGCCUGA G GCGAGUGU	5485
3644	CTGGACAC GGCTAGCTACAACGA TCGCTCAG	2707	CUGAGCGA G GUGUCCAG	5486
3646	GGCTGGAC GGCTAGCTACAACGA ACTCGCTC	2708	GAGCGAGU G GUCCAGCC	5487
3651	CCCTTGGC GGCTAGCTACAACGA TGGACACT	2709	AGUGUCCA G GCCAAGGG	5488
3658	CACTCAGC GGCTAGCTACAACGA CCTTGGCT	2710	AGCCAAGG G GCUGAGUG	5489
3663	CTGGACAC GGCTAGCTACAACGA TCAGCCCT	2711	AGGGCUGA G GUGUCCAG	5490
3665	TGCTGGAC GGCTAGCTACAACGA ACTCAGCC	2712	GGCUGAGU G GUCCAGCA	5491
3670	AGGTGTGC GGCTAGCTACAACGA TGGACACT	2713	AGUGUCCA G GCACACCU	5492
3672	GCAGGTGT GGCTAGCTACAACGA GCTGGACA	2714	UGUCCAGC A ACACCUGC	5493
3674	CGGCAGGT GGCTAGCTACAACGA GTGCTGGA	2715	UCCAGCAC A ACCUGCCG	5494
3678	AAGACGGC GGCTAGCTACAACGA AGGTGTGC	2716	GCACACCU G GCCGUCUU	5495
3681	GTGAAGAC GGCTAGCTACAACGA GGCAGGTG	2717	CACCUGCC G GUCUUCAC	5496
3687	GGGAAGT GGCTAGCTACAACGA GAAGACGG	2718	CCGUCUUC A ACUUCCCC	5497

3695	CAGCCTGT GGCTAGCTACAACGA GGGGAAGT	2719	ACUUCCCC A ACAGGCUG	5498
3699	GCGCCAGC GGCTAGCTACAACGA CTGTGGGG	2720	CCCCACAG G GCUGGCGC	5499
3703	CCGAGCGC GGCTAGCTACAACGA CAGCCTGT	2721	ACAGGCUG G GCGCUCGG	5500
3705	AGCCGAGC GGCTAGCTACAACGA GCCAGCCT	2722	AGGCUGGC G GCUCGGCU	5501
3710	GGTGGAGC GGCTAGCTACAACGA CGAGCGCC	2723	GGCGCUCG G GCUCCACC	5502
3715	CCTGGGGT GGCTAGCTACAACGA GGAGCCGA	2724	UCGGCUCC A ACCCCAGG	5503
3723	AAGCTGGC GGCTAGCTACAACGA CCTGGGGT	2725	ACCCAGG G GCCAGCUU	5504
3727	GGAAAAGC GGCTAGCTACAACGA TGGCCCTG	2726	CAGGGCCA G GCUUUUCC	5505
3737	CTCCTGGT GGCTAGCTACAACGA GAGGAAAA	2727	UUUUCCUC A ACCAGGAG	5506
3744	AGCCGGGC GGCTAGCTACAACGA TCCTGGTG	2728	CACCAGGA G GCCCGGCU	5507
3749	GTGGAAGC GGCTAGCTACAACGA CGGGCTCC	2729	GGAGCCCG G GCUUCCAC	5508
3755	TGGGGAGT GGCTAGCTACAACGA GGAAGCCG	2730	CGGCUUCC A ACUCCCCA	5509
3762	TCCTATGT GGCTAGCTACAACGA GGGGAGTG	2731	CACUCCCC A ACAUAGGA	5510
3764	ATTCCTAT GGCTAGCTACAACGA GTGGGGAG	2732	CUCCCCAC A AUAGGAAU	5511
3770	TGGACTAT GGCTAGCTACAACGA TCCTATGT	2733	ACAUAGGA A AUAGUCCA	5512
3773	GGATGGAC GGCTAGCTACAACGA TATTCTTA	2734	UAGGAAUA G GUCCAUC	5513
3777	CTGGGGAT GGCTAGCTACAACGA GGAATATT	2735	AAUAGUCC A AUCCCCAG	5514
3785	TGGCGAAT GGCTAGCTACAACGA CTGGGGAT	2736	AUCCCCAG A AUUCGCCA	5515
3789	ACAATGGC GGCTAGCTACAACGA GAATCTGG	2737	CCAGAUUC G GCCAUUGU	5516
3792	TGAACAAT GGCTAGCTACAACGA GGCGAATC	2738	GAUUCGCC A AUUGUUA	5517
3795	GGGTGAAC GGCTAGCTACAACGA AATGGCGA	2739	UCGCCAUU G GUUCACCC	5518
3799	CGAGGGGT GGCTAGCTACAACGA GAACAATG	2740	CAUUGUUC A ACCCCUCG	5519
3806	GGCAGGGC GGCTAGCTACAACGA GAGGGGTG	2741	CACCCUC G GCCCUGCC	5520
3811	AGGAGGGC GGCTAGCTACAACGA AGGGCGAG	2742	CUCGCCCU G GCCCUCCU	5521
3821	TGGAAGGC GGCTAGCTACAACGA AAAGGAGG	2743	CCUCCUUU G GCCUCCA	5522
3828	GTGGGGGT GGCTAGCTACAACGA GGAAGGCA	2744	UGCCUUC A ACCCCAC	5523
3834	TGGATGGT GGCTAGCTACAACGA GGGGGTGG	2745	CCACCCCA A ACCAUCCA	5524
3837	ACCTGGAT GGCTAGCTACAACGA GGTGGGGG	2746	CCCCCACC A AUCCAGGU	5525
3843	GTCTCCAC GGCTAGCTACAACGA CTGGATGG	2747	CCAUCAG G GUGGAGAC	5526
3849	CTCAGGGT GGCTAGCTACAACGA CTCCACCT	2748	AGGUGGAG A ACCCUGAG	5527
3861	CCCAGGGT GGCTAGCTACAACGA CCTTCTCA	2749	UGAGAAGG A ACCCUGGG	5528
3870	CCCAGAGC GGCTAGCTACAACGA TCCCAGGG	2750	CCCUGGGA G GCUCUGGG	5529
3879	CTCCAAAT GGCTAGCTACAACGA TCCCAGAG	2751	CUCUGGGA A AUUUGGAG	5530
3886	TTGGTCAC GGCTAGCTACAACGA TCCAAATT	2752	AAUUUGGA G GUGACCAA	5531
3889	CCTTTGGT GGCTAGCTACAACGA CACTCCAA	2753	UUGGAGUG A ACCAAAGG	5532
3896	GGGCACAC GGCTAGCTACAACGA CTTTGGTC	2754	GACCAAAG G GUGUGCCC	5533
3898	CAGGGCAC GGCTAGCTACAACGA ACCTTTGG	2755	CCAAAGGU G GUGCCCUG	5534
3900	TACAGGGC GGCTAGCTACAACGA ACACTTT	2756	AAAGGUGU G GCCCUGUA	5535
3905	CTGTGTAC GGCTAGCTACAACGA AGGGCACA	2757	UGUGCCCU G GUACACAG	5536
3907	GCCTGTGT GGCTAGCTACAACGA ACAGGGCA	2758	UGCCCUGU A ACACAGGC	5537
3909	TCGCCTGT GGCTAGCTACAACGA GTACAGGG	2759	CCCUGUAC A ACAGGCGA	5538
3913	GTCCTCGC GGCTAGCTACAACGA CTGTGTAC	2760	GUACACAG G GCGAGGAC	5539
3919	TGCAGGGT GGCTAGCTACAACGA CCTCGCCT	2761	AGGCGAGG A ACCCUGCA	5540
3924	CCAGGTGC GGCTAGCTACAACGA AGGGTCCT	2762	AGGACCCU G GCACCUGG	5541
3926	ATCCAGGT GGCTAGCTACAACGA GCAGGGTC	2763	GACCCUGC A ACCUGGAU	5542
3932	ACCCCAT GGCTAGCTACAACGA CCAGGTGC	2764	GCACCUGG A AUGGGGGU	5543
3938	ACAGGGAC GGCTAGCTACAACGA CCCCATCC	2765	GGAUGGGG G GUCCUGU	5544

3944	TGACCCAC GGCTAGCTACAACGA AGGGACCC	2766	GGGUCCCU G GUGGGUCA	5545
3948	AATTTGAC GGCTAGCTACAACGA CCACAGGG	2767	CCCUGUGG G GUCAAAUU	5546
3953	CCCCCAAT GGCTAGCTACAACGA TTGACCCA	2768	UGGGUCAA A AUUGGGGG	5547
3964	CACAGCAC GGCTAGCTACAACGA CTCCCCC	2769	GGGGGAG G GUGCUGUG	5548
3966	CCCACAGC GGCTAGCTACAACGA ACCTCCCC	2770	GGGGAGGU G GCUGUGGG	5549
3969	ACTCCAC GGCTAGCTACAACGA AGCACCTC	2771	GAGGUGCU G GUGGGAGU	5550
3975	TATTTTAC GGCTAGCTACAACGA TCCCACAG	2772	CUGUGGGA G GUAAAAUA	5551
3980	TTCAGTAT GGCTAGCTACAACGA TTTACTCC	2773	GGAGUAAA A AUACUGAA	5552
3982	TATTCAGT GGCTAGCTACAACGA ATTTTACT	2774	AGUAAAAU A ACUGAAUA	5553
3987	TCATATAT GGCTAGCTACAACGA TCAGTATT	2775	AAUACUGA A AUAUAUGA	5554
3989	ACTCATAT GGCTAGCTACAACGA ATTCAGTA	2776	UACUGAAU A AUAUGAGU	5555
3991	AAACTCAT GGCTAGCTACAACGA ATATTCAG	2777	CUGAAUAU A AUGAGUUU	5556
3995	TGAAAAAC GGCTAGCTACAACGA TCATATAT	2778	AUAUAUGA G GUUUUUCA	5557
4003	TTCAAAAC GGCTAGCTACAACGA TGAAAAAC	2779	GUUUUUCA G GUUUUGAA	5558

Seq1 = TERT (Homo sapiens telomerase reverse transcriptase (TERT) mRNA, 4015 bp); Nakamura *et al.*, Science 277 (5328), 955-959 (1997)

Cut Site = R/Y (Purine/Pyrimidine)

Stem Length = 8 . Core Sequence = GGCTAGCTACAACGA

Table VII: Anti-TERT HH and G-Cleaver Ribozymes

Alias	Ribozyme Sequence	Seq ID Number	Length (nt)
<b>HH</b>			
TERT-1051	AGGAGUA CUGAUGAGGCCCGUUAGGCCGAA AGGAAGU	5559	36
TERT-1053	UGAGGAG CUGAUGAGGCCCGUUAGGCCGAA AGAGGAA	5560	36
TERT-1918	UGAAGCG CUGAUGAGGCCCGUUAGGCCGAA AGUCUGG	5561	36
TERT-2383	GAGCCAC CUGAUGAGGCCCGUUAGGCCGAA AACUGUC	5562	36
TERT-2485	UGAAGCG CUGAUGAGGCCCGUUAGGCCGAA AGGAAGA	5563	36
TERT-2566	GCGUGGA CUGAUGAGGCCCGUUAGGCCGAA AGGAUGG	5564	36
TERT-3181	AGUAGCA CUGAUGAGGCCCGUUAGGCCGAA AGGGAGG	5565	36
TERT-3691	CUGUGGG CUGAUGAGGCCCGUUAGGCCGAA AAGUGAA	5566	36
TERT-3758	AUGUGGG CUGAUGAGGCCCGUUAGGCCGAA AGUGGAA	5567	36
TERT-3794	GGUGAAC CUGAUGAGGCCCGUUAGGCCGAA AUGGCGA	5568	36
<b>G-Cleaver</b>			
TERT-757	UUGGG UGAUGGCAUGCACUAUGCGCG AACGGCAGAC	4332	36
TERT-2353	UCUGU UGAUGGCAUGCACUAUGCGCG AAGGUAGAGA	4471	36
TERT-3795	GUGAA UGAUGGCAUGCACUAUGCGCG AAUGGCGAAU	4594	36